CN1235513A - Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof - Google Patents

Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof Download PDF

Info

Publication number
CN1235513A
CN1235513A CN97199233A CN97199233A CN1235513A CN 1235513 A CN1235513 A CN 1235513A CN 97199233 A CN97199233 A CN 97199233A CN 97199233 A CN97199233 A CN 97199233A CN 1235513 A CN1235513 A CN 1235513A
Authority
CN
China
Prior art keywords
seq
helicobacter pylori
polypeptide
nucleic acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97199233A
Other languages
Chinese (zh)
Inventor
D·史密斯
R·A·阿尔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of CN1235513A publication Critical patent/CN1235513A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful for diagnostics and vaccine compositions.

Description

Nucleic acid and the amino acid sequence relevant with helicobacter pylori and vaccine combination thereof
Background of invention
Helicobacter pylori is gram-negative, S shape, micro-aerobic bacteria, and it is found and is incubated at people's stomach biological biopsy samples (Warren, J.R. and B.Marshall, (1983) " lancet " 1:1273-1275; With Marshall etc., (1984) " microorganism communication " 25 volumes, 83-88).Helicobacter pylori is very relevant with chronic gastritis and duodenal ulcer disease.(Rathbone etc., (1986) " digestion " 27 volumes, 635-641 page or leaf).And relevant helicobacter pylori accumulates (Blaser M.J., (1993) " microbiology trend " 1 volume, 255-260 page or leaf) at the evidence of the teiology effect of non-ulcer dyspepsia, gastric ulcer, sdenocarcinoma of stomach.Bacterium is propagated through fecal oral route, and the danger of infecting increased with the age.(Taylor, D.N. and M.J.Blaster, (1991), " epiphytology summary " 13 volumes, 42-50 page or leaf).Helicobacter pylori is settled in people's gastric mucosa, sets up the infection that common energy continues many decades.The infection of helicobacter pylori is worldwide popular.The infection rate of developed country surpasses 50% in adult colony, and developing country's infection rate in the adult more than 20 years old reaches 90%.(Hopkins R.J. and J.G.Morris (1994) " JAMA " 97 volumes, 265-277 page or leaf).
About being settled in the necessary bacterial factor of gastric environment and toxicity, this pathogene understands seldom.The example of the virulence factor of generally acknowledging comprises following: urease, a kind of may in and the enzyme (Eaton etc., (1991) " infecting and immunity " 59 volumes, the 2470-2475 page or leaf that work among the hydrochloric acid in gastric juice pH; Ferrero, R.L. and A.Lee (1991) " Microb.Eclo.Hlth.Dis " 4 volumes, 121-134 page or leaf; Labigne etc., (1991) " bacteriology magazine " 173 volumes, 1920-1931 page or leaf); Bacterial flagellin (Hazell etc., " infectious diseases magazine " 153 volumes, the 658-663 page or leaf of mucous layer passed in responsible motion; Leying etc., (1992) " molecular microbiology " 6 volumes, 2863-2874 page or leaf; With Haas etc., (1993) " molecular microbiology " 8 volumes, 753-760 page or leaf); VacA, a kind of bacteriotoxin that vacuole forms in the inducing cell in epithelial cell (Schmitt, W and R.Haas, (1994) " molecular microbiology " 12 volumes (2), 307-319 page or leaf); With several gastric tissue specific adhesion elements.(Boren etc., (1993) " science " 262 volume 1892-1895 pages or leaves; Evans etc., (1993) " bacteriology magazine " 175 volumes, 674-683 page or leaf; With Folk etc., (1993) " institute of American Academy of Sciences newspaper " 90 volumes, 2035-203 page or leaf).
There is a large amount of therapeutic agents can be used at present at external removing helicobacter pylori (Huesca etc., (1993) " Zbl.Bakt. " 280 volumes, 244-252 page or leaf; Hopkins, R.J. and J.G.Morris, above).But, because the resistance of bacterium, change that medicine distributes, patient's non-compliance or medicine is inapplicable, in them many can not reach in vivo optimum efficiency (Hopkins, R.J. and J.G.Morris, above).Treating with the agent of antibiotic combination bismuth is a part (Malfertheiner.P and J.E.Dominguez-Munoz, (1993) " clinical treatment " 15 volume supplementary issue B, 37-48 page or leaf) that is used for the treatment of the standard care of helicobacter pylori infections.Recently, a kind of ionic pump inhibitor and a kind of single antibiotic combination shown can alleviate dudenal disease ((Malfertheiher.P and J.E.Dominguez-Munoz, above).But, use the method for antibiotic medicine may run into a kind of like this problem, promptly occur to these drug resistants bacterial isolates (Hopkins, R.J. and J.G.Morris, above).These limitation show, need new, more effective, resist the method for helicobacter pylori infections in vivo, particularly be starved of and design the novel vaccine that can stop this bacterial infection.
The invention summary
The present invention relates to new gene, for example encode such as gene and other related gene of polypeptide such as bacterium surface albumen from organism helicobacter pylori (Helicobacter pylori); Its product; And uses thereof.Nucleic acid of the present invention and peptide are used for the diagnosis and the treatment of helicobacter pylori and other screw rod bacterial classification.They also can be used for surveying helicobacter pylori and other screw rod bacterial classification existence in sample; And be used to screen the compound that can disturb the helicobacter pylori life cycle or suppress helicobacter pylori infections.Specifically, the present invention describes in detail corresponding to helicobacter pylori protein, the composition of nucleic acid that comprises the whole code area of surface protein or secretory protein or its part, thereby can be, and adopt the synthetic and recombinant DNA technology of peptide to prepare the method for helicobacter pylori protein or its part in conjunction with the nucleic acid of the mRNA impede protein matter of helicobacter pylori protein translation.The present invention also describes the antibody and the nucleic acid that can detect helicobacter pylori infections as probe in detail.In addition, be used to provide the protective effect of opposing helicobacter pylori infections or treat the vaccine combination of described infection and method also within the scope of the invention.
The accompanying drawing summary
Fig. 1 is the bar figure that describes with antibody titer in the serum of mouse after the immunity of specificity Heliobacter pylori antigen.
Fig. 2 is the bar figure that describes with antibody titer in the mucous membrane of mouse after the immunity of specificity Heliobacter pylori antigen.
Fig. 3 describes with being dissolved in the bar figure of the specific antigen of HEPES buffer solution to the therapeutic immunization of helicobacter pylori infections mouse.
Fig. 4 is the description bar figure of the specific antigen of the buffer solution dissolving that contains DOC to the therapeutic immunization of helicobacter pylori infections mouse.
Fig. 5 describes amino acid sequence in the partial sequence of 5 helicobacter pylori proteins to arrange and (represent with single-letter amino acid code; From left to right, show that N holds the end to C).
Fig. 6 describes amino acid sequence in the partial sequence of 4 helicobacter pylori proteins to arrange and (represent with single-letter amino acid code; From left to right, show that N holds the end to C).
Fig. 7 describes amino acid sequence in the partial sequence of 2 helicobacter pylori proteins to arrange and (represent with single-letter amino acid code; From left to right, show that N holds the end to C).
Fig. 8 describes amino acid sequence in the partial sequence of 2 helicobacter pylori proteins to arrange and (represent with single-letter amino acid code; From left to right, show that N holds the end to C).
Detailed Description Of The Invention
On the one hand, the present invention describes the reorganization of helicobacter pylori polypeptide SEQ ID NO:74 or the prepared product of purifying basically in detail.The present invention also comprises the nucleic acid of the purifying basically of coding helicobacter pylori polypeptide SEQ ID NO:74, and this nucleic acid is contained among the SEQ ID NO:1.Here the helicobacter pylori peptide sequence of the present invention of Jie Shaoing is contained in the sequence table, and the nucleic acid of the helicobacter pylori polypeptide of the present invention of encoding also is contained in the sequence table.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:75 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:2.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:76 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:3.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:77 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:4.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:78 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:5.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:79 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:6.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:80 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:7.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:81 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:8.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:82 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:9.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:83 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:10.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:84 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:11.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:85 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:12.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:86 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:13.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:87 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:14.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:88 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:15.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:89 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:16.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:90 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:17.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:91 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:18.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:92 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:19.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:93 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:20.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:94 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:21.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:95 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:22.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:96 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:23.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:97 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:24.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:98 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:25.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:99 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:26.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:100 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:27.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:101 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:28.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:102 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:29.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:103 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:30.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:104 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:31.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:105 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:32.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:106 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:33.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:107 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:34.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:108 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:35.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:109 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:36.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:110 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:37.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:111 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:38.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:112 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:39.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:113 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:40.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:114 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:41.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:115 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:42.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:116 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:43.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:117 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:44.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:118 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:45.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:119 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:46.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:120 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:47.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:121 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:48.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:122 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:49.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:123 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:50.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:124 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:51.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:125 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:52.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:126 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:53.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:127 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:54.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:128 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:55.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:129 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:56.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:130 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:57.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:131 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:58.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:132 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:59.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:133 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:60.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:134 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:61.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:135 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:62.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:136 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:63.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:137 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:64.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:138 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:65.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:139 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:66.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:140 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:67.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:141 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:68.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:142 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:69.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:143 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:70.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:144 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:71.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:145 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:72.
On the other hand, the present invention describes the nucleic acid of purifying basically that coding contains the helicobacter pylori polypeptide of amino acid sequence SEQ ID NO:146 in detail, as contains the nucleic acid of nucleotide sequence SEQ ID NO:73.
Particularly preferably be the isolating nucleic acid of the nucleotide sequence that comprises coding helicobacter pylori cell membrane polypeptide or its fragment.This nucleic acid is selected from: SEQ ID NO:3, SEQ ID NO:25, SEQ IDNO:48, SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ ID NO:43, SEQID NO:11, SEQ ID NO:71, SEQ ID NO:17, SEQ ID NO:57, SEQ IDNO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:21.
In another embodiment, helicobacter pylori cell membrane polypeptide or its fragment are by membrane polypeptides in the helicobacter pylori that is selected from following nucleic acid coding or its fragment: SEQ ID NO:3, SEQ ID NO:25 and SEQ ID NO:48.
In another embodiment, helicobacter pylori cell membrane polypeptide or its fragment are by the helicobacter pylori ospa polypeptide that is selected from following nucleic acid coding or its fragment: SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQID NO:14, SEQ ID NO:43, SEQ ID NO:11 and SEQ ID NO:71.
In another embodiment, helicobacter pylori ospa polypeptide or its fragment are by being selected from helicobacter pylori polypeptide or its fragment following nucleic acid coding, that have the terminal tyrosine of terminal phenylalanine residue and C bunch: SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ IDNO:43, SEQ ID NO:11 and SEQ ID NO:71.
In another embodiment, helicobacter pylori ospa polypeptide or its fragment are by being selected from helicobacter pylori polypeptide following nucleic acid coding, that have terminal phenylalanine residue or its fragment: SEQ IDNO:16, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56 and SEQ ID NO:58.
Particularly preferably be the isolating nucleic acid of the nucleotide sequence that contains coding helicobacter pylori secrete polypeptide or its fragment, this nucleic acid is selected from SEQ ID NO:72, SEQ ID NO:32, SEQ ID NO:51, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68.
Particularly preferably be the isolating nucleic acid of the nucleotide sequence that contains coding helicobacter pylori cell polypeptide or its fragment, this nucleic acid is selected from SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:73.
Particularly preferably be helicobacter pylori cell membrane polypeptide or its fragment purifying or that separate, wherein polypeptide is selected from SEQ ID NO:76, SEQ ID NO:98, SEQ ID NO:121, SEQ IDNO:89, SEQ ID NO:83, SEQ ID NO:118, SEQ ID NO:108, SEQ IDNO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ IDNO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ IDNO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ IDNO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ IDNO:84, SEQ ID NO:144, SEQ ID NO:90, SEQ ID NO:130, SEQ IDNO:78, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:94.
In another embodiment, helicobacter pylori cell membrane polypeptide or its fragment are to be selected from membrane polypeptides or its fragment in the following helicobacter pylori: SEQ ID NO:76, SEQ ID NO:98 and SEQID NO:121.
In another embodiment, helicobacter pylori cell membrane polypeptide or its fragment are to be selected from following helicobacter pylori ospa polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:83, SEQID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84, SEQ ID NO:144, SEQ ID NO:90 and SEQ ID NO:130.
In another embodiment, helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have the terminal tyrosine of terminal phenylalanine residue and C bunch helicobacter pylori polypeptide or its fragment: SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84 and SEQ ID NO:144.
In another embodiment, helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have terminal phenylalanine residue helicobacter pylori polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129 and SEQ ID NO:131.
Particularly preferably be helicobacter pylori secrete polypeptide or its fragment of purifying or separation, wherein polypeptide is selected from SEQ ID NO:145, SEQ ID NO:105, SEQ ID NO:124, SEQ IDNO:75, SEQ ID NO:77, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:95, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:122, SEQ ID NO:126, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140 and SEQ ID NO:141.
Particularly preferably be helicobacter pylori cell polypeptide or its fragment of purifying or separation, wherein polypeptide is selected from SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:93, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:133, SEQ ID NO:137, SEQ ID NO:142, SEQ ID NO:143 and SEQ ID NO:146.
On the other hand, the present invention relates to any single helicobacter pylori polypeptide member of above-mentioned definite helicobacter pylori polypeptide family or this member's that encodes nucleic acid.
On the other hand, describe in detail can be in conjunction with the nucleic acid of helicobacter pylori mRNA in the present invention.This class nucleic acid can be controlled the translation of helicobacter pylori mRNA as antisensenucleic acids.One further the aspect describe the nucleic acid that can combine with helicobacter pylori nucleic acid specifically in detail.These nucleic acid are also referred to as complementary nucleic acid at this, and can be used as probe and capture reagent.
On the other hand, the present invention describes the expression system that contains corresponding to the open reading frame of helicobacter pylori nucleic acid in detail.This nucleic acid further contains the control sequence compatible with required host.This expression system can be used for preparing the polypeptide corresponding to helicobacter pylori nucleic acid.
On the other hand, the present invention describes in detail with above-mentioned expression system cell transformed, and this cell is used for producing the helicobacter pylori polypeptide.
On the other hand, the present invention describes the preparation method at the antibody of helicobacter pylori polypeptide in detail, and this antibody capable combines with the helicobacter pylori polypeptide specifically.This antibody can be used as immunological assay reagents, is used for estimating the content and the distribution of helicobacter pylori specific antigen.
On the other hand, the present invention describes the preparation method who is used for individuality is carried out the vaccine of helicobacter pylori specific aim immunity in detail.This immunization method comprises: with at least a helicobacter pylori polypeptide of the present invention such as surface or secrete polypeptide or its active part and pharmaceutically suitable carrier acceptor is carried out immunity.This vaccine can be used for treatment and prevention.
On the other hand, the invention provides the method for preparing vaccine, this vaccine contains immunogenicity helicobacter pylori polypeptide such as surface or secrete polypeptide or its active component and pharmaceutically suitable carrier of modification.
On the other hand, the present invention describes a kind of compound such as the fragment of polypeptide such as host cell polypeptide and a kind of method of helicobacter pylori polypeptide binding ability estimated in detail.Whether this method comprises: testing compound is contacted with a kind of helicobacter pylori polypeptide, and detect this compound and combine with the helicobacter pylori polypeptide or interact.Can just can be used as the candidate's activator or the inhibitor of bacterium life cycle in conjunction with the compound of helicobacter pylori.These tests can be carried out in external or body.
On the other hand, the present invention describes the fragment of assessing compound such as polypeptide such as host cell polypeptide and the method for helicobacter pylori nucleic acid such as DNA or RNA binding ability in detail.Whether this method comprises: testing compound is contacted with helicobacter pylori nucleic acid, and detect this compound and combine with the helicobacter pylori polypeptide or interact.Can just can be used as the candidate's activator or the inhibitor of bacterium life cycle in conjunction with the compound of helicobacter pylori.These tests can be carried out in external or body.
The present invention describes the helicobacter pylori polypeptide in detail, is preferably the prepared product of the purifying basically of helicobacter pylori polypeptide, or the helicobacter pylori polypeptide of reorganization.In preferred embodiments: polypeptide has biologic activity; Polypeptide contain at least with sequence table in listed amino acid sequence of the present invention the amino acid sequence of 60%, 70%, 80%, 90%, 95%, 98% or 99% identical or homology is arranged, preferably with sequence table in have an appointment 65% sequence homogeneity of listed amino acid sequence of the present invention, most preferably with sequence table in have an appointment 92% to 99% sequence homogeneity of listed amino acid sequence of the present invention; Polypeptide contain with sequence table in the substantially the same amino acid sequence of amino acid sequence of the present invention; Polypeptide length is at least 5,10,20,50,100 or 150 amino acid residues; Polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, is more preferably the continuous amino acid residue of the present invention shown at least 50,100 or 150 sequence tables.In another preferred embodiment, the present invention comprises that also its sequence homogeneity has 7% to 8% different amino acid sequence approximately with the helicobacter pylori amino acid sequence of the present invention shown in the sequence table.
In preferred embodiments, the helicobacter pylori polypeptide is by the nucleic acid coding of the present invention shown in the sequence table, or by the nucleic acid coding that 60%, 70%, 80%, 90%, 95%, 98% or 99% homology is arranged with the nucleic acid of the present invention shown in the sequence table at least.
In a preferred embodiment, helicobacter pylori polypeptide of the present invention amino acid sequence 1,2,3,5,10 or the more contained sequence of the present invention of the amino acid residue of many places and sequence table is different.But these differences still can make described helicobacter pylori polypeptide demonstrate the helicobacter pylori biologic activity, and for example, described helicobacter pylori polypeptide keeps the biologic activity of the helicobacter pylori polypeptide of natural generation.
In a preferred embodiment, polypeptide contains the whole of the amino acid sequence of the present invention shown in the ordered list or a fragment; In reading frame, merge extra amino acid residue, preferably merge the genomic DNA 5 ' of sequence of the present invention shown in the code sequence tabulation or 3 ' the coded residue of genomic DNA.
And in another preferred embodiment, the helicobacter pylori polypeptide is the recombination fusion protein that contains one first helicobacter pylori polypeptide portion and one second polypeptide portion, second polypeptide portion is as having the polypeptide with the irrelevant amino acid sequence of helicobacter pylori, and second polypeptide portion can be such as in following any: glutathione S-transferase, a DNA land or a polymerase active region.In preferred embodiments, fusion can be used in the double cross test.
Polypeptide of the present invention comprises the polypeptide that is produced by alternative transcription incident, alternative RNA splicing incident and variable translation and translation back incident.
The present invention also comprises a kind of immunogenicity component, and this component comprises at least a helicobacter pylori polypeptide in the immunogenicity prepared product; This immunogenicity component can cause special immune response at the helicobacter pylori polypeptide, as humoral response, antibody response or cell response.In preferred embodiments, the immunogenicity component contains at least one antigenic determinant from polypeptide of the present invention shown in the sequence table.
On the other hand, the invention provides the nucleic acid of purifying basically, these nucleic acid contain the nucleotide sequence of coding helicobacter pylori polypeptide.In preferred embodiments: encoded polypeptide has biologic activity; Encoded polypeptide contain at least with sequence table in listed amino acid sequence of the present invention the amino acid sequence of 60%, 70%, 80%, 90%, 95%, 98% or 99% homology is arranged; Encoded polypeptide contains and the substantially the same amino acid sequence of amino acid sequence of the present invention shown in the sequence table; Encoded polypeptide length is at least 5,10,20,50,100 or 150 amino acid residues; Encoded polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, is more preferably the continuous amino acid residue of the present invention shown at least 50,100 or 150 sequence tables.
In preferred embodiments, nucleic acid of the present invention is the nucleic acid shown in the sequence table; This nucleic acid has 60%, 70%, 80%, 90%, 95%, 98% or 99% autoploidy with the nucleotide sequence of the present invention shown in the sequence table at least.
In a preferred embodiment, coded helicobacter pylori polypeptide is at 1,2,3,5,10 or the amino acid residue different with the sequence of the present invention shown in the sequence table (for example replace, add or deletion by the amino acid of at least one amino acid residue) of many places more of amino acid sequence.But these differences still can make coded helicobacter pylori polypeptide demonstrate the helicobacter pylori biologic activity, and for example, coded helicobacter pylori enzyme keeps the biologic activity of the helicobacter pylori of natural generation.
In preferred embodiments, encoded polypeptide contains the whole of amino acid sequence of the present invention shown in the ordered list or a fragment; In reading frame, merge extra amino acid residue, preferably merge the genomic DNA 5 ' of sequence of the present invention shown in the code sequence tabulation or 3 ' the coded residue of genomic DNA.
In preferred embodiments, helicobacter pylori nucleic acid of the present invention can comprise a transcriptional regulatory sequences, at least one in transcripting promoter or the transcriptional enhancer sequence for example, this transcriptional regulatory sequences, be connected in helicobacter pylori group sequence effectively, for example make the helicobacter pylori gene order be suitable in recombinant host cell, expressing.
At one further in the embodiment, the nucleic acid of code book invention helicobacter pylori polypeptide under stringent condition with nucleic acid probe hybridization corresponding at least 8 continuous nucleotides of the present invention shown in the sequence table; More preferably with nucleic acid probe hybridization corresponding at least 12 continuous nucleotides of the present invention shown in the sequence table; More preferably with nucleic acid probe hybridization corresponding at least 20 continuous nucleotides of the present invention shown in the sequence table; More preferably with nucleic acid probe hybridization corresponding at least 40 continuous nucleotides of the present invention shown in the sequence table.
In a preferred embodiment, a kind of peptide of this nucleic acid coding, this peptide has at least an amino acid residue different with the sequence of the present invention shown in the sequence table.
In a preferred embodiment, the nucleotide sequence of the present invention shown in the sequence table of the amino acid sequence of the present invention shown in the tabulation of this nucleic acid and code sequence has at least a nucleotide different.
On the other hand, the present invention includes: the carrier that contains the nucleic acid of helicobacter pylori polypeptide that coding introduces or helicobacter pylori polypeptide variants here; Host cell with this carrier transfection; And the method for preparing recombinant helicobacterpylori polypeptide or helicobacter pylori polypeptide variants, comprise cultured cell, for example in a kind of cell culture medium, cultivate, and separate helicobacter pylori polypeptide or helicobacter pylori polypeptide variants, for example from cell or cell culture medium, separate.
On the other hand, the present invention describes the recombinant nucleic acid that has the purifying of 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% homology with the sequence of the present invention shown in the sequence table at least in detail.
The present invention also provides and contains the probe or the primer of the oligonucleotides of purifying basically.Oligonucleotides comprises one section nucleotides sequence column region, and there are at least 8 continuous nucleotides hybridization of the mutant of justice or antisense sequences or its natural generation in this zone with of the present invention shown in the sequence table under stringent condition.In preferred embodiments, probe or primer further comprise connection labelling groups thereon, and this labelling groups can be the co-factor such as radioisotope, fluorescent chemicals, enzyme and/or enzyme.Preferably, the length of oligonucleotides is less than 10,30,50,100 or 150 nucleotide at least 8.
The present invention also provides the helicobacter pylori polypeptide that separates, described polypeptide by under stringent condition with the nucleic acid coding of nucleic acid hybridization shown in the sequence table.
The present invention further provides the nucleic acid of coding polypeptide of the present invention, for example RNA or DNA.This comprises double-strandednucleic acid and coding and strand antisense.
The determined helicobacter pylorus bacteria strain of genome sequence is at American type culture collection (ATCC#55679; By the preservation of Genome Therapeutics company, 100 BeaverStreet, Waltham, MA 02154) carried out preservation as bacterial strain HP-J99.
The present invention includes: allelic variation, spontaneous mutation, bring out sudden change; (" modern molecular biology method " seen in height and low tight definition by albumen that can be coded with the DNA that the nucleic acid of the polypeptide of the present invention shown in the code sequence tabulation is hybridized under height or low stringent condition, John Wiley﹠Sons, New York, 1989,6.3.1-6.3.6 and 6.4.1-6.4.10, be hereby incorporated by); And can be by at the antiserum of helicobacter pylori polypeptide, especially can be by polypeptide at the antiserum specificity combination of the avtive spot of helicobacter pylori polypeptide or calmodulin binding domain CaM.The present invention also comprises fragment, preferred bioactive fragment.These and other polypeptide is also referred to as helicobacter pylori polypeptide analog or variant at this.
Several helicobacter pylori polypeptide of the present invention are carried out the mensuration of estimation function, seen Table 1.
Correspondingly, said helicobacter pylori polypeptide based on these application of determining function and other function as herein described also within the scope of the invention.
In addition, the present invention includes the helicobacter pylori polypeptide of having identified shown in the following table 1, comprising: helicobacter pylori epicyte protein, helicobacter pylori secretory protein and helicobacter pylori cell protein.The member of these groups determines with the retrieval of BLAST homology and secretion signal or the retrieval of transmembrane protein primitive.There is the polypeptide of obvious affinity also can consider to classify with the polypeptide of table 1 by the homologue mode shown in the table 1.
Table 1
ORF_ title and group nt?SeaID aa?SeqID
A. cell membrane
A.1 inner membrane protein
02ge11622_23494043_f1_6 ????3 ????76
hp5p15212_13095752_c3_36 ????25 ????98
06ep30223_20173437_f1_37 ????48 ????121
A.2 outer membrane protein
05ee10816_14495437_f2_13?????? ????10 ????83
A.2.1 terminal phe residue
06ep11509_35954752_f2_1 ????16 ????89
06ep10615_14495437_f3_47 ????45 ????118
03ae10804_14495437_c2_38 ????35 ????108
05ae30220_917200_c3_172 ????37 ????110
04cp11202_23646885_f2_26 ????7 ????80
05ep10815_16131925_c2_97 ????39 ????112
09cp61003_5860877_f2_23 ????55 ????128
09ae10512_48768_c3_67 ????18 ????91
09cp11003_5860877_f3_7 ????19 ????92
hp6e12267_30078562_f3_33 ????28 ????101
06cp30603_34174212_c3_71 ????30 ????103
09cp10224_1962590_f3_31 ????52 ????125
09cp61003_30478562_c3_106 ????54 ????127
11ae80818_10553192_f2_16 ????56 ????129
11ee11408_10584582_c3_51 ????58 ????131
A.2.2 the terminal tyrosine of terminal phe residue and C-bunch
01ae12001_116018_c2_40 ????1 ????74
06ap10609_116018_c3_50 ????42 ????115
06cp30603_4687507_f1_9 ????14 ????87
06cp30603_4687507_f1_7 ????43 ????116
05ee10816_36126938_f3_16 ????11 ????84
01cp20708_4960952_c1_43 ????71 ????144
A.3 through autoploidy
07ap80601_5083193_f3_8 ????17 ????90
11ap20714_4797137_f3_45 ????57 ????130
A.4 other epicyte protein
00ap12016_25501501_f1_1 ????5 ????78
04cp11202_20415937_f2_25 ????6 ????79
00ee11108_3906963_f1_7 ????8 ????81
29ep10720_25501501_c2_33 ????21 ????94
B. secretory protein
hp3e10342_22448587_c2_15 ????72 ????145
hp5p15212_24276587_f1_2 ????32 ????105
09ce10413_35336707_f2_9 ????51 ????124
01ae12001_32462543_c2_43 ????2 ????75
03ee11215_1416312_c3_35 ????4 ????77
05ae30220_14570443_c2_94 ????9 ????82
06cp30603_2772578_c1_46 ????13 ????86
29ep10720_289077_f2_12 ????22 ????95
03ee11215_22542803_f1_7 ????29 ????102
09ae10512_3166040_c1_40 ????31 ????104
01ce11104_10742963_c2_12 ????33 ????106
02ge10116_36335436_f3_66 ????34 ????107
04ep41903_11876461_f1_4 ????36 ????109
05ce10208_23631292_f1_6 ????38 ????111
05ep10815_22447252_c3_110 ????40 ????113
05ep10815_30283516_c3_109 ????41 ????114
06ee30709_33851038_c3_30 ????44 ????117
06ep11202_21687842_c3_35 ????46 ????119
06ep30223_2774062_f1_33 ????49 ????122
09cp10713_23912707_c1_26 ????53 ????126
11ee11408_4882318_f3_24 ????59 ????132
hp4e13394_5908553_f1_1 ????61 ????134
hp4e53394_1416312_c3_119 ????62 ????135
hp5e15211_24328910_c3_38 ????63 ????136
hp6p10606_23493756_c1_21 ????65 ????138
hp6p22217_23564012_f1_5 ????66 ????139
hp6p22217_272058_f1_2 ????67 ????140
hp6p22217_2922143_f2_9 ????68 ????141
C. other cell protein
06ap11119_14726542_f3_21 ????12 ????85
06ee10709_6136430_c1_11 ????15 ????88
12ap10605_14094816_c1_5 ????20 ????93
hp2p10272_34042518_f1_2 ????23 ????96
hp5e15211_25411557_c1_22 ????24 ????97
hp5p15641_3907968_f1_3 ????26 ????99
hp6e10967_657638_f3_9 ????27 ????100
06ep11202_4569693_c2_28 ????47 ????120
06ep30223_3930468_c1_110 ????50 ????123
hp2e10911_960952_c2_86 ????60 ????133
hp6p10509_14842217_c2_17 ????64 ????137
hp6p80503_20964382_f2_11 ????69 ????142
hp7e10192_5917593_f1_2 ????70 ????143
hp6p10509_14642217_c3_25 ????73 ????146
(" nt " represents nucleotide sequence ID number in table 1, " aa " represented amino acid serial ID number)
Definition:
Here, term " polypeptide of purifying " can exchange use with " polypeptide that separates " and " the polypeptide prepared product of purifying basically ", is meant that polypeptide is from therewith separating naturally occurring other albumen, fat and the nucleic acid.Preferably, polypeptide also separates from being used for its material of purifying such as antibody or gel-type vehicle such as polyacrylamide.Preferably, at least 10,20,50,70,80 or 95% of the prepared product dry weight of polypeptide composition purifying.Preferably, prepared product comprises: the polypeptide that enough is used for protein sequencing; At least 1,10 or 100 ug polypeptide; At least 1,10 or the 100mg polypeptide.In addition, term used herein " polypeptide of purifying " and " polypeptide that separates " and " the polypeptide prepared product of purifying basically " had both referred to the polypeptide of natural generation, also referred to the polypeptide that produces by recombinant DNA technology as herein described.
For example, " separation " or " purifying " protein or its biologically-active moiety are substantially free of cellular material or other contaminating protein matter in the cell or tissue source that produces helicobacter pylori protein, or when by chemosynthesis, be substantially free of compound precursor or other compound.A speech comprises the helicobacter pylori protein prepared product " to be substantially free of cellular material ", wherein protein with isolate the cellular component that protein or reorganization produce the cell of protein and separate.In one embodiment, the speech that " is substantially free of cellular material " comprises having and is lower than the non-helicobacter pylori protein of about 30% (accounting for dry weight) (this paper also is referred to as " contaminating protein matter "), more preferably have and be lower than about 20% non-helicobacter pylori protein, more preferably have and be lower than about 10% non-helicobacter pylori protein, most preferably have the helicobacter pylori protein prepared product that is lower than about 5% non-helicobacter pylori protein.When reorganization produces helicobacter pylori protein or its biologically-active moiety, also preferably be substantially free of medium, promptly medium is the about below 20% of protein prepared product amount, more preferably from about below 10%, most preferably from about below 5%.
A speech comprises the helicobacter pylori protein prepared product " to be substantially free of compound precursor or other compound ", and wherein protein separates with the compound precursor or other compound that participate in protein synthesis.In one embodiment, the speech that " is substantially free of compound precursor or other compound " comprises having and is lower than about 30% (accounting for dry weight) compound precursor or non-helicobacter pylori compound, more preferably have and be lower than about 20% compound precursor or non-helicobacter pylori compound, more preferably have and be lower than about 10% compound precursor or non-helicobacter pylori compound, most preferably have the helicobacter pylori protein prepared product that is lower than about 5% compound precursor or non-helicobacter pylori compound.
The prepared product of the purifying of cell is meant cells in vitro prepared product rather than complete plant or animal when plant or zooblast; Be meant that when cultured cells or microbial cell prepared product contains at least 10% and 50% target cell more preferably.
Purifying or that separate or the nucleic acid of purifying basically, as the DNA of purifying basically, (these terms are used interchangeably in this article) is one or both following nucleic acid: not with naturally occurring genome in the organism that obtains nucleic acid in the coded sequence at two ends closely adjacent (promptly hold another 3 ' to hold 5 ') closely adjacent; Or the nucleic acid that in the organism that obtains nucleic acid, does not have basically.This speech comprises: for example be incorporated into a carrier as the plasmid that is integrated into self-replicating or virus or be integrated into the recombinant DNA of eucaryote or procaryotic genomic DNA, or do not rely on other dna sequence dna have the recombinant DNA of (as handling cDNA or the genomic DNA fragment that produces) with independent molecular forms by PCR or restriction restriction endonuclease.Basically the DNA of purifying also comprises the recombinant DNA of part of the heterozygous genes that is the other helicobacter pylori dna sequence dna of coding.
Here, " contig " is the continuous fragment of expression organism genome sequence.
" open reading frame " is also referred to as ORF here, is the nucleic acid region of a polypeptide of coding.But part of this zone presentation code sequence or whole sequence can be measured it from terminator to terminator or from initiation codon to terminator.
" coded sequence " here is the nucleic acid that can be transcribed into mRNA under the control that places the suitable adjustable sequence time and/or translate into polypeptide.The border of coded sequence is by the translation stop codon decision of the translation initiation codon and 3 ' the primer end of 5 ' primer end.Coded sequence can include but not limited to mRNA, synthetic DNA and recombinant nucleic acid sequence.
Here, " the complementary composition " of nucleic acid is meant the antiparallel or antisense sequences that participates in the Watson-Crick base pairing with former sequence.
" gene outcome " is gene specific encoded protein or structure RNA.
Here, " probe " speech is nucleic acid, peptide or other chemical entities that can be specifically combines with the institute molecule (s) of interest.Probe usually with or can be connected with a label.Label is the detected chemical part of energy.Typical label comprises dyestuff, radioisotope, luminous or chemiluminescent moiety, fluorescence, enzyme, agglutination reagent, extension increasing sequence etc.Similarly, can be referred to herein as " capturing part " with institute's molecule (s) of interest specific bond and nucleic acid, peptide or other chemical entities that this molecule is fixed.Capture part usually with or can be connected with a kind of matrix such as cellulose nitrate, glass, nylon membrane, pearl, particle.The specificity of hybridization depends on conditions such as the temperature of base composition such as nucleotide, reaction and salinity.These conditions can be used normal experiment to determine easily by the common staff of this area.
Homology is meant the sequence similarity or quite between two polypeptide or two nucleic acid molecules.When the same position of two sequences that compared was occupied by identical base or amino acid monomer subunit, if when for example two kinds of dna moleculars position is all occupied by adenylate, then two molecules were in this position homology.The percent homology of two sequences is that two sequences are complementary or with the number of source position number * 100 results that obtained divided by institute's comparison position.For example, if having 6 to be complementary or homology in 10 positions of two sequences, then two sequences have 60% autoploidy.Give an example, dna sequence dna ATTGCC and TATGGC have 50% autoploidy.In general, two sequences compare to be arranged in the mode that can provide maximum homology.
When a chain of nucleic acid can be annealed under defined stringent condition with other nucleic acid at least, nucleic acid can the phase mutual cross.The stringency of hybridization is by following definite: (a) hybridize and/or the temperature when washing; (b) ion strength and the polarity of hybridization and wash solution.Hybridization needs two kinds of nucleic acid to contain complementary series, but according to the stringency of hybridizing, mispairing can be tolerated.(for example, in 0.5 * SSC solution, 65 ℃ time) needed sequence homology fully basically when in general, two kinds of sequences were hybridized under the height stringent condition.The full complementarity that needs between the hybridization sequences under the condition of medium tight (for example 2 * SSC, 65 ℃ time) or low tight (as 2 * SSC, 65 ℃) is corresponding few.(1 * SSC is 0.15M NaCl, 0.015M sodium citrate).Tight hybridization conditions preferred, nonrestrictive example is in the time of about 45 ℃, hybridization in 6 * sodium chloride/sodium citrate (SSC), then in the time of 50-65 ℃, with 0.2 * SSC, 0.1%SDS washs 1 or 2 time.
Speech such as peptide, albumen and polypeptide can be general at this.
Here, " surface protein " speech refers to that all can arrive the albumen on surface, for example interior and outer membrane protein, the albumen that adheres to cell wall and secretory protein.
If polypeptide contains one, two and preferred more following characteristic, it just has the helicobacter pylori biologic activity: (1) when it was expressed in the helicobacter pylori infections process, it can promote or mediate helicobacter pylori and adhere to cell; (2) it has the enzymic activity of helicobacter pylori protein, structure or regulatory function feature; (3) lethal mutation that its gene can save a helicobacter pylori gene of encoding, (4) or it are immunogenic to the experimenter.If polypeptide is antagonist, activator or a super-agonists with polypeptide of above-mentioned feature, it just has biologic activity.
Biological active fragment or analog are to have in the body or the fragment of external activity, these activity are features of the helicobacter pylori polypeptide of the helicobacter pylori polypeptide of the present invention shown in the sequence table or other natural generation, for example one or more biologic activity of introducing here.Particularly preferably be the fragment that is present in the body, for example result from the fragment of transcribing the back process or resulting from alternative splicing RNA translation.These fragments comprise and are expressed in natural or endogenous cell and be prepared in expression system such as the fragment of Chinese hamster ovary celI.Because peptide such as helicobacter pylori polypeptide show widely physiologically active usually and because these features can ascribe the different piece of molecule to, useful helicobacter pylori polypeptide fragment or helicobacter pylori analog are the fragments that can show biologic activity in any helicobacter pylori biological activity test.Most preferred fragment or analog are in vivo or have 10%, preferred 40%, more preferably 60%, 70%, 80% or 90% or more helicobactor pylori activity in the in vitro test.
The helicobacter pylori polypeptide of analog and natural generation different can be amino acid sequences or different in the mode that do not relate to sequence, perhaps both.Non-sequence modification comprises that acetylization, formylated, phosphorylation, carboxylation or glycosylation change.Preferred analog comprises that those sequences compare with wild-type sequence, there are one or more conserved amino acids to replace or the replacement of non-conserved amino acid, deletion or insertion, but do not eliminate the helicobacter pylori polypeptide (or its biological active fragment) of helicobacter pylori polypeptide biologic activity basically.Conservative replacement generally includes an amino acid is had the amino acid of similar features to replace by another, for example replaces in the group below: valine, glycine; Glycine, alanine; Valine, isoleucine, leucine; Aspartic acid, glutamic acid; Asparagine, glutamine; Serine, threonine; Lysine, arginine; And phenyl alanine, tyrosine.Other conservative replacement is summarized in following table.
Table 2
Conserved amino acid is replaced
Amino acid Code Replace with any one
Alanine A ?D-Ala,Gly,β-Ala,L-Cys,D-Cys
Arginine R ?D-Arg,Lys,D-Lys,homo-Arg,D-homo-Arg,Met,Ile, ?D-Met,D-Ile.Orn.D-Orn
Asparagine N ?D-Asn,Asp,D-Asp,Glu,D-Glu,Gln,D-Gln
Aspartic acid D ?D-Asp,D-Asn,Asn,Glu,D-Glu,Gln,D-Gln
Cysteine C ?D-Cys,S-Me-Cys,Met,D-Met,Thr,D-Thr
Glutamine Q ?D-Gln,Asn,D-Asn,Glu,D-Glu,Asp,D-Asp
Glutamic acid E ?D-Glu,D-Asp,Asp,Asn,D-Asn,Gln,D-Gln
Glycine G ?Ala,D-Ala,Pro,D-Pro,β-Ala,Acp
Isoleucine I ?D-Ile,Val,D-Val,Leu,D-Leu,Met,D-Met
Leucine L ?D-Leu,Val,D-Val,Leu,D-Leu,Met,D-Met
Lysine K ?D-Lys,Arg,D-Arg,homo-Arg,D-homo-Arg,Met,D- ?Met,Ile,D-Ile,Orn,D-Orn
Methionine M ?D-Met,S-Me-Cys,Ile,D-Ile,Leu,D-Leu,Val.D-Val
Phenyl alanine F ?D-Phe,Tyr,D-Thr,L-Dopa,His,D-His,Trp,D-Trp, ?Trans-3,4,or?5-phenylproline,cis-3,4, ?or?5-phenylproline
Proline P ?D-Pro,L-I-thioazolidine-4-carboxylic?acid,D-or?L-1- ?oxazolidine-4-carboxylic?acid
Serine S ?D-Ser,Thr,D-Thr,allo-Thr,Met,D-Met,Met(O), ?D-Met(O),L-Cys,D-Cys
Threonine T ?D-Thr,Ser,D-Ser,allo-Thr,Met,D-Met,Met(O), ?D-Met(O),Val,D-Val
Tyrosine Y ?D-Tyr,Phe,D-Phe,L-Dopa,His,D-His
Valine V ?D-Val,Leu,D-Leu,Ile,D-Ile,Met,D-Met
Other analog of the present invention is those analogs that have the modification that can increase polypeptide stability; Such analog can contain for example one or more non-peptide bonds (replacement peptide bond) in peptide sequence.What also comprise has: for example D-amino acid or non-natural produce or the analog and the annular analog of synthesizing amino acid such as β or γ amino acid residue to contain the L amino acid that is not natural generation.
Here, " fragment " speech when being used for the helicobacter pylori analog, normal length 20 residues of having an appointment at least, more typical have at least about 40 residues, preferably at least about 60 residues.The fragment of helicobacter pylori polypeptide can prepare with method well known to those skilled in the art.The ability of the biologic activity of fragment demonstration helicobacter pylori polypeptide to be measured can be estimated with the method for introducing here well-known to those having ordinary skill in the art.What also comprise has: the helicobacter pylori polypeptide that contains the active unwanted residue of biology of peptides or produced by variable mRNA montage or variable protein matter processing incident.
" immunogenic components " is used for being meant separately herein or unites the part that can cause body fluid and/or cellullar immunologic response at host animal, for example helicobacter pylori polypeptide, its analog or a fragment with adjuvant.
" antigenic component " is used for is to combine the part that forms a kind of detectable antigen-antibody complex with sufficiently high affinity with specific antibody herein, for example helicobacter pylori polypeptide, its analog or a fragment.
Be used for herein, the meaning of " transgenosis " speech is that a nucleic acid partially or completely is allos concerning transgenic animal or cell that it was introduced into, and is promptly external; The endogenous gene homology of transgenic animal that perhaps are introduced into or cell with it, but it is by to change the mode of its cellular genome that is inserted into, be designed to insert, or be inserted in the genome of cell (for example, it be inserted into the position or its insertion that are different from original gene cause a rejecting).A transgenosis can contain one or more transcriptional regulatory sequences and other any nucleic acid, for example intron.These sequences and nucleic acid are essential to the optimum expression of selected nucleic acid, and they are connected in selected nucleic acid with all handling; Transgenosis also can contain enhancer sequence.
Be used for herein, " transgenic cell " speech refers to contain genetically modified cell.
Be used for herein, " transgenic animal " are a kind of so arbitrarily animals, this animal one or more, preferably basically all cells contain a transgenosis.Transgenosis can be passed through autotelic genetic manipulation, for example with competent cell conversion method, microinjection or use recombinant virus infection, with the mode of the precursor of direct or indirect transfered cell, transfered cell.This molecule can be incorporated in the chromosome, and perhaps it can be an extrachromosomal replication DNA.
" antibody " speech is used for being intended to comprising herein can be specifically and the fragment of helicobacter pylori polypeptide reaction.
Be used for herein, the meaning of " cell specificity promotor " speech is to be used as a promotor, promptly regulates the expression of the selected dna sequence dna that effectively is connected in this promotor, and the dna sequence dna that the selected dna sequence dna of influence is expressed in the special organization cell.Said " leakage type " promotor also contained in this speech, and this promotor is mainly regulated the expression of selected DNA in a kind of tissue, but also can cause expression in other tissue.
False demonstration is used for herein, is meant the non-wild type pattern of gene expression.It comprises: express promptly super or low the expression on non-wild type level; With regard to the time or the stage expression pattern different of gene expression with wild type, for example, in the expression (comparing) of predetermined developmental stage or stage raising or reduction with wild type; Expression (comparing) expression pattern different with regard to reducing in predetermined cell type or types of organization with wild type with wild type; Just modify or the biologic activity expression pattern different after the sub-size of the montage of expressed polypeptide, amino acid sequence, the transportation with wild type; With regard to environmental stimulus or the extracellular stimulus expression pattern different with wild type, for example, when existing stimulus intensity to improve or reducing, improve or reduce the expression pattern of (comparing) with wild type to the influence of gene expression.
Be used for herein, " host cell " and other expression are meant the cell that can become or be used as the acceptor of recombinant vector or other transfer DNA with the speech of unicellular entity form cultured microorganism or senior eukaryotic cells system, and comprise the offspring of transfected naive cell.It will be understood by those of skill in the art that because chance or the sudden change had a mind to, it is identical with the just the same or full DNA of former parent's genome that the filial generation of single parent's cell does not need.
Be used for herein, " regulating and controlling sequence " thus a speech refers to contain the nucleic acid that the coded sequence that can be attached thereto by the base sequence influence that host's organism is discerned is expressed.The essence of this regulating and controlling sequence has nothing in common with each other according to host's organism; In prokaryotes, this regulating and controlling sequence generally comprises a promotor, ribosome bind site, and terminator also comprises operon sometimes; In eucaryote, this regulating and controlling sequence generally comprises promotor, terminator and comprises enhancer in some cases.Regulating and controlling sequence comprises that under minimum level all its existence concerning expressing are essential compositions, can comprise that also its existence is useful extra composition, for example targeting sequencing.
Be used for herein, " effectively connecting " refers to that sequence is can exercise the mode combination or the connection of required function.For example, a regulating and controlling sequence effectively is connected in coded sequence; Its connected mode makes the ability success in the environment that is complementary with regulating and controlling sequence and host that is expressed in of coded sequence.
Be used for herein, a kind of meaning of metabolism of material is any aspect of this material expression, function, effect or adjusting.The metabolism of material comprises modification, for example the covalently or non-covalently modification of material.The metabolism of material comprises modification, for example covalently or non-covalently modifies, and this material is induced in other material.The metabolism of material also comprises the change of this species distribution.The metabolism of material comprises that this material induces the change of other species distribution.
" sample " is used for referring to biological sample herein, such as, for example from individual (including but not limited to blood plasma, serum, celiolymph, lymph, tear, saliva and histologic section) or the tissue or the liquid that from vitro cell culture, separate, and the sample that from environment, separates.
Unless otherwise indicated, enforcement of the present invention will be used biochemistry, molecular biology, microbiology, recombinant DNA and the immunologic routine techniques in the scope of this area.The existing in the literature detailed introduction of these technology is seen in as Sambrook, Gritsch and Maniatis " molecular cloning: lab guide " the 2nd edition (1989); " dna clone " I volume and II volume (D.N.Glover compiles, 1985); " oligonucleotides is synthetic " (M.J.Gait compiles, 1984) " nucleic acid hybridization " (B.D.Hames﹠amp; S.J.Higgins compiles 1984); (AcademicPress, Inc), particularly 154 volumes and 155 are rolled up (Wu and Crossman compile) and " PCR Getting Started Steps " (McPherson, Quirke and Taylor compile, 1991) to " Enzymology method " series.
The separation and the use thereof of I helicobacter pylori nucleic acid
The helicobacter pylori genome sequence
The invention provides the nucleotide sequence of helicobacter pylori genome, thereby comprise the dna sequence dna library of helicobacter pylori genome DNA.Below detailed introduction the nucleotide sequence of helicobacter pylori is provided, and to introduce these sequences are how determining with ORFs and albumen coded sequence of how obtaining.Also introduced the using method of disclosed helicobacter pylori sequence in comprising diagnostic and therapeutic application method.And the library can be used as the medically important sequence that this or other helicobacter pylorus bacteria strain was differentiated and compared to database.
For measuring the genome sequence of helicobacter pylori, from a helicobacter pylorus bacteria strain (ATCC#55679; By the preservation of Genome Therapeutics company, 100 Beaver Street, Waltham, MA 02154) middle DNA isolation, and cut into the median size of 2kb by the machinery that atomizes, after carrying out size fractionation with gel electrophoresis,, be connected with the adapter oligonucleotides with the fragment blunt endsization, and be cloned into (Rice etc. in 20 kinds of different pMPX carriers respectively, Genome Atlas and order-checking conference summary, cold spring port, NY, 5/11-5/15,1994,225 pages), be built into a series of " air gun " subclone library.
Dna sequencing is used basically as Church etc. 1988, and " science " 240 rolled up, and 185 pages, U.S. Patent No. 4,942, disclosed multiple sequence measurement is finished in 124 and 5,149,625.Extracting DNA from mixed culture, and carry out chemistry or enzyme order-checking, the sequencing reaction thing separates with electrophoresis, and product is shifted and be covalently attached to nylon membrane.At last, with the oligonucleotide hybridization of film and a series of marks, described oligonucleotides be present in different shotgun cloning carriers in the complementation of " sign " sequence.In this way, from the sequencing reaction of a single group, just can obtain a large amount of sequences.Clone and sequence measurement are introduced in more detail at embodiment.
Read in this way single sequence use FALCON TMProgram (church etc., 1994, " automated DNA order-checking and analysis ", J.C.venter edits, Academic publishing house) and PHRAP (P.Green, Abstract of DOE Human Genome Program Contractor-Grantee Workshop V, in January, 1996,157 pages) carry out layout.The average length of contig is about 3-4kb.
Diverse ways can be used for contig sorted and obtain to represent the continuous sequence of whole helicobacter pylori genome.The artificial synthetic oligonucleotide of the sequence complementation of design and each contig end.With these oligonucleotides and such as helicobacter pylori genome DNA library hybridization in λShi Juntizaiti or the plasmid vector, determine to contain clone corresponding to the sequence of different contig join domains.Then with these clones as separating template DNA, and same oligonucleotides is used as primer, with polymerase chain reaction (PCR) junction fragment that increases, measure its nucleotide sequence then.
Analyze in the helicobacter pylori sequence and whether have the open reading frame (ORFs) that contains at least 180 nucleotide.As the result that the ORFs that reads based on terminator-terminator analyzes, should be appreciated that these ORFs are can be not corresponding with the ORF of the helicobacter pylori polypeptide of natural generation.These ORF can contain the synthetic initiation codon that starts of the helicobacter pylori polypeptide protein of representing natural generation.Here the initiation codon among these ORFs that provide can be measured by those of ordinary skill in the related art, and the ORF that is obtained and coded helicobacter pylori polypeptide are also within the scope of the invention.For example, in ORFs, codon such as AUG or GUG (coding methionine or valine) can measure, and ORF can be modified to corresponding with the helicobacter pylori polypeptide of natural generation, and codon such as AUG or GUG are the parts of the synthetic initial signal of albumen.By using program GENEMARK TM(Borodovsky and McInich, 1993 " Comp.Chem. " 17 volumes, 123 pages) are estimated the code capacity of these sequences, determine the coding region of expection.
Other helicobacter pylori nucleic acid
Nucleic acid of the present invention can obtain from the DNA of helicobacter pylorus bacteria strain above-mentioned with polymerase chain reaction (PCR).About " PCR Getting Started Steps " (McPherson, Quirke and Taylor compile, and IRL publishes, Oxford, UK, 1991) seen in the detailed introduction of PCR.Before expression, can use hi-fi PCR to guarantee loyal DNA copy.In addition, the reliability of amplified production can detect with conventional sequence measurement.Carry the clone of the required sequence of the present invention's introduction, can screen the library with PCR method well known in the art, or obtain (to be seen in as Sambrook, Gritsch and the 2nd edition (1989) cold spring port of Maniatis " molecular cloning: lab guide " and to publish, NY) with the filter hybridization that covers on the oligonucleotide probe of synthetic and library clone or the phage.
Can also from the cDNA library, obtain the nucleic acid of coding helicobacter pylori polypeptide according to the method for introducing here.The cDNA of coding helicobacter pylori polypeptide can obtain by the method for separating whole mRNA from suitable bacterial strain.Double-stranded cDNA can be by obtaining among the mRNA.Subsequently, any one in the available known multiple technologies inserts cDNA in suitable plasmid or virus (for example bacteriophage) carrier.The also available polymerase chain reaction of setting up according to nucleic acid sequence information provided by the invention of gene of coding helicobacter pylori polypeptide is cloned.Nucleic acid of the present invention can be DNA or RNA, and preferred nucleic acid of the present invention is shown in sequence table.
The nucleic acid of the present invention also technology of available standards carries out chemosynthesis.The known method that the synthetic poly-deoxynucleotide of number of chemical is arranged comprises solid-phase synthesis, and this method is synthetic as peptide, can on commercial dna synthesizer, synthesize automatically fully (be seen in as Itakura etc., U.S. Patent No. 4,598,049; U.S. Patent No.s such as Caruther 4,458,066 and Itakufa etc., U.S. Patent No. 4,401,796 and 4,373,071, be hereby incorporated by).
The separation of feature or nucleic acid can be used as such as, but not limited to probe, primer, capture part, antisense gene according to the present invention, and are used to develop protein and the synthetic expression system of peptide corresponding to these sequences.As probe, primer, capture part, antisense reagent, these nucleic acid generally by nucleic acid shown in the sequence table all or part of (be specificity and form stable hybridization product, be about 20 or more nucleotide).
These are applied in more detail below and introduce.
Probe
Separation or nucleic acid according to listed nucleotide sequence in the sequence table can be as the probes that detects helicobacter pylori specifically.Utilize sequence information listed among the application, can identify 20 or the sequence of more a plurality of nucleotide, they can provide required inclusive and removing property information with respect to helicobacter pylori, and the external nucleic acid that may run in the hybridization environment.More preferably, sequence contains 20 to 30 nucleotide at least, makes the hybridization product that forms between probe and the required target molecule have stability.
Length is synthetic very difficult greater than the sequence of 1000 nucleotide, but available recombinant DNA technology production.Those skilled in the art should understand easily, and the nucleic acid that is used as probe can have is convenient to hybridize the mark that product detects.
Separate or synthetic nucleic acid also can be used as probe and adopts the suitable tight hybridization conditions of introducing to detect the homology zone (particularly homologous gene) of other Helicobacterium kind here according to the contained sequence of the present invention of sequence table.
Capture part
For as capturing part, can be easy to link to each other with holder with the top nucleic acid of selecting about the method for probe.The method that nucleic acid is connected with holder is known.The nucleic acid that contains 20 or more a plurality of nucleotide of the sequence of the present invention shown in the ordered list can be used for helicobacter pylori nucleic acid being separated from each other and separating with other organic nucleic acid.The nucleic acid that contains 20 or more a plurality of nucleotide in the sequence of the present invention shown in the ordered list also can be used to other Helicobacterium kind is separated each other and with other organism.Preferably, sequence should comprise at least 20 nucleotide, so that the hybridization product that forms between probe and the required target molecule is stable.Length is difficult to synthesize greater than the sequence of 1000 nucleotide, but the preparation of available recombinant DNA technology.
Primer
Separate or synthetic nucleic acid can be as the primer helicobacter pylori nucleic acid that increases according to the sequence of introducing here.These nucleic acid also can be used as increase nucleic acid in other helicobacter pylorus Pseudomonas kind of primer.About polymerase chain reaction (PCR) technology, the nucleic acid of the present invention shown in the sequence table 〉=10-15 nucleotide can make the copy that is used for producing helicobacter pylori nucleic acid with suitable enzyme and reagent.More preferably, sequence should comprise at least 20 or more nucleotide, and the hybridization product that forms between primer and the required target molecule is stablized.Primer greater than 100 nucleotide obtains specific in conjunction with the very difficult control of condition.Before expression, can guarantee to obtain loyal DNA copy with high-fidelity PCR.In addition, amplified production can detect with traditional sequence measurement.
Copy can be used for detecting special sequence in diagnostic test, comprises the gene from helicobacter pylori and/or other Helicobacterium kind.Copy also can be incorporated into the polypeptide for preparing in clone and the expression vector corresponding to the synthetic nucleic acid of PCR, will be described in detail at this.
Antisense
Can be used as antisense reagent according to the separation of the sequence of introducing or nucleic acid or nucleic acid hybridization derivative here and hinder the helicobacter pylori expression of gene.These sequences also can be used as antisense reagent and hinder other Helicobacterium kind expression of gene.
In one embodiment, nucleic acid or in a kind of appropriate carriers such as liposome or phage, imported bacterial cell by load corresponding to the derivative of helicobacter pylori nucleic acid.For example, one contain 20 or the nucleic acid of more a plurality of nucleotide can combine with bacterial nucleic acid or bacterium mRNA.Preferably, antisensenucleic acids comprise 20 or more nucleotide nucleic acid that non-natural is produced stablize with the hybridization product of bacterial nucleic acid and/or bacterium mRNA.Sequence length is difficult to synthesize greater than the nucleic acid of 1000 nucleotide, but the preparation of available recombinant DNA technology.The antisensenucleic acids load is known in this area in the method for liposome, and example is seen the U.S. Patent No. 4,241,046 that licensed to Papahadjopoulos etc. on December 23rd, 1980.
II helicobacter pylori expression of nucleic acids
Separate or synthetic nucleic acid can be used for preparing polypeptide according to the sequence of introducing here.The nucleic acid of the present invention that the sequence table of coding helicobacter pylori polypeptide active part is lifted or the fragment of said nucleic acid can be cloned in the suitable carriers or be used for isolating nucleic acid.The nucleic acid that separates is connected with suitable DNA joint, and is cloned into appropriate carriers.
The function of special gene or operon can be identified by expressing in a bacterial isolates, under the condition that the special gene product of query gene or operon can be detected specifically.In addition, can prepare gene outcome in a large number in an expression strain comes as antigen, industrial reagent, is used for structural research etc.This expression can or not produce in the bacterial strain of homologous genes product the mutant strain that lacks testing gene and finishes.This includes but not limited to other Helicobacterium bacterial strain and other bacterial isolates such as Escherichia coli, Nocardia, Corynebacterium, the kind of Campylobacter and streptomyces.In some occasion, expressive host can use natural helicobacter promotor, and in other occasions, need drive gene (for example Escherichia coli beta galactosidase promotor is used at expression in escherichia coli) with the promotor that obtains from express organism.
In order to use natural helicobacter pylori promoter expression gene outcome, can use such as following method.Natural promoter element that contains interested to some extent gene and be attached thereto and the restriction fragment of regulating sequence (determining with dna sequence data) are cloned into and are contained replication origin that an energy works and suitably in the suitable recombinant plasmid of selected marker in host's organism.This available multiple method well-known to those having ordinary skill in the art is finished.Most preferred method is a digested plasmid, and the fragment that will clone also cuts to produce compatible termini with identical enzyme, and compatible termini can be connected together two fragments by connecting.Use to transform such as electricity recombinant plasmid is imported host's organism, the cell that contains recombinant plasmid is identified by the mark on the screening plasmid.The expression of required gene outcome detects with the special test of this gene outcome.
The occasion that needs different promotors at gene, entity (coded sequence) specificity cutting with gene, and be cloned in the suitable expression plasmid, this subclone can carry out with several methods, but the easiest method of finishing is, the pcr amplification specific fragment after handling the end that is suitable for cloning with generation with restriction enzyme or exonuclease, is connected in the expression vector.
The host cell that is suitable for gene expression can be any protokaryon or eukaryotic.For example the helicobacter pylori polypeptide can be expressed in bacterium such as Bacillus coli cells, insect cell (baculoviral), yeast or mammalian cell such as Chinese hamster ovary cell (CHO).Other proper host cell is known to one skilled in the art.
Can cause the relevant interchain of partially or completely glycosylation and/or recombinant peptide product or intrachain disulfide bond to form at eukaryotic such as mammal, yeast or expressed in insect cells.The example of expression vector comprises pYepSecl (Bal dari etc. in the brewer's yeast, (1987), " EMBL J " 6 volumes, the 229-234 page or leaf), pMFa (Kurjan and Herskowitz (1982) " cell " 30 volumes, the 933-943 page or leaf), pJRY88 (Schultz etc., (1987) " gene " 54 volumes, 113-123 page or leaf) and pYES2 (Invitrogen Corporation, San Diego, CA).The baculovirus vector that is suitable for expressing protein in the insect cell of cultivating (SF9 cell) comprises pAc series (Smith etc. (1983) " molecular cytobiology " 3 volumes, the 2156-2165 page or leaf) and pVL series (Lucklow, V.A. and Summer, M.D. (1989) " virology " 170 rolled up the 31-39 page or leaf).Usually, COS cell (Gluzman.Y. (1981) " cell " 23 volumes, the 175-182 page or leaf) with such as pCDM8 (Aruffo, A. and Seed, B. (1987) " institute of American Academy of Sciences newspaper " 84 volumes, the 8573-8577 page or leaf) carrier uses together, be used in mammalian cell, carrying out instantaneous amplification/expression, and CHO (dhfr-Chinese hamster ovary) cell is with (Kaufman etc. " EMBO J " 6 roll up such as pMT2PC, the 187-195 page or leaf) carrier uses together, is used for stablizing in mammalian cell amplification/expression.Carrier DNA can transform with the transfection of routine techniques such as calcium phosphate or calcium chloride co-precipitation, the mediation of DEAE-glucan or electricity and import mammalian cell.The visible Sambrook of proper method of transformed host cell etc. (" molecular cloning: lab guide " the 2nd edition, cold spring harbor laboratory publishes (1989)) and other experiment textbook.
In prokaryotes, express generally and in Escherichia coli, carry out with fusion or nonfused inducible expression carrier.Fusion vector adds the NH of some usually in the target gene of expressing 2End amino acid.These NH 2End amino acid is commonly called reporter group.These reporter groups have two purposes: 1) increase the dissolubility of target recombinant protein, 2) in affinity purification, promote the purifying of target recombinant protein as part.Usually in fusion expression vector, introduce a protease cutting site at the joint of reporter group and target recombinant protein, thereby target recombinant protein and reporter group are separated.Such enzyme and relevant recognition sequence thereof comprise Xa factor, fibrin ferment and erepsin.Typical fusion expression vector comprises pGEX ((Amrad Corp., Melbourne, Australia), pMAL (New England BioLabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ), glutathione S-transferase, maltose E merge with the target recombinant protein respectively in conjunction with albumen or albumin A in these carriers.A preferred reporter group is poly (His), and the amino of it and albumen or carboxyl terminal merge, and make recombination fusion protein can use the immobilized metal ion afinity chromatography purifying easily.
Induction type non-fusion expression carrier comprises pTrc (Amann etc. (1988) " gene " 69 volumes, the 301-315 page or leaf) and pET11d (Studier etc. " gene expression technique: Enzymology method " 185 volume, Academic Press, San Diego, California (1990) 60-89 page or leaf).Target gene expression relies on the host RNA polymerase to transcribe from trp-lac heterozygosis promoter, fusion in pTrc, inserts the transcribing from T7gn10-lac0 promoter, fusion of the target gene expression dependence of pET11d by viral rna polymerase (T7ng1) mediation of coexpression.This varial polymerases is provided by the bacteriophage lambda that exists among host strain BL21 (DE3) or the HMS174 (DE3), and this bacteriophage lambda is carrying the T7ng1 under the control of transcribing that places the lacUV5 promotor.
For example, can cultivate under suitable condition with the host cell of the nucleic acid carrier transfection of the nucleotide sequence that instructs coding helicobacter pylori polypeptide and make expression of polypeptides.Polypeptide can be secreted out and separate from the cell that contains peptide and medium mixture.In addition, polypeptide can be retained in the cell, collecting cell, cracking and protein isolate.Cell culture comprises host cell, medium and other accessory substance.The medium that is suitable for cell culture is known in this area.Polypeptide of the present invention can separate from medium, host cell or the mixture of the two with method for purifying proteins well known in the art, and these methods comprise ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and carry out immunoaffinity purification with the special antibody of these peptides.In addition, in many occasions, polypeptide can prepare (as trypsinization) by chemical cracking by native protein, then pyrolysis product available standards technology purifying.
When the situation of embrane-associated protein, by the embrane-associated protein fraction is separated to form the solubility complex with the detergent contact, wherein embrane-associated protein is present in the film fraction no longer fully, can separate from the film fraction with chromatogram thereby can dissolve at least to a certain extent.There are several different standards to be used for selecting to be applicable to the detergent of these complexs of dissolving.For example, the characteristic of a consideration is that detergent makes the helicobacter pylori protein dissolving but make the embrane-associated protein sex change on minimum degree in the film fraction, thereby makes albumen recover the ability of embrane-associated protein activity or function when renaturation.Another characteristic of considering when selecting detergent is the critical micelle concentration (CMC) of detergent, and in this respect, thereby detergent preferably has high CMC value can remove easily after renaturation.The 3rd characteristic of considering when selecting detergent is its hydrophobicity.Generally, embrane-associated protein is highly hydrophobic, and therefore hydrophobic detergent is useful as triton series for solubilizing hydrophobic albumen.Another key property of detergent is that detergent is removed the ability of helicobacter pylori protein with the protein-protein interaction of minimum, thereby is convenient to be further purified.The 5th characteristic that is considered of detergent is the electric charge of detergent.For example, make spent ion exchange resin if desired in purification step, then preferred detergent should be uncharged detergent.The chromatographic technique that can use in final purification step is known in the art, comprises hydrophobic interaction, agglutinin is affine, ion exchange, dyestuff is affine and immune affinity chromatographic.
A strategy of farthest expressing the helicobacter pylori polypeptide in Escherichia coli is expressing protein (Gottesman in the impaired host bacteria of protease hydrolytic cutting recombinant protein ability, S., " gene expression technique: Enzymology method " 185 volumes, Academic Press, San Diego, Carlifonia (1990) 119-128).Another strategy is that the nucleic acid that will be inserted into the coding helicobacter pylori polypeptide in the expression vector changes, thereby the codon that makes the every seed amino acid of coding is the preferential codon (Wada etc. that use in the e. coli protein of high expressed, (1992) " nucleic acids research " 20 volumes, 2111-2118).The DNA synthetic technology of this change available standards of nucleic acid of the present invention is carried out.
Nucleic acid of the present invention is the chemosynthesis of available standards technology also, and the synthetic poly-deoxynucleotide of known chemical has several different methods, comprises solid phase synthesis, this method is synthetic as peptide, and complete useful commercial dna synthesizer carries out (being seen in as, Itakura etc. automatically, United States Patent (USP) NO.4,598,049; Caruthers etc., U.S. Patent No. 4,458,066; And Itakura etc., United States Patent (USP) NO.4,401,796 and 4,373,071, be hereby incorporated by).
III. the helicobacter pylori polypeptide
The present invention includes helicobacter pylori polypeptide, comprise the polypeptide of the present invention shown in the sequence table by the separation of disclosed helicobacter pylori genome sequential coding.Polypeptide length of the present invention is preferably at least 5 amino acid.Here the dna sequence dna information that provides is provided, and the included amino acid sequence of the present invention can be derived with method well known in the art.The sequence that should be appreciated that the complete nucleic acid of coding helicobacter pylori polypeptide is that isolation identification is come on the basis with the ORF that relates to an associated protein coding region part.This can be by such as isolating nucleic acid or its fragment of using coding ORF, be primer, be template with helicobacter pylori genome DNA, carry out polymerase chain reaction and finish, subsequently product order-checking being increased.
Polypeptide of the present invention can from the helicobacter pylorus bacterial cell of wild type or sudden change or from import with allos organism of having expressed helicobacter pylori nucleic acid or cell (including but not limited to bacterium, yeast, insect, plant and mammalian cell) separate.In addition, polypeptide can be the part of recombination fusion protein.
Helicobacter pylori polypeptide of the present invention can be used such as the commercialization automatic synthesis method of introducing here and come chemosynthesis.
IV coding vaccine component and the effectively evaluation of the nucleic acid of the medicament target site of anti-helicobacter pylori
Disclosed helicobacter pylori genome sequence comprises adjusting sequence and the intergenic nucleic acid that instructs the synthetic section of ribonucleic acid and polypeptide and replication initiation zone, promotor, other type.The present invention includes the immunogenicity component and the effective nucleic acid of the target site of the medicament of anti-helicobacter pylori of coding vaccine.This available several different methods of evaluation that relates to the definite immunogenicity component of open functional nucleotide sequence is finished.The nonrestrictive example of these methods briefly introduces below.
The autoploidy of known array: it is useful that computer assisted disclosed helicobacter pylori sequence has the helicobacter pylori nucleic acid of function and peptide sequence with the comparison that is present in the sequence of the former report in the common data base for discriminating.Be to be understood that the sequence of encoding proteins, for instance, should do as a whole comparing, the height homology of two albumen sequence on amino acid levels (for example,＞80-90%) hint that these two albumen also have function autoploidy in a way, for example, for instance, participating between metabolism, DNA is synthetic or cell wall the is synthetic enzyme, and participating between the albumen of transportation, cell division etc.In addition, many architectural features of specific protein family have identified and are relevant with specific consensus sequence, for example, for instance, nucleotide, DNA, metal ion and other micromolecular calmodulin binding domain CaM; The site of covalent modification such as phosphorylation, acetylization etc.; Albumen: the site of protein-interacting etc.These consensus sequences may be very short, and they may only represent the part of the coded sequence of intact proteins like this.Therefore determine in the helicobacter pylori sequence that such feature is very useful for the useful target site of the function of measuring coded albumen and definite antibacterials.
Relevant especially with the present invention, concerning secreting type, stride very common architectural feature film and the surface protein, comprise secreting signal peptide and hydrophobic transmembrane zone.The helicobacter pylori protein contained the burst of inferring by identifying and/or to stride diaphragm area is very useful as the immunogenicity component of vaccine.
The evaluation of indispensable gene: coding is that the nucleic acid of essential protein is preferred drug targets for the growth of helicobacter pylori or survival.The technology of using those skilled in the relevant art to know by checking deletion and/or destroying gene, is promptly used so-called gene " rejecting ", can detect helicobacter pylori gene and this organic biology relation.Can identify indispensable gene in this way.
The bacterial strain specific sequence: owing to the evolutionary relationship between the different helicobacter pylorus bacteria strains, it is believed that the evaluation of helicobacter pylori sequence disclosed herein in the past known and new helicobacter pylorus bacteria strain, and/or differentiate between them, is useful.It is believed that other helicobacter pylorus bacteria strain can show the sequence homology with sequence at least 70% disclosed herein.Dna sequence dna from the sample that contains the helicobacter pylorus bacteria strain is carried out system and conventional analysis, and compare with sequence of the present invention, just can identify the sequence that those can be used for distinguishing different strains, and concerning all helicobacter pylorus bacteria strains, be common sequence.In one embodiment, the invention provides the nucleic acid of distinguishing different helicobacter pylorus bacteria strains, comprise probe, and peptide and peptide sequence.Also available their generations of bacterial strain specificity component can be discerned the antibody of one or more helicobacter pylorus bacteria strains specifically or identify with the ability of these antibody responses.
In another embodiment, the invention provides to all helicobacter pyloris be have but nucleic acid that do not have to find in other bacterium kind comprises probe, and peptide and peptide sequence.
Specific embodiment: the candidate albumen antigen of determining exploitation antibody and vaccine
The candidate albumen antigen of selection exploitation vaccine can come the nucleic acid of own coding helicobacter pylori polypeptide.At first, ORFs is analyzed itself and other the known output or the autoploidy of memebrane protein.And with Klein etc. ((Klein, P., Kanehsia, M. and Delisi, C. (1985), Biophysicaet Biophysica Acta, 815 volumes, 468-476 page or leaf) techniques of discriminant analysis analysis of introducing is sought the output and the memebrane protein of expection.
Homology is retrieved available Wisconsin Sequence Analysis Package (GeneticsComputer Group, University Research Park, 575, Science Drive, Madison, contained BLAST algorithm compares the ORF amino acid sequence of every kind of expection and sequence that all are found at present and carries out in Genebank, SWISS-PROT and PIR database in WI53711).BLAST seeks the part coupling between ORF and the database sequence, and reports a possibility mark, and this fraction representation is found the chance possibility of this sequence in database.Remarkable autoploidy is arranged (as only being lower than 1 * 10 with film or output albumen because of change at random causes the possibility of autoploidy -6) the proteantigen of ORFs representative exploitation vaccine.Based on other organism in the sequence homology of cloned genes, we can expect the possible function of helicobacter pylori.
(Klein etc. above) can be used to check the ORF amino acid sequence in discriminant analysis.This algorithm uses contained internal information in the ORF amino acid sequence, and compares with it and available from the information of known membrane with the feature of output albumen.This comparison can expect which kind of albumen will be output, and combines with film or is present in the born of the same parents.With this algorithm be accredited as output or membrane-bound ORF amino acid sequence be likely the exploitation vaccine proteantigen.
The outer membrane protein that the surface exposes may be represented the best antigen that protective immune response can be provided at helicobacter pylori.The algorithm that can be used for these outer membrane proteins of aid forecasting is included in the C end and has a kind of amphipathic beta sheet zone.This zone is detected in a large amount of outer membrane proteins of Gram-negative bacteria.This regional feature is to have the hydrophobic residue (Phe or Tyr) of cluster (for example, to see Fig. 5, F module (block F) from the convertible position of C end; Fig. 7, the E module).Importantly, these sequences are not detected in periplasm protein.So just can carry out preliminary difference to these protein families based on preliminary sequence data.This phenomenon was by (" molecular biology magazine " 218 volumes, 141-148 page or leaf, 1991) former reports such as Struyve.
Also shown the additional amino acid sequence motif of in many outer membrane proteins of helicobacter pylori, finding among Fig. 5.Amino acid sequence among Fig. 5 is arranged the sequence part (representing with single-letter amino acid code) of having described 5 helicobacter pylori proteins, and they all use its amino acid sequence to indicate for ID number, and shows that from right to left N is terminal to the C end.5 or 6 different similar amino acid residue modules (being marked as A to E or F) are found and contain near the frequent distinctive hydrophobic residue that occurs in the position C of outer membrane protein end (Phe or Tyr are F or Y according to the single-letter code of amino acid residue).The similitude between the member of this albumen family has clearly been determined in the existence of several total primitives.
Separation is arranged from the amino acid of other 4 outer membrane proteins of helicobacter pylori and is shown in Fig. 6.
Separation is from the often total other primitive of the outer membrane protein of helicobacter pylori, two protein of the terminal hydrophobic residue of also total C among described primitive such as Fig. 7 are with the terminal hydrophobic residue primitive of total C among Fig. 8 but shown in two protein of the total different terminal primitives of C.
Those skilled in the art should be known in that these total sequence motifs have important meaning, and has set up a kind of similitude in this family's albumen.
Generally can distinguish multiple possible nucleotide at the given position of nucleotide sequence. shows duality with following squat-shaped handwriting matrix in this case: this is the amino non-C of (A or C) K ketone (G or T) S strong interaction (C or G) W weak interaction (A or T) H non-G (A or C or T) B non-T of non-A (C or G or T) V (non-U) (A or C or G) D (A or G or the T) N of bases G guanine A adenine T thymidine C cytimidine R purine (A or G) Y pyrimidine (C or T or U) M arbitrarily (A or C or G or T) of public IUPAC-IUB single-letter residue code code description
Amino acid of the present invention translation is by being that alphabetical X illustrates the duality in the nucleotide sequence with the duality code translation.On all occasions, by nucleotide sequence is checked that based on standard heredity code the amino acid residue of a position permission all is clearly.
The fragment of V helicobacter pylori nucleic acid and polypeptide and the preparation of analog
Based on the discovery of the helicobacter pylori gene outcome that is provided in the sequence table, those skilled in the art can change disclosed structure (the helicobacter pylori gene), for example, and by preparation fragment or analog, and the activity of the inspection structure that produces.That those skilled in the relevant art know, as can be used for preparing and detecting fragment and analog technology discussion in the back for example, these and similarly method can be used to preparation and screening polypeptide libraries, random peptide library or have for example in conjunction with the fragment of the cell protein of helicobacter pylori polypeptide ability or the library of analog.This screening is useful to the mortifier of identifying helicobacter pylori.
The preparation of fragment
The fragment of albumen can be prepared with several method, for example recombination method, with protease digestion or chemosynthesis.The inside of polypeptide or terminal fragment can prepare by removing one or more nucleotide from the end (preparation terminal fragment) of the nucleic acid of this polypeptide of encoding or two ends (preparation interior segments).The DNA expression of mutagenesis is just produced polypeptide fragment.The DNA that can prepare a series of fragments of encoding with " terminal aggressivity " endonuclease digestion.The DNA of encoding proteins fragment also can be by at random the combination of shearing, restrictive diges-tion or method discussed above prepare.
The also available technology well known in the art of fragment is come chemosynthesis, for example, and traditional Merrifield solid phase f-Moc or t-Boc chemical method.For example, polypeptide of the present invention can be divided into the fragment that does not have the overlapping Len req of fragment arbitrarily, or is divided into the overlapping fragments of Len req.
The change of nucleic acid and polypeptide: random device
The mutagenesis that the amino acid sequence variant of albumen can be undertaken at random by ad hoc structure territory or the regional DNA to encoding proteins or albumen prepares, and available method comprises PCR mutagenesis and saturation mutagenesis.The also available synthetic cover degenerate oligonucleotide sequence in the library of random amino acid sequence variants prepares (method of screening albumen is other local introduction of this paper from a variant library).
(A) PCR mutagenesis
In PCR mutagenesis, Taq enzyme fidelity is lowered to be used for random mutation is introduced the cloned sequence (Leung etc., 1989, " technology " 1 volume, 11-15 page or leaf) of DNA.Use polymerase chain reaction (PCR) the DNA zone that mutagenesis is treated in amplification under the condition of the fidelity that can reduce the DNA that the Taq archaeal dna polymerase synthesize, for example, usage ratio is 5 dGTP/dATP, and adds Mn in PCR reacts 2+The amplification of DNA fragments that mixes is inserted suitable cloning vector the random mutation library is provided.
(B) saturation mutation
Saturation mutation can allow a large amount of single bases is replaced the dna fragmentation (Mayers etc., 1985, " science " 229 volumes, 242 pages) that imports the clone rapidly.This technology comprises, for example external single stranded DNA is carried out chemical treatment or radiation, and synthetic complementary dna chain, produces sudden change.Mutation frequency can be regulated by regulating the degree of handling, and all possible basically base mutation can both obtain.Select because this process does not comprise the heredity of the fragment of suddenling change, the replacement of neutral replacement and change function all can obtain.Conservative sequential element is not partial in the distribution of point mutation.
(C) degenerate oligonucleotide
The homologue library also can be prepared by a cover degenerate oligonucleotide sequence.The chemosynthesis degenerate sequence can carry out on automatic dna synthesizer, then synthetic gene is connected in the suitable expression vector.Degenerate oligonucleotide synthesize in this area be know (be seen in as Narang SA (1983) " tetrahedron " 39 volumes; Itakura etc., (1981) " recombinant DNA progress, the 3rd Cleveland conference, big molecule ", editor AG Walton, Amsterdam; The Elsevier273-289 page or leaf; Itakura etc. (1984) " biochemistry year summary " 53 volumes, 323 pages; Itakura etc. (1984) " science " 198 volumes, 1056 pages; Ike etc. (1983), " nucleic acids research " 11 volumes, 477 pages).These technology have been applied to (being seen in as (1990) " science " such as Scott 249 volumes, 386-390 page or leaf in the orthogenesis of other albumen; Roberts etc. (1992) " institute of American Academy of Sciences newspaper " 89 volumes, the 2429-2433 page or leaf; Devlin etc. (1990) " science " 249 volume 404-406 pages or leaves; Cwirla etc. (1990) " institute of American Academy of Sciences newspaper " 87 volumes, the 6378-6382 page or leaf; And United States Patent(USP) Nos. 5,233,409,5,198,346 and 5,096,815).
The change of nucleic acid and polypeptide: the method for directed mutagenesis
Nonrandom or directed induced-mutation technique can be used for providing the sudden change in special sequence or the special area.These technology can be used for preparing the mutant that comprises such as deletion, insertion or the replacement of the known amino acid sequence residue of protein.Site to be suddenlyd change can be modified separately or series is modified, for example use (1) at first to replace with conserved amino acid, replace with more radical residue according to the result who is obtained then, (2) deletion target residue, or (3) insert the residue of identical or different family in adjacent site, the perhaps combination of option one-3.
(A) alanine scanning mutagenesis
Alanine scanning mutagenesis is a kind of process useful of identifying most preferred sudden change position or zone in desirable proteins, Canningham and Wells (" science " 244 volumes, 1081-1085,1989).In alanine scanning, identified (for example charged residue such as Arg, Asp, His, Lys and Glu) for one or one group in the target residue, and replaced (more preferably alanine or phenyl alanine) by neutrality or electronegative amino acid residue.An amino acid whose replacement can influence in amino acid and the cell and the interaction of extracellular ambient water environment.Be proved to be to replace responsive zone then be used in replace introduce further on the site that the site maybe will replace or the method for other variation in addition accurate.Like this, when a site that is used for importing a variant amino acid sequence was determined in advance, the character of sudden change itself did not need to pre-determine.For example best performance is arranged, can on target codon or zone, carry out alanine scanning or random mutagenesis, in expressed desirable proteins subunit variant, screen the combination that best required activity is arranged then for making at a given site mutation.
(B) oligonucleotide mediated mutagenesis
Oligonucleotide mediated mutagenesis is the process useful of replacement, deletion and the insertion mutant of preparation DNA, is seen in as (" DNA " 2 volumes, 183 pages, 1983) such as Adelman.In brief, required DNA is hybridized with the oligonucleotides of an encoding mutant and a dna profiling and is changed, and wherein template DNA is the plasmid of a unaltered or natural DNA sequence that contains desirable proteins or the single stranded form of phage.After the hybridization, synthesize complete second complementary strand of template with a kind of archaeal dna polymerase.Second complementary strand will be integrated Oligonucleolide primers and be coded in required change among the DNA of desirable proteins.In general, use length to be at least the oligonucleotides of 25 nucleotide.Best oligonucleotides has 12 to 15 nucleotide, and the complete and template complementation on the nucleotide both sides of encoding mutant.This has guaranteed that oligonucleotides hybridizes with the single stranded DNA template molecule rightly.Oligonucleotides can be synthetic easily with technology well known in the art, for example the introduction (" institute of American Academy of Sciences newspaper " 75 rolled up, 5765 pages (1978)) of Crea etc.
(C) cassette mutagenesis
Another kind is used for preparing the method-cassette mutagenesis of variant, and based on the technology (" gene " 34 volumes, 315 pages (1985)) of introductions such as Wells, initial substance is the plasmid (or other carrier) that contains the protein subunit DNA that will suddenly change.The codon that will suddenly change among the protein subunit DNA is determined.Each side in definite mutational site a single restriction site all must be arranged.If there is not this restriction site to exist, just must introduce them in the appropriate site of the DNA of desirable proteins subunit with the oligonucleotide mediated method of mutagenesis of introducing above.After restriction site is introduced into plasmid, plasmid is made it linearisation in these site cuttings.With the dna sequence dna between two restriction sites of standard technique composite coding but contain the double chain oligonucleotide of required mutagenesis.Article two, chain is synthetic separately, hybridizes to together with standard technique then.This double chain oligonucleotide is called as box.This box is designed to have 3 ' and the 5 ' end that is complementary with the linearization plasmid end, and it just can directly be connected with plasmid like this.Plasmid just contains the desirable proteins subunit dna sequence dna of sudden change now.
(D) combinatorial mutagenesis
Combinatorial mutagenesis also can be used to prepare mutant, and (Ladner etc. WO88/06630), arrange the amino acid sequence of one group of homologue or other associated protein in this method, preferably improve its possible highest homology.All amino acid that the given position of listed sequence occurs are selected to produce the composite sequence of a cover degeneracy.The diversified library of variant prepares with the combinatorial mutagenesis on the nucleic acid level, and by a diversified gene library coding.For example, the mixture of synthetic oligonucleotides can be linked in the gene order by enzyme, thereby makes the formal representation of the possible sequence of a cover degeneracy with single peptide.Perhaps, the formal representation that contains the bigger fusion of this cover degenerate sequence with a cover.
Other modification of helicobacter pylori nucleic acid and polypeptide
The structure that can modify the helicobacter pylori polypeptide for following purpose promptly increases solubility, improves stability (resistance being arranged as the outer life-span of extension body with to the protease in the body).Can prepare its amino acid sequence and be changed helicobacter pylori protein or the polypeptide of for example modifying here with the aminoacid replacement of introducing, deletion or interpolation.
The helicobacter pylori polypeptide also can be modified the dimer that reduces through disulfide bond formation by replacing cysteine residues, preferably use alanine, serine, threonine or glutaminic acid residue, in addition, the amino acid side chain of protein fragments of the present invention also can be by chemical modification.The another kind of modification is the cyclisation of peptide.
For increasing stability and/or reactivity, the helicobacter pylori polypeptide comprises one or more polymorphy in can the amino acid sequence by the albumen that produces at any natural allelic variation and modifies.In addition, within the scope of the invention, also available D-amino acid, alpha-non-natural amino acid or non-amino acid analogue replace or add the albumen for preparing modification.And the also available polyethylene glycol of helicobacter pylori polypeptide (PEG) is modified according to A.Sehon and partner's's (Wie etc. above) method and is prepared the albumen that engages with PEG.In addition, can in the chemosynthesis of albumen, add PEG.Other modification of helicobacter pylori protein comprises reduction/alkylation (Tarr; " albumen micro-analysis method " J.E.Silver edits; Humana Press; Clifton NJ 155-194 page or leaf (1986)); acidylate (Tarr; above); (Mishell and Shiigi edit with suitable carrier chemical coupling; " selecting method of cellular immunology " WH Freeman; SanFrancisco, CA (1980), United States Patent (USP) 4; 939; 239); or gentle formalin is handled (Marsh, (1971), Int.Arch.of Allergy and Appl.Immunol; 41 volumes, the 199-215 page or leaf).
For ease of purifying with improve the solubility of helicobacter pylori protein or peptide as much as possible, can on peptide backbone, add an amino acid and merge part.For example, 6 histidines can be added albumen to carry out purifying (Hochuli, E. etc. (1988) " biology/technology " 6 volumes, 1321-1325 page or leaf) with curing metal ion affinity chromatography.In addition, for the ease of separating the peptide that does not contain irrelevant sequence, the restriction enzyme site of specific endo protease can be introduced and merge between part and the peptide.
For helping the suitable antigen processing of epi-position in the helicobacter pylori polypeptide as much as possible, available genetic engineering method is incorporated into the responsive site of the protease of standard between the zone, makes each all contain an epi-position at least with reorganization or synthetic method.For example, charged amino acid is right, as KK or RR, can be introduced between the zone of albumen or fragment in the recombination to construct process.The peptide that is produced will be to the cutting sensitivity of the enzyme of cathepsin or other trypsin-like, thereby produces the protein part that contains one or more epi-positions.In addition, this charged amino acid residue can increase the dissolubility of peptide.
The first level method of screening polypeptide and analog
The known mutator gene product that has several different methods to screen to be produced in this area.The technology of screening a large amount of gene libraries generally includes is cloned into gene library in the reproducible expression vector, transform suitable cell with the vector library that is produced, detecting the required activity expressing gene under the condition that the carrier of the product gene that detects separates that helps encoding, for example, in this example be and helicobacter pylori polypeptide or an interactional protein combination.Every kind of technology introducing below can both be applicable to the high throughput analysis that a large amount of sequences that for example produced by the random mutagenesis technology are screened.
(A) two-hybrid system
The system that the double cross test is for example introduced above (as other screening technique of introducing here), also can be used for identifying polypeptide, for example the helicobacter pylori polypeptide of natural generation such as cell protein or the fragment or the analog of the polypeptide that can combine of generation at random with helicobacter pylori protein.(the helicobacter pylori domain is as bait albumen, and the variant library is expressed as the fish fusion), similarly, double cross test (comparing with other screening technique of introducing here) can be used to seek the polypeptide that can combine with the helicobacter pylori polypeptide.
(B) show the library
In the method for a screening test, candidate's polypeptide is shown in the surface of a kind of cell or virion, and specific cells or virion can detect with one " washing in a pan the sieve test " through the ability that shown product combines with suitable receptor protein.For example, gene library can be cloned in the gene of surface membrane protein of coding bacterial cell, and the fusion that is produced detects (Ladher etc., WO88/06630 by washing in a pan sieve; Fuchs etc. (1991) " biology/technology " 9 volumes, the 1370-1371 page or leaf; And (1992) " TEBS " such as Goward 18 volume 136-140 pages or leaves).Similarly, one can be detected the part of mark can be used for estimating the polypeptide homologue that has function.Fluorescently-labeled part such as acceptor can be used to detect the homologue that has kept ligand-binding activity.The use of fluorescence labeling part makes cell can use visual observation, and separates under fluorescence microscope, perhaps under the condition that cytomorphology allows, is separated by fluorescence-activated cell sorter.
Gene library can fusion formal representation in the surface of virion.For example in the filobactivirus system, the exogenous peptide sequence can be expressed in the surface of infectious phage, and two tangible benefits are arranged like this.At first, since the phagocytosis physical efficiency with much larger than every milliliter 10 13The concentration of phage adds to affinity substrate, and therefore a large amount of phages can once be screened.The second, because each infectious phage all shows a gene outcome on the surface, if specific phage is very low from the output that affinity substrate reclaims, phage is taken turns to infect with regard to available another and increases.Much at one Escherichia coli filobactivirus M13, fd and f1 family are the most frequently used in phage display library.Phage g III or g VIII capsid protein all can be used to produce fusion and the last packing of break virus particle not.Foreign epitope can be expressed in the NH of p III 2End carries the phage of this epi-position and reclaim (Landner etc., PCT publication, WO90/02909 from the phage of this epi-position of shortage of huge amount; Garrard etc., PCT publication WO92/09690; Mark etc., (1992) " biological and chemical magazine " 267 volumes, 16007-16010; Griffths etc. (1993) " EMBOJ " 12 volumes, the 725-734 page or leaf; Clackson etc. (1991) " nature " 352 volumes, the 624-628 page or leaf; Barbas etc. (1992) " institute of American Academy of Sciences newspaper " 89 volumes, the 4457-4461 page or leaf).
(outer membrane protein is LamB) as peptide fusion partners (Charbit etc., (1986), " EMBO J " 5 volumes, 3029-3037 page or leaf) with Escherichia coli maltose acceptor for a common method.Oligonucleotides is inserted in the plasmid of coding LamB gene, produce the peptide in the born of the same parents' outer shroud that is fused to albumen.These peptides can be used to binding partner, as antibody, and can cause immune response after giving animal with cell inoculation.Other cell surface protein, for example (Schorr etc. (1991) " vaccine " 91 roll up OmpA, the 387-392 page or leaf), PhoE (Agterberg etc. (1990) " gene " 88 volumes, the 37-45 page or leaf) and PAL (Fuchs etc. (1991) " biology/technology " 9 volume, 1369-1372 page or leaf) and big bacterium surface structure be used as carrier and carry out peptide and show.Peptide can be integrated into pilin, and pilin is a kind of albumen, and its can polymerization and form the pili pipeline, is used for crossing over inheritance information between bacterium (Thiry etc. (1989) " using and environmental microorganism " 55 volumes, 984-993 page or leaf).Because it is in the effect aspect other cell interaction, pili can provide the support of usefulness to displayed polypeptides in extracellular environment.The another kind of big surface texture that can be used for the peptide demonstration is locomotive organ-flagellum of bacterium.Peptide is fused to the dense arrangement (Kuwajima etc. " biology/technology " 6 volumes, 1080-1083 page or leaf) that flagellin subunit can produce many peptide copies at host cell surface.The surface protein of other bacterium kind also can be used as the peptide fusion partners.Such example comprises the adventitia IgA protease (174 pages of Hansson etc. (1992) " bacteriology magazine ", (1990) " EMBO J " such as 4239-4245 page or leaf and Klauser 9 volume 1991-1999 pages or leaves) of SP and Nai Se Salmonella.
In the above in filobactivirus system of Jie Shaoing and the LamB system, the physics of peptide and its coding DNA is got in touch and is that DNA is contained on its surface and carries in the particle (cell or phage) of this peptide.Capturing peptide is exactly the DNA of trap particles and institute's combination thereof.Another scheme uses DNA to come to form a kind of contact (Cull etc., (1992) " institute of American Academy of Sciences newspaper " 89 volumes, 1865-1869 page or leaf) in conjunction with albumen LacI between peptide and DNA.This system is with a plasmid that contains the LacI gene and an oligonucleotides cloning site is arranged at its 3 ' end.Induce down in check arabinose, produce a LacI-peptide fusion protein.This fusion has kept the natural binding ability of LacI with the dna sequence dna that is called as LacO promotor (LacO) of weak point.Be installed on the expression plasmid by the LacO with two copies, the LacI-peptide fusion protein closely combines with its plasmid of coding.Because plasmid only contains single oligonucleotide sequence in each cell, and each cell only expresses single peptide sequence, and peptide is therefore just special and stably combine with instructing its synthetic dna sequence dna.With the gentle cracking of the cell in storehouse, peptide-DNA compound contacts with the matrix that the curing acceptor is arranged and reclaims the compound that contains active peptide.Then the plasmid DNA of institute's combination transfered cell is again increased, and dna sequence dna checked order the peptide part is identified.As the proof of the method practicality, we have prepared a big storehouse of dodecapeptide at random, and at an enterprising row filter of monoclone antibody that produces with the opioid peptides dynorphin B.One group of peptide is recovered, and (Cull etc., (1992) " institute of American Academy of Sciences newspaper " 89 volumes, 1869 pages) all are connected with a consensus sequence corresponding to the 6 residues part of dynorphin B.
This scheme is also sometimes referred to as the peptide on the plasmid, and is different with phage display technology aspect important at two.At first peptide sticks to the C end of fusion, causes the member in storehouse to be shown as the peptide with free carboxy end.Two kinds of filobactivirus capsid protein p III and p VIII are all passed through its C end anchors due to phage, and exogenous peptide places outside N end structure territory.In some design, the peptide that phage shows just in time is present in the aminoterminal (Cwirla etc., (1990) " institute of American Academy of Sciences newspaper " 87 volumes, 6378-6382 page or leaf) of fusion.Second difference is the peptide colony quantity that influence actually exists in the storehouse that is provided with of biology bias.The LacI fusion molecule is limited in the kytoplasm of host cell.And phage capsid fusion is exposed to kytoplasm momently in translation process, but be secreted in the pericentral siphon chamber very soon by inner membrance, the terminal hydrophobic domains of C that only remains them is anchored on the film, has the N end that contains peptide that stretches in the pericentral siphon, prepares to be installed into phage particle.LacI has tangible difference with peptide in the phage library owing to they are exposed to different proteinase activities.The phage capsid protein need pass the inner membrance transportation, and needs signal peptidase processing as the prelude that is integrated into phage.Some Toplink produces injurious effects to these process, and there be (Callop etc., (1994) " journal of medicinal chemistry " 37 volumes (9), 1233-1251 page or leaf) in minuent in the storehouse.These special bias are not a factor in the LacI display system.
Reorganization is huge with the number of little peptide available in the hangar.Usually preparation 10 7-10 9The library of independent cloning.Having prepared size is the library of 1011 recons, but this size is near the practical limit of clone library.The restriction of this library size results from the step that the DNA that will contain the randomization fragment is transformed into the host bacteria cell.For overcoming this restriction, developed a kind of recently based on the vitro system that in the polysome compound, shows nascent peptide.This display packing is had the ability preparation than the phage/phasmid that obtains at present or the library of the big 3-6 of a plasmid library order of magnitude.And the structure in library, the expression of peptide and screening are carried out under the mode of cell not having fully.
(Gallop etc., (1994) " journal of medicinal chemistry " 37 volumes (9), 1233-1251 page or leaf) made up coding 10 in an application of the method 12The molecular dna library of individual decapeptide, express in the transcribing of the external coupling of an Escherichia coli S30/translation system in the library.Alternative condition is trapped on the mRNA ribosome, makes quite a few RNA accumulate in polysome, and produces and to comprise still the nascent peptide compound that links together with its coding RNA.Polysome is enough stable, and identical mode is carried out affinity purification when screening in the recombinant peptide demonstration library that can be enough with more traditional on the acceptor that solidifies.Reclaim RNA from the complex of combination, change into cDNA, and it is synthetic and screen used template to prepare lower whorl with pcr amplification.The polysome Display Technique can with the coupling of phage display system, through several take turns screening after, will be cloned in the phasmid carrier from the cDNA of the enrichment mixture of polysome.This carrier both can be used as the peptide expression vector and had shown the peptide that is blended in capsid protein, also can be used as the evaluation that the dna sequencing carrier carries out peptide.By on phage, expressing the peptide in polysome source, we can continue affine option program with this pattern, or the combination of peptide in phage E LISA that detects on the single clone is active, or the binding specificity (Barret etc. in stopping phage E LISA, (1992) " biochemistry yearbook " 204 volumes, the 357-364 page or leaf).Be the sequence of identified activity polypeptide, we can check order to the DNA that is produced by phasmid.
The secondary screening of polypeptide and analog
The secondary screening can be then carried out in the test of the high throughput of introducing above, identifies further biologic activity, and for example, this can allow those skilled in the art to distinguish activator and antagonist.The type of used secondary screening will depend on the required activity that needs detection.For example, can develop a kind of like this test, wherein suppress institute protein of interest part and the interactional ability of its respective ligand and can be used to one group of primary screen of introducing from above and choose in the polypeptide fragment that separates and differentiate antagonist.
Therefore, preparation fragment and analog and the method that detects their activity are known in this area.In case interested core sequence is identified that those skilled in the art just can obtain analog and fragment routinely.
The peptide mimics of helicobacter pylori polypeptide
The present invention also provides the protein combination zone of reducing helicobacter pylori polypeptide of the present invention to prepare analogies, for example, and peptide or non-peptide reagent.Peptide mimics can destroy combining of polypeptide and its part when for example the helicobacter pylori polypeptide combines with the part of its natural generation.The helicobacter pylori polypeptide Key residues of the present invention that participates in the molecular recognition of polypeptide can be determined and be used to prepare the polypeptide analogies in helicobacter pylori source, these peptide species analogies competitively or noncompetitive ground suppress the helicobacter pylori polypeptide and combine with the individual interactional polypeptide of one and (see for example European patent application EP-412,762A and EP-B31,080A).
For example, scanning mutagenesis can be used for the amino acid residue mapping to the special helicobacter pylori polypeptide that participates in combining with an interactional polypeptide, can prepare the peptide simulated compound (as diaza _ or isoquinilone derivatives), the residue that these simulated compound simulations combine with interactional polypeptide, and therefore can suppress the helicobacter pylori polypeptide and combine, thereby the function of interference helicobacter pylori polypeptide with interactional polypeptide.The non-water-disintegrable peptide analogues that for example, can prepare these residues with following material: benzodiazepine (is for example seen Freidinger etc., " peptide; Chemistry and biology " G.R.Marshall edits, and ESCOM publishes; Leiden, Netherlands, 1988), azepine _ (for example see Huffman etc., " peptide; Chemistry and biology " G.R.Marshall edits, and ESCOM publishes; Leiden, Netherlands, 1988), the gamma-lactam ring (Garvey etc. the, " peptide that replace; Chemistry and biology " G.R.Marshall edits, and ESCOM publishes; Leiden, Netherlands, 1988), false peptide (the Ewenson etc. of ketone-methylene, (1986) " journal of medicinal chemistry " 29 volumes, " peptides: structure and function " such as 295 pages and Ewenson (the 9th boundary U.S. peptide meeting progress) Pierce Chemical Co., Rockland, IL, 1985), B-corner-dipeptides core (Nagai etc. (1985) " tetrahedron communication " 26 volumes, (1986) " J Chem Soc Perkin Trans " such as 647 pages and Sato 1 volume, 1231 pages) and beta-alkamine (Gordon etc. (1985) " biochemistry biophysics research interchange " 126 volumes, 419 pages; With Dann etc., (1986) " biochemistry biophysics research interchange " 134 volumes, 71 pages).
The bacterin preparation of VI helicobacter pylori polypeptide and nucleic acid
The present invention also describes vaccine combination or the preparation (this paper is used interchangeably) that protection or treatment helicobacter pylori infections are provided for the opposing helicobacter pylori infections in detail.Term used herein " treatment helicobacter pylori infections " refers to be handled the treatment of existing or the helicobacter pylori infections set up.Term " for the opposing helicobacter pylori infections provides protection " or " preventative processing " refer to use helicobacter pylori vaccine preparation might be by the experimenter's of helicobacter pylori infections the infection risk or the generation of protecting from infection to reduce.In one embodiment, vaccine combination contains from one or more immunogenicity components of helicobacter pylori such as surface protein or its part, and a kind of pharmaceutically suitable carrier.For example, in one embodiment, bacterin preparation of the present invention contains at least one helicobacter pylori polypeptide that derives from identical or different Heliobacter pylori antigen or its segment or their associating.The nucleic acid and the helicobacter pylori polypeptide that are used for bacterin preparation of the present invention comprise listed nucleic acid of sequence table and polypeptide, are preferably the helicobacter pylori nucleic acid of coded surface albumen and surface protein or its segment.For example, be used for the preferred nucleic acid of vaccine combination of the present invention and the nucleic acid that the helicobacter pylori polypeptide is selected from coding schedule 1 listed epicyte protein and helicobacter pylori epicyte protein.Yet the nucleic acid of a kind of immunogenicity helicobacter pylori protein of any coding and helicobacter pylori polypeptide or its fragment can both be applied to the present invention.These vaccines have therapeutic and/or preventative purposes.
One aspect of the present invention provides the vaccine combination that helicobacter pylori infections is provided protection, and it contains the immunogenic fragments of at least a helicobacter pylori protein, and a kind of pharmaceutically suitable carrier.Preferred fragment comprises that length is at least the peptide of about 10 amino acid residues, and preferred length is about the 10-20 amino acid residue, and preferred length is about 12-16 amino acid residue.
Immunogene component of the present invention can be with for example obtaining from the recombinate polypeptide of generation of the respective segments screening of the nucleic acid of coding total length helicobacter pylori protein.In addition, fragment can use the Merrifield solid phase f-Moc of technology well known in the art such as routine or t-Boc chemical method to come chemosynthesis.
In one embodiment, the immunogenicity component stimulates the ability of T cell to identify with peptide, and the peptide that stimulates the T cell is by determining such as T cell proliferation or cytokine secretion, can stimulate the peptide of T cell to be restricted at this and contain a t cell epitope at least.T cell epitope it is believed that the initial sum ensured sustained development of participation to the immune response of protein allergen, and allergen causes allergic clinical symptoms.These t cell epitopes may stimulate the T cell subsets with the relevant TXi Baoshouti of epi-position then by combining with the suitable HLA molecule on a kind of antigen presenting cell surface and exciting early stage incident in the t helper cell level.These incidents cause T cell proliferation, lymphokine secretion, local inflammation reaction and cause site and the activation B cell cascade reaction of other immunocyte to antigen/T cell interaction, cause production of antibodies.T cell epitope is the primary element or the least unit of TXi Baoshouti identification, and epi-position contains that acceptor is discerned is essential amino acid (for example, about 6 or 7 amino acid residues).The amino acid sequence of simulation t cell epitope also within the scope of the invention.
In another embodiment, immunogenicity component of the present invention is inoculated by genome and is identified.Basic skills is based on a kind of like this thinking, and promptly the expression library of being made up of all or part of antigen gene group such as helicobacter pylori genome provides protection being used for a kind of host Shi Neng of inherent immunity.This expression library immunization (ELI) is similar to expression cloning, comprises that the genomic expression library with pathogene such as helicobacter pylori imports the plasmid of an energy as genetic vaccine.Plasmid also can be designed to the genetic coding adjuvant, and hereditary adjuvant can stimulate humoral response significantly.These inheritance adjuvants can be introduced into site far away, work in extracellular and cell.
This is a kind of new method for preparing vaccine, has the multiple advantage of alive/attenuated pathogens but the danger that do not have to infect.The expression library of pathogene DNA be used to the immunity host, produce thus live vaccine the antigen submission effect and do not have danger.For example, in the present invention, from the random fragment of helicobacter pylori genome or clay or plasmid clone, and the PCR product that comes free gene order-checking institute genes identified, all can be used for immune host.The feasibility of this method has been used mycoplasma pneumoniae (Barry etc.; " nature " 377 volumes; the 632-635 page or leaf; 1995) prove; even wherein the part expression library of mycoplasma pneumoniae also can provide protection to the immune attack of pathogene, mycoplasma pneumoniae is a kind of natural pathogen of rodent.
The ELI technology allows the noninfective polyvaccine of preparation, even also be so under situation about the biology of pathogene being known seldom, because ELI uses immune system to screen candidate gene.In case after separating, these genes can be used as genetic vaccine or are used for developing recombinant protein vaccine.ELI allows to produce vaccine with system, a large amount of, mechanization mode like this.
Screening immunogenicity component can be finished with one or more different tests.For example, external, the T cell-stimulating activity of peptide is with known or suspiciously analyze for immunogenic peptide contacts in the T cell culture with the antigen presenting cell of the suitable MHC molecule of energy submission.The immunogenicity helicobacter pylori peptide submission that will combine with suitable MHC molecule is given the T cell and in conjunction with necessary secondary stimulus, signal can be passed to the T cell, and the trigger cell factor, particularly proleulzin and the raising of interleukin-4 level.Can obtain the culture supernatant and analyze proleulzin or cell factor that other is known, for example can use in several traditional proleulzins tests any one.For example " institute of American Academy of Sciences newspaper " 86 rolled up, and the test that relative section is introduced in 1333 pages (1989) is hereby incorporated by.(Cambridge, assay kit MA) is analyzed the generation of interferon to also available Genzyme Corporation.
In addition, the conventional test of a T cell proliferation need detect the integration of tritium-labeled thymidine.The propagation of T cell can be used on external test 3The quantity that the thymidine of H mark is incorporated into the repetition DNA of cultured cell detects.Therefore, the synthesis rate of DNA and fissional speed can be measured.
Vaccine combination or the preparation that contains one or more immunogenicity components (for example nucleic acid of helicobacter pylori polypeptide or its fragment or coding helicobacter pylori polypeptide or its fragment) of the present invention preferably comprises a kind of pharmaceutically useful carrier." pharmaceutically suitable carrier " speech desire to comprise can be compatible with using of medicine any and all solvents, dispersion medium, coating agent, antibacterial agent and antifungal agent wait to blend absorption delayer or the like.Suitable pharmaceutically suitable carrier comprises, such as in water, salt solution, phosphate-buffered saline, dextrose, glycerine, the ethanol etc. one or more, and their combination.Pharmaceutically suitable carrier can further comprise minor amounts of auxiliary substances such as moistening or emulsifier, preservative or buffer, and they can improve the storage period or the effect of helicobacter pylori nucleic acid or polypeptide.For the bacterin preparation of the present invention that contains the helicobacter pylori polypeptide, preferred polypeptide is with a kind of suitable adjuvant and/or as herein describedly transport system's administration.
To one skilled in the art, the treatment effective dose that it is evident that DNA of the present invention or albumen depends on, particularly, whether unit dose, albumen or the nucleic acid of treatment sequence, helicobacter pylori nucleic acid or the polypeptide given is with the therapeutic activity of other therapeutic agent administration, patient's immune state and health and specific protein and nucleic acid.
The common parenterai administration of bacterin preparation is for example in injection, the subcutaneous or muscle.Immunization method is by (1990) " science " such as Wolff 247 volumes in the muscle, and (1994) " immunologys " such as 1465-1468 and Sedegah 91 are rolled up, and the 9866-9870 page or leaf is introduced.Other mode of administration comprises oral or lung sucks preparation, suppository and percutaneous drug delivery.With regard to the protective effect of reactance helicobacter pylori, oral immunity is better than the parenterai administration method.Czinn etc. (1993) " vaccine " 11 volumes, the 637-642 page or leaf.Oral formulations comprises normally used excipient, as the mannitol of pharmaceutical grade, lactose, starch, dolomol, saccharin sodium, cellulose, magnesium carbonate etc.
In one embodiment; bacterin preparation can comprise that a kind of adjuvant is as pharmaceutically useful carrier; the example that is used for the proper adjuvant of bacterin preparation of the present invention includes but not limited to aluminium hydroxide; N-acetyl group-muramyl-L-Threonyl-D-isoglutamine (thr-MDP); the N-acetyl group-just-muramyl-L-alanyl-D-isoglutamine (CGP11637; be called positive MDP); the different glutamyl of N-acetyl muramyl-L-alanyl-D--L-alanine-2-(1 '; 2 '-two palmityls-sn-glyceryl-3-hydroxyl phosphoryl-phoryloxy)-ethamine (CGP19835A; be called MTP-PE); RIBI; it contains three kinds of components from bacterium: monophogphoryl lipid A; trehalose dimycodoate; be dissolved in the cell wall skeleton (MPL+TDM+CWS) among 2% shark alkene/Tween80, and cholera toxin etc.Other operable non-toxic derivative that cholera toxin is arranged, the bond or the genetic engineering fusion that comprise its B subunit and/or helicobacter pylori and cholera toxin or its B subunit, prodholeragenoid, fungi polysaccharide, comprise row pleat rhzomorph, muramyl dipeptide, muramyl dipeptide derivative, Buddhist ripple ester, Escherichia coli labile toxin, non-helicobacter pylori bacterial lysate, block polymer or saponin(e.
In another embodiment, bacterin preparation comprises that the system of transporting is as pharmaceutically useful carrier.The system that suitably transports that is used for bacterin preparation of the present invention comprises biodegradable micro-capsule or immunostimulating complex (ISCOMs), the live vector of volute spoon (cochleate) or liposome, genetic engineering attenuation such as virus or bacterium and reorganization (chimeric) virus-like particle are as blue tongue rims.In another embodiment of the invention, bacterin preparation had both comprised that the system of transporting also comprised adjuvant.
The system that transports in the human body can comprise the enteron aisle release capsule; in the sour environment of stomach, protect antigen; comprise the helicobacter pylori polypeptide is included in the insoluble form of fusion that the suitable carrier of vaccine of the present invention is casing capsule and polyactide-glycotide microsphere.Suitable diluent is the NaCO of 0.2N 3And/or salt solution.
Vaccine of the present invention can be used as elementary prevention reagent and carry out administration in adult or children, or in an infected host, successfully removed after the helicobacter pylori protection, or be that purpose is used as healing potion and prevents helicobacter pylori infections with induce immune response in easy receptor as secondary.Vaccine of the present invention carries out administration with the dosage that those of ordinary skill in the art is easy to determine.Like this, for adult's proper dosage at 10 μ g in the scope of 10g, preferred 10 μ g are to 100mg, for example 50 μ g are to 50mg.To the adult, proper dosage also can be at 5 μ g in the scope of 500mg.Similar dosage range also can be used for children.
The amount of used adjuvant depends on the type of used adjuvant.For example, when mucosal adjuvants is cholera toxin, be suitable for using the dosage of 5 μ g to 50 μ g, for example 10 μ g are to 35 μ g.When using with the micro-capsule form, dosage will depend on the amount that reaches required dosage in the microcapsule matrix that is applied in.This dosage fixes within those of ordinary skill in the art's the limit of power really.
It will be understood by those of skill in the art that body weight, disease, method of administration and the other factors of dose,optimum, can increase or reduce according to patient.Those skilled in the art it should also be understood that, the proper dosage level can be based on known oral vaccine for example, such as vaccine (every day, 6mg arrived 540mg altogether) based on the Escherichia coli lysate, antigen (1mg with the enterotoxigenic Escherichia coli purifying, 4 doses) (Schulman etc. " J Urol. " 150 volumes, 917-921 page or leaf (1993); Boedecker etc., American Gastroenterological Assoc.999:A-222 (1993)) result obtains.The quantity of dosage is based on disease, prescription with from the efficacy data of clinical testing.For therapeutic process not being carried out any restriction, treatment can be carried out initial immunity (Boedeker etc., AmericanGastroenterological Assoc.888:A-222 (1993)) by 3 to 8 dosage of administration in one month.
In preferred embodiments, vaccine combination of the present invention can be based on the complete Escherichia coli goods that kill, described goods have the immunogenicity segment at the helicobacter pylori protein of the present invention of its surface expression, perhaps, vaccine combination also can be based on the Escherichia coli lysate, and wherein killed Escherichia coli are worked as carrier or adjuvant.
To one skilled in the art, it is evident that some vaccine combination of the present invention is only useful to preventing helicobacter pylori infections, some is only useful to the treatment helicobacter pylori infections, and some is to preventing and to treat helicobacter pylori infections all useful.In a preferred embodiment, vaccine combination of the present invention provides protective effect to helicobacter pylori infections by activating at the body fluid of helicobacter pylori and/or cell-mediated immunity.Should be appreciated that the alleviation to any helicobacter pylori infections symptom all is required clinical target, comprise and reduce the medical dosage that is used for the treatment of the microbial disease of helicobacter pylorus, or increase the output of antibody in patients serum or the mucous membrane.
The antibody of VII and the reaction of helicobacter pylori polypeptide
The present invention also comprises specifically the antibody with helicobacter pylori polypeptide reaction of the present invention.(be seen in as " antibody, laboratory manual ", Harlow and Lane edit, (publish at the cold spring port, 1988) for the antiserum of anti-albumen/anti-peptide or the preparation of monoclone antibody available standards method.A kind of mammal such as mouse, hamster or rabbit can carry out immunity with the immunogene form of peptide.The technology of giving albumen or peptide with immunogenicity comprises with carrier and combining or other technology well known in the art.The immunogene part of helicobacter pylori polypeptide of the present invention can administration in the presence of a kind of adjuvant.In the immunologic process in available detection blood plasma or the serum method of antibody titer monitor.The ELISA of standard or other immunity test can be with the levels of estimating antibody as the immunogene of antigen.
In a preferred embodiment, antibody of the present invention for the antigenic determinant of helicobacter pylori polypeptide of the present invention as shown in sequence table polypeptide of the present invention or the antigenic determinant of closely-related people or inhuman mammal homologue (for example 90% homology, more preferably at least 95% homology) have immunologic opsonin.In a preferred embodiment of the present invention, helicobacter pylori antibody basically not with the albumen cross reaction (being specific reaction) that for example is lower than 80% with the sequence homology of the present invention shown in the sequence table.The meaning of " not cross reaction basically " is, antibody is lower than and 10% of the binding affinity of the albumen of the present invention shown in the sequence table the binding affinity of non-homogeneous albumen, more preferably less than 5%, more preferably less than 1%.In a preferred embodiment, there is not cross reactivity between bacterium and the mammalian antigen.
Antibody one speech be used for comprising herein its still can with the fragment of helicobacter pylori polypeptid specificity reaction.Antibody can be used the routine techniques fragmentation, can be to be to use the fragment that screening comes with the same mode of the whole antibody of introducing previously.For example, F (ab ') 2Fragment can prepare with trypsin treatment antibody.The F that is produced (ab ') 2Fragment can prepare Fab ' fragment through the reduction disulfide bond.Antibody of the present invention also comprises bispecific and the chimeric molecule with anti-helicobacter pylori part.
At the monoclone antibody and the polyclonal antibody (Ab) of helicobacter pylori polypeptide or helicobacter pylori polypeptide variants, and antibody fragment such as Fab' and F (ab ') 2All can be by anti-helicobacter pylori polypeptide antibody of the present invention be carried out the effect that microinjection is used to block the helicobacter pylori polypeptide, and study specific helicobacter pylori polypeptide of the present invention effect in signal transmission and the normal helicobacter pylori cell function in distortion or harmful cell.
The immunohistochemical staining that can also can be used for tissue sample specifically in conjunction with the antibody of helicobacter pylori epi-position is estimated abundance and collection of illustrative plates that Heliobacter pylori antigen is expressed.The a part of diagnostic ground that the antibody of anti-helicobacter pylori polypeptide can be used as the clinical examination program is used for immunoprecipitation and Western blotting, detect with evaluation of tissue or body fluid in the helicobacter pylori level.Equally, the ability of monitoring helicobacter pylori polypeptide level in the body one by one can be used to determine the effect of a kind of given therapeutic scheme to the individuality that is subjected to this disease and torments.Detect in the cell that the level of helicobacter pylori polypeptide can be found in body fluid such as urine sample, or in tissue as in tissue, detect by stomach biopsy preparation.Use the diagnostic test of helicobacter pylori antibody to comprise, for example, the immunity test of the early diagnosis of helicobacter pylori infections is assisted in design.The present invention also can use specific Heliobacter pylori antigen to come the antibody that contains as in the sample of detection from the individuality of this bacterial infection.
The Another application of anti-helicobacter pylori polypeptide antibody of the present invention is to carry out immunoscreening in the cDNA library in being implemented in expression vector such as λ gt11, λ gt18-23, λ ZAP and λ ORF8.Such courier library has the coded sequence that is inserted into correct open reading frame and correct orientation.It can be used to prepare fusion.For example, λ gt11 can prepare that amino terminal is made up of the beta galactosidase amino acid sequence and fusion that carboxyl terminal is made up of allogenic polypeptide.The epitope available antibodies of helicobacter pylori polypeptide of the present invention then detects, for example, and will be available from the nitrocellulose membrane that infects plate and the antibody response of anti-helicobacter pylori polypeptide.To separate from infecting plate with the phage of this test data sheet then.Like this, just can from other kind, detect and clone helicobacter pylori gene homologue, and other isoform (comprising splice variant) can detected and clone.
VIII contains the kit of nucleic acid of the present invention, polypeptide or antibody
Nucleic acid of the present invention, polypeptide and antibody can be formed kit with other reagent and material.The kit that is used for diagnostic purpose generally contains nucleic acid, polypeptide or the antibody that is sub-packed in tubule or other suitable vessel.Kit generally contains the reagent that is used for carrying out hybridization reaction, polymerase chain reaction (PCR) or freeze-dried component reprovision, for example aqueous medium, salt, buffer solution etc.Kit also contains the reagent that is useful on sample processing, for example detergent, chaotropic salt etc.Kit also can comprise setting tool, as particle, holder, hole, gage etc.Kit also can comprise marking tool such as dyestuff, colour reagent, radioisotope, fluorometric reagent, luminous agent or chemical illuminating reagent, enzyme, intercalator etc.According to nucleic acid that provides here and amino acid sequence information, those skilled in the art can easily assemble kit and be used for their specific purposes, and kit can further comprise operation instruction.
IX is used the drug screening test of helicobacter pylori polypeptide
To be used for the normal cell function be the activator of helicobacter pylori polypeptide of the present invention or their effect of signal conduction in cell or the drug screening test of antagonist at this by preparing the helicobacter pylori polypeptide of available purifying and reorganization, the invention provides.This inhibitor or synergist can be used as new medicine, are used for resisting helicobacter pylori infections at human body.Multiple testing program can be satisfied the demand, and can both be understood by the technical staff according to the present invention.
In the drug screening in many check compounds and natural extract storehouse in the works, all need the high throughput test, make that the compound that detects is maximum in preset time.Experimentizing in as the system from purifying or half purifying protein at cell free system is commonly called " elementary screening ", and they can be used to carrying out quick and relatively easy detection by the change of the molecule target of testing compound mediation.And, the cytotoxicity of testing compound and the influence of biological applicability generally can be ignored in vitro system, the influence of medicine to the molecule target then mainly paid attention in test, and the change of the binding affinity that this can be by molecule target and other albumen or the change of zymetology feature show.Correspondingly, in screening test of the present invention was given an example, compound of interest contacted with a kind of helicobacter pylori polypeptide that separate or purifying.
Screening test can be used a kind of helicobacter pylori polypeptide or its fragment of purifying in external foundation, the helicobacter pylori polypeptide that for example has enzymic activity, and the activity of polypeptide produces a kind of detectable product like this.The available dose-effect curve that obtains available from the data with the testing compound of variable concentrations of the effect of compound is estimated.And also can carry out check experiment provides a comparison base.Suitable product comprises that for example those have the product of light absorption, fluorescence or the chemiluminescent properties that can differentiate, carries out because detect automation easily.Multiple compound synthetic or natural generation can detect in test identifies that those can suppress or strengthen the compound of helicobacter pylori polypeptide active.Some such reactive compounds also can be directly or by chemical modification to improve membrane permeability or dissolubility, come in the helicobacter pylorus bacterial cell of complete work, to suppress or wild phase with activity (for example enzymic activity).
The present invention further describes with the following examples, and these embodiment can not be understood that restriction.All references of quoting in this application and the content of disclosed patent application all are hereby incorporated by.
Embodiment
Clone of I helicobacter pylori and order-checking
The extraction of helicobacter pylori chromosomal DNA is according to 98 pages of Schleif R.F. and Wensink P.C. " molecular biology practical approach ", Springer-Verlag, and NY, the basic DNA operation sequences of 1981 general introductions, and revise a little.In brief, centrifugal collecting cell, (10mM Tris, 1mM EDTA pH7.6), add GES lysis buffer (5.1M sulphur cyanoguanidine, 0.1M EDTA, pH8.0, the acid of 0.5%N-lauryl creatine) to be resuspended in TE.With the suspension cooling, and add ammonium acetate (NH 4Ac) to final concentration 2.0M.Extracting DNA uses chloroform earlier, then uses phenol-chloroform, uses the chloroform extracting again.DNA with isopropanol precipitating, 70% ethanol wash twice, dry, be resuspended in TE.
After extracting the helicobacter pylori complete genome DNA, it is atomized into the medium sized fragment of 2000bp (Bodenteich etc., " DNA automatic sequencing and analysis " (J.C.Venter edits), Academic Press, 1994).After the atomizing, DNA is concentrated, and on 1% Ago-Gel of standard, separate.Downcut several fractions from gel corresponding to the about 900-1300bp of size, 1300-1700bp, 1700-2200bp, 2200-2700bp, and with GeneClean program (Bio101, Inc.) purifying.
Then the dna fragmentation of purifying is used the terminal passivation of T4 archaeal dna polymerase.The doubly excessive single BstX I-joint of the DNA that will make up and 100-1000 is connected then.The pMPX carrier complementation that these joints and BstX I enzyme are cut, and not self complementation of their jag.Therefore, joint can not form concatermer, and the carrier that enzyme is cut also is not easy self connection.The insert that will have joint separates with the joint of not integrating on 1% Ago-Gel, and uses the GeneClean purifying.Then each with 20 kinds of pMPX carriers of the insert of belt lacing is connected, is built into a series of " air gun " subclone library.Carrier contains a LacZ gene outside the frame on cloning site, it becomes in the frame behind joint binary clone, thereby can get rid of by its blue look.
Institute subsequently all rolls up based on Church G.M. and Kieffer-Higgins S. " science " 240 in steps, 185-188 page or leaf, the multiple dnas order-checking programs of 1988 general introductions.Have only big modification just to indicate.In brief, each of 20 kinds of carriers all is transformed into (Gibco/BRL, DH5 α method for transformation) in the bacillus coli DH 5 alpha competent cell.The library is estimated by being laid on the antibiotic flat board that contains ampicillin, heterocyclic group containing and IPTG/Xgal.Flat board is incubated overnight at 37 ℃, and the transformant with success is used to clone bed board and is mixed into multiplex mixture then.The picking clone also is mixed in the 40mL growth medium culture.Culture is 37 ℃ of grow overnight.With Qiagen Midi-prep kit and Tip-100 post (Qiagen, Inc.) purify DNA.In the method, every mixture obtains 100ug DNA.Prepare 15 96 orifice plates that contain DNA and obtain the 5-10 sequence that to have average base reading length be the redundancy of 250-300 doubly.
DNA sample with these purifying checks order according to chemical degradation method (ChurchG.M. and Kieffer-Higgins S. " science " 240 volumes with multiple dna then, the 185-188 page or leaf, 1988) or with Sequithrem (Epicenter Technologies) dideoxy sequencing method check order.(Richerich P. and Church G.M. " Enzymology method " 218 roll up from 40cm glue with sequencing reaction thing electrophoresis and with the method for direct electrophoretic blotting, the 187-222 page or leaf, 1993) transfer on the nylon membrane, or (Church etc. above) carry out with the electroblotting transfer.Every glue runs 24 samples.With the film of 45 successes of chemistry order-checking preparation, with 8 of dideoxy sequencing preparations.Make DNA and film covalent bond by being exposed to uviol lamp, and the oligonucleotide hybridization of having used with the mark of carrier flag sequence complementation (Church above), washes the probe that film is removed non-specific binding, and single ladder is observed in exposure on x-ray film.Behind the radioactive automatic developing, remove the probe of hybridization, use another flag sequence recross process then 65 ℃ of insulations, up to concerning the film of chemistry order-checking, film by with probe hybridization 38 times, and be 10 times to the dideoxy sequencing film.Like this, every glue has all produced a large amount of films, and every film all contains new order-checking information.When any one new trace is operated, initial all join internal standard sequence in each mixture with probe in detecting.
(Molecular Dynamics, Sunnyvale CA) prepare the digital image of film with the laser scanning opacimeter.Digital image is gone up at computer workstation (VaxStation 4000 ' s) and is used program REPLICA TMHandle (Chruch etc., " DNA automatic sequencing and analysis " (J.C.Venter edits), Academic Press, 1994).Image processing comprises that swimming lane is stretching, adjust with contrast and to eliminate strength difference, and simplify with the Gauss of repetition and to improve resolution.Then at REPLICA TMIn automatic picking sequence and showing, before depositing project data in, proofread and correct flexibly.Correction is finished by the rapid visual scanning of film image is made amendment to the base of its calling with the shown band of mouse click then.Many sequence errors can be detected and correct, because the multiple order-checking of covering gene group DNA same section can provide enough sequence redundancies to be used for editor.Each sequence automatically obtains one to be identified number (corresponding to microtiter plate, probe signals and swimming lane are provided with number).This number can be used as the parameter of differentiating sequence, and the specific database of therefore generally can seeking help just can be determined any original particular sequence.
The conventional spread of helicobacter pylori program FALCON TMCarry out (Church, Church etc., " DNA automatic sequencing and analysis " (J.C.Venter edits), Academic Press, 1994).It is rapidly and reliably that this program is proved to be most of sequences.Arrangement contig well shows that with the revision of GelAssemble this program is by GeneticComputer Group (GCG) (Devereux etc., " nucleic acids research " 12 volumes, 387-95 page or leaf, 1984) exploitation, and energy and REPLICA TMCompatible.This just provides a complete editing machine, makes multiple sequencing gel image promptly from REPLICA TMAccess and show, come contig is scanned fast, and the discrepant gel trace of different sequence readings in alignment processes is proofreaied and correct.
Evaluation, clone and the expression of II helicobacter pylori recombinant DNA sequence
For ease of clone, expression and purification film and secretory protein from helicobacter pylori, we selected for use a kind of in Escherichia coli the strong basis of cloning and expression recombinant protein because of expression system, PET system (Novagen).And, the dna sequence dna of coded polypeptide sign one a histidine sign be fused to 3 ' end of dna sequence dna interested so that the purifying of recombinant protein.Select 3 ' end to merge to be change for fear of to any 5 ' terminus signal sequence.An exception of above-mentioned situation is ppiB, and it is one and is cloned as the gene that contrasts in the expression study.In this research, the sequence of helicobacter pylori ppiB contains one and is fused to the dna sequence dna that full-length gene 5 ' terminal coding His indicates, because the protein product of this gene does not contain burst, and is expressed as cytoplasmic protein.
Pcr amplification and clone contain the dna sequence dna of the ORF of film and secretory protein from helicobacter pylori J99 bacterial strain
Preparation is selected to the sequence (for example, being selected from dna sequence dna table of the present invention) of cloning from helicobacter pylori J99 bacterial strain, with polymerase chain reaction (PCR) clone that increases.Design is to reading 5 ' and 3 ' terminal special synthetic oligonucleotide primer thing (table 3) of frame (ORFs), and from GibcoBRL Life Technologies (Gaithersburg, MD, USA) purchase.All forward primers (5 ' end to sequence is special) all are designed to contain a Nco I cloning site at 5 ' least significant end, have only HpSeq.4821082 to use the Nde I.These primers are designed to allow protein translation from methionine, the back is the coded sequence of a valine and remaining natural helicobacter pylori dna sequence dna, has only helicobacter pylori sequence 4821082 to be right after remaining natural helicobacter pylori dna sequence dna in initial methionine back.All reverse primers (3 ' end to any helicobacter pylori ORF is special) all contain an EcoR I site at 5 ' least significant end, thereby each helicobacter pylori sequence all is cloned in the reading frame of pET28b.The sequence (at the C end) that the pET28b carrier provides coding to contain 20 extra carboxyl terminal amino acid (only being 19 amino acid) of 6 histidine residues in HpSeq.26380318 and HpSeq.14640637, this sequence contain the His sign.An exception to above-mentioned situation is said the same with the front, is to be the gene constructed carrier of ppiB.To 5 ' terminal special synthetic oligonucleotide primer thing of ppiB gene in its BamH I site of 5 ' least significant end coding, to 3 ' terminal special primer of ppiB gene then in its Xho I site of 5 ' least significant end coding.
Table 3
The Oligonucleolide primers that is used for helicobacter pylori dna sequence dna pcr amplification
Outer membrane protein Forward primer 5 ' to 3 ' Reverse primer 5 ' to 3 '
Protein 16225006 ?5′-TATACCATGGTGGG ?CGCTAA-3′(SEQ?ID ?NO:147) ?5′- ?ATGAATTCGAGTAAG ?GATTTTTG-3′(SEQ?ID ?NO:148)
Protein 26054702 ?5′- ?TTAACCATGGTGAAA ?AGCGATA-3′(SEQ?ID ?NO:149) ?5′- ?TAGAATTCGCATAAC ?GATCAATC-3′(SEQ?ID ?NO:150)
Protein 7116626 ?5′- ?ATATCCATGGTGAGT ?TTGATGA-3′(SEQ?ID ?NO:151) ?5′- ?ATGAATTCAATTTTT ?TATTTTGCCA-3′(SEQ ?ID?NO:152)
Protein 29479681 ?5′- ?AATTCCATGGTGGGG ?GCTATG-3′(SEQ?ID ?NO:153) ?5′- ?ATGAATTCTCGATAG ?CCAAAATC-3′(SEQ?ID ?NO:154)
Protein 14640637 ?5′- ?AATTCCATGGTGCAT ?AACTTCCATT-3′(SEQ ?ID?NO:155) ?5′- ?AAGAATTCTCTAGCA ?TCCAAATGGA-3′(SEQ ?ID?NO:156)
Pericentral siphon/secretory protein
Protein 30100332 ?5′-ATTTCCATGGTCATG ?TCTCATATT-3′(SEQ?ID ?NO:157) ?5′- ?ATGAATTCCATCTTT ?TATTCCAC-3′(SEQ?ID ?NO:158)
Protein 472106l ?5′-AACCATGGTGATTT ?TAAGCATTGAAAG-3′ ?(SEQ?ID?NO:159) ?5′- ?AAGAATTCCACTCA ?AAATTTTTTAACAG-3′ ?(SEQ?ID?NO:160)
Other surface protein
Protein 4821082 ?5′-GATCATCCATATGTT ?ATCTTCTAAT-3′(SEQ ?ID?NO:161) ?5′- ?TGAATTCAACCATT ?TAACCCTG-3′(SEQ?ID ?NO:162)
Protein 978477 ?5′-TATACCATGGTGAA ?ATTTTTTCTTTTA-3′ ?(SEQ?ID?NO:163) 5′- AGAATTCAATTGCG TCTTGTAAAAG-3′ (SEQ?ID?NO:164)
Inner membrane protein
Protein 26380318 ?5′-TATACCATGGTGAT ?GGACAAACTC-3′(SEQ ?ID?NO:165) 5′-ATGAATTCCCACTT GGGGCGATA-3′(SEQ ID?NO:166)
Cytoplasmic protein
ppi ?5′-TTATGGATCCAAAC ?CAATTAAAACT-3′(SEQ ?ID?NO:167) 5′-TATCTCGAGTTATA GAGAAGGGC-3′(SEQ ID?NO:168)
From helicobacter pylori J99 bacterial strain (ATCC#55679; By the preservation of Genome Therapeutics company, 100 Beaver Street, Waltham, MA 02154) genomic DNA of preparation is used as template DNA source (" molecular biology fresh approach " John Wiley and Sons of pcr amplification reaction, Inc., editors such as F.Ausubel, 1994).The dna sequence dna that contains helicobacter pylori ORF in order to increase is packed genomic DNA (50 nanogram) in the reaction tubule that contains following composition into: 2mM MgCl 2, 1 micromole and the synthetic oligonucleotide primer thing (forward and reverse primer) of specific helicobacter pylori ORF and both wings complementation thereof, every kind of deoxynucleoside triphosphate of 0.2mM be the heat endurance archaeal dna polymerase (Amplitaq of dATP, dGTP, dCTP, dTTP and 2.5 units, Roche Molecular Systems, Inc., Branchburg, NJ, USA), the reaction cumulative volume is 100 microlitres.Use Perkin Elmer Cetus/GeneAmp PCRSystem 9600 thermal cyclers, adopt following thermal cycle conditions to obtain the DNA amplification product of each ORF:
Protein 26054702, protein 7116626, protein 29479681, protein 30100332 and protein 4821082;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 30 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 55 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 23 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
Protein 16225006;
94 ℃ of thermal denaturations 2 minutes;
95 ℃, 15 seconds, 55 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 25 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
Protein 4721061;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 36 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 60 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 23 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
Protein 26380318;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 38 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 62 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 23 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
Protein 14640637;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 33 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 55 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 30 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
The amplification condition of helicobacter pylori ppiB;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 32 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 56 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 25 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
After finishing thermal cycle reaction, with the washing of the DNA sample of each amplification with QiaquickSpin PCR purification kit (Qiagen, Gaithersburg, MD, USA) purifying.All DNA amplification samples restriction enzyme NcoI and EcoRI (New England BioLabs, Beverly, MA, USA), or for HpSeq.4821082 (SEQ ID NO:1309) use Nde I and EcoR I digestion (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994).Then with the DNA sample at 1.0%NuSeive (FMC BioProducts, Rockland, ME, USA) electrophoresis on the Ago-Gel.DNA handled with the pyridine of bromination second and excite and observe with long wave ultraviolet.(Bio 101 Vista, CA USA) carry out purifying to DNA contained from the band that gel separates with Bio 101 GeneClean kits.
The helicobacter pylori dna sequence dna is cloned into the pET-28b prokaryotic expression carrier
PET-28b carrier restriction enzyme Nco I and EcoR I, or use Nde I and the digestion of EcoR I to be prepared for helicobacter pylori protein 4821082 to be used for clone (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994).During ppiB, use the pET-28a carrier the clone, His sign of this vector encoded, this sign can be fused to the 5 ' end that inserts gene, and the cloning site that is used for cloning the ppiB gene prepares with BamH I and Xho I digestion with restriction enzyme.
After the digestion, the DNA insert is cloned into (" molecular biology fresh approach " John Wiley and Sons, Inc. in the pET-28b expression vector that has before been digested, editors such as F.Ausubel, 1994), exception be the amplification insert of ppiB, it is cloned into pET-28a expression vector.Connect product then and be used for transformed into escherichia coli BL21 bacterial strain (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) as follows.
Use the recombinant plasmid transformed competence colibacillus bacterium
The competent cell of e. coli strain bl21 or Escherichia coli DL21 (DE3) bacterial strain transforms (" molecular biology fresh approach " John Wiley and Sons with the pET expression plasmid of the helicobacter pylori sequence of having carried the clone according to the method for standard, Inc., editors such as F.Ausubel, 1994).In brief, with 1 microlitre coupled reaction thing and 50 microlitre electroreception attitude mixing with cells, high voltage in addition then, afterwards, with sample at 0.45 milliliter of SOC medium (0.5% yeast extract, 2.0% tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl 2, 10mM MgSO 4With 20mM glucose) in 37 ℃ of shaken cultivation 1 hour.Then sample is laid on grow overnight on the LB agar plate that contains 25 milligrams/ml kanamycin sulfate.The transformed clone of picking BL21 is also analyzed the insert of estimating the clone as follows then.
Have the evaluation of the reorganization pET expression plasmid of helicobacter pylori sequence
The single BL21 clone who has transformed reorganization pET-28b helicobacter pylori ORFs analyzes with the method for the insert that pcr amplification is cloned, and amplification is used in pcr amplification cloning reaction originally used to every kind of sequence-specific identical forward of helicobacter pylori and reverse primer.Successful amplification just can be verified the integration (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) of helicobacter pylori sequence in expression vector.
From the BL21 transformant, separate and the preparation plasmid DNA
Picking carries the single clone of the reorganization pET-28b carrier of the helicobacter pylori ORFs that contains suitable clone, and is incubated overnight in 5ml is added with the LB meat soup of 25 micrograms/ml kanamycin sulfate.Second day with Qiagen plasmid purification method (CA USA) separates and plasmid DNA purification for Qiagen Inc, Chatsworth.
Helicobacter pylori sequence in the expression in escherichia coli reorganization
PET can breed in any e. coli k12 strain, and for example HMS174, HB101, JM09, DH5 etc. are used for the preparation of clone or plasmid.Expressive host comprises the coli strain of a chromosome copies that contains the T7 rna polymerase gene.These hosts are lysogens of phage DE3, and DE3 is the λ derivative that has carried LacI gene, LacUV5 promotor and T7 rna polymerase gene.The T7 RNA polymerase is induced by adding isopropyl-β-thiogalactoside (IPTG).T7 rna polymerase can be transcribed any target plasmid that has carried T7 promotor and its target gene, for example pET-28b.The bacterial strain that uses comprises: BL21 (DE3) (Studier, F.W., Rosenberg, A.H., Dunn, J.J. and Dubendoff, J.W. (1990) " Enzymology method " 185 volumes, 60-89 page or leaf).
Be express recombinant helicobacter pylori sequence, by as above method with 50 nanograms by as above BL21 (DE3) bacterium (Novagen provides, as the part of pET expression system kit) of the plasmid transformed competence colibacillus of method separation.LacZ gene (beta-galactosidase) is by being presented in the pET system of helicobacter pylori recombination to construct expressed.Cell after transforming was cultivated 1 hour in the SOC medium, culture is laid on the flat board of the kanamycin sulfate that contains 25 micrograms/ml then.Second day, bacterial clump is mixed, and to be incubated at the sulfur acid kanamycin (in the LB medium of 25 micrograms/ml) be 0.5 to 1.0 O.D. unit at the 600nM place to optical density, at this moment, in culture, add 1 mM IPTG and handle the expression of inducing the helicobacter pylori recombinant DNA constructs in 3 hours.
After with the IPTG inducible gene expression, use Sorvall RC-3B centrifuge on 3500 * g, 4 ℃ of centrifugal 15 minutes collection bacteriums.Precipitation is suspended among the ice-cold 10mMTris-HCl of 50 microlitres, pH8.0,0.1M NaCl and the 0.1mM EDTA (STE buffer solution) again.Then that cell is centrifugal 20 minutes 2000 * g, 4 ℃.The weight in wet base of weighing precipitation, and freeze in-80 ℃, in order to protein purification.
III is purification of recombinant proteins from Escherichia coli
Analytical method
The absorption coefficient that the concentration of purifying protein uses amino acid contained calculating to get carries out spectrophotometer measurement (Perkins, S.J., 1986 " european journal of biological chemistry " 157 volumes, 169-180 page or leaf).The also available Bradford of protein concentration, M.M. (1976) " analytical biochemistry " 72 volumes, 248-254 page or leaf and Lowry, O.H., Rosebrough, N., Farr, A.L.﹠amp; Randall R.J. (1951) " biological and chemical magazine " 193 volumes, the method for 265-275 page or leaf is measured, and uses bovine serum albumin(BSA) as standard.
(Hercules, CA USA), and use coomassie brilliant blue staining to SDS-polyacrylamide gel (12% or 4.0 to 25% acrylamide gradient gel) available from BioRad.Molecular weight standard comprises that rabbit skeletal muscle myosin (200kDa), Escherichia coli galactosidase (116kDa), rabbit muscle phosphorylase B (97.4kDa), bovine serum albumin(BSA) (66.2kDa), ovalbumin (45kDa), carbonic anhydrase (31kDa), soybean trypsin inhibitor (21.5kDa), hen egg white lysozyme (14.4kDa) and ox press down enzyme peptide (6.5kDa).
1. the purifying of soluble protein
Institute all carries out at 4 ℃ in steps.Freezing cell is melted, be resuspended in (20mM Tris in the lysis buffer of 5 times of volumes, pH7.9,0.5M NaCl, the 5mM imidazoles, and contain 10% glycerine, the 0.1%2-mercaptoethanol, 200 μ g/ml lysozymes, 1mM phenylmethylsulfonyl fluoride (PMSF), and the leupeptin of 10ug/ml, press down the enzyme peptide, pepstatin, L-1-chloro-3-[4-methyl sulfanilamide (SN)]-7-amino-2-heptanone (TCLK), L-1-chloro-3-[4-methyl sulfanilamide (SN)]-4-benzene-2-butanone (TPCK) and soybean trypsin inhibitor), and several is by microfluidizer (the model M-110S of a small size, Microfluidics InternationalCorporation, Newton, MA).Make the homogenate that is produced contain 0.1% Brij35.And centrifugal 1 hour of 10,000 * g to produce limpid supernatant (thick extract).
With the Supor filter of thick extract by one 0.8 μ m (Gelman Sciences, FRG) after, directly with Ni on the thick extract 2+-nitrolotriacetate-agarose (NTA) post, the bed volume of this post is 5 milliliters of (Hochuli, E., Dbeli, H. and Schacheer, A. (1987) " chromatogram magazine " 411 volumes, the 179-184 page or leaf), in advance with containing 10% glycerine, the lysis buffer balance of 0.1%Brj35 and 1mM PMSF, post is with 10% glycerine that contains of 250ml (50 times of bed volumes), the lysis buffer washing of 0.1%Brj35, and subsequently with containing 10% glycerine, 0.05%Brij35,1mM PMSF and 20,100,200 and the lysis buffer gradient elution of 500mM imidazoles continuous gradient.Use OD 280The absorption value at nm place is monitored each fraction, and the peak value fraction is analyzed with SDS-PAGE.When imidazoles is 100mM, contain the fraction of recombinant protein under the wash-out.
Recombinant protein 14640637 and protein beta galactosidase (lacZ) and peptidyl-propyl cis-trans isomerase (ppiB)
Merging is from Ni 2+The fraction that contains recombinant protein of-NTA-agarose column, then by centrifugal filtration (Centriprep-10, Amicon, MA) this fraction is concentrated into about 5ml, and directly be splined on buffer A (10mM Hepes, pH7.5,150mM NaCl, 0.1mM EGTA) the 180ml post of the Sephacryl S-100 HR gel filtration medium of balance (on 1.6 * 91cm), is washed post with buffer A with the flow velocity of 18ml/h.Absorbance by 280nm is identified and is contained the fraction of recombinant protein and analyze by SDS-PAGE.Collect fraction and concentrate it by centrifugal filtration.
Recombinant protein 7116626
Merging is from Ni 2+The fraction that contains recombinant protein of-NTA-agarose column is to 1 liter of dialysis buffer liquid (10mM MOPS, pH6.5,50mM NaCl, 0.1mM EGTA, 0.02%Brij 351mM PMSF) dialysed overnight.Morning, centrifugally remove thin white depositions, the gained supernatant is splined on buffer B (the 10mM MOPS that contains 50mM NaCl, pH6.5,0.1mM the EGTA) 8ml of balance (8 * 75mm) MonoS high performance liquid chroma-tography post (PharmaciaBiotechnology, Inc., Piscataway, NJ, USA).With 10 times of buffer B column scrubbers that contain 50mM NaCl, launch with raise the gradually linear gradient of (50 to 500mM) of 50ml NaCl concentration to bed volume.When NaCl was 300mM, recombinant protein 7116626 was a spike by wash-out.
2. contain purifying insoluble protein the body from look
Following step is carried out at 4 ℃, and cell precipitation suspends in the lysis buffer that contains 10% glycerine, 200 μ g/ml lysozymes, 5mM EDTA, 1mM phenylmethylsulfonyl fluoride (PMSF), 0.1% mercaptoethanol again.With cell suspension by behind clasmatosis device, make the homogenate of generation contain 0.2 deoxycholic acid, stirred 10 minutes, 20, centrifugal 30 minutes of 000 * g, precipitation is followed with the lysis buffer washing that contains 1M urea, 1mM PMSF and 0.1%2-mercaptoethanol for several times with the lysis buffer washing that contains 10% glycerine, 10mM EDTA, 1%TritonX-199,1mM PMSF and 0.1% mercaptoethanol, the white precipitate that is produced mainly is made up of inclusion body, does not contain not broken cell and membrane substance.
Recombinant protein 26054702,16225006,30100332,4721061
At room temperature carry out the following step.In the lysis buffer that contains 1mM PMSF and 0.1%2-mercaptoethanol, with the inclusion body of 20ml 8.0M urea dissolving purifying, insulation is 1 hour under the room temperature.Centrifugally remove undissolved material, filter limpid supernatant, then supernatant is splined on Ni with the 8.0M urea pre-equilibration in the lysis buffer 2+-NTA-agarose column.Post contains 8M urea with 250ml's (50 times of bed volumes), 1.0mM the lysis buffer of PMSF and 0.1%2-mercaptoethanol washing, and subsequently with containing 8M urea, 1mM PMSF, 0.1%2-mercaptoethanol and 20,100,200 and the lysis buffer gradient expansion of 500mM imidazoles continuous gradient.Use OD 280The absorption value at nm place is monitored each fraction, and the peak value fraction is analyzed with SDS-PAGE.When imidazoles is 100mM, contain the fraction of recombinant protein under the wash-out.
Recombinant protein 29479681,26380318
With containing 8M urea, 1mM PMSF, the buffer B dissolving of 0.1%2-mercaptoethanol contains the sediment of inclusion body, and insulation is 1 hour under the room temperature.By removing undissolved material in centrifugal 30 minutes with 20000 * g, limpid supernatant is splined on containing 6M urea, 1mM PMSF, the 15ml of the buffer B pre-equilibration of 0.1%2-mercaptoethanol is (on 1.6 * 7.5cm) the SP-Sepharose posts.After 10 times of bed volume column scrubbers, use from the linear gradient of 0 to 500mM NaCl and launch post.
The dialysis of protein sample and concentrated
Urea is slowly removed from protein sample and is undertaken by following method, with sample to containing the Tris buffer salt (TBS of 0.5% deoxycholic acid; 10mM Tris, pH8.0,150mM NaCl) dialyse, and urea concentration successively decreases by following: 6M, 4M, 3M, 2M, 1M, 0.5M, use not urea-containing TBS at last.Each is dialysed, and step is at room temperature minimum carried out 4 hours.
After the dialysis, sample concentrates by pressure filtration with the Amicon teeter chamber.Protein concentrated solution Perkins, (1986, " european journal of biological chemistry " 157 volumes, the 169-180 page or leaf), Bradford (1976, " analytical biochemistry " 72 volumes, 248-254 page or leaf) and Lowry (1951, " biological and chemical magazine " 193 volumes, the method for 265-275 page or leaf is measured.
Recombinant protein by the said method purifying is summarized in following table 4.
Table 4
J99 Sequence Identification number Homologue by the Blast evaluation The gene symbol of homologue The bacterial cell fraction that is used for purification of recombinant proteins matter Purification process Relative molecular weight on the SDS-PAGE gel The final concentration of protein purification Buffer solution is formed
Outer membrane protein
16225006 ????P28635 ?YEAC Inclusion body His-Tag ?18kDa ?5mg/ml ????B
26054702 ????P15929 ?flgH Inclusion body His-Tag ?37kDa ?1.18mg/ml ????B
???---- Dried sediment
?7116626 ?P26093 ?e(P4) Soluble fraction ?His-Tag ?29kDa ?0.8mg/ml ????A
?1.85mg/ml ????C
?29479681 ?P13036 ?fecA Inclusion body ???SP- Sepharose ?23kDa ?2.36mg/ml ????B
?0.5mg/ml ????B
???---- Dried sediment
?14640637 ?P16665 ?TPF1 Soluble fraction His-Tag ?17kDa ?2.4mg/ml ????A
Gel filtration S100HR
Pericentral siphon/secretory protein
??3010032 ????P23847 ?dppA Inclusion body His-Tag ?11kDa ?2.88mg/ml ????B
??4721061 ????P36175 ?GCP Inclusion body His-Tag ?38kDa ?2.8mg/ml ????B
Other surface protein
4821082 ?P08089 ???M Inclusion body His-Tag ?20kDa ?1.16mg/ml ????B
978477 ?L28919 ?FBP54 Inclusion body ???SP- Sepharose ?44kDa ?2.56mg/ml ????B
?0.3mg/ml ????B
Inner membrane protein
26380318 ????P15933 ????fliG Inclusion body ????SP- ?Sepharose ?11kDa 22mg/ml ????B
Control protein with His label
????P00722 ????lacz Soluble fraction His-Tag ?116kDa ?10mg/ml ????A
Gel filtration S200HR
????ppiB Soluble fraction His-Tag ?21kDa ?4.4mg/ml ????A
Gel filtration S100HR
Buffer solution is formed
A=10mM?Hepes?pH7.5,150mM?NaCl,0.1mM?EGTA
B=10mM?Tris?pH8.0,150mM?NaCl,0.5％DOC
C=10mM?MOPS?pH6.5,300mM?NaCl,0.1?EGTA
IV is as the analysis of the helicobacter pylori protein of candidate vaccine
Be the immunoregulation effect of research helicobacter pylori, we have used a mouse/helicobacter pylori model.This model has been simulated people's helicobacter pylori infections in many aspects.Focus on the effect of oral immunity in the helicobacter pylori infections animal, thus the notion of check therapeutic oral immunity treatment.
Animal
Female SPF BALB/c mouse is available from Bomholt Bteeding Center (Denmark), and they are raised in common big cage, fully give food and water.These animals are 4-6 age in week when arriving.
Infect
After the process adaptation in a minimum week, with helicobacter pylori (bacterial strain 224 separates from a canker philtrum at first) infection animal of a kind of 2 types (VacA feminine gender).We prove that already this bacterial strain can be settled in the stomach of mouse well.Bacterium is in the brucella broth of having added 10% hyclone, at 37 ℃ of little aerobic environment (10%CO 2, 5%O 2) middle grow overnight.Give the oral Omeprazole of these animals (400umol/kg), and after 3-5 hour helicobacter pylori (about 10 in the oral vaccination meat soup 8The cfu/ animal), after week, in some animals, detect the positive rate that infects at inoculation 2-3.
Antigen
Recombinant helicobacterpylori antigen is selected according to them and export-oriented the getting in touch of helicobacter pylori cell membrane that exposes.Antigen is selected from following family: (1) outer membrane protein; (2) pericentral siphon/secretory protein; (3) outer surface protein; (4) inner membrane protein.All recombinant proteins contain a 6-histidine sign owing to the reason of purifying all is built as.The reference protein of non-helicobacter pylori (colibacillary beta galactosidase; LazZ) also make up by same way as.
All antigen all is soluble form, promptly or be dissolved in the HEPES buffer solution, perhaps is dissolved in the buffer solution that contains 0.5% deoxycholic acid (DOC).
Antigen is listed in the table below 5.
Table 5
Helicobacter pylori protein
Outer membrane protein
Albumen 7116626
Protein 47 21061
Protein 16 225006
Protein 29 479681
Protein 14 640637
Pericentral siphon/secretory protein
Albumen 30100332
Other epicyte protein
Albumen 4821082
The flagellum associated protein
Protein 26 380318
Reference protein
Beta galactosidase (LazZ)
Immunity inoculation
Every group of 10 animals immunity inoculation 4 times (1,15,25 and 35 day) in 34 days.The dosage of the purifying antigen in solution or the suspension is the 100mg/ mouse.As adjuvant, when immune at every turn the administration animal is also given the cholera toxin (CT) of 10ug/ mouse.Before immunity inoculation, gave the oral Omeprazole of animal (400mmol/kg) as preventing that antigen is by a kind of method of acid degradation in 3-5 hour.Infect control animals received HEPES buffer solution+CT or DOC buffer solution+CT.2-4 week is put to death animal after the immunity inoculation the last time.The general general introduction of this research is shown in following table 6.
Table 6
Research overview, therapeutic immunization
Mouse all infected substrate mouse product dosage/mouse administration date at the 30th day with helicobacter pylori strains A h224
System
(n=10) 1. contrast, PBS Balb/c 0.3ml 0,14,24,34 2. cholera toxins, 10ug Balb/c 0.3ml 0,14,24,34 3. protein 16s 225006,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 4. protein 26s 054702,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 5. protein 26s 380318,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 6. protein 29s 479681,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 7. albumen 30100332,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 8. protein 47s 21061,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34 9. albumen 4821082,100ug+CT 10ug Balb/c 0.3ml 0,14,24,3410. albumen 7116626,100ug+CT 10ug Balb/c 0.3ml 0,14,24,3411. protein 14 640637,100ug+CT 10ug Balb/c 0.3ml 0,14,24,34
The analysis of infecting
Mucosal infections: mouse is used CO 2Put to death with disconnected cervical vertebra method, open the abdominal cavity, take out stomach, cut stomach, in salt solution, wash along greater curvature.Scrape 25mm from gastral cavity and body of stomach respectively with surgical knife 2Mucous membrane.The mucous membrane that scrapes is suspended in brucella broth, and is laid on Blood Skirrow selection flat board.Dull and stereotyped under little aerobic condition incubation 3-5 days, and calculate clump count.Helicobacter pylori is proved conclusively with direct sediments microscope inspection or Gram with urease and catalase test.
Urease test is performed as follows basically, and reagent-urea agar base concentrate is available from DIFCOLaboratories Detroit, MI (Catalog#0284-61-3).Urea agar base concentrate water was with dilution in 1: 10, and with the helicobacter pylori mixing with cells of dilution concentrate and the 100-200ul active growth of 1ml, color transfers magenta to and represents that then cell is a urease-positive.
Catalase test is performed as follows basically, and reagent-N, N, N ', N '-tetramethyl-p-phenylenediamine (PPD) be all available from Sigma, St Louis, MO (Catalog#T3134).A kind of solution (1%w/v is in water) of preparation reagent.Scrape the helicobacter pylorus bacterial cell on the Whatman filter paper and cover 1% solution, color transfers dirty-green to and represents that cell is the hydrogen peroxide positive.
Serum antibody: in all mouse, serum is prepared with the blood of cardiac puncture collection.Serum antibody identifies that with conventional elisa technique what wherein spread is the helicobacter pylori specific antigen.
Mucoantibody: in 50% mouse, scrape the privileged site of body of stomach and duodenum 4cm gently, be used for detecting the existence of antibody in the mucous membrane.Antibody titer is measured with conventional ELISA same in the serum antibody.
Statistical analysis: use the Wilcoxon-Mann-Whitneg signed rank sum test to measure the significance effect that antigen is settled down helicobacter pylori, p＜0.05 is considered to have significance, since gastral cavity be helicobacter pylori mainly settle down the site, therefore focus on measuring the change that the chamber is settled down.
The result
Serum antibody: all test antigens with the CT administration have all produced detectable special titre in serum.The highest replying sees albumen 7116626,4721061,26380318,14640637 and 4821082 (see figure 1)s.
Antibody in the mucous membrane: in the mucous membrane that scrapes, can see the specific antibody at all antigens, up to now, the strongest replying sees albumen 30100332, then is 14640637 and 26380318 (see figure 2)s.
The effect of therapeutic immunization:
All control-animals (BALB/c mouse) can both be settled down by helicobacter pylori (strains A H224) in gastral cavity and body of stomach well.In the antigen of all detections, 3 kinds of albumen (protein 47 21061,4821082 and 14640637) can be better and are reduced significantly and/or eliminate helicobacter pylori infections.Compared with the control, behind immunity inoculation albumen 7116626 and 26380318, the degree of settling down of gastral cavity is lower.Protein 16 225006,29479681 and 30100332 influence and contrast indifference.Reference protein LacZ, promptly non-helicobacter pylori protein does not have scavenging action, and in fact with HEPES+CT contrast mutually specific energy more settle down helicobacter pylori in the highland.All data that are dissolved in the albumen of HEPES and DOC are shown in Fig. 3 and Fig. 4 respectively, and data show n=8-10, Wilcoxon-Mann-Whitney signed rank sum test *=p＜0.05 with the form of geometric mean; X/10=shows the mouse number that helicobacter pylori is removed in the sum of all check mouse.
The helicobacter pylori associated protein that shown data show, all these researchs comprise, when using with oral adjuvant CT as the oral immunity source, the stimulation that can both produce immune response, this can measure by specific serum and mucoantibody.Most of albumen can cause the reduction that helicobacter pylori is settled down in this animal model, can cause under certain conditions removing completely.Should be noted that the reason that reduces or remove is allos protection rather than same source protection (polypeptide is used for anti-different inoculated bacteria (AH244) based on helicobacter pylori J99 bacterial strain sequence in therapeutic immunization research).This shows that vaccine has the potentiality of the multiple helicobacter pylorus bacteria strain of opposing.
The highest settling down in gastral cavity sees the animal of handling with non-pylori protein LacZ, and this shows that with the being seen effect of Heliobacter pylori antigen be specific.
These data centralizations are got up, and strong the support is used for a kind of pharmaceutical preparation with these helicobacter pylori proteins, are used for treating and/or prevent helicobacter pylori infections at human body.
The sequence difference analysis of gene in the V helicobacter pylorus bacteria strain
From several helicobacter pylorus bacteria strains, 4 genes are cloned and check order, come comparison dna and deduced amino acid.This information is used to determine that helicobacter pylorus bacteria strain J99 and other separate the sequence difference between patient's helicobacter pylorus bacteria strain.
The preparation of chromosomal DNA
The culture of helicobacter pylorus bacteria strain (as shown in table 9) grows to OD in BLBB (1% tryptone, 1%Peptamin, 0.1% glucose, 0.2% yeast extract, 0.5% sodium chloride, 5% hyclone) 600Be 0.2.In a Sorvall RC-3B centrifuge at 4 ℃ with 3, centrifugal 15 minutes collecting cells of 500 * g, and precipitation is resuspended among 10mMTris-HCL, the 0.1mM EDTA (TE) of 0.95ml, adding lysozyme to final concentration is 1mg/ml, also add SDS to 1%, RNAse+T1 to 0.5mg/ml and 5 units/ml simultaneously respectively, and 37 ℃ of insulations 1 hour.Adding Proteinase K to final concentration then is 0.4mg/ml, and is incubated 1 hour or more at 55 ℃ sample.Add NaCl to concentration 0.65M in sample, careful mixing, and add the 10%CTAB (final concentration is 1%CTAB/70mMNaCl) that 0.15ml is dissolved in 0.7M NaCl is then 65 ℃ of incubations 20 minutes.At this moment, sample chloroform: isoamyl alcohol extracting, with the phenol extracting, use chloroform again: isoamyl alcohol extracting.DNA precipitated at-70 ℃ with ethanol (1.5 times of volumes) or isopropyl alcohol (0.6 volume) in 10 minutes, and with 70% washing with alcohol, and be resuspended in TE.
Pcr amplification and clone
Use the template DNA source (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) of the genomic DNA of 12 helicobacter pylorus bacteria strain preparations as pcr amplification reaction.For amplification contains the dna sequence dna of helicobacter pylori ORF, genomic DNA (10 nanogram) is packed in the reaction tubule that contains following composition: 2mM MgCl 2, 1 micromole and specific helicobacter pylori ORF and both wings complementation thereof synthetic oligonucleotide primer thing (forward and reverse primer, see Table 7), every kind of deoxynucleotide triphosphoric acid of 0.2mM is the heat endurance archaeal dna polymerase (Amplitaq of dATP, dGTP, dCTP, dTTP, 0.5 unit, RocheMolecular Systems, Inc., Branchburg, NJ, USA) the reaction cumulative volume is 20 microlitres, and does two repetitions.
Table 7
The Oligonucleolide primers that is used for pcr amplification helicobacter pylori DNA row
Outer membrane protein Forward primer 5 ' to 3 ' Reverse primer 5 ' to 3 '
Protein 26 054702 (strains A H4, AH15, AH61,5294,5640, AH18, and AH244) ?5′- ?TTAACCATGGTGAAA ?AGCGATA-3′(SEQ?ID ?NO:169) 5′- TAGAATTCGCCTCTA AAACTTTAG-3′(SEQ ID?NO:170)
Protein 26 054702 (strains A H5,5155,7958, AH24, and J99) ?5′- ?TTAACCATGGTGAAA ?AGCGATA-3′(SEQ?ID ?NO:171) 5′- TAGAATTCGCATAAC GATCAATC-3′(SEQ?ID NO:172)
Albumen 7116626 ?5′- ?ATATCCATGGTGAGT ?TTGATGA-3′(SEQ?ID ?NO:173) 5′- ATGAATTCAATTTTT TATTTTGCCA-3′(SEQ ID?NO:174)
Protein 29 479681 ?5′- ?AATTCCATGGCTATC ?CAAATCCG-3′(SEQ?ID ?NO:175) 5′- ATGAATTCGCCAAAA TCGTAGTATT-3′(SEQ ID?NO:176)
Albumen 346 ?5′- ?GATACCATGGAATTT ?ATGAAAAAG-3′(SEQ ?ID?NO:177) 5′- TGAATTCGAAAAAGT GTAGTTATAC-3′(SEQ ID?NO:178)
Use Perkin Elmer Cetus/GeneAmp PCR System9600 thermal cycler, the thermal cycle conditions below adopting obtains the DNA amplification product of every kind of ORF.
Albumen 7116626 and albumen 346;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 30 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 55 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 23 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
The protein 26 054702 of strains A H5,5155,7958, AH24 and J99;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 30 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 55 ℃, 15 seconds, 72 ℃, 1.5 minutes, carry out 25 circulations;
Finish after being reflected at 72 ℃, 6 minutes.
The protein 26 054702 of strains A H4, AH15, AH61,5294,5640, AH18 and Hp244 and protein 29 4796813;
94 ℃ of thermal denaturations 2 minutes;
94 ℃, 15 seconds, 30 ℃, 20 seconds, 72 ℃, 2 minutes, carry out 2 circulations;
94 ℃, 15 seconds, 55 ℃, 20 seconds, 72 ℃, 2 minutes, carry out 25 circulations;
Finish after being reflected at 72 ℃, 8 minutes.
After thermal cycle reaction is finished, with every pair of sample mix.And be used for directly being cloned in the pCR cloning vector according to the method for introducing below.
The helicobacter pylori dna sequence dna is cloned in the pCR TA cloning vector
The insert of all amplifications is all pressed at initial TA clone kit (Invirogen, SanDiego, CA) method of introducing in is cloned into pCR2.1 carrier, then with the coupled reaction product by the following TOP10F ' bacterial strain of introducing transformed into escherichia coli (being INVaF ' when the helicobacter pylori sequence 350).
Use the recombinant plasmid transformed competence colibacillus bacterium
Competence bacteria Escherichia coli bacterial strain TOP10F ' or Escherichia coli INVaF ' are according to the method for standard, reorganization pCR expression plasmid with the helicobacter pylori sequence that has the clone transforms (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994).In brief, the 0.5 micromolar BME adding of 2 microlitres is equipped with in each bottle of 50ul competent cell, then 2 microlitre coupled reaction things are mixed with competent cell, be incubated 30 minutes on ice, then with cell and attachment 42 ℃ " heat shocks " 30 seconds, then placed again 2 minutes on ice, then sample is added 0.45 milliliter of SOC medium (0.5% yeast extract, 2.0% tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl 2, 10mMMgSO 4With 20mM glucose) at 37 ℃ of vibration incubations 1 hour.Then sample is laid on and contains kanamycin 25 micrograms/ml or contain overnight incubation on the LB agar plate of ampicillin 100 micrograms/ml.The conversion bacterium colony of picking TOP10F ' or INVaF ' then, and analyze the insert of estimating the clone by following introduction.
Carry the evaluation of the recombinant PCR plasmid of helicobacter pylori sequence
The method that has transformed the insert that the single TOP10F ' of reorganization pCR helicobacter pylori ORFs or INVaF ' clone clone with pcr amplification is analyzed, and amplification is used in pcr amplification cloning reaction originally used to every kind of sequence-specific identical forward of helicobacter pylori and reverse primer.Successful amplification just can be verified the integration (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) of helicobacter pylori sequence in cloning vector.
Picking has the single clone of reorganization pCR carrier of suitable clone's helicobacter pylori ORF, is used for sequence analysis.Sequence analysis is carried out with standard method (Perkin Elmer) on the ABI sequenator, use the special primer of the carrier shown in the following table 8 (be found in pCRII or pCR2.1, Invitrogen, San Diego, CA) and the sequencing primer special to ORF.
Table 8
The Oligonucleolide primers that is used for the helicobacter pylori dna sequencing
Outer membrane protein Forward primer 5 ' to 3 ' Reverse primer 5 ' to 3 '
Protein 26 054702 ?5′- ?CCCTTCATTTTAGAAATC ?G-3′(SEQ?ID?NO:179) ?5′- ?ATTTCAACCAATTCAAT ?GCG-3′(SEQID?NO:180) ?5′- ?GCCCCTTTTGATTTGAAG ?CT-3′(SEQ?ID?NO:181) ?5′- ?TCGCTCCAAGATACCAA ?GAAGT-3′(SEQ?ID ?NO:182) ?5′- ?CTTGAATTAGGGGCAAA ?GATCG-3′(SEQ?ID ?NO:183) ?5′- ?ATGCGTTTTTACCCAAA ?GAAGT-3′(SEQ?ID ?NO:184) ?5′- ?ATAACGCCACTTCCTTAT ?TGGT-3′(SEQID?NO:185) 5′- CTTTGGGTAAAAACGCA TC-3′(SEQ?ID?NO:186) 5′- CGATCTTTGATCCTAATT CA-3′(SEQ?ID?NO:187) 5′- ATCAAGTTGCCTATGCT GA-3′(SEQ?ID?NO:188)
Albumen 7116626 ?5′- ?TTGAACACTTTTGATTAT ?GCGG-3′(SEQ?ID?NO:189) ?5′- ?GGATTATGCGATTGTTTT ?ACAAG-3′(SEQ?ID ?NO:190) 5′- GTCTTTAGCAAAAATGG CGTC-3′(SEQ?ID?NO:191) 5′- AATGAGCGTAAGAGAGC CTC-3′(SEQ?ID?NO:192)
Protein 29 479681 ?5′- ?CTTATGGGGGTATTGTC ?A-3′(SEQ?ID?NO:193) ?5′- ?AGCATGTGGGTATCCAG ?C-3′(SEQ?ID?NO:194) 5′- AGGTTGTTGCCTAAAGA CT-3′(SEQ?ID?NO:195) 5′- CTGCCTCCACCTTTGATC -3′(SEQ?ID?NO:196)
Albumen 346 5′- ACCAATATCAATTGGCA CT-3′(SEQ?ID?NO:197) 5′- ACTTGGAAAAGCTCTGC A-3′(SEQ?ID?NO:198) 5′- CTTGCTTGTCATATCTAG C-3′(SEQ?ID?NO:199) 5′- GTTGAAGTGTTGGTGCT A-3′(SEQ?ID?NO:200)
5′- CAAGCAAGTGGTTTGGT TTTAG-3′(SEQ?ID?NO:201) 5′- TGGAAAGAGCAAATCAT TGAAG-3′(SEQ?ID NO:202) 5′- GCCCATAATCAAAAAGC CCAT-3′(SEQ?ID?NO:203) 5′- CTAAAACCAAACCACT GCT TGTC-3′(SEQ?ID?NO:204)
The carrier primer 5′- GTAAAACGACGGCCAG- 3′(SEQ?ID?NO:205) 5′- CAGGAAACAGCTATGAC -3′(SEQ?ID?NO:206)
The result
For in these experiments, determining the error rate of PCR, we have prepared 5 independent clones of protein 26 054702 from 5 of helicobacter pylorus bacteria strain J99 independent PCR reactant mixtures, these 5 clones have been carried out the order-checking of total length 897 nucleotide, and accumulative total is the dna sequence dna of 4485 bases altogether.With 5 clones' dna sequence dna with before with diverse ways promptly at random the dna sequence dna that obtained of shotgun cloning and order-checking compared.Here the error rate of the PCR in the experiment of Jie Shaoing is measured as 2 sequence changes in 4485 bases, this is less than or equals 0.04% consistent with estimated.
Dna sequence analysis carries out on 4 kinds of different open reading frame, and these open reading frame have been accredited as gene, and with the acquisition of from 12 kinds of different helicobacter pylorus bacteria strains, increasing of the method for PCR.In the open reading frame that four kinds of these researchs are selected, have three kinds derivation amino acid sequence show with other bacterium kind in the specific protein that exists significant BLAST autoploidy on the statistics is arranged.These ORF comprise: the val A﹠amp of abc transport of encoding in the protein 26 054702, it and F.novicida; The B dna homolog; Albumen 7116626, it be present in lipoprotein e (P4) homology in the bloodthirsty influenza bacterium adventitia; Protein 29 479681, it and fecA homology, fecA is an outer membrane receptor of colibacillary two ironic citrates (III) transportation.Albumen 346 is accredited as unknown open reading frame, because sequence has low-down autoploidy in its demonstration and the public data storehouse.
For the degree of the conservative or difference of estimating between each bacterial strain of helicobacter pylori ORF, the DNA that finds in the protein sequence of the change of dna sequence dna and derivation and helicobacter pylori 99 bacterial strains and the protein sequence of derivation are compared (seeing the following form 9).The result uses with the same percentage of the helicobacter pylori J99 bacterial strain of using shotgun cloning order-checking at random to obtain and represents.In order to control any variation in the J99 bacterial strain sequence, 4 kinds of open reading frame are all cloned from the J99 bacterial isolates again and are checked order once for every kind, and the sequence information that obtains and sequence information with the insert collection of the shotgun cloning at random of J99 bacterial strain compared, digital proof, the scope that makes a variation in the dna sequence dna is 0.12% a difference (albumen 346, the J99 bacterial strain) to about 7% change (protein 26 054702, strains A H5).The protein sequence of deriving shows not have variation (albumen 346, strains A H18 and AH24) or up to 7.66% amino acid change (protein 26 054702, strains A H5).
Table 9
Many bacterial strains dna sequence analysis J99 albumen #:26054702 2,054,702 7,116,626 7,116,626 29,479,681 29,479,681 346 346 order-checking zone lengths of helicobacter pylori vaccine candidate: 248a.a. 746nt. 232a.a. 96nt. 182a.a. 548nt. 273a.a. 819nt. test strain
AA????????Nuc???????AA????????Nuc.???????AA????????Nuc.???????AA???????Nuc.
J99 100.00％ 100.00％ 100.00％ 100.00％ 100.00％ 100.00％ 99.63％ 99.88％AH244 95.16％ 95.04％ n.d. n.d. 99.09％ 96.71％ 98.90％ 96.45％AH4 95.97％ 95.98％ 97.84％ 95.83％ n.d. n.d. 97.80％ 95.73％AH5 92.34％ 93.03％ 98.28％ 96.12％ 98.91％ 96.90％ 98.53％ 95.73％AH15 95.16％ 94.91％ 97.41％ 95.98％ 99.82％ 97.99％ 99.63％ 96.09％AH61 n.d. n.d 97.84％ 95.98％ 99.27％ 97.44％ n.d. n.d.5155 n.d. n.d. n.d. n.d. 99.45％ 97.08％ 98.53％ 95.60％5294 94.35％ 94.37％ 98.28％ 95.40％ 99.64％ 97.26％ 97.07％ 95.48％7958 94.35％ 94.10％ 97.84％ 95.40％ n.d. n.d. 99.63％ 96.46％5640 95.16％ 94.37％ 97.41％ 95.69％ 99.09％ 97.63％ 98.53％ 95.48％AH18 n.d. n.d. 98.71％ 95.69％ 99.64％ 97.44％ 100.00％ 95.97％AH24 94.75％ 95.04％ 97.84％ 95.40％ 99.27％ 96.71％ 100.00％ 96.46％n.d.=
VI determines to can be used as the knock-out experiment method of the essential helicobacter pylori gene of potential treatment target
The treatment target is selected from the gene that its protein product may play a crucial role must cellular pathways.The example of such cellular pathways has that cell membrane is synthetic, DNA synthesizes, transcribes, regulates and control, translates and settle down/virulence.
The part of deletion helicobacter pylori gene/ORF and the insertion mutation of kanamycin resistance cassette revised come (Labigne-Roussel etc. for the technology of essential gene by former reported method to identify pair cell, 1988, " bacteriology magazine " 170 volumes, 1704-1708 page or leaf, Cover etc., 1994, " journal of biological chemistry " 269 volumes, 10566-10573 page or leaf, Reyrat etc., 1995 " institute of American Academy of Sciences newspaper " 92 volumes, the 8768-8772 page or leaf), the result is gene " rejecting ".
The evaluation of helicobacter pylori gene order and clone
Gene or ORF (open reading frame) that selection is used as rejecting target identify from the helicobacter pylori genome sequence, and be used for the primer that design can specific amplification gene/ORF.All synthetic Oligonucleolide primers all are at 0LIGO program (National Biosciences, Inc.Plymouth, MN 55447, design under help USA), and available from Gibco/BRL LifeTechnologies (Gaithersburg, MD USA).If ORF is less than 800 to 1000 base-pairs, the both wings primer is just selected outside open reading frame.
(ATCC 55679 by helicobacter pylori HpJ99 bacterial strain; By the preservation of Genome Therapeutics company, 100 Beaver Street, Waltham, MA 02154) genomic DNA of preparation is used as template DNA source (" molecular biology fresh approach " John Wiley and Sons of PCR (polymerase chain reaction) amplification ORF, Inc., editors such as F.Ausubel, 1994).Prepare genomic DNA from helicobacter pylori, see the embodiment I, pcr amplification carries out as follows, the genomic DNA of 10 nanogram HpJ99 is packed in the reaction tubule that contains following composition: 10mM Tris pH8.3,50mM KCl, 2mM MgCl 2, 2 micromole's synthetic oligonucleotide primer things (forward=F1, reverse primer=R1), every kind of deoxynucleotide triphosphoric acid (dATP, dGTP, dCTP, dTTP) of 0.2mM, the heat endurance archaeal dna polymerase (Amplitaq of 1.25 units, Roche Molecular Systems, Inc., Branchburg, NJ, USA) the reaction cumulative volume is 40 microlitres.PCR uses Perkin Elmer Cetus/GeneAmp System9600 thermal cycler to carry out.
Finish after the thermal cycle reaction, the DNA sample of each amplification is observed (" molecular biology fresh approach " John Wiley and Sons with bromination second pyridine dyeing on the 2%TAE Ago-Gel, Inc., editors such as F.Ausubel, 1994), determine the single product generation from reaction of required size.Then with DNA amplification washing with Qiagen Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA) purifying.
The PCR product is cloned into pT7Blue T-carrier (Catalog#69820-1, Novagen, Inc.Madison, WI USA) with TA clone's strategy (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994).The PCR product is connected in the carrier to mix with 10 nanogram pT7Blue T-carriers (Novagen) by the PCR product with 6 times of molar excess numbers finishes.(MA USA) and the T4 dna ligase (New England BioLabs) of 200 units, connects 16 hours at 16 ℃ for New England BioLabs, Beverly to add 1 microlitre T4DNA ligase buffer solution in 10 microlitre end reaction volumes.
The attachment electricity is transformed (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) change (Clontech Lab., Inc., Palo Alto in competent XL1-Blue or the DH5 α Bacillus coli cells to electricity, CA, USA).In brief, with 1 microlitre coupled reaction thing and 40 microlitre electroreception attitude mixing with cells, and in addition high voltage impacts (25 microfarads, 2.5kv, 200 ohm), then with sample at the SOC of 0.45ml medium (0.5% yeast extract, 2.0% tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl.10mM MgSO 4With 20mM glucose) in 37 ℃ of shaken cultivation 1 hour.Then sample is laid on LB (10g/ rises bacto-tryptone, 5g/ rises bacterium and rises sodium chloride with yeast extract, the 10g/) flat board that contains 100 micrograms/ml ampicillin, 0.3%X-gal and 100 micrograms/ml IPTG.With these flat boards 37 ℃ of incubated overnight.Select albescent amicillin resistance bacterium colony, in 5ml contains the liquid LB of 100 micrograms/ml ampicillin, cultivate.And with Qiagen preparation method (Qiagen, Gaithersburg, MD, USA) isolated plasmid dna in a small amount.
For the helicobacter pylori DNA insert of justifying is cloned,, and use used identical forward and the reverse primer of initial amplification J99 helicobacter pylori sequence with the template of these pT7Blue plasmid DNA as pcr amplification clone's insert.Observing the primer and the PCR product of correct size on the Ago-Gel of 2%TAE, bromination second pyridine dyeing is cloned with regard to provable correct insert.Reject target by each and obtain 2 to 6 this certified clones, and be stored in-70 ℃.For reducing the mistake of PCR, these plasmid DNA that are proved the clone are mixed, and be used for clone's step of back.
The sequence that reuses gene/ORF designs second pair of primer, and the 2nd pair of primer is positioned the both wings in the helicobacter pylori DNA zone of ORF inside corrupted or deleted (can reach 250bp), but direction is opposite mutually.The mixture of the ring-like plasmid DNA of front separating clone is taken turns the template of PCR as this, since this to the deletion primer the amplification direction towards rightabout, ORF part between primer will not be included in the PCR product that is produced, the PCR product is one section linear DNA, two ends are helicobacter pylori DNA, it between them the pT7Blue carrier framework, just can produce the part deletion of ORF so in principle, on the Ago-Gel of 1%TAE, smelling second pyridine dyeing, observe the single product that the PCR product proves the correct size that increased.
With the TA cloning process that adopts previously (" molecular biology fresh approach " John Wiley and Sons, Inc., editors such as F.Ausubel, 1994) with a kanamycin resistance cassette (Labigue-Roussel etc., (1988) " bacteriology magazine " 170 volumes, the 1704-1708 page or leaf) be connected in this PCR product.The EcoRI of the kanamycin box that contains a campylobacter kalamycin resistance gene by recombinant plasmid pCTB8:kan (Cover etc., " journal of biological chemistry " 269 volumes, 10566-10573 page or leaf) digests and obtains.Suitable fragment (1.4kb) is separated on the 1%TAE gel and (MD USA) separates for Qiagen, Gaithersburg with QIAquick gel extraction agent box.Mend flat method with Klenow this fragment is carried out end reparation, this comprises the 4ugDNA fragment is mixed with the big fragment (New England Biolabs) of Klenow dna polymerase i (Klenow) of dATP, dGTP, dCTP, dTTP, 2 microlitre Klenow buffer solutions (New England Biolabs) and 5 units of 1 microlitre 0.5mM, the reaction cumulative volume is 20 microlitres, 30 ℃ of insulations 15 minutes, made enzyme deactivation in 10 minutes 75 ℃ of heating then.(MD USA) carries out purifying to remove nucleotide for Qiagen, Gaithersburg by a QIAquick post with the kanamycin box of terminal passivation then.Then with the kanamycin box of the terminal passivation of 5 micrograms and 10mM Tris pH8.3,50mM KCl, 2mM MgCl 2, 5 units archaeal dna polymerase (Amplitaq, Roche Molecular Systems Inc.Branchbury, NJ, USA), the 5mM dTTP of 20 microlitres mixes, the reaction cumulative volume is 100 microlitres, 37 ℃ of reactions 2 hours, it was outstanding to produce " T ".(MD USA) carries out purifying to " Kan-T " box for Qiagen, Gaithersburg with the QIAquick post.Deletion primer (F2 and R2) PCR product is connected with the Kan-T box by the following method: Kan-T box DNA, 1 microlitre, 10 * T4DNA coupled reaction mixture, 0.5 microlitre T4 ligase (the New England BioLabs of deletion primer PCR product 10-25 nanogram and 50-75 nanogram, Beverly, MA, USA) mix, the reaction cumulative volume was 10 microlitres, 16 ℃ of incubations 16 hours.
Connecting product is transformed in XL1-Blue or the DH5 α Bacillus coli cells by the electric method for transformation of introducing previously.After in SOC, reclaiming, cell is laid on the LB flat board that contains 100 micrograms/ml ampicillin, 37 ℃ of grow overnight.Then copy on the flat board that contains 25 micrograms/ml kanamycin these flat boards and grow overnight.The bacterium colony that is obtained has the ampicillin resistance gene on the pT7Blue, and contains the kalamycin resistance gene of new introducing.Bacterium colony is chosen among the LB that contains 25 micrograms/ml kanamycin, and with Qiagene preparation method (Qiagen, Gaithersburg, MD, USA) isolated plasmid dna in a small amount.
These plasmids are carried out the several test with pcr amplification confirm that kanamycin has been inserted into helicobacter pylori gene/ORF, and definite kalamycin resistance gene is with respect to the direction of insertion of helicobacter pylori gene/ORF.For confirming that the kanamycin box has inserted the helicobacter pylori sequence, plasmid DNA is used as the template of pcr amplification, and primer is right with the primer that was used to clone helicobacter pylori gene/ORF originally.Correct PCR product is the size of deletion gene/ORF, but has increased by one the 1.4 right kanamycin box of kilobase.For preventing the potential polar effect of kanamycin resistance cassette in helicobacter pylori gene expression, determine kalamycin resistance gene with respect to the direction of rejecting gene/ORF, and the insert of two kinds of directions all is used for helicobacter pylori conversion (as follows) the most at last.Be the direction of determining that kalamycin resistance gene inserts, by the two ends design primer (" Kan-1 " 5 '-ATCTTACCTATCACCTCAAAT-3 ' (SEQ ID NO:207) and " Kan-2 " 5 '-AGACAGCAACATCTTTGTGAA-3 ' (SEQ ID NO:208)) of kalamycin resistance gene.By using each clone's primer and each Kan primer (four kinds of combinations of primer), the kanamycin box is determined with respect to the direction of helicobacter pylori sequence.Positive colony is divided into " A " direction (helicobacter pylori gene and kalamycin resistance gene are at same transcriptional orientation), or " B " direction (transcriptional orientation opposite of helicobacter pylori gene and kalamycin resistance gene).The clone (A or B) that will have equidirectional mixes, and transforms helicobacter pylori respectively independently.
Plasmid DNA is transformed into helicobacter pylorus bacterial cell
Two helicobacter pylorus bacteria strains are used to transform: ATCC55679 and AH224.ATCC 55679 is clinical separation strains that the DNA that has obtained the helicobacter pylori sequence library can be provided, and AH224 is the separated strain that is admitted to and can be settled in the mouse stomach.Be used for cell transformed at 37 ℃, 10%CO 2, under 100% humidity or growing on the sheep blood agar plate or in brucella broth liquid.Cell grows to exponential phase, and microscopy determines that cell is " health " (active cell) and pollution-free, if on flat board, grow, scrape cell with asepsis ring from flat board and come collecting cell, be suspended in the 1ml brucella broth, centrifugally get off (1 minute, eppendorf centrifuge the most at a high speed), and be resuspended in the 200ul brucella broth.If in brucella broth liquid, grow, centrifuge cell (with Beckman TJ6 centrifuge centrifugal 15 minutes of 3000rpm), cell precipitation is resuspended in 200 microlitre brucella broths, gets 1 aliquot cell and determine optical density, be used for calculating the concentration of cell at the 600nm place.With 1 aliquot (1 to 5 OD 600Unit/25 microlitres) re-suspended cell is laid on the sheep blood agar plate of preheating, and is dull and stereotyped at 37 ℃, 6%CO 2, further cultivated 4 hours under 100% humidity, behind the incubation, 10 microlitre plasmid DNA (100 mcg/ml) are added these cells.Also do a positive control (having the plasmid that the ribonuclease H gene is interrupted by kanamycin gene) and a negative control (plasmid-free DNA) simultaneously.Flat board is again at 37 ℃, 6%CO 2Following continuation was cultivated 4 hours, with a cotton swab that in brucella broth, soaks cell spread out on flat board then, and at 37 ℃, 6%CO 2Under grew 20 hours, bacterium is gone on the sheep blood agar plate that contains 25 micrograms/ml kanamycin then, and at 37 ℃, 6%CO 2, cultivated 3 to 5 days under 100% humidity.If there is bacterium colony to occur, it is chosen, make it containing on the fresh sheep blood plate of 25 micrograms/ml kanamycin growth in flakes.
Carry out three cover PCR (three tests) and confirm that these transform bacterium colony is to be produced by the homologous recombination on suitable chromosomal foci.The template of PCR (from the DNA of bacterium colony) obtains with the following preparation method that boils fast.In the solution that contains 1%Triton-X-100,20mM Tris, pH8.5 with an aliquot bacterium colony (getting) 100 microlitres of packing into the toothpick point, and boiled 6 minutes, add isopyknic phenol: chloroform (1: 1), and vibration shakes up, with centrifugal 5 minutes of mixture, supernatant uses the combination of following primer simultaneously as the dna profiling of PCR, confirms the homologous recombination at suitable chromosome position.
TEST1 PCR uses and to be used for clone's primer of amplification gene/ORF at first.Positive findings in correct chromosome position generation homologous recombination should show a single PCR product, and the size of this product should be that the deletion gene/ORF of expection adds the size of 1.4 kilobase to the kanamycin box.The PCR product is just in time for the size of gene/ORF then proves, gene is not disallowable, and transformant is not the result in correct chromosome position homologous recombination.
TEST2 uses F3 (by the primer of the sequences Design of gene/ORF upstream, be not present on the plasmid) and primer Kan-1 or Kan-2 (by the tip designs of kalamycin resistance gene), it is " A " or " B " direction that the selection of Kan-1 or Kan-2 is based on used plasmid DNA.The positive findings of the homologous recombination on the chromosome tram should show the PCR product of a single expection size (promptly from the position of F3 to the insertion site of kalamycin resistance gene).The PCR product of no PCR product or different sizes proves that plasmid is not incorporated into correct site, and this gene is not disallowable.
TEST3 uses R3 (primer by the downstream sequence design of gene/ORF is not present on the plasmid) and Kan-1 or Kan-2, and it is " A " or " B " direction that the selection of Kan-1 or Kan-2 is based on used plasmid DNA.Homologous recombination on the chromosome tram should produce the PCR product of a single expection size (promptly from the insertion position of kalamycin resistance gene to the downstream position of R3).Equally, the PCR product of no PCR product or different sizes proves that plasmid is not incorporated into correct site, and this gene is not disallowable.
Any transformants to all three the test demonstration positives all can be reached a conclusion, and the external existence of this gene pairs is optional.
Above-mentioned three any one negative findingses of test to each transformant all can be reached a conclusion, and this gene is not interrupted, and the external survival of this gene pairs is essential.
Two independently conversion test all do not have bacterium colony, and can produce under the situation of transformant with the ribonuclease H plasmid DNA that interrupts, before bed board is used for bacterium colony and forms, with PCR to further analyzing from the plasmid DNA of the DNA of transformant colony, confirm that plasmid can enter cell, and can form homologous recombination in correct site, in brief, according to above-mentioned method for transformation incubation plasmid DNA, extracting DNA from cell immediately behind plasmid and helicobacter pylorus bacterial cell incubation, and with the template of DNA as above-mentioned TESE2 and TEST3, the positive findings of TEST2 and TEST3 will confirm, plasmid DNA can enter cell and in chromosomal tram homologous recombination, if TEST2 and TEST3 are positive, but the transformant that all can not obtain to survive shows that then gene is essential, if this gene is destroyed, cell just can not form bacterium colony.
VII. the drug screening test of high throughput
Clone, expression and protein purification
Basically carry out helicobacter pylori target gene and protein thereof used in the drug screening test of high throughput by above embodiment II and III are described,, transform, express and purifying as the clone of helicobacter pylori enzyme.Special helicobacter pylori gene outcome has hereinafter been described, the development and application of peptidyl-propyl cis-trans isomerase screening test in the specific embodiment.
Enzymatic determination
The mensuration of enzyme is carried out (Fisher etc., 1984, " Biomed.Biochim.Acta " 43 volumes, 1011-1111 page or leaf) by the method that Fisher introduces basically.This experimental measurement is in test peptides N-succinyl-Ala-Ala-Pro-Phe-paranitroanilinum (Sigma#S-7388, lot#84H5805) cis-trans isomerism of middle Ala-Phe key.This test and alpha-chymotrypsin coupling, wherein to occur over just Ala-Phe be under the trans situation to the protease cracking test peptides.In test, then on Beckman Model Du-650 spectrophotometer, observe after test peptides being converted into transisomer at the 390nm place.Using average sweep time is to collect the data of each second in 0.5 second.Analysis is carried out in 35mM HEPES, pH8.0, and the reaction cumulative volume is 400 microlitres, and contain 10uM alpha-chymotrypsin (from the 1-5 type of little Pancreas Bovis seu Bubali, Sigma#C-7762, lot23H7020) and 10nM PPIase.When the reaction beginning, at room temperature 10ul substrate (the N-succinyl-Ala-Ala-Pro-Phe-paranitroanilinum among the 2mM DMSO) is joined in the 390ul reactant mixture.
Enzymatic determination in the thickness bacterium extract
From 50ml exponential phase (OD 600～1) collect bacterium in the brucella broth culture of helicobacter pylori (bacterial strain J99), and be resuspended in the lysis buffer that contains following protease inhibitors: 1mM PMSF and each 10ug/ml press down enzyme peptide, pepstatin, leupeptin, TCLK, TPCK and soybean trypsin inhibitor.Suspension multigelation (70 ℃ 15 minutes, at room temperature 30 minutes then) three times, ultrasonication then (3 20 seconds impact).Centrifugal lysate (12,000g * 30 minute) and the enzymic activity of pressing the said determination supernatant.
Escherichia coli can be with the helicobacter pylori enzyme of a lot of activity forms of high level expression.This high yield of protein purification can be used for designing a plurality of high throughput drug screening tests.
Statement of equal value
Those skilled in the art should know or just can determine the specific embodiment that this paper introduces and the many equivalent method and the product of method by normal experiment that they are also contained in the following claim scope.
Sequence table 1) physical data: (ⅰ) applicant:
(A) name: Astra Aktiebolag
(B) street: S-151 85
(C) city: Sodertalje
(D) state:
(E) country: Sweden
(F) postcode: (ⅱ) denomination of invention: helicobacter pylori associated nucleic acid and amino acid sequence
And vaccine combination (ⅲ) sequence number: 208 (ⅳ) computer-reader form:
(A) media type:
(B) calculator:
(C) operating system:
(D) software: (ⅴ) present application materials:
(A) application number:
(B) applying date: (ⅵ) application materials formerly:
(A) application number: US 08/739,150
(B) applying date: 28-OCT-1996 (ⅶ) is application materials formerly:
(A) application number: US 08/759,739
(B) applying date: 06-DEC-1996 (ⅷ) is application materials formerly:
(A) application number: US 08/891,928
(B) applying date: 14-JULY-1997 (ⅸ) mailing address:
(A) contact person: LAHIVE ﹠amp; COCKFIELD
(B) street: 28 State Street
(C) city: Boston
(D) state: Massachusetts
(E) country: the U.S.
(F) postcode: 02109-1875 (ⅹ) agent/act on behalf of data:
(A) name: Mandragouras, Amy E.
(B) registration number: 36,207
(C) data/number of documents: GTN-001CP10PC (ⅹ ⅰ) communications data:
(A) phone: (617) 227-7400
(B) fax: the data of (617) 742-4214 (2) SEQ ID NO:1: (ⅰ) sequence signature:
(A) length: 561 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..561 ( ⅹⅰ ) ：SEQ ID NO:1:ATGATTAAAA GAATTGCTTG TATTTTAAGC TTGAGCGCGA GTTTAGCGTT AGCTGGCGAA 60GTGAATGGGT TTTTCATGGG TGCGGGTTAT CAACAAGGTC GTTATGGCCC TTATAACAGC 120AATTACTCTG ATTGGCGTCA TGGCAATGAC CTTTATGGTT TGAATTTCAA ATTAGGTTTT 180GTAGGCTTTG CCAATAAATG GTTTGGGGCT AGGGTGTATG GCTTTTTAGA TTGGTTTAAC 240ACTTCAGGGA CTGAACACAC CAAAACCAAT TTGCTCACCT ATGGCGGCGG TGGCGATTTG 300ATTGTCAATC TCATTCCTTT GGATAAATTC GCTCTAGGTC TCATTGGTGG CGTTCAATTA 360GCCGGAAACA CTTGGATGTT CCCTTATGAT GTCAATCAAA CCAGATTCCA GTTCTTATGG 420AATTTAGGCG GAAGAATGCG TGTTGGGGAT CGCAGTGCGT TTGAAGCGGG CGTGAAATTC 480CCTATGGTTA ATCAGGGTAG CAAAGATGTA GGGCTTATCC GCTACTATTC TTGGTATGTG 540GATTATGTCT TCACTTTCTA G 561 ( 2 ) SEQ ID NO:2： ( ⅰ ) ：
(A) length: 351 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..351 (ⅹ ⅰ) sequence description: the data of SEQ ID NO:2:TTGATGCGCA TTATCATAAG GTTACTTT CA TTTAAAATGA ACGCTTTTTT AAAACTCGCG 60CTCGCTTCTT TGATGGGGGG GCTTTGGTAT GCTTTCAATG GCGAAGGCTC TGAGATTGTC 120GCTATAGGGA TTTTTGTGTT GATCTTGTTT GTTTTTTTTA TCCGCCCTGT GAGTTTCCAA 180GACCCAGAAA AACGAGAAGA ATACATAGAA CGGCTTAAAA AAAACCATGA GAGGAAAATG 240ATCTTACAAG ACAAGCAAAA AGAAGAGCAA ATGCGCCTCT ATCAAGCCAA AAAAGAGCGA 300GAGAGCAGGC AAAAACAAGA CCTTAAAGAA CAAATGAAAA AATACTCATA A 351 (2) SEQ ID NO:3: (ⅰ) sequence signature:
(A) length: 1038 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1038 ( ⅹⅰ ) ：SEQ ID NO:3:ATGGTTAAAC ACTATCTTTT CATGGCGGTT TCGCAGGTCT TTTTCTCCTT CTTTTTAGTG 60CTGTTTTTTA TCTCTTCCAT TGTGTTATTA ATCAGTATTG CAAGCGTAAC GCTCGTGATT 120AAAGTGAGCT TTTTGGATCT GGTGCAACTC TTTTTGTATT CCTTGCCAGG AACCATTTTT 180TTTATTTTGC CGATCACTTT TTTTGCGGCT TGCGCTTTGG GGCTTTCAAG GCTTAGCTAT 240GACCATGAAT TGTTAGTGTT TTTCTCTTTA GGGGTTTCGC CTAAAAAAAT GACTAAAGCG 300TTTGTGCCTT TAAGTTTGTT AGTGAGCGCG ATTTTATTAG CGTTTTCGCT CATCTTAATC 360CCCACTTCTA AGAGCGCTTA TTACGGGTTT TTGCGTCAAA AAAAAGACAA GATTGACATT 420AACATCAGAG CGGGTGAATT CGGGCAAAAA TTAGGCGATT GGCTCGTGTA TGTGGATAAG 480ACTGAAAACA ATTCCTATGA TAATTTGGTG CTTTTTTCTA ATAAAAGTCT CTCTCAAGAA 540AGCTTTATTT TGGCTCAAAA AGGCAATATC AACAATCAAA ACGGCGTGTT TGAATTGAAT 600TTGTATAACG GGCATGCGTA TTTCACTCAA GGCGATAAAA TGCGTAAGGT TGATTTTGAA 660GAATTGCATT TGCGCAACAA GCTCAAGTCT TTCAATTCTA ATGATGCGGC TTATTTGCAA 720GGCACGGATT ATTTGGGTTA TTGGAAAAAA GCCTTTGGTA AAAACGCTAA TAAAAATCAA 780AAACGCCGTT TTTCTCAAGC GATCTTAGTT TCCTTGTTCC CTTTAGCGAG CGTGTTTTTA 840ATCCCCTTAT TTGGCATCGC CAACCCGCGA TTCAAAACGA ATTGGAGTTA TTTCTATGTC 900CTTGGAGCGG TTGGGGTTTA TTTTTTAATG GTGCATGTGA TTTCTACGGA TTTGTTTTTG 960ATGACCTTTT TCTTCCCCTT TATTTGGGCG TTTATTTCTT ATTTATTGTT TAGAAAATTC 1020ATTTTAAAGC GTTATTAA 1038 ( 2 ) SEQ ID NO:4： ( ⅰ ) ：
(A) length: 831 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..831 ( ⅹⅰ ) ：SEQ ID NO:4:ATGAAGAAAA AAGCAAAAGT CTTTTGGTGT TGTTTTAAAA TGATTCGTTG GTTGTATTTG 60GCGGTCTTTT TTTTGTTGAG CGTATCAGAC GCTAAAGAAA TCGCTATGCA ACGATTTGAC 120AAACAAAACC ATAAGATTTT TGAAATCCTT GCGGATAAAG TGAGCGCCAA AGACAATGTG 180ATAACCGCCT CAGGGAATGC GATCCTATTG AATTATGACG TGTATATTCT AGCGGATAAG 240GTGCGTTATG ACACCAAGAC TAAAGAAGCG TTATTAGAAG GCAATATTAA GGTTTATAGG 300GGCGAGGGCT TGCTCGTTAA AACCGATTAT GTGAAATTGA GTTTGAACGA AAAATATGAG 360ATCATTTTCC CCTTTTATGT CCAAGACAGC GTGAGCGGGA TTTGGGTGAG CGCGGATATT 420GCTAGCGGGA AGGATCAAAA ATATAAGATT AAAAACATGA GCGCTTCAGG GTGCAGCATT 480GACAACCCCA TTTGGCATGT CAATGCGACT TCAGGCTCAT TTAACATGCA AAAATCGCAT 540TTGTCAATGT GGAATCCTAA GATTTATGTC GGCGATATTC CTGTATTGTA TTTGCCCTAT 600ATTTTCATGT CCACGAGCAA TAAAAGAACT ACCGGGTTTT TATACCCTGA GTTTGGCACT 660TCCAACTTAG ACGGCTTTAT TTATTTGCAA CCCTTTTATT TAGCCCCCAA AAACTCATGG 720GATATGACCT TTACCCCACA AATCCGTTAC AAAAGGGGTT TTGGCTTGAA TTTTGAAGCG 780CGCTACATCA ACTCTAAGAC GCAGGTTTTT ATTCAATGCG CGCTATTTTA G 831 ( 2 ) SEQ ID NO:5： ( ⅰ ) ：
(A) length: 675 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..675 ( ⅹⅰ ) ：SEQ ID NO:5:ATGATTAGAT TAAAAGGTTT GAATAAAACT TTAAAAACAA GCTTATTAGC TGGGGTTTTA 60CTAGGTGCTA CTGCTCCCTT AATGGCAAAG CCTTTATTAA GCGATGAAGA CTTATTGAAA 120CGAGTAAAAC TACACAATAT CAAAGAAGAT ACGCTGACTA GCTGTAATGC TAAGGTGGAC 180GGCTCTCAAT ACTTGAATAG TGGTTGGAAT TTATCTAAAG AATTTCCGCA AGAATATAGA 240GAAAAGATTT TTGAATGCGT AGAAGAAGAA AAACATAAAC AAGCCCTTAA TTTAATCAAT 300AAAGAAGACA CTAAAGATAA AGAAGAACTT GCAAAAAAAA TCAAAGAAAT TAAAGAAAAA 360GCTAAAGTTT TAAGGCAAAA ATTTATGGCT TTTGAAATGA AAGAACACTC TAAAGAATTC 420CCAAATAAAA AGCAACTTCA AACCATGCTT GAGAACGCTT TTGATAATGG AGCTGAAAGT 480TTTATTGATG ATTGGCACGA ACGCTTTGGG GGTATAAGTA GAGAGAATAC TTATAAAGCA 540CTTGGCATTA AAGAATATAG TGATGAAGGA AAGATATTGC CTTTGGCGAA AGAAGTTATA 600TTAGACAATA TAAAAAAGAT TTTGAAGAAA GCACTTATGA TACTAGACAA CCCTTATCTG 660CTATGGCTAG TATGA 675 ( 2 ) SEQ ID NO:6： ( ⅰ ) ：
(A) length: 1290 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1290 ( ⅹⅰ ) ：SEQ ID NO:6:ATGCCATACG CCTTAAGAAA AAGATTTTTC AAACGCCTTT TATTGTTTTT TTTAATTGTT 60TGTATGATAA ATTTGCATGC CAAAAGCTAT CTGTTTTCTC CTTTGCCCCC AGCGCACCAG 120CAAATCATTA AGACAGAGCC TTGCTCTTTG GAGTGCTTGA AAGACTTGAT GCTGCAAAAT 180CAAATCTTTT CTTTTGTATC CCAATACGAT GATAACAACC AAGATGAGAG CCTTAAAACT 240TATTACAAGG ACATCTTAAA CAAACTCAAC CCCGTATTCA TCGCTTCTCA AACTCCAGCT 300AAAGAAAGCT ATGAGCCTAA GATTGAATTA GCGATTTTAC TGCCTAAAAA GGTGGTGGGC 360CGTTATGCGA TTTTAGTGAT GAACACCCTT TTAGCGTATT TGAACACCAG AAACAACGAT 420TTCAATATCC AAGTCTTTGA CAGCGATGAA GAAAGCCCTG AAAAATTAGA AGAAACCTAT 480AAAGAAATTG AAAAAGAAAA ATTCCCTTTT ATCATCGCTT TATTGACTAA AGAGGGCGTG 540GAAAATTTGC TCCAAAATAC GACTATCAAT ACCCCTACTT ATGTGCCTAC GGTGAATAAA 600ACGCAATTAG AAAATCATAC CGAGCTTTCT TTAAGCGAGC GCTTGTATTT TGGGGGGATT 660GATTATAAAG AGCAATTAGG CATGCTCGCA ACTTTCATTA GCCCTAATTC GCCCGTGATT 720GAATACGATG ATGATGGCCT GATAGGTGAA CGCTTGAGGC AAATCACGGA GTCTTTAAAC 780GTTGAAGTCA AACACCAAGA AAACATTTCT TACAAACAAG CGACCAGTTT TTCTAAAAAT 840TTTAGAAAAC ATGATGCGTT TTTTAAAAAT TCTACCTTAA TTTTGAACAC CCCTACCACT 900AAAAGCGGTC TGATCCTTTC TCAAATAGGG CTTTTAGAGT ATAAGCCTCT TAAAATCCTT 960TCCACACAAA TCAATTTCAA CCCCTCTTTA CTCTTGCTCA CCCAGCCTAA AGACAGGAAA 1020AATTTATTCA TTGTCAATGC CTTGCAAAAC AGCGATGAAA CGCTGATAGA ATACGCTTCC 1080TTATTAGAGA GCGATTTAAG GCATGATTGG GTGAATTATT CCAGCGCGAT AGGGCTAGAG 1140ATGTTTTTAA ACACGCTAGA TCCGCATTTT AAAAAGTCTT TTCAAGAGAG TTTGGAAGAC 1200AATCAAGTCC GTTACCACAA TCAAATTTAT CAGGCTTTAG GGTATTCTTT TGAGCCGATA 1260AAAAACGAAA GCGAAACAAA AAAAAGAATAA 1290 ( 2 ) SEQ ID NO:7: ( ⅰ ) ：
(A) length: 1368 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1368 ( ⅹⅰ ) ：SEQ ID NO:7:GTGTTAAAAT TTCAAAAATT ACCCTTATTG TTTGTTTCCA TTCTTTATAA TCAAAGCCCT 60TTATTGGCTT TTGATTATAA GTTTAGTGGG GTAGCGGAAT CTGTTTCTAA AGTGGGGTTT 120AACCATTCCA AACTCAATTC CAAAGAAGGG ATTTTCCCTA CAGCCACCTT TGTAACCGCC 180ACGATCAAGC TTCAAGTGGA TTCCAATCTG CTCCCTAAAA ACATTGAAAA ACACAGCTTA 240AAAATAGGCG TTGGGGGGAT TTTAGGAGCG CTCGCTTACG ATTCCACCAA AACGCTCATA 300GACCAAGCCA CGCATCAAAT CTATGGCTCA GAACTTTTTT ACCTCATAGG GCGTTGGTGG 360GGGTTTTTAG GCAACGCTCC TTGGAAAGAC TCCCTCATAG AATCTGACGC TCACACCCGT 420AATTATGTGC TGTATAATTC CTATCTGTTT TATTCTTATG GCGATAAATT CCACCTAAAA 480TTAGGGCGTT ATCTCTCTAA CATGGATTTT ATGAGTTCCT ACACACAGGG TTTTGAACTG 540GATTATAAAA TCAATTCTAA AATAGCGTTA AAATGGTTTA GCTCTTTTGG GAGGGCGTTG 600GCTTTTGGGC AATGGATACG GGATTGGTAT GCCCCTATTG TAACTGAAGA TGGCAGAAAA 660GAAGTTTATG ATGGCATCCA TGCCGCGCAA CTCTATTTTT CTAGCAAGCA TGTTCAAGTC 720ATGCCTTTTG CTTATTTTTC GCCTAAGATT TACGGAGCGC CCGGTGTTAA AATCCATATT 780GATAGCAACC CGAAATTCAA AGGCTTAGGG TTAAGGGCTC AAACCACTAT TAATGTGATT 840TTCCCTGTTT ATGCTAAAGA TTTATACGAT GTGTATTGGC GTAACTCTAA GATTGGCGAG 900TGGGGCGCAT CGCTTTTGAT CCACCAACGC TTTGACTACA ACGAATTTAA CTTTGGCTTT 960GGTTATTACC AAAATTTTGG CAACGCTAAC GCAAGGATTG GCTGGTATGG TAACCCCATC 1020CCTTTTAATT ATAGAAATAA CAGCGTTTAT GGTGGGGTCT TCAGTAACGC TATTACCGCA 1080GACGCCGTTT CTGGGTATGT CTTTGGTGGG GGGGTGTATA GAGGGTTTTT ATGGGGTATT 1140TTAGGCAGAT ACACTTATGC CACTAGAGCG AGCGAAAGAT CCATCAACTT GAACTTGGGC 1200TATAAATGGG GTTCTTTTGC TAGAGTTGAT GTGAATTTAG AATACTATGT GGTCAGCATG 1260CACAACGGCT ATAGATTAGA CTATCTCACC GGCCCTTTCA ACAAAGCCTT TAAGGCTGAC 1320GCACAAGATA GGAGTAACCT TATGGTTAGC ATGAAATTCT TTTTTTAA 1368 ( 2 ) SEQ ID NO:8： ( ⅰ ) ：
(A) length: 849 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..849 ( ⅹⅰ ) ：SEQ ID NO:8:ATGGGGTGTT CGTTTATCTT TAAAAAAGTT AGGGTTTATT CTAAAATGTT GGTTGCTTTG 60GGGCTTTCAA GCGTGTTGAT CGGTTGCGCG ATGAATCCAA GCGCTGAGAC AAAAAAACCA 120AATGACGCCA AAAACCAACA ACCAGTTCAA ACTCATGAAA GAATGACAAC AAGTTCTGAA 180CATGTTACGC CACTAGATTT TAATTACCCG GTGCATATTG TTCAAGCCCC ACAAAACCAT 240CATGTTGTAG GTATTTTAAT GCCACGCATT CAAGTGAGCG ATAATCTAAA ACCCTATATT 300GATAAGTTTC AAGACGCTTT AATTAATCAA ATCCAAACTA TTTTTGAAAA AAGAGGCTAT 360CAAGTGTTGC GTTTTCAAGA TGAAAAAGCT TTGAATGTGC AAGATAAGAA AAAGATTTTT 420TCCGTTTTGG ATTTGAAAGG GTGGGTAGGA ATCTTAGAAG ATTTGAAAAT GAATTTAAAA 480GATCCCAATA GTCCCAATTT AGACACGCTA GTGGATCAAA GCTCAGGCTC TGTATGGTTT 540AATTTTTATG AACCAGAAAG CAATCGTGTC GTCCATGATT TTGCTGTAGA AGTAGGAACT 600TTTCAGGCAA TAACATACAC ATACACCTCT ACTAATAACG CTTCAGGAGG GTTTAATTCT 660TCAAAAAGCG TTATCCATGA AAATTTGGAT AAGAATAGAG AAGACGCGAT ACACAAGATT 720TTAAACAGAA TGTATGCGGT TGTCATGAAA AAAGCTGTAA CAGAACTTAC AAAAGAAAAT 780ATCGCCAAAT ACAGAGACGC TATTGATAGA ATGAAAGGCT TTAAAAGTTC TATGCCTCAA 840AAAAAGTAG 849 ( 2 ) SEQ ID NO:9： ( ⅰ ) ：
(A) length: 843 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..843 ( ⅹⅰ ) ：SEQ ID NO:9:ATGAAACTGA GAGCAAGTGT TTTAATCGGT GTGGCAATTC TGTGCTTAAT TTTAAGTGCG 60TGCAGTAACT ATGCGAAAAA AGTGGTGAAA CAAAAGAACC ATGTTTATAC GCCTGTGTAT 120AATGAACTGA TAGAGAAGTA TAGTGAGATC CCCTTAAATG ACAAACTCAA AGACACACCA 180TTCATGGTGC AAGTGAAGTT GCCAAATTAC AAGGACTATT TGTTGGATAA TAAACAAGTT 240GTACTAACTT TCAAACTTGT TCACCATTCT AAAAAGATTA CGCTCATAGG CGATGCCAAT 300AAGATCCTCC AATACAAGAA TTACTTCCAA GCTAACGGGG CAAGATCTGA CATTGATTTT 360TACTTGCAAC CCACTTTGAA TCAAAAGGGT GTGGTGATGA TAGCGAGTAA CTACAATGAT 420AATCCCAACA ACAAAGAAAA ACCACAGACC TTTGATGTGT TGCAAGGAAG TCAGCCAATG 480CTAGGAGCTA ACACAAAAAA CTTGCATGGC TATGATGTGA GTGGAGCAAA CAACAAGCAA 540GTGATCAATG AAGTGGCAAG AGAAAAAGCT CAGCTAGAAA AAATCAATCA GTATTACAAG 600ACTCTCTTGC AAGACAAGGA ACAAGAATAT ACCACTAGGA AAAATAACCA ACGAGAAATT 660TTAGAAACAT TGAGTAATCG TGCAGGTTAT CAAATGAGGC AGAATGTGAT TAGTTCTGAG 720ATTTTTAAGA ATGGCAACTT GAACATGCAA GCCAAAGAAG AAGAAGTTAG GGAGAAGCTA 780CAAGAAGAAA GAGAGAATGA ATACTTGCGC AATCAAATCA GAAGTTTGCT CAGTGGTAAG 840TGA 843 ( 2 ) SEQ ID NO:10： ( ⅰ ) ：
(A) length: 1179 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1179 ( ⅹⅰ ) ：SEQ ID NO:10:ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT TAGAAGCGAA CGAGAAAAAC 60GGCTTTTTCA TAGAAGCCGG CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120AAAAGACACA CCACCACAAA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180ATTTTAAAAA GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAAAAC 300TTCTTGCCTT ATAATTTAAA TAATGTTAAG CTTAGTTTTA CAGACGCTCA AGGCAATGTG 360ATCGATCTAG GCGTGATAGA GACTATCCCC AAACACTCTA AGATTGTTTT GCCCGGAGAG 420GCATTTGATA GTCTAAAAAT TGACCCCTAT ACTTTATTTC TTCCAAAAAT TGAAGCCACT 480AGCACTTCTA TTTCTGACGC TAACACGCAG AGGGTGTTTG AAACGCTCAA TAAGATTAAG 540ACAAATTTGG TCGTAAATTA TAGGAATGAA AACAAATTTA AAGATCACGA AAATCATTGG 600GAAGCCTTTA CCCCACAAAC CGCAGAAGAA TTCACTAATT TAATGTTGAA CATGATCGCT 660GTTTTAGACT CCCAATCTTG GGGCGATGCG ATCTTAAACG CTCCTTTTGA GTTCACTAAC 720AGCCCAACAG ATTGCGATAA TGATCCTTCA AAATGCGTAA ATCCTGGGAC AAACGGGCTT 780GTCAATTCTA AAGTCGATCA AAAATATGTG TTAAACAAAC AAGACATTGT CAATAAATTT 840AAAAACAAAG CGGATCTTGA TGTAATTGTT TTAAAGGATT CAGGGGTTGT AGGGCTTGGG 900AGTGATATTA CCCCTAGCAA CAATGATGAT GGCAAGCATT ATGGCCAGTT AGGGGTAGTA 960GCTTCTGCTT TAGATCCTAA AAAACTCTTT GGCGATAACC TTAAGACTAT CAATTTAGAG 1020GATTTAAGAA CCATCTTGCA TGAATTCAGC CACACTAAAG GCTATGGGCA TAACGGGAAT 1080ATGACCTATC AAAGAGTGCC GGTAACGAAA GATGGTCAAG TGGAAAAGGA TAGTAATGGC 1140AAGCCAAAAG ATTCTGATGG CCTCCCCTAT AATGTGTGT 1179 ( 2 ) SEQ ID NO:11： ( ⅰ ) ：
(A) length: 813 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..813 ( ⅹⅰ ) ：SEQ ID NO:11:ATGAAAAAGT TTGTAGCTTT AGGGCTTCTA TCCGCGGTTT TAAGCTCTTC GTTGTTAGCC 60GAAGGTGATG GTGTTTATAT AGGGACTAAT TATCAGCTTG GACAAGCCCG TTTGAATAGC 120AATATTTATA ATACAGGGGA TTGCACAGGG AGTGTTGTAG GTTGCCCCCC AGGTCTTACC 180GCTAATAAGC ATAATCCAGG AGGCACCAAT ATCAATTGGC ACTCCAAATA CGCTAATGGG 240GCTTTGAATG GTTTTGGGTT GAATGTGGGT TATAAGAAAT TCTTCCAATT CAAGTCGCTA 300GATATGACAA GCAAGTGGTT TGGTTTTAGA GTGTATGGGC TTTTTGATTA CGGGCATGCC 360GATTTAGGTA AACAAGTTTA TGCACCTAAT AAAATCCAGT TGGATATGGT CTCTTGGGGT 420GTGGGGAGCG ATTTGTTAGC TGATATTATT GATAAAGACA ACGCTTCTTT TGGTATTTTT 480GGTGGGGTCG CTATCGGCGG TAACACTTGG AAAAGCTCTG CAGCAAACTA TTGGAAAGAG 540CAAATCATTG AAGCCAAAGG TCCTGATGTT TGTACCCCTA CTTATTGTAA CCCTAATGCC 600CCTTATAGCA CCAACACTTC AACCGTCGCT TTTCAAGTGT GGTTGAATTT TGGGGTGAGA 660GCCAATATCT ACAAGCATAA TGGCGTGGAA TTTGGCGTGA GAGTGCCGCT ACTCATCAAT 720AAATTTTTGA GCGCGGGTCC TAACGCTACT AACCTTTATT ACCATTTGAA ACGGGATTAT 780TCGCTTTATT TGGGGTATAA CTACACTTTT TAA 813 ( 2 ) SEQ ID NO:12： ( ⅰ ) ：
(A) length: 423 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..423 ( ⅹⅰ ) ：SEQ ID NO:12:ATGCATCCTA TAATGTTTGC CTATATCGCT AACGCGCTCG CTCAAGCTAG AAAGATCAAC 60GGAACACTTT GCATGGCGTT TCAAAAAATA TCTCAAGTCA AAGAATTAGG CATTGATAAA 120GCAAAGAGTT TGATAGGCAA CCTTTCTCAA GTGATTATCT ACCCCACAAA AGATACTGAT 180GAATTAATAG AATGTGGCGT CCCATTAAGC GATAGTGAAA TCAATTTCTT ACACAACACG 240GACATGAGAG CCAGACAAGT GCTAGTAAAA AATATCGTTA CAAACGCTTC AGCTTTTATT 300GAAATTGATT TAAAAAAGAT TTGCAAGAAC TACTTTATAT TCTTGATAGC AATGCTGGTA 360ATAGAAAAAT CCTCAATGAT CTTAAAAAAG CAAACCAAGA AACTTATAAG GAAGAGTATT 420 TAA 423 ( 2 ) SEQ ID NO:13： ( ⅰ ) ：
(A) length: 771 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..771 ( ⅹⅰ ) ：SEQ ID NO:13:ATGTTGGGGA GCGTCAAAAA AGCGGTTTTT AGGGTTTTGT GTTTGGGGGC GTTGTGTTTA 60TGCGGGGGGT TAATGGCAGA GCAAGATCCT AAAGAGCTTA TATTTTCAGG TATAACTATT 120TACACGGATA AAAATTTCAC TAGAGCTAAG AAATATTTTG AAAAAGCTTG CAAATCAAAC 180GATGCTGATG GCTGTGCAAT CTTAAGAGAG GTTTATTCTA GTGGTAAAGC CATAGCGAGA 240GAAAACGCAA GAGAGAGCAT TGAAAAAGCT CTTGAACACA CCGCTACTGC TAAAGTTTGT 300AAATTAAACG ATGCTGAAAA ATGCAAGGAC TTAGCAGAGT TTTATTTTAA TGTAAACGAT 360CTTAAAAATG CTTTAGAATA TTACTCTAAA TCTTGTAAGT TAAATAATGT TGAAGGGTGT 420ATGCTGTCAG CAACTTTTTA TAACGATATG ATAAAGGGTT TGAAAAAAGA TAAAAAAGAT 480CTAGAATATT ATTCTAAAGC TTGCGAGTTA AATAACGGTG GAGGGTGTTC TAAATTAGGA 540GGGGATTATT TTTTTGGTGA AGGCGTAACA AAAGATTTCA AAAAAGCTTT TGAATATTCT 600GCCAAAGCTT GTGAGTTGAA CGATGCTAAA GGGTGTTACG CTCTAGCAGC GTTTTATAAT 660GAGGGTAAAG GCGTGGCAAA GGATGAAAAG CAAACGACAG AAAACCTTGA AAAGAGTTGC 720AAGCTAGGAT TAAAAGAAGC ATGCGATATT CTCAAAGAAC AAAAACAATA A 771 ( 2 ) SEQ ID NO:14： ( ⅰ ) ：
(A) length: 729 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..729 ( ⅹⅰ ) ：SEQ ID NO:14:ATGAAAAAAT TTTTTTCTCA ATCTTTGTTA GCTCTTATTA TCTCTATGAA TGCGGTATCT 60GGCATGGATG GTAATGGCGT TTTTTTAGGG GCGGGTTATT TGCAAGGACA GGCGCAAATG 120CATGCGGATA TTAATTCTCA AAAACAAGCC ACCAACGCTA CGATCAAAGG CTTTGACGCG 180CTCTTGGGGT ATCAATTTTT CTTTGAAAAA CACTTTGGCT TACGCCTTTA TGGGTTTTTT 240GACTACGCTC ATGCCAATTC TATTAAGCTT AAAAACCCTA ACTATAATAG CGAAGCGGCG 300CAAGTGGCTA GTCAAATTCT TGGGAAACAA GAAATCAATC GTTTAACAAA CATTGCCGAT 360CCCAGAACTT TTGAGCCGAA CATGCTCACT TATGGGGGGG CTATGGACGT GATGGTTAAT 420GTCATCAATA ACGGCATCAT GAGTTTGGGG GCTTTTGGCG GGATACAATT GGCCGGCAAT 480TCATGGCTTA TGGCGACACC GAGCTTTGAG GGCATTTTAG TGGAACAAGC CCTTGTGAGC 540AAGAAAGCCA CTTCTTTCCA ATTTTTATTC AATGTGGGGG CTCGCTTAAG GATCTTAAAA 600CATTCTAGCA TTGAAGCGGG CGTGAAATTC CCCATGCTAA AGAAAAACCC CTACATCACT 660GCAAAAAATT TGGATATAGG GTTTAGGCGC GTGTATTCGT GGTATGTGAA TTACGTGTTC 720ACTTTCTAG 729 ( 2 ) SEQ ID NO:15： ( ⅰ ) ：
(A) length: 804 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..804 ( ⅹⅰ ) ：SEQ ID NO:15:ATGAACTACC CTAATCTACC TAACAGCGCT TTAGAGATAA GCGAACAGCC AGAAGTGAAA 60GAAATCACTA ACGAGCTTTT AAAGCAATTA CAAAACGCTT TAAGGAGCAA CGCGCATTTT 120AGCGAGCAAG TGGAATTAAG CCTTAAATGC ATCGTTAGGA TTTTAGAAGT GCTTTTGAGT 180TTGGATTTTT TTAAGAATGC GAATGAGATT GATAGCAGTT TAAGAAATTC CATTGAGTGG 240CTGACTAACG CCGGCGAGAG CTTGAAATTA AAAATGAAAG AATACGAGCG CTTTTTTAGC 300GAGTTTAATA CGAGCATGCA TGCCAACGAG CAGGAAGTAA CCAATACCTT AAACGCTAAC 360GCCGAGAACA TTAAAAGCGA AATTAAAAAG CTAGAAAATC AATTGATAGA AACCACGACA 420AGACTTTTAA CGAGCTATCA AATCTTTTTA AACCAAGCCA GAGATAACGC TAACAACCAA 480ATCACAAAAA ACAAAACCCA AAGCCTTGAA GCGATTACAC AAGCTAAAAA CAACGCTAAT 540AATGAAATAA GCAACAATCA AACGCAAGCG ATAACTAATA TCACCGAAGC GAAAACGAAC 600GCTAATAATG AAATAAGCAA CAATCAAACG CAAGCGATAA CTAACATTAA CGAAGCCAAA 660GAAAGCGCTA CAACGCAAAT AAACGCCAAT AAGCAAGAAG CAATAAATAA CATCACGCAA 720GAAAAAACCC AAGCCACAAG CGAGATCACC GAAGCGAAAA AGACCGATCA TTATCAAAAC 780ATTGATTTTT TTGAGTTTGA ATAA 804 ( 2 ) SEQ ID NO:16： ( ⅰ ) ：
(A) length: 1632 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1632 ( ⅹⅰ ) ：SEQ ID NO:16:GTGATAGAGA CCATCCCCAA ACACTCTAAG ATTGTTTTAC CCGGGGAGGC GTTTGATAGT 60TTAAAAGAGG CGTTTGATAA AATTGACCCC TATACTTTCT TTTTTCCAAA ATTTGAAGCC 120ACTAGCACTT CTATTTCTGA TACTAACACG CAGAGGGTGT TTGAAACGCT CAATAACATT 180AAAACAAATC TTATAATGAA ATATAGTAAT GAAAATCCAA ACAATTTCAA CACTTGTCCT 240TACAATAATA ATGGTAATAC AAAAAATGAT TGTTGGCAAA ATTTCACCCC ACAAACCGCA 300GAAGAATTCA CCAATTTAAT GTTGAACATG ATCGCTGTCT TAGACTCCCA ATCTTGGGGC 360GATGCGATCT TAAACGCTCC TTTTGAATTC ACTAACAGCT CAACAGATTG CGATAGCGAT 420CCTTCAAAAT GCGTAAATCC CGGAGTAAAT GGGCGTGTTG ATACTAAAGT CGATCAACAA 480TATATACTCA ACAAACAAGG TATTATTAAT AATTTTAGAA AAAAAATAGA AATTGATGCG 540GTTGTTTTAA AAAATTCAGG GGTTGTAGGG TTAGCCAATG GATATGGCAA TGATGGTGAA 600TATGGCACAT TAGGGGTAGA AGCCTATGCT TTAGATCCTA AAAAACTCTT TGGCAACGAC 660CTTAAGACTA TCAATTTAGA AGATTTAAGA ACCATCTTGC ATGAATTCAG CCACACTAAA 720GGCTATGGGC ATAACGGGAA TATGACCTAT CAAAGAGTGC CGGTAACGAA AGATGGTCAA 780GTGGAAAAGG ATAGTAATGG CAAGCCAAAA GATTCTGATG GCCTCCCCTA TAATGTGTGT 840TCGCTTTATG GGGGATCCAA TCAGCCCGCT TTCCCTAGCA ACTACCCTAA TTCCATCTAT 900CACAATTGTG CGGATGTCCC GGCTGGCTTT TTAGGGGTAA CAGCAGCGGT TTGGCAGCAG 960CTCATCAATC AAAACGCCTT GCCGATCAAC TACGCTAACT TGGGGAGTCA AACAAACTAC 1020AACCTAAACG CTAGTTTAAA CACGCAAGAT TTAGCCAATT CCATGCTCAG CACCATCCAA 1080AAAACCTTTG TAACTTCTAG CGTTACCAAC CACCATTTTT CAAACGCATC GCAAAGTTTT 1140AGAAGCCCTA TTTTAGGGGT TAACGCTAAA ATAGGCTATC AAAACTACTT TAATGATTTC 1200ATAGGGTTGG CTTATTATGG CATCATCAAA TACAATTACG CTAAAGCTGT TAATCAAAAA 1260GTCCAGCAAT TGAGCTATGG TGGGGGGATA GATTTGTTAT TGGATTTCAT CACCACTTAC 1320TCCAATAAAA ATAGCCCTAC AGGCATTCAA ACCAAAAGGA ATTTTTCTTC ATCTTTTGGT 1380ATCTTTGGGG GGTTAAGGGG CTTGTATAAC AGCTATTATG TGTTGAACAA AGTCAAAGGA 1440AGCGGCAATT TAGATGTGGC TACCGGGTTG AACTACCGCT ATAAGCATTC TAAATATTCT 1500GTAGGGATTA GCATCCCTTT AATCCAAAGA AAAGCTAGCG TCGTTTCTAG CGGTGGCGAT 1560TATACGAACT CTTTTGTTTT CAATGAAGGG GCTAGCCACT TTAAGGTGTT TTTCAATTAC 1620GGTGGGTGTT TT 1632 ( 2 ) SEQ ID NO:17： ( ⅰ ) ：
(A) length: 1071 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1071 ( ⅹⅰ ) ：SEQ ID NO:17:TTGATGAAAA GCATTTTGCT CTTTATGATT TTTGTAGTTT GTCAGTTAGA AGGCAAAAAA 60TTTTCACAAG ATAATTTTAA GGTGGATTAT AACTACTATT TGCGCAAACA GGATTTGCAC 120ATCATTAAAA CGCAAAACGA TTTGTCCAAT GCCTGGTATC TCCCTCCACA AAAAGCCCCC 180AAAGAACATT CTTGGGTGGA TTTTGCTAAA AAATATTTAA ACATGATGGA TTATCTAGGC 240ACTTATTTTT TGCCTTTTTA TCATAGTTTC ACCCCCATTT TTCAATGGTA CCACCCTAAT 300ATCAACCCCT ACCAACGCAA TGAGTTTAAG TTCCAAATCA GTTTTAGAGT GCCTGTATTT 360AGGCATATTC TTTGGACTAA AGGCACGCTT TATCTGGCTT ATACCCAAAC TAACTGGTTT 420CAAATTTATA ATGACCCTCA ATCCGCCCCC ATGCGAATGA TCAATTTCAT GCCTGAACTC 480ATCTATGTTT ATCCTATTAA TTTTAAACCT TTTGGGGGTA AAATAGGGAA TTTTTCTGAA 540ATTTGGATAG GTTGGCAGCA CATTTCTAAT GGTGTGGGGG GTGCGCAATG TTACCAGCCT 600TTTAATAAAG AAGGTAATCC TGAAAACCAG TTTCCAGGAC AACCTGTAAT CGTTAAAGAT 660TATAACGGGC AAAAAGATGT GCGCTGGGGG GGGTGTCKTT CGGTGARCSC GGGCAACSCC 720CTGTGTTTCG TTTTGGTGTG GGAAAAGGGA GGCCTAAAAA TCATGGTCGC TTATTGGCCC 780TATGTCCCTT ATGATCAATC CAACCCTCAA TTGATTGATT ACATGGGGTA TGGTAACGCT 840AAAATTGATT ACAGGAGAGG GCGCCACCAT TTTGAATTGC AACTTTATGA TATTTTCACG 900CAATACTGGC GTTATGATCG CTGGCATGGA GCTTTCCGCT TAGGCTATAC CTACCGCATT 960AACCCTTTTG TGGGGATTTA TGCGCAGTGG TTTAACGGCT ATGGCGATGG CTTGTATGAA 1020TACGATGTTT TTTCCAATCG TATAGGGGTA GGAATACGCT TGAACCCTTA A 1071 ( 2 ) SEQ ID NO:18： ( ⅰ ) ：
(A) length: 2028 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..2028 ( ⅹⅰ ) ：SEQ ID NO:18:TTGTCTAAAG GTTTGAGTAT CGGTAATAAA ATCATATTGT GCGTGGCGTT GATTGTGATC 60GTGTGCGTGA GCATTTTAGG GGTGTCCTTA AACAGCAGGG TGAAAGAGAT TTTAAAAGAA 120AGCGCTCTGC ATTCAATGCA AGATAGTTTG CATTTCAAGG TTAAGGAAGT GCAAAGTGTT 180TTGGAAAACA CTTATACGAG CATGGGCATT GTCAAAGAAA TGCTCCCTGA AGACACCAAA 240AGAGAAATCA AAATCCAGTT GTTAAAAAAC TTCATTTTAG CCAATTCGCA TGTCGCTGGG 300GTGAGCATGT TTTTTAAAGA CAGAGAGGAT TTGAGATTGA CGCTTTTACG AGATAACGAT 360ACGATCAAGT TGATGGAAAA CCCGTCATTA GGGAGTAACC CTTTAGCGCA AAAAGCGATG 420AAAAATAAAG AAATTTCTAA AAGCTTGCCT TATTACAGGA AAATGCCTAA CGGGGCGGAA 480GTTTATGGCG TGGATATTCT TTTACCACTA TTCAAGGAAA ACACGCAAGA AGTGGTGGGG 540GTTCTGATGA TTTTCTTTTC CATTGACAGC TTCAGTAATG AAATCACTAA AAACAGGAGC 600GATTTATTTT TAATTGGCGT TAAAGGTAAA GTGCTTTTGA GCGCGAATAA AAGCTTGCAA 660GACAAATCCA TCACCGAAAT TTATAAAAGC GTGCCTAAAG CCACTAATGA AGTGATGGCT 720ATTTTAGAAA ATGGCTCTAA AGCGACTTTA GAATACTTGG ATCCCTTTAG CCATAAGGAG 780AATTTTTTAG CCGTTGAAAC CTTTAAAATG CTAGGCAAAA CAGAAAGTAA AGACAATCTT 840AATTGGATGA TCGCTTTGAT CATTGAAAAA GACAAGGTCT ATGAGCAAGT GGGATCGGTG 900CGTTTTGTGG TGGTTGCAGC GAGTGCTATC ATGGTGTTAG CCTTAATCAT AGCGATCACT 960CTTTTAATGC GAGCGATCGT GAGCAATCGT TTGGAAGTCG TTTCTAGCAC CTTGTCTCAT 1020TTCTTTAAAT TATTGAACAA TCAAGCCCAT TCTAGCGACA TTAAATTGGT TGAAGCGCGA 1080TCTAATGACG AATTAGGGCG CATGCAAACA GCGATCAATA AAAATATCTT GCAAACCCAA 1140AAAACCATGC AAGAAGACAG GCAAGCCGTC CAAGACACCA TTAAAGTGGT TTCAGACGTG 1200AAAGCGGGGA ATTTTGCGGT GCGCATCACG GCTGAACCCG CAAGCCCTGA TTTGAAAGAA 1260TTGAGAGACG CGCTAAATGG GATCATGGAT TATTTGCAAG AAAGCGTAGG GACTCACATG 1320CCAAGCATTT TCAAAATCTT TGAAAGCTAT TCTGGCTTGG ATTTTAGAGG GCGGATCCAA 1380AACGCTTCGG GTAGGGTGGA ATTGGTTACT AACGCTTTAG GGCAAGAAAT CCAAAAAATG 1440CTAGAAACTT CGTCTAATTT TGCCAAAGAT CTAGCGAACG ATAGCGCGAA TTTAAAAGAA 1500TGCGTGCAAA ATTTAGAAAA GGCTTCAAAC TCCCAACACA AAAGCCTGAT GGAAACTTCC 1560AAAACGATAG AAAATATCAC CACTTCCATT CAAGGCGTGA GCTCTCAAAG TGAAGCCATG 1620ATTGAACAAG GGAAAGACAT TAAAAGCATT GTAGAAATCA TTAGAGATAT TGCCGATCAA 1680ACGAATCTAT TAGCCCTAAA CGCTGCTATT GAAGCCGCAC GAGCCGGCGA GCATGGCAGA 1740GGCTTTGCGG TGGTGGCTGA TGAGGTGAGG AAGCTCGCTG AAAGGACGCA AAAATCCCTC 1800AGTGAGATTG AAGCCAATAT TAATATTCTC GTTCAAAGCA TTTCAGACAC GAGCGAAAGC 1860ATTAAAAACC AGGTTAAAGA AGTAGAAGAG ATCAACGCTT CTATTGAAGC CTTAAGATCG 1920GTTACTGAGG GCAATCTAAA AATCGCTAGC GATTCTTTAG AAATCAGTCA AGAAATTGAC 1980AAAGTCTCTA ACGATATTTT AGAAGATGTG AATAAAAAGC AGTTTTAA 2028 ( 2 ) SEQ ID NO:19： ( ⅰ ) ：
(A) length: 816 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..816 ( ⅹⅰ ) ：SEQ ID NO:19:ATGAACATAT TCAAGCGTAT TATTTGCGTA ACCGCTATTG TTTTAGGTTT TTTTAACCTT 60TTAGACGCCA AACACCACAA AGAAAAAAAA GAAGACCACA AAATCACTCG TGAGCTTAAA 120GTGGGCGCTA ACCCTGTGCC GCATGCGCAA ATCTTGCAAT CAGTTGTGGA TGATTTGAAA 180GAGAAAGGGA TCAAATTAGT GATCGTGTCT TTTACGGATT ATGTGTTGCC TAATTTAGCG 240CTCAATGACG GCTCTTTAGA CGCGAATTAC TTCCAGCACC GCCCTTATTT GGATCGGTTT 300AATTTGGACA GAAAAATGCA CCTTGTTGGT TTGGCCAATA TCCATGTGGA GCCTTTAAGA 360TTTTATTCTC AAAAAATCAC AGACATTAAA AACCTTAAAA AAGGCTCAGT GATTGCTGTG 420CCAAATGATC CGGCCAATCA AGGCAGGGCG TTGATTTTAC TCCATAAACA AGGCCTTATC 480GCTCTCAAAG ACCCAAGCAA TCTATACGCT ACGGAGTTTG ATATTGTCAA AAATCCTTAC 540AACATCAAAA TCAAACCCCT AGAAGCTGCG TTATTGCCTA AGGTTTTAGG GGATGTGGAT 600GGGGCTATCA TAACAGGGAA TTATGCCTTG CAAGCAAAAC TCACCGGAGC CTTATTTTCA 660GAAGATAAGG ACTCGCCTTA TGCTAATCTT GTAGCCTCTC GTGAGGATAA TGCGCAAGAT 720GAAGCGATAA AAGCGTTGAT TGAAGCCTTA CAGAGCGAAA AGACCAGGAA ATTCATTTTG 780GATACCTATA AGGGGGCGAT TATCCCGGCT TTTTAA 816 ( 2 ) SEQ ID NO:20： ( ⅰ ) ：
(A) length: 486 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..486 ( ⅹⅰ ) ：SEQ ID NO:20:ATGTTTTTTA AAACTTATCA AAAATTACTG GGCGCGAGCT GTTTGGCGCT GTATTTAGTG 60GGCTGTGGGA ATGGTGGTGG CGGTGAATCG CCGGTTGAGA TGATTGCAAA TAGCGAGGGT 120ACGTTTCAAA TCGACTCCAA AGCAGATAGC ATTACTATTC AAGGCGTGAA GCTTAATAGA 180GGTAATTGTG CTGTCAATTT TGTTCCAGTA AGTGAGACGT TTCAAATGGG TGTTTTAAGT 240CAAGTTACTC CAATCTCTAT ACAGGATTTT AAAGATATGG CAAGCACTTA TAAGATATTT 300GATCAAAAGA AAGGGTTGGC AAACATAGCA AATAAAATTT CTCAATTAGA GCAAAAGGGT 360GTGATGATGG AACCTCAAAC CCTTAATTTT GGAGAAAGTT TAAAAGGCAT TTCTCAAGGG 420TGCAATATTA TAGAGGCAGA AATACAAACC GACAAAGGCG CTTGGACTTT TAACTTTGAT 480AAATAA 486 ( 2 ) SEQ ID NO:21： ( ⅰ ) ：
(A) length: 1014 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1014 ( ⅹⅰ ) ：SEQ ID NO:21:ATGATTAGAT TAAAAGGTTT GAATAAAACT TTAAAAACAA GCTTATTAGC TGGGGTTTTA 60CTAGGTGCTA CTGCTCCCTT AATGGCAAAG CCTTTATTAA GCGATGAAGA CTTATTGAAA 120CGAGTAAAAC TACACAATAT CAAAGAAGAT ACGCTGACTA GCTGTAATGC TAAGGTGGAC 180GGCTCTCAAT ACTTGAATAG TGGTTGGAAT TTATCTAAAG AATTTCCGCA AGAATATAGA 240GAAAAGATTT TTGAATGCGT AGAAGAAGAA AAACATAAAC AAGCCCTTAA TTTAATCAAT 300AAAGAAGACA CTGAAGATAA AGAAGAACTT GCAAAAAAAA TCAAAGAAAT TAAAGAAAAA 360GCTAAAGTTT TAAGGCAAAA ATTTATGGCT TTTGAAATGA AAGAACACTC TAAAGAATTC 420CCAAATAAAA AGCAACTTCA AACCATGCTT GAGAACGCTT TTGATAATGG AGCTGAAAGT 480TTTATTGATG ATTGGCACGA ACGCTTTGGG GGTATAAGTA GAGAGAATAC TTATAAAGCA 540CTTGGCATTA AAGAATATAG TGATGAAGGA AAGATATTAG CCTTTGGCGA AAGAAGTTAT 600ATTAGACAAT ATAAAAAAGA TTTTGAAGAA AGCACTTATG ATACTAGACA AACCTTATCT 660GCTATGGCTA ATATGAGTGG CGAAAACGAT TATAAAATTA CTTGGTTAAA ACCCAAATAT 720CAGCTCCATA GTTCAAATAA TATTAAACCC TTAATGTCAA ACACAGAGTT GTTAAATATG 780ATAGAGCTAA CCAATATCAA AAAAGAATAT GTTATGGGCT GTAATATGGA AATAGATGGT 840TCTAAATATC CCATTCATAA AGATTGGGGA TTTTTTGGTA AGGCAAAAGT CCCAGAAACT 900TGGAGAAATA AGATTTGGGA ATGTATTAAG AATAAAGTAA AGTCCTATGA CAACACTACC 960GCTGAAATAG GAATAGTTTG GAAAAAAAAT ACTTATTCTA TCTCTCATCA CTAA 1014 ( 2 ) SEQ ID NO:22： ( ⅰ ) ：
(A) length: 1251 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1251 ( ⅹⅰ ) ：SEQ ID NO:22:ATGAAAAAAT TAGTTTTTAG CATGCTTTTA TGTTGTAAAA GCGTGTTTGC AGAGGGGGAA 60ACTCCTTTGA TTGTCAATGA CCCAGAAACC CATGTAAGTC AAGCCACTAT CATAGGCAAA 120ATGGTAGATA GTATCAAAAG ATACGAAGAG ATTATTTCTA AGGCTCAAGC TCAAGTCAAT 180CAGTTACAAA AAGTCAATAA CATGATAAAT ACGACTAATT CTTTGATTAG TAGTAGTGCT 240ATCACTTTAG CCAATCCTAT GCAAGTTTTA CAAAACGCTC AGTATCAAAT AGAGAGCATT 300AGATACAACT ATGAGAATTT AAAGCAAAGC ATAGAAAATT GGAACGCACA AAATTTGTTA 360AGAAACAAAT ACTTACAGCA ACAATGCCCT TGGCTTAATG TCAATGCTCT TACTAACAAT 420AAGATTGTCA ATCTTAAAGA TCTCAATAAC CTAATCACCA AAAATGGCGA ACAAACCCAA 480ACCGCAAGAG ATGTGCAAAA TCTCATTCAG TCCATTAGTG GCAGTGGCTA TGGAAACATG 540CAATCACTTG CTGGGGAATT GAGTGGTAGA GCGTGGGGGG AAATGTTGTG TAAAATGGTA 600AACGATAGTA ATTATGAAAG CGAGCAAGCT CTTTTAGCAA CAGGCAATAA CCCAGAAGAG 660CAAAAACGAA GATTTTTGCT TAGAGTAAAG AAAAAGGTTA ATGATAATAA GCAGTTAAAA 720GATAAACTTG ACCCATTTCT AAAAAGACTT GATGTCCTAC AAACTGAGTT TGGTGTAACT 780GACCCTACAG CTAACCATAA TAAGCAAGGG ATACATTATT GCACAGAAAA TAAAGAGACA 840GGTAAATGCG ACCCTATTAA AAATGTATTT AGGACAACTC GCTTAGATAA CGAATTAGAA 900CAAGAAATCC AAACGCTCAC ACTTGATTTA ATCAAAGCCT CCAATAAAGA CGCTCAAAGC 960CAAGCCTACG CAAATTTCAA TCAAAGGATT AAATTACTTA CTCTAAAATA TTTAAAAGAA 1020ATTACCAATC AAATGCTCTT TTTAAATCAA ACAATGGCAA TGCAAAGCGA GATTATGACA 1080GATGATTATT TTAGGCAAAA TAATGATGGC TTTGGGGAAA AAGAAAACCA TATAGACAAA 1140CAATTAACGC AAAAAAGAAT AAACGAAAGA GAAAGAGCTA GAATATACTT TCAAAACCCT 1200AATGTTAAAT TTGACCAATT TGGCTTTCCC ATTTTTAGTA TATGGGATTA A 1251 ( 2 ) SEQ ID NO:23： ( ⅰ ) ：
(A) length: 1131 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1131 ( ⅹⅰ ) ：SEQ ID NO:23:GTGAATAAGT GGATTAAAGG GGCGGTTGTT TTTGTAGGGG GTTTTGCAAC GATTACAACC 60TTTTCTTTAA TCTACCACCA AAAGCCAAAA GCCCCCCTAA ATAACCAGCC TAGCCTTTTG 120AATGACGATG AGGTGAAATA CCCCTTACAA GACTACACTT TCACTCAAAA CCCACAGCCA 180ACTAACACGG AAAGCTCCAA AGACGCTACC ATCAAAGCCT TACAAGAACA GCTCAAAGCC 240GCTTTAAAAG CCCTAAACTC CAAAGAAATG AATTATTCCA AAGAAGAGAC TTTTACTAGC 300CCTCCCATGG ATCCAAAAAC AACCCCCCCT AAAAAAGACT TTTCTCCAAA ACAATTAGAT 360TTACTGGCCT CTCGCATCAC CCCTTTCAAG CAAAGCCCTA AAAATTACGA AGAAAACCTG 420ATTTTCCCTG TGGATAACCC TAATGGCATT GATAGTTTCA CTAACCTTAA AGAAAAAGAC 480ATCGCCACTA ATGAAAACAA GCTTTTACGC ACCATTACAG CTGACAAAAT GATACCCGCT 540TTTTTGATTA CGCCCATTTC TAGCCAGATC GCTGGTAAAG TGATTGCGCA AGTGGAGAGC 600GATATTTTTG CAAGCATGGG CAAAGCCGTC TTAATCCCCA AAGGCTCTAA AGTCATAGGC 660TATTACAGCA ACAATAACAA AATGGGCGAA TACCGCTTGG ATATTGTATG GAGTCGAATC 720ATCACTCCCC ATGGCATTAA TATCATGCTC ACTAACGCTA AAGGGGCGGA CATTAAAGGC 780TATAACGGCT TAGTGGGGGA ATTGATTGAA AGGAATTTCC AACGCTATGG CGTGCCGTTA 840CTGCTTTCTA CGCTCACTAA CGGCCTATTG ATTGGGATCA CTTCGGCTTT AAACAACAGA 900GGCAATAAAG AAGAGGTGAC TAATTTCTTT GGGGATTATC TTTTATTGCA ATTGATGAGG 960CAAAGCGGCA TGGGGATCAA TCAAGTGGTC AATCAAATTT TAAGAGACAA GAGCAAGATC 1020GCCCCCATTG TGGTGATTAG AGAGGGGAGT AGGGTCTTCA TTTCGCCCAA TACTGACATC 1080TTCTTCCCTA TACCCAGAGA GAATGAAGTC ATCGCTGAGT TTTTGAAGTG A 1131 ( 2 ) SEQ ID NO:24： ( ⅰ ) ：
(A) length: 2751 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..2751 ( ⅹⅰ ) ：SEQ ID NO:24:GTGGATTTGA GGATCCAATC TAAAGAAGTC AGTCATAATT TAAAGGAATT ATCAAAAACG 60CTAATCAGCT ATCCTTTTGA AAAACATGTA GAAGCTTTAG GGGAACAATG CAGTAACTTC 120GTTTCTATTC CCATTAACAA TGACGACTAT TCAAATATTT GCACTTTTGT GAGTGATTTT 180ATAAATCTTA TAGCTTCTTA CAATTTATTA GAATCATTTT TAGATTTTTA TAAAGATAAA 240TTAAAATTGA GCGAGCTTGT AACTGAATAT GCCAACGTAA CCAATAATCT GCTTTTCAAA 300AAATTAATCA AACATTTAAG CGGCAACAAT CAATTGGTTA AAAATTTTTA TCAGTGTATA 360AGAGAAATTA TAAAATACAA CGCCCCTAAT AAAGAATACA AACCCAATCA ATTTTTTATA 420ATAGGGAAAG GCAAACAAAA ACAATTAGCA AAAATTTATT CTCATTTAAA AGAACTTAGT 480GCAAGTGAAA TTAAACCACA AGATATGGAA GACATCTTAA AAAAGCTAGA GGAATTAGAT 540AAAATTTTTA AAACTACCGA CTTTACAAAA TTCACACCAA AAACTGAAAT TAAGGATATT 600ATTAAAGAAA TAGACGAAAA ATACCCTATC AATGAAAATT TTAAACGGCA ATTTAATGAG 660TTTGAATCAA ATATTGAAAA ACATGATGAA ATAAAAAAGG ATTTTGAGCG AAACAAAGAG 720TCGCTGATCC GAGAAATTGA AAATCACTGC AAAAATGAAT GCAATAGCGA AGAAGAGCCG 780GAGTATAAGA TTAATGATCT GCTCAAAAAT ATCCAACAAA TATGCAAAAA TTATATAGAA 840AGTCATGCCG TTAATGATGT GTCTAAAGAT ATTAAATCCA TGATGTGTCA GTTTTATTTG 900AAACAGATAG ATTTATTAGT CAATTCAGAA ATTGTGCGAT ACAGATACAG CAATCTTTTT 960GAACCAATAC AAAGATCTTT ATGGGAGAGT ATAAAAATTT TAGATAATGA AAGTGGCATT 1020TATTTGTTCC CTAAAAATAT TGGTGAAATC AAGGATAAAT TTGAAGCAAA CAAGGAAAAA 1080TTCAAACAAA GCAAAAATGT TTCTGAGTTC GCAGAATATT GCCGAGAGTG TAACCCCTAT 1140ACAGCGTTTA ACTTTCATCT AAATATAAAT AATGGTTTAT CTCATCAATT TGAAAAATTC 1200GTGCCAATCA TGAAAGAATA CAAAGAGCCA AAAATCACAG ATAATGACCT TGAAGCCATA 1260TCAACCAAAG AGACTGGTCT TGCTAGCCAA TTATCTGGGC ACTGGTTTTT TCAGCTTTCG 1320TTATTTAATA AAACAAACTT TAATCCTAAT AAAATTTGGA TTCCTTTAGA GTTCAATAAA 1380AGATCAAAAA TAAAGTTTGA TAAAGATTTA GAAATCTATT TTGATAGTCA TGAATCGTTC 1440AATATCTCTA AAAAATACTT GCAAGAAATA GATCAAGAAT CACTAAAAAA GATCAAACAA 1500TCAAAAGATT TTTTTTCAAT TCAAAAAATA GAGAGTAAGC ATGATAATAA CGATATACTG 1560CAACTTGAAT TTTTTGAGAA TGATACAAGT TTTCTTTTTG CTAAAGGAAG TTTTGCAGAA 1620ATTTTAGAAT ACAACATGCA ATTAAAAATA GATTCTTTAA TTACAAAAGA ATTTAATAAG 1680CTTTTAGCGA TCGTTCAAGA TAGTCCCCAA GATAGTTACC AATTAAAAAT TCGTGTCCGA 1740CATAACAATA AGCTTCCTAG AGAGAAATAT ACGGAACATG AAATAAAACT TGAAGTTTAT 1800GATTGCAGAA AATCCCACGA TCACAATGAG CCAATCATCT TAAGCCAGCA AAGCACCGGC 1860TTCCAATGGG CGTTTAATTT CATGTTTGGC TTTCTTTATA ATGTGGGATC ACATTTTAGT 1920TTTAACCATA ATATTATCTA TGTCATGGAC GAGCCAGCCA CTCATTTGAG CGTGCCAGCC 1980AGAAAGGAGT TTAGGAAATT TTTAAAAGAA TACGCTCATA AAAATCATGT TACTTTTGTT 2040TTAGCCACCC ATGACCCCTT TTTAGTGGAT ACGGATCATT TAGATGAAAT AAGGATTGTG 2100GAAAAGGAAA CAGAAGGCTC TGTAATTAAG AATCACTTTA ACTATCCCCT AAATAATGCA 2160AGCAAAGACT CCGACGCTTT GGACAAAATC AAACGCTCTT TAGGAGTGGG CCAGCATGTT 2220TTTCATAACC CCCAAAAACA CCGAATCATT TTTGTAGAAG GCATCACGGA TTATTGTTAT 2280TTGAGCGCTT TTAAATTGTA TTTGCGTTAC AAAGAATACA AGGACAACCC CATTCCTTTC 2340ACTTTCTTAC CCATTTCAGG GCTTAAAAAC GATTCAAACG ATATGAAAGA AACCATTGAA 2400AAACTTTGCG AGTTAGACAA TCACCCTATT GTTTTGACAG ACGATGACAG AAAATGCGTT 2460TTTAACCAAC AAGCAACGAG CGAACGATTT AAAAGAGCTA ATGAAGAAAT GCATGATCCC 2520ATCACCATCC TACAACTCTC AGACTGCGAT AGGCATTTCA AACAAATTGA AGATTGTTTC 2580AGCGCAAACG ATAGAAACAA ATACGCTAAA AATAAGCAAA TGGAATTGAG CATGGCTTTT 2640AAAACAAGGC TTTTGTATGG CGGAGAAGAT GCGATAGAAA AACAAACAAA AAGAAATTTT 2700TTAAAATTAT TCAAATGGAT TGCATGGGCT ACAAACTTGA TCAAAAACTA A 2751 ( 2 ) SEQ ID NO:25： ( ⅰ ) ：
(A) length: 531 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..531 ( ⅹⅰ ) ：SEQ ID NO:25:ATGACTGCAA TGATGCGTTA TTTTCACATC TATGCGACCA CTTTTTTCTT CCCTTTGGCG 60CTTCTTTTTG CGGTTAGTGG GCTTTCATTG CTCTTTAAAG CGCGCCAAGA CACTGGCGCT 120AAGATCAAAG AATGGGTTTT AGAAAAATCC TTAAAAAAAG AAGAACGATT GGACTTTTTA 180AAAGGCTTTA TAAAAGAAAA CCATATCGCT ATGCCTAAAA AGATAGAGCC TAGAGAGTAT 240AGGGGAGCGT TAGTCATTGG CACGCCTTTG TATGAAATCA ACCTTGAAAC TAAAGGCACT 300CAAACGAAAA TCAAGACCAT TGAAAGGGGC TTTTTAGGCG CGCTCATCAT GCTGCATAAG 360GCTAAGGTGG GCATCGTGTT TCAGGCGCTT TTAGGGATTT TTTGCGTGTT TTTATTGTTG 420TTTTACTTGA GCGCGTTTTT AATGGTGGCT TTTAAAGACA CTAAACGCAT GTTTATAAGC 480GTTTTAATAG GGAGCGTGGT GTTCTTTGGA GCGATCTATT GGTCTTTGTA G 531 ( 2 ) SEQ ID NO:26： ( ⅰ ) ：
(A) length: 669 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..669 ( ⅹⅰ ) ：SEQ ID NO:26:ATGTTTAAAA ACGCTTTAAA TATACAAGAT TTTTCATTTA AAAATCATAC TAGTACAGCC 60ATTATTGGCA CAAATGGTGC TGGAAAATCA ACGCTTATCA ACACTATTCT AGGCATTAGA 120TCAGACTATA ATTTTAAAGC ACAAAACAAT AATATTCCAT ACCACGACAA TGTTATACCA 180CAACGCAAGC AATTGGGAGT TGTCTCTAAC CTATTCAACT ACCCACCTGG ATTAAACGCA 240AACGACCTTT TTAAATTCTA TCAATTTTTT CACAAAAACT GCACTCTAGA TTTGTTTGAA 300AAAAATCTTT TAAATAAAAC CTACGAACAC CTAAGCGACG GACAAAAACA GCGCTTAAAA 360ATTGACTTAG CTCTTAGCCA TCACCCACAA TTAGTTATTA TGGATGAACC AGAAACCAGT 420TTAGAGCAAA ACGCTCTTAT AAGACTATCA AATCTCATAA GCTTGCGCAA CACCCAACAA 480CTTACAAGTA TCATCGCCAC TCATGATCCT ATTGTCTTAG ATAGTTGCGA ATGGGTATTG 540CTCCTTAAGA ATGGCAACAT TGCTCAATAC AAACCTTTAA ATTCTATATT AAAATCTGTA 600GCTAAAACTT TTAACTTTAA AGAAAAACCA ACCACAAAAG ACTTATTAGC GTTACTAAAG 660GATATTTAA 669 ( 2 ) SEQ ID NO:27： ( ⅰ ) ：
(A) length: 1221 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1221 ( ⅹⅰ ) ：SEQ ID NO:27:ATGTATGCGG CTCATCCTAT TAAACCCATA AAAGCCCCTA AACTCAAATC TCAATTTTTA 60AGGCGTGTGT TTGTGGGCGC GTCCATTAGG CGCTGGAATG ACCAAGCATG CCCTTTGGAA 120TTTGTGGAAT TAGACAAGCA AGCCCATAAA GCGATGATTG CGTATCTGCT CGCTAAAGAT 180TTAAAAGATA GGGGTAAAGA TTTAGATTTA GATCTTTTAA TCAAATATTT TTGCTTTGAG 240TTTTTGGAGC GCTTGGTTTT AACCGATATT AAACCCCCTA TTTTTTACGC CCTCCAACAA 300ACGCATAGTA AAGAGTTAGC TTCCTATGTT GCGCAAAGTT TGCAAGATGA AATCAGTGCG 360TATTTTTCTT TAGAGGAACT CAAAGAGTAT TTAAGCCACA GGCCTCAAAT TTTAGAAACT 420CAAATTTTAG AGAGCGCGCA TTTTTATGCG TCTAAGTGGG AGTTTGATAT TATCTATCAT 480TTTAACCCCA ACATGTATGG CGTGAAAGAG ATTAAAGATA AAATTGACAA GCAACTCCAC 540AATAACGATC ATTTGTTTGA AGGGCTTTTT GGGGAAAAAG AAGATTTGAA AAAATTGGTG 600AGCATGTTTG GGCAGTTGCG TTTCCAAAAG CGCTGGAGCC AAACCCCAAG AGTGCCACAA 660ACCAGTGTTC TAGGGCATAC TTTATGCGTG GCGATTATGG GGTATTTATT GAGTTTTGAC 720TTGAAAGCTT GTAAAAGCAT GCGGATCAAT CATTTTTTGG GCGGGCTTTT CCATGATTTA 780CCCGAAATTT TAACCCGAGA CATTATCACG CCCATCAAAC AAAGCGTTGC AGGGCTTGAT 840CATTGCATTA AAGAGATTGA AAAAAAGGAA ATGCAAAACA AAGTCTATTC CTTTGTGTCT 900TTGGGCGTTC AAGAAGATTT GAAATATTTC ACCGAAAACG AGTTTAAAAA CCGCTACAAA 960GACAAGTCTC ATCAAATCGT TTTCACTAAA GACGCTGAAG AATTATTCAC GCTTTATAAT 1020AGCGATGAAT ATCTTGGGGT TTGCGGGGAG CTTTTGAAGG TGTGCGATCA TTTGAGCGCG 1080TTTTTAGAAG CCCAAATCTC TCTTTCTCAT GGCATTTCTA GCTACGATTT AATCCAAGGA 1140GCTAAAAACC TTTTAGAATT GCGATCCCAA ACGGAACTGC TTGATTTGGA TTTAGGGAAA 1200TTGTTTAGAG ATTTTAAGTA A 1221 ( 2 ) SEQ ID NO:28： ( ⅰ ) ：
(A) length: 1008 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1008 ( ⅹⅰ ) ：SEQ ID NO:28:GTGTTGTGGG TGCTATATTT TTTAACCAGT TTATTTATTT GCTCTTTGAT TGTTTTGTGG 60TCTAAAAAAT CCATGCTCTT TGTGGATAAC GCTAATAAAA TCCAAGGCTT CCATCATGCA 120AGAACCCCAC GAGCCGGGGG GCTTGGGATC TTTCTTTCTT TTGCGTTGGC TTGTTATCTT 180GAACCTTTTG AGATGCCTTT TAAGGGGCCT TTTGTTTTCT TAGGGCTATC GCTAGTGTTT 240TTGAGCGGTT TTTTAGAAGA CATTAACCTT TCATTAAGCC CCAAAATACG CCTTATTTTG 300CAAGCTGTAG GGGTCGTTTG CATCATTTCA TCAACGCCTT TAGTGGTGAG CGATTTTTCG 360CCCCTTTTTA GCTTGCCTTA TTTCATCGCT TTTTTATTCG CTATTTTTAT GCTGGTGGGT 420ATCAGTAACG CTATTAATAT CATTGACGGG TTTAACGGGC TTGCATCTGG GATTTGCGCG 480ATCGCGCTTT TAGTCATTCA TTATATAGAC CCTAGCAGTT TGTCTTGTTT GCTCGCTTAC 540ATGGTGCTTG GGTTTATGGT GTTAAATTTC CCTTCAGGAA AGATTTTTTT AGGCGATGGG 600GGGGCGTATT TTTTGGGTTT GGTGTGCGGG ATTTCTCTCT TGCATTTGAG TTTGGAGCAA 660AAAATCAGCG TGTTTTTTGG GCTCAATTTA ATGCTTTATC CGGTCATAGA GGTGCTTTTT 720AGTATCCTTA GGCGCAAAAT AAAACGCCAG AAAGCCACCA TGCCGGATAA TTTGCATTTG 780CACACCCTTT TATTTAAATT CTTGCAACAA CGCTCTTTCA ATTACCCTAA CCCTTTATGC 840GCGTTTATCC TTATTCTATG CAACCTGCCT TTTATTTTAA TAAGCGTTTT GTTTCGCTTG 900GACGCTTATG CGCTCATTGT GATTAGCCTA GTCTTTATCG CATGCTATTT AATAGGCTAT 960GCTTATTTGA ATAGGCAAGT TTGCGCTTTA GAAAAGCGGG CGTTTTAA 1008 ( 2 ) SEQ ID NO:29： ( ⅰ ) ：
(A) length: 291 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..291 (ⅹ ⅰ) sequence description: the data of SEQ ID NO:29:ATGAAAAAGG TTATTGTGGC TTTAGGCGTT TTGGCGTTCG CAAATGTTTT AATGGCAACC 60GATGTTAAGG CTCTTGTAAA AGGTTGTGCC GCTTGCCATG GGGTTAAGTT TGAAAAGAAA 120GCTTTAGGTA AAAGCAAAAT CGTTAACATG ATGAGCGAAA AAGAGATTGA AGAGGATCTT 180ATGGCTTTTA AAAGCGGTGC CAACAAGAAT CCTGTCATGA CCGCGCAAGC TAAAAAATTA 240AGCGATGAAG ACATCAAAGC TTTAGCCAAA TACATCCCCA CTCTCAAATA A 291 (2) SEQ ID NO:30: (ⅰ) sequence signature:
(A) length: 471 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..471 ( ⅹⅰ ) ：SEQ ID NO:30:ATGCGAGATT TCAATAACAT TCAAATCACA CGCTTAAAAG TGCGTCAAAA TGCCGTTTTT 60GAAAAACTGG ATCTGGAGTT TAAAGATGGC TTGAGCGCGA TTAGTGGGGC TAGTGGGGTG 120GGGAAAAGCG TCCTTATTGC GAGCCTTTTA GGGGCGTTTG GGCTTAAAGA GAGCAACGCT 180TCAAACATTG AAGTGGAATT GATCGCGCCT TTTTTAGACA CGGAAGAATA CGGCATTTTT 240AGAGAAGATG AGCATGAACC CTTAGTTATT AGCGTGATTA AAAAAGAAAA AACACGCTAT 300TTTTTAAACC AAACAAGCCT ATCTAAAAAC ACGCTCAAAG CGTTATTAAA GGGGCTTATT 360AAACGCTTAT CTAACGACAG ATTCAGCCAG AATGAACTCA ACGATATTTT AATGCTCTCC 420TTATTAGATG GCTATATCCA AAATAAAAAT AGGCGTTTAG CCCCCTTTTA G 471 ( 2 ) SEQ ID NO:31： ( ⅰ ) ：
(A) length: 357 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..357 (ⅹ ⅰ) sequence description: the data of SEQ ID NO:31:GTGATGCTAA TGGCAATTTT TACCCCTTAT ATTCTTATTT TGAAAATGAT GAAAAAGTCT 60ATGAGTTTAT TCGCCAATAT GGGGTTGGAG CAAATTTTTT GCAACAGAGA CATTAAAGAT 120TTAAATGATT TTGTTTTTGG TATAGAAGTG GGGCTTGATA GCAATGCGAG AAAAAATCGT 180AGCAGAAAGG CTATGGAAAA TCATCTTATC GGTCTTTTTG TCCAAGCTCA ATTAAATTTT 240AAAGAACAAG TAGATATTAG AGAATTTGAG GATTTACGCC AGGCTTTTGG AAATGATACT 300AAAAAATTTG ATTTTGTTAT TTTTAGCAAA GAGAAAACTT ATTTTCATAG AAGCTAA 357 (2) SEQ ID NO:32: (ⅰ) sequence signature:
(A) length: 1068 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1068 ( ⅹⅰ ) ：SEQ ID NO:32:ATGAATATCA AAATTTTAAA AATATTAGTT GGAGGGTTAT TTTTTTTGAG CTTGAACGCC 60CATTTATGGG GGAAACAAGA CAATAGCTTT TTAGGGATTG GTGAAAGAGC CTATAAAAGC 120GGGAATTATT CTAAAGCGGC GTCTTATTTT AAAAAAGCAT GCAACGATGG GGTGAGTGAA 180GGCTGCACGC AATTAGGAAT CATTTATGAA AACGGGCAAG GCACTAGAAT AGATTATAAA 240AAAGCCCTAG AATATTATAA AACCGCATGC CAGGCTGATG ATAGGGAAGG GTGTTTTGGC 300TTAGGGGGGC TTTATGATGA GGGTTTAGGC ACGGCTCAAA ATTATCAAGA AGCCATTGAC 360GCTTACGCTA AGGCATGCGT TTTAAAACAC CCTGAGAGTT GCTACAATTT AGGCATCATT 420TATGATAGAA AAATCAAAGG CAATGCCGCT CAAGCGGTTA CTTACTATCA AAAAAGCTGT 480AATTTTGATA TGGCTAAGGG GTGTTATATT TTAGGCACTG CCTATGAAAA AGGCTTTTTA 540GAAGTCAAAC AGAGCAACCA TAAAGCCGTT ATCTATTATT TGAAAGCGTG CCGATTGAAT 600GAGGGGCAGG CTTGCCGAGC GTTAGGGAGT TTGTTTGAAA ATGGCGATGC AGGGCTTGAT 660GAAGATTTTG AAGTGGCGTT TGATTATTTG CAAAAAGCTT GCGCTTTAAA CAATTCTGGT 720GGTTGCGCGA GTTTAGGCTC TATGTATATG TTGGGCAGGT ATGTTAAAAA AGACCCCCAA 780AAGGCTTTTA ACTATTTCAA GCAAGCATGC GATATGGGGA GCGCGGTGAG TTGCTCTAGG 840ATGGGCTTTA TGTATTCGCA AGGGGACACT GTTTCAAAAG ACTTGAGGAA AGCCCTTGAT 900AATTATGAAA GAGGTTGCGA TATGGGCGAT GAAGTGGGTT GCTTCGCTCT AGCGGGCATG 960TATTACAACA TGAAAGATAA AGAAAACGCC ATAATGATTT ATGACAAGGG CTGTAAATTG 1020GGCATGAAAC AGGCATGCGA AAATCTCACC AAACTCAGGG GGTATTAG 1068 ( 2 ) SEQ ID NO:33： ( ⅰ ) ：
(A) length: 582 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..582 ( ⅹⅰ ) ：SEQ ID NO:33:ATGAAAGAAA AAAACTTTTG GCCTTTAGGA ATCATGAGCG TGCTTATTTT TGGGCTTGGG 60ATCGTGGTGT TTTTAGTGGT GTTTGCCCTA AAAAATTCGC CTAAAAATGA TTTAGTGTAT 120TTCAAGGGTC ATAACGAAGT GGATTTAAAC TTTAACGCCA TGCTTAAAAC TTATGAAAAC 180TTTAAATCCA ATTATCGTTT TTCAGTGGGT TTAAAGCCTC TTACCGAAAG CCCTAAAACC 240CCCATTTTGC CCTATTTTTC TAAAGGCACG CATGGGGATA AAAAAATCCA AGAAAACCTT 300TTAAACAACG CTTTGATTTT AGAAAAGTCC AACACGCTTT ATGCACAATT GCAACCGCTC 360AAACCCGCTT TAGATTCGCC AAATATTCAA GTGTATTTAG CGTTCTATCC CAGCCAATCC 420CAGCCCAGAT TATTAGGAAC GCTTGATTGT AAAAACGCAT GCGAACCTTT AAAATTTGAT 480TTGTTAGAGG GCGATAAAGT GGGGCGCTAT AAGATCCTTT TTAAATTTGT TTTTAAAAAT 540AAAGAAGAAT TGATTTTGGA GCAACTGGCT TTTTTTAAGT AG 582 ( 2 ) SEQ ID NO:34： ( ⅰ ) ：
(A) length: 870 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..870 ( ⅹⅰ ) ：SEQ ID NO:34:TTGGGTATCA ATATGTGTTC TAAAAAAATA AGAAATCTCA TTTTATGCTT TGGTTTTATT 60TTAAGCTTGT GCGCTGAAGA AAATATCACC AAAGAAAACA TGACTGAAAC GAACACGACT 120GAAGAAAACA CCCCTAAAGA CGCTCCCATT CTTTTGGAAG AAAAACGCGC CCAAACTCTA 180GAGCTTAAAG AAGAAAATGA AGTGGCAAAA AAGATTGATG AAAAAAGCCT GCTTGAAGAA 240ATCCATAAGA AAAAACGCCA GCTTTACATG CTCAAAGGGG AATTGCATGA AAAGAATGAA 300TCCATCTTAT TCCAACAAAT GGCTAAAAAT AAGAGCGGCT TTTTTATAGG CGTGATCCTT 360GGCGATATAG GGATTAACGC TAATCCTTAT GAGAAGTTTG AACTTTTAAG CAATATTCAA 420GCTTCTCCCT TGCTGTATGG TTTAAGGAGC GGGTATCAAA AGTATTTCGC TAACGGGATT 480AGCGCCTTAC GCTTTTATGG GGAATATTTA GGGGGGGCGA TGAAAGGGTT TAAAAGCGAT 540TCTTTAGCTT CTTATCAAAC CGCAAGCTTG AATATTGATC TGTTGATGGA TAAGCCTATT 600GACAAAGAAA AAAGGTTTGC GTTAGGGATA TTTGGAGGCG TTGGAGTGGG GTGGAATGGG 660ATGTATCAAA ATTTAAAAGA GATTAGAGGG TATTCACAGC CTAACGCCTT TGGGTTGGTG 720TTAAATTTAG GGGTGAGCAT GACGCTCAAC CTCAAACACC GCTTTGAATT AGCCCTAAAA 780ATGCCTCCCT TAAAAGAAAC TTCGCAAACC TTTTTATATT ATTTTAAAAG CACTAATATT 840TATTATATTA GTTACAACTA TTTATTGTAA 870 ( 2 ) SEQ ID NO:35： ( ⅰ ) ：
(A) length: 2007 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..2007 ( ⅹⅰ ) ：SEQ ID NO:35:ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT TAGAAGCGAA CGAGAAAAAC 60GGCTTTTTCA TAGAAGCCGG CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120AAAAGACACA CCACCACAAA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180ATTTTAAAAA GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAAAAC 300TTCTTGCCTT ATAATTTAAA TAATGTTAAG CTTAGTTTTA CAGACGCTCA AGGCAACACG 360ATTGATCTAG GCGTGATAGA GACCATCCCC AAACACTCTA AGATTGTTTT ACCCGGGGAG 420GCGTTTGATA GTTTAAAAGA GGCGTTTGAT AAAATTGACC CCTATACTTT ATTTCTTCCA 480AAATTTGAAG CCACTAGCAC TTCTATTTCT GATACTAACA CGCAGAGGGT GTTTGAAACG 540CTCAATAACA TTAAAACAAA TCTATAATG AAATATAGTA ATGAAAATCC AAAACAATTTC 600AACACTTGTC CTTACAATAA TAATGGTAAT ACAAAAAATG ATTGTTGGCA AAATTTCACC 660CCACAAACCG CAGAAGAATT CACCAATTTA ATGTTGAACA TGATCGCTGT CTTAGACTCC 720CAATCTTGGG GCGATGCGAT CTTAAACGCT CCTTTTGAAT TCACTAACAG CTCAACAGAT 780TGCGATAGCG ATCCTTCAAA ATGCGTAAAT CCCGGAGTAA ATGGGCGTGT TGATACTAAA 840GTCGATCAAC AATATATACT CAACAAACAA GGTATTATTA ATAATTTTAG AAAAAAAATA 900GAAATTGATG CGGTTGTTTT AAAAAATTCA GGGGTTGTAG GGTTAGCCAA TGGATATGGC 960AATGATGGTG AATATGGCAC ATTAGGGGTA GAAGCCTATG CTTTAGATCC TAAAAAACTC 1020TTTGGCAACG ACCTTAAGAC TATCAATTTA GAAGATTTAA GAACCATCTT GCATGAATTC 1080AGCCACACTA AAGGCTATGG GCATAACGGG AATATGACCT ATCAAAGAGT GCCGGTAACG 1140AAAGATGGTC AAGTGGAAAA GGATAGTAAT GGCAAGCCAA AAGATTCTGA TGGCCTCCCC 1200TATAATGTGT GTTCGCTTTA TGGGGGATCC AATCAGCCCG CTTTCCCTAG CAACTACCCT 1260AATTCCATCT ATCACAATTG TGCGGATGTC CCGGCTGGCT TTTTAGGGGT AACAGCAGCG 1320GTTTGGCAGC AGCTCATCAA TCAAAACGCC TTGCCGATCA ACTACGCTAA CTTGGGGAGT 1380CAAACAAACT ACAACCTAAA CGCTAGTTTA AACACGCAAG ATTTAGCCAA TTCCATGCTC 1440AGCACCATCC AAAAAACCTT TGTAACTTCT AGCGTTACCA ACCACCATTT TTCAAACGCA 1500TCGCAAAGTT TTAGAAGCCC TATTTTAGGG GTTAACGCTA AAATAGGCTA TCAAAACTAC 1560TTTAATGATT TCATAGGGTT GGCTTATTAT GGCATCATCA AATACAATTA CGCTAAAGCT 1620GTTAATCAAA AAGTCCAGCA ATTGAGCTAT GGTGGGGGGA TAGATTTGTT ATTGGATTTC 1680ATCACCACTT ACTCCAATAA AAATAGCCCT ACAGGCATTC AAACCAAAAG GAATTTTTCT 1740TCATCTTTTG GTATCTTTGG GGGGTTAAGG GGCTTGTATA ACAGCTATTA TGTGTTGAAC 1800AAAGTCAAAG GAAGCGGCAA TTTAGATGTG GCTACCGGGT TGAACTACCG CTATAAGCAT 1860TCTAAATATT CTGTAGGGAT TAGCATCCCT TTAATCCAAA GAAAAGCTAG CGTCGTTTCT 1920AGCGGTGGCG ATTATACGAA CTCTTTTGTT TTCAATGAAG GGGCTAGCCA CTTTAAGGTG 1980TTTTTCAATT ACGGGTGGGT GTTTTAG 2007 ( 2 ) SEQ ID NO:36： ( ⅰ ) ：
(A) length: 192 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..192, (ⅹ ⅰ) sequence description: SEQ ID NO:36:ATGAATACAG AAATTTTAAC CATCATGTTA GTTGTCTCCG TGCTTATGGG ATTGGTAGGC 60TTAATAGCGT TTTTATGGGG GGTTAAAAGC GGTCAGTTTG ACGATGAAAA ACGCATGCTT 120GAAAGCGTGT TGTATGACAG CGCGAGCGAC TTGAACGAAG CGATTTTACA AGAAAAACGC 180CAAAAGAATT AA 192, (2) data of SEQ ID NO:37:, (ⅰ) sequence signature:
(A) length: 1221 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1221 ( ⅹⅰ ) ：SEQ ID NO:37:ATGGTATTTT TTCATAAGAA AATTATTTTA AATTTtATCT ATTCTTTAAT GGTTGCTTTT 60TTATTCCATT TATCCTATGG GGTTCTTTTA AAAGCCGATG GAATGGCTAA AAAGCAAACT 120CTTTTAGTGG GTGAAAGGCT TGTGTGGGAT AAGCTCACGC TGTTAGGGTT TTTAGAAAAA 180AACCATATCC CCCAAAAACT CTACTACAAT TTGAGCTCTC AAGATAAAGA ATTGAGTGCT 240GAAATCCAAA GCAATGTTAC CTACTACACT TTAAGAGATG CAAATAACAC GCTCATTCAA 300GCCCTTATCC CTATTAGCCA GGATTTGCAA ATCCATATTT ACAAAAAAGG AGAGGATTAT 360TTTTTAGACT TTATCCCCAT TGTTTTCACT CGTAAAGAAA GAACCCTCCT TCTTTCCTTA 420CAAACTTCGC CCTATCAAGA TATTGTCAAA GCCACCAATG ACCCCCTTTT AGCCAACCAA 480TTGATGAACG CGTATAAAAA AAGCGTGCCT TTTAAACGCC TAGTGAAAAA CGATAAAATC 540GCTATCGTTT ATACAAGGGA TTATCGTGTG GGGCAAGCGT TTGGCCAGCC GACCATCAAA 600ATGGCGATGG TTAGCTCTCG TTTGCACCAA TACTATCTTT TTTCCCATTC AAACGGGCGT 660TATTACGATT CAAAAGCGCA AGAAGTGGCA GGGTTTTTAC TAGAAACCCC GGTGAAATAC 720ACCCGCATTT CTTCGCCTTT TTCGTATGGG AGGTTCCATC CTGTTTtAAA AGTTAAACGG 780CCTCATTACG GCGTGGATTA TGCGGCTAAA CATGGCAGTT TGATCCATTC TGCTTCAGAC 840GGCCGTGTGG GTTTTATAGG GGTTAAGGCG GGTTATGGGA AGGTGGTTGA AATCCATTTG 900AATGAATTGC GCTTGGTGTA TGCTCACATG AGCGCGTTCG CTAACGGATT AAAAAAAGGC 960TCGTTCGTTA AAAAAGGGCA AATCATAGGA AGAGTGGGAA GCACGGGTTT AAGCACCGGG 1020CCGCATTTGC ATTTTGGCGT GTATAAAAAC TCCCGCCCCA TTAATCCTTT AGGCTATATC 1080CGCACCGCTA AAAGCAAGCT GCATGGCAAA CAAAGAGAGG TTTTTTTAGA AAAAGCTCAG 1140TATTCTAAGC AAAAATTAGA AGAACTTTTT AAAACCCATT CTTTTGAAAA AAATTCATTT 1200TATCTTTTAG AGGGTTTTTA A 1221 ( 2 ) SEQ ID NO:38： ( ⅰ ) ：
(A) length: 891 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..891 ( ⅹⅰ ) ：SEQ ID NO:38:TTGTTTTTAG TCAAAAAAAT AGGCGTGGTA ATAATGATTT TAGTCTGCTT TTTAGCTTGC 60TCGCAAGAGA GCTTTATCAA AATGCAAAAA AAAGCCCAAG AGCAAGAAAA TGACGGCTCT 120AAACGCCCCA GCTATGTGGA TTCGGATTAT GAAGTCTTTA GCGAAACGAT TTTTTTACAA 180AACATGGTGT ATCAGCCTAT AGAGGAAAGA AACGCTTTTT TCCAACTGAC TAAAGATGAA 240GACAATTCTT TTAACCCTGA AAATTCCGTG ATTTTACTGA ATGAGCCAAG CGATAATAGT 300GAAAAAAACC TACTCTCATA CCCAAACGAT CCCAATAACA ATGAAGACAA CGCTAATAAT 360AGTCAAAAAA ATCCGTTCCT TTACAAGCCC AAAAGAAAAA CAAAAAACCC AAAACTCATT 420GAATATTCCC AACAAGATTT CTACCCCCTA AAAAATGGGG ATATTATCAT GAGTAAAGAA 480GGGGATCAAT GGTTGATAGA AATCCAATCC AAAGCCTTGA AGCGTTTTTT AAAAGATCAA 540AACGATAAAG ATCGCCAGAT CCAAACTTTC ACTTTTAATG ACACTAAAAC GCAAATCGCG 600CAAATTAAGG GCAAAATTTC TTCGTATGTT TATACCACCA ATAACGGTAG CTTGAGTTTA 660AGGCCTTTTT ATGAATCGTT TTTGTTAGAA AAAAAGAGCG ATAATGTTTA TACGATAGAG 720AATAAGGCTT TAGATACTAT GGAGATTTCA AAGTGTCAAA TGGTGTTAAA AAAGCATTCA 780ACCGATAAAT TAGACAGCCA GCATAAAGCC ATCAGTATTG ATTTGGATTT TAAAAAAGAG 840CGCTTTAAGA GCGATACGGA ACTCTTTTTA GAATGTCTTA AGGAAAGTTA G 891 ( 2 ) SEQ ID NO:39： ( ⅰ ) ：
(A) length: 747 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..747 ( ⅹⅰ ) ：SEQ ID NO:39:GTGAGCTATG ACAACACCGA TGATTATTAT TTCCCTAGAA ATGGGGTTAT CTTTAGTTCC 60TATGCGACAA TGTCTGGTTT GCCAAGCTCT GGCACGCTCA ATTCTTGGAA CGGGTTAGGC 120GGGAATGTCC GTAACACCAA AGTTTATGGT AAATTCGCCG CTTACCACCA TTTGCAAAAA 180TATTTATTGA TAGATTTGAT CGCTCGTTTT AAAACGCAAG GGGGCTATAT CTTTAGGTAT 240AACACCGATG ATTACTTGCC CTTAAACTCC ACTTTCTACA TGGGGGGCGT AACCACGGTG 300AGAGGCTTTA GGAACGGCTC AATCACACCT AAAGATGAGT TTGGCTTGTG GCTTGGAGGC 360GATGGGATTT TTACCGCTTC TACTGAATTG AGCTATGGGG TGTTAAAAGC GGCTAAAATG 420CGTTTAGCGT GGTTTTTTGA CTTTGGTTTC TTAACCTTTA AAACCCCAAC TAGGGGGAGT 480TTCTTCTATA ACGCTCCCAC CACGACGGCG AATTTTAAAG ATTATGGCGT TGTAGGGGCT 540GGGTTTGAAA GGGCGACTTG GAGGGCTTCT ACAGGCTTAC AGATTGAATG GATTTCGCCC 600ATGGGGCCTT TGGTGTTGAT TTTCCCTATA GCGTTTTTCA ACCAATGGGG CGATGGCAAT 660GGCAAAAAAT GTAAAGGGCT GTGCTTTAAC CCTAACATGA ACGATTACAC GCAACATTTT 720GAATTTTCTA TGGGAACAAG GTTTTAA 747 ( 2 ) SEQ ID NO:40： ( ⅰ ) ：
(A) length: 1008 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1008 ( ⅹⅰ ) ：SEQ ID NO:40:GTGCAACACT TCAATTTCCT CTATAAAGAT TCTTTATTTT CTATCGCTTT ATTCACTTTC 60ATTATCGCTC TTGTGATTTT ATTAGAACAG GCTAGAGCGT ATTTCACCCG AAAGAGAAAC 120AAAAAATTTT TGCAAAAATT CGCCCAAAAT CAAAACGCCT ATGCGAGCAG CGAGAATTTA 180GACGAGCTTT TAAAGCATGC TAAAATTTCC AGTTTGATGT TTTTAGCTAG GGCGTATTCT 240AAAGCGGATG TGGAAATGAG CATTGAAATC TTAAAAGGGC TTTTGAATCG CCCCTTAAAA 300GATGAAGAAA AAATCGCTGT TTTAGATTTA TTGGCTAAAA ATTATTTTAG CGTGGGGTAT 360TTGCAGAAAA CAAAAGACAC CGTGAAAGAA ATTTTGCGCT TTTCCCCAAG GAATGTGGAA 420GCGTTGTTGA AGCTTTTGCA TGCGTATGAA TTAGAAAAAG ATTATTCAAA GGCTTTAGAA 480ACTTTGGAAT GTTTGGAAGA ATTAGAGGTG CCTAAAATTG AAACGATTAA AAATTACCTC 540TATTTAATGC ATTTAATAGA GAATAAGGAA GATGCGGCTA AAATCTTGCA TGTTTCAAAA 600GCGTCGTTAG ATTTCAAAAA AATCGCTCTG AATCACTTAA AATCGCATGA TGAAAATCTT 660TTTTGGCAAG AAATTGATAC AACCGAACGG CTAGAAAATG TGATCGATCT TTTATGGGAT 720ATGAATATCC CTGCTTTTAT TTTAGAAAAA CATGCCCTTT TGCAGGACAT CGCGCGATCT 780CAAGGGTTGC TTTTGGATCA CAAACCTTGC CAAATTTTTG AATTAGAGGT TTTACGCGCT 840CTATTGCATA GCCCTATAAA AGCGAGTCTG ACTTTTGAAT ACCGCTGCAA GCATTGCAAA 900CAAATCTTTC CTTTTGAAAG CCATAGGTGT CCTGTGTGTT ACCAGTTAGC GTTTATGGAT 960ATGGTGCTTA AAATCTCTAA AAAAACGCAT GCTATGGGAG TGGATTAA 1008 ( 2 ) SEQ ID NO:41： ( ⅰ ) ：
(A) length: 1242 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1242 ( ⅹⅰ ) ：SEQ ID NO:41:ATGAGGAAAA TTTTTTCTTA TATTTCTAAG GTTCTATTAT TTATTGGGGT GGTTTATGCA 60GAGCCTGATT CTAAAGTGGA AGCCTTAGAA GGGAGGAAGC AAGAGTCTTC TTTGGATAAA 120AAAATCCGCC AAGAATTGAA GAGTAAGGAA TTGAAGAATA AGGAATTAAA GAATAAGGAT 180TTGAAAAATA AAGAAGAAAA GAAAGAAACA AAAGCCAAGA GAAAACCCAG AGCAGAAGTC 240CATCATGGGG ACGCCAAAAA TCCCACTCCA AAGATCACGC CTCCTAAAAT CAAAGGGAGT 300AGTAAGGGCG TTCAAAATCA AGGCGTTCAA AACAACGCGC CAAAACCTGA AGAAAAAGAT 360ACAACCCCTC AAGCTACTGA AAAAAATAAG GAAACAAGCC CTAGCTCTCA ATTCAATTCC 420ATTTTTGGTA ATCCTAATAA CGCTACCAAC AACACCCTTG AAGATAAGGT CGTAGGGGGC 480ATTTCATTGC TTGTTAATGG TTCGCCTATC ACGCTGTATC AAATCCAAGA AGAGCAAGAA 540AAATCTAAAG TGAGTAAGGC TCAAGCTAGG GATCGTTTGA TCGCTGAACG CATTAAAAAC 600CAAGAAATTG AGCGCTTAAA AATCCATGTA GATGATGACA AGCTAGACCA AGAAATGGCG 660ATGATGGCGC AACAACAAGG CATGGATTTA GACCATTTCA AACAGATGCT TATGGCTGAG 720GGGCATTATA AACTCTATAG AGATCAACTT AAAGAGCATT TAGAAATGCA AGAATTGTTG 780CGTAATATTT TGCTCACGAA TGTGGATACC AGCTCTGAAA CCAAAATGCG CGAATATTAC 840AACAAACACA AGGAGCAATT CAGTATCCCC ACAGAAATAG AAACCGTGCG CTACACTTCC 900ACCAATCAAG AGGATTTAGA AAGGGCTATG GCAGACCCTA ATTTGGAAGT CCCAGGGGTG 960 AGTAAGGCCA ATGAAAAAAT AGAGATGAAA ACCCTAAACC CTCAAATCGC CCAAGTCTTT 1020ATTTCGCATG AGCAAGGCTC TTTCACGCCC GTTATGAATG GGGGTGGGGG GCAGTTCATC 1080ACCTTTTATA TCAAGGAAAA AAGGGGTAAA AATGAAGTGA GCTTCAGTCA GGCCAAGCAA 1140TTCATCGCCC AAAAATTAGT GGAAGAATCT AAGGATAAGA TTTTAGAAGA GCATTTTGAA 1200AAATTGCGCG TTAAGTCTAG GATTGTGATG ATCAGAGAGT GA 1242 ( 2 ) SEQ ID NO:42： ( ⅰ ) ：
(A) length: 561 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..561 ( ⅹⅰ ) ：SEQ ID NO:42:ATGATTAAAA GAATTGCTTG TATTTTAAGC TTGAGCGCGA GTTTAGCGTT AGCTGGCGAA 60GTGAATGGGT TTTTCATGGG TGCGGGTTAT CAACAAGGTC GTTATGGCCC TTATAACAGC 120AATTACTCTG ATTGGCGTCA TGGCAATGAC CTTTATGGTT TGAATTTCAA ATTAGGTTTT 180GTAGGCTTTG CCAATAAATG GTTTGGGGCT AGGGTGTATG GCTTTTTAGA TTGGTTTAAC 240ACTTCAGGGA CTGAACACAC CAAAACCAAT TTGCTCACCT ATGGCGGCGG TGGCGATTTG 300ATTGTCAATC TCATTCCTTT GGATAAATTC GCTCTAGGTC TCATTGGTGG CGTTCAATTA 360GCCGGAAACA CTTGGATGTT CCCTTATGAT GTCAATCAAA CCAGATTCCA GTTCTTATGG 420AATTTAGGCG GAAGAATGCG TGTTGGGGAT CGCAGTGCGT TTGAAGCGGG CGTGAAATTC 480CCTATGGTTA ATCAGGGTAG CAAAGATGTA GGGCTTATCC GCTACTATTC TTGGTATGTG 540GATTATGTCT TCACTTTCTA G 561 ( 2 ) SEQ ID NO:43： ( ⅰ ) ：
(A) length: 729 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅰ ⅹ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..729 ( ⅹⅰ ) ：SEQ ID NO:43:ATGAAAAAAT TTTTTTCTCA ATCTTTGTTA GCTCTTATTA TCTCTATGAA TGCGGTATCT 60GGCATGGATG GTAATGGCGT TTTTTTAGGG GCGGGTTATT TGCAAGGACA GGCGCAAATG 120CATGCGGATA TTAATTCTCA AAAACAAGCC ACCAACGCTA CGATCAAAGG CTTTGACGCG 180CTCTTGGGGT ATCAATTTTT CTTTGAAAAA CACTTTGGCT TACGCCTTTA TGGGTTTTTT 240GACTACGCTC ATGCCAATTC TATTAAGCTT AAAAACCCTA ACTATAATAG CGAAGCGGCG 300CAAGTGGCTA GTCAAATTCT TGGGAAACAA GAAATCAATC GTTTAACAAA CATTGCCGAT 360CCCAGAACTT TTGAGCCGAA CATGCTCACT TATGGGGGGG CTATGGACGT GATGGTTAAT 420GTCATCAATA ACGGCATCAT GAGTTTGGGG GCTTTTGGCG GGATACAATT GGCCGGCAAT 480TCATGGCTTA TGGCGACACC GAGCTTTGAG GGCATTTTAG TGGAACAAGC CCTTGTGAGC 540AAGAAAGCCA CTTCTTTCCA ATTTTTATTC AATGTGGGGG CTCGCTTAAG GATCTTAAAA 600CATTCTAGCA TTGAAGCGGG CGTGAAATTC CCCATGCTAA AGAAAAACCC CTACATCACT 660GCAAAAAATT TGGATATAGG GTTTAGGCGC GTGTATTCGT GGTATGTGAA TTACGTGTTC 720ACTTTCTAG 729 ( 2 ) SEQ ID NO:44： ( ⅰ ) ：
(A) length: 771 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..771 ( ⅹⅰ ) ：SEQ ID NO:44:ATGGGATACG CAAGCAAATT AGCTTTAAAG ATTTGTTTGG TAGGTTTATG TTTATTTAGC 60ACCCTTGGTG CAGAACACCT TGAGCAAAAA GGGAATTATA TTTATAAGGG AGAGGAGGCT 120TATAATAATA AGGAATATGA GCGAGCGGCT TCTTTTTATA AGAGCGCTAT TAAAAATGGT 180GAGTCGCTTG CTTATATTCT TTTAGGGATC ATGTATGAAA ATGGTAGGGG TGTACCTAAA 240GATTACAAGA AAGCGGTTGA ATATTTCCAA AAAGCTGTTG ATAACGATAT ACCTAGAGGG 300TATAACAATT TGGGCGTGAT GTATAAAGAG GGTAAGGGAG TTCCTAAAGA TGAAAAGAAA 360GCGGTGGAAT ATTTTAGAAT AGCTACAGAG AAAGGTTATA CTAACGCTTA TATCAACTTA 420GGCATCATGT ATATGGAGGG CAGGGGAGTT CCAAGTAACT ATGCGAAAGC GACAGAATGT 480TTTAGAAAAG CGATGCATAA GGGCAATGTG GAAGCTTATA TTCTCCTAGG GGATATTTAT 540TATAGCGGGA ATGATCAATT GGGTATTGAG CCGGACAAAG ATAAGGCTGT TGTCTATTAT 600AAAATGGCGG CTGATGTGAG TTCTTCTAGA GCTTATGAAG GGTTGTCAGA GTCTTATCGG 660TATGGGTTAG GCGTGGAAAA AGATAAAAAA AAGGCTGAAG AATACATGCA AAAAGCATGC 720GATTTTGACA TTGATAAAAA TTGTAAGAAA AAGAACACTT CAAGCCGATA A 771 ( 2 ) SEQ ID NO:45： ( ⅰ ) ：
(A) length: 1974 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1974 ( ⅹⅰ ) ：SEQ ID NO:45:ATGAGAAAAC TATTCATCCC ACTTTTATTA TTCAGCGCTT TAGAAGCGAA CGAGAAAAAC 60GGCTTTTTCA TAGAAGCCGG CTTTGAAACT GGGCTATTAG AAGGCACACA AACGCAAGAA 120AAAAGACACA CCACCACAAA AAACACTTAC GCAACTTACA ATTATTTACC CACAGACACG 180ATTTTAAAAA GAGCGGCTAA TTTATTCACC AATGCCGAAG CGATTTCAAA ATTAAAATTC 240TCATCTTTAT CCCCTGTTAG AGTGTTGTAT ATGTATAATG GTCAATTAAC TATAGAAAAC 300TTCTTGCCTT ATAATTTAAA TAATGTTAAG CTTAGTTTTA CAGACGCTCA AGGCAATGTG 360ATCGATCTAG GCGTGATAGA GACTATCCCC AAACACTCTA AGATTGTTTT GCCCGGAGAG 420GCATTTGATA GTCTAAAAAT TGACCCCTAT ACTTTATTTC TTCCAAAAAT TGAAGCCACT 480AGCACTTCTA TTTCTGACGC TAACACGCAG AGGGTGTTTG AAACGCTCAA TAAGATTAAG 540ACAAATTTGG TCGTAAATTA TAGGAATGAA AACAAATTTA AAGATCACGA AAATCATTGG 600GAAGCCTTTA CCCCACAAAC CGCAGAAGAA TTCACTAATT TAATGTTGAA CATGATCGCT 660GTTTTAGACT CCCAATCTTG GGGCGATGCG ATCTTAAACG CTCCTTTTGA GTTCACTAAC 720AGCCCAACAG ATTGCGATAA TGATCCTTCA AAATGCGTAA ATCCTGGGAC AAACGGGCTT 780GTCAATTCTA AAGTCGATCA AAAATATGTG TTAAACAAAC AAGACATTGT CAATAAATTT 840AAAAACAAAG CGGATCTTGA TGTAATTGTT TTAAAGGATT CAGGGGTTGT AGGGCTTGGG 900AGTGATATTA CCCCTAGCAA CAATGATGAT GGCAAGCATT ATGGCCAGTT AGGGGTAGTA 960GCTTCTGCTT TAGATCCTAA AAAACTCTTT GGCGATAACC TTAAGACTAT CAATTTAGAG 1020GATTTAAGAA CCATCTTGCA TGAATTCAGC CACACTAAAG GCTATGGGCA TAACGGGAAT 1080ATGACCTATC AAAGAGTGCC GGTAACGAAA GATGGTCAAG TGGAAAAGGA TAGTAATGGC 1140AAGCCAAAAG ATTCTGATGG CCTCCCCTAT AATGTGTGTT CGCTTTATGG GGGATCCAAT 1200CAGCCCGCTT TCCCTAGCAA CTACCCTAAT TCCATCTATC ACAATTGTGC GGATGTCCCG 1260GCTGGCTTTT TAGGGGTAAC AGCAGCGGTT TGGCAGCAGC TCATCAATCA AAACGCCTTG 1320CCGATCAACT ACGCTAACTT GGGGAGTCAA ACAAACTACA ACCTAAACGC TAGTTTAAAC 1380ACGCAAGATT TAGCCAATTC CATGCTCAGC ACCATCCAAA AAACCTTTGT AACTTCTAGC 1440GTTACCAACC ACCATTTTTC AAACGCATCG CAAAGTTTTA GAAGCCCTAT TTTAGGGGTT 1500AACGCTAAAA TAGGCTATCA AAACTACTTT AATGATTTCA TAGGGTTGGC TTATTATGGC 1560ATCATCAAAT ACAATTACGC TAAAGCTGTT AATCAAAAAG TCCAGCAATT GAGCTATGGT 1620GGGGGGATAG ATTTGTTATT GGATTTCATC ACCACTTACT CCAATAAAAA TAGCCCTACA 1680GGCATTCAAA CCAAAAGGAA TTTTTCTTCA TCTTTTGGTA TCTTTGGGGG GTTAAGGGGC 1740TTGTATAACA GCTATTATGT GTTGAACAAA GTCAAAGGAA GCGGCAATTT AGATGTGGCT 1800ACCGGGTTGA ACTACCGCTA TAAGCATTCT AAATATTCTG TAGGGATTAG CATCCCTTTA 1860ATCCAAAGAA AAGCTAGCGT CGTTTCTAGC GGTGGCGATT ATACGAACTC TTTTGTTTTC 1920AATGAAGGGG CTAGCCACTT TAAGGTGTTT TTCAATTACG GGTGGGTGTT TTAG 1974 ( 2 ) SEQ ID NO:46： ( ⅰ ) ：
(A) length: 504 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..504 ( ⅹⅰ ) ：SEQ ID NO:46:ATGAAATTGG TGAGTCTTAT TGTAGCGTTA GTTTTTTGTT GTTTTTAGG GGCTGTAGAG 60TTGCCTGGAG TTTATCAAAC TCAAGAATTT TTATACATGA AAAGCTCTTT TGTGGAGTTT 120TTTGAGCATA ACGGGAAGTT CTATGCCTAT GGTATTTCTG ATGTGGATGG CTCTAAAGCC 180AAAAAAGACA AACTCAATCC TAACCCAAAG CTAAGGAATC GCAGCGATAA AGGCGTGGTG 240TTTTTAAGCG ATTTGATTAA GGTTGGGGAA CAATCTTATA AAGGCGGTAA GGCGTATAAT 300TTTTATGACG GCAAGACCTA CCATGTGAGA GTCACTCAAA ATTCAAACGG GGATTTGGAA 360TTCACTTCAA GCTATGACAA ATGGGGGTAT GTGGGCAAAA CCTTCACCTG GAAACGCCTG 420AGCGATGAAG AAATCAAAAA TCTAAAGCTC AAGCGTTTTA ACTTGGACGA AGTCCTTAAA 480ACCCTCAAAG ATAGCCCTAT TTAA 504 ( 2 ) SEQ ID NO:47： ( ⅰ ) ：
(A) length: 885 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..885 ( ⅹⅰ ) ：SEQ ID NO:47:ATGAGTAATC AAGCGAGCCA TTTGGATAAT TTTATGAACG CTAAAAATCC CAAAAGTTTT 60TTTGATAATA AGGGGAATAC CAAATTCATC GCTATCACAA GCGGTAAGGG GGGCGTGGGG 120AAATCCAACA TTAGCGCTAA TTTAGCTTAC TCTTTATACA AGAAAGGTTA TAAGGTAGGG 180GTATTTGATG CGGATATTGG TTTAGCGAAT TTAGATGTCA TTTTTGGGGT GAAAACCCAT 240AAAAATATCT TGCATGCCTT AAAAGGCGAA GCCAAATTGC AAGAAATCAT TTGCGAGATT 300GAACCCGGGC TTTGCTTAAT CCCTGGGGAT AGCGGCGAAG AAATTTTAAA ATACATCAGC 360GGCGCGGAAG CTTTGGATCG ATTCGTAGAT GAAGAGGGGG TTTTAAGCTC TTTAGATTAT 420ATTGTGATTG ATACGGGTGC TGGGATTGGG GCCACTACGC AAGCGTTTTT GAATGCGAGC 480GATTGCGTGG TGATTGTTAC CACACCCGAT CCTTCAGCGA TTACCGATGC GTATGCATGC 540ATTAAAATCA ACTCCAAGAA TAAAGATGAA TTGTTCCTTA TCGCTAACAT GGTAGCCCAA 600CCTAAAGAAG GCAGGGCGAC TTATGAAAGG CTATTCAAGG TGGCTAAAAA CAATATCGCT 660TCATTAGAAT TGCACTATTT AGGGGCGATT GAAAACAGCT CCTTATTGAA ACGCTATGTG 720AGGGAGCGAA AGATTTTGAG GAAAATAGCC CCTAACGATT TGTTTTCGCA ATCCATTGAC 780CAGATAGCGA GCCTTTTAGT TTCTAAACTA GAAACCGGCA CTTTAGAAAT ACCAAAAGAA 840GGTTTAAAAA GCTTTTTTAA AAGGCTTTTG AAGTATTTGG GGTAG 885 ( 2 ) SEQ ID NO:48： ( ⅰ ) ：
(A) length: 1119 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1119 ( ⅹⅰ ) ：SEQ ID NO:48:TTGGAACCTT CAAGAAATCG CCTAAAACAT GCCGCCTTTT TTGTGGGGCT TTTTATCGTT 60TTGTTTTTAA TTATAATGAA GCACCAAACC TCCCCCTATG CTTTCACGCA TAATCAAGCC 120CTTGTCACTC AAACCCCCCC CTATTTCACG CAACTCACTA TCCCTAAACC AAATGACGCT 180TTAAGCGCGC ATGCGAGCTC TTTAATCAGC TTGCCTAACG ACAATCTTTT GAGCGCTTAT 240TTTAGCGGCA CTAAAGAAGG GGCAAGGGAT GTGAAAATCA GCGCGAATCT TTTTGACAGC 300AAGACTAATC GCTGGAGCGA AGCCTTCATT CTTTTAACCA AAGAAGAGCT TTCTCATCAT 360TCGCATGAAT ACATCAAAAA ATTAGGTAAC CCCTTGCTTT TTTTGCATGA TAATAAAATT 420TTGTTGTTTG TCGTAGGGGT GAGCATGGGC GGGTGGGCCA CTTCTAAAAT CTATCAATTT 480GAAAGCGCTT TAGAGCCGAT TCATTTTAAG TTTGCGCGAA AACTCTCTTT AAGCCCTTTT 540TTAAATTTGA GCCATTTAGT AAGGAATAAG CCTTTAAACA CCACTGATGG CGGGTTTATG 600CTACCACTCT ATCACGAATT AGCCACCCAA TACCCCTTGT TGTTGAAATT TGACCAACAA 660AATAACCCAA GAGAGCTTTT AAGGCCTAAT ACCTTAAACC ACCAGCTCCA ACCAAGCTTA 720ACCCCCTTTA AAGACTGCGC TGTCATGGCG TTTAGAAACC ATTCTTTTAA AGATAGCCTC 780ATGCTAGAAA CCTGTAAAAC CCCCACTGAT TGGCAAAAAC CCATTTCTAC AAATCTTAAA 840AACTTAGATG ATTCTTTAAA TTTACTCAAT TTAAATGGAA TATTGTATTT GATCCACAAC 900CCTAGCGATT TATCACTGCG TCGTAAAGAA CTTTGGCTTT CTAAATTAGA AAACTCCAAC 960TCGTTTAAAA CCTTAAAAGT TTTGGATAAA GCGAATGAAG TGAGTTACCC AAGCTATAGC 1020CTTAATCCGC ATTTTATAGA TATTGTCTAT ACTTACAACC GCTCTCATAT CAAACACATC 1080CGTTTCAATA TGGCTTATTT AAATTCCCTT CTCAAGTGA 1119 ( 2 ) SEQ ID NO:49： ( ⅰ ) ：
(A) length: 2937 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..2937 ( ⅹⅰ ) ：SEQ ID NO:49:ATGAAGAAAA GAAAACATGT ATCCAAGAAA GTGTTTAATG TCATTATCTT GTTTGTGGCA 60GTATTCACTC TTTTAGTCGT CATTCACAAA ACCCTTTCAA ACGGCATTCA CATACAAAAT 120TTAAAAATTG GAAAACTTGG CATTTCTGAA TTATACTTAA AACTCAATAA CAAGCTTTCT 180TTGGAAGTTG AGCGGGTTGA TCTCTCTTCT TTCTTCCATC AAAAACCCAC TAAAAAGCGT 240TTAGAAGTTT CTGATTTGAT TAAAAATATC CGTTATGGCA TTTGGGCGGT GTCTTATTTT 300GAAAAACTTA AAGTCAAAGA AATCATTTTA GACGATAAAA ATAAAGCCAA TATCTTTTTT 360GATGGGAATA AATACGAGTT AGAATTTCCA GGAATCAAAG GGGAATTTTC CCTAGAAGAC 420GATAAAAATA TCAAGCTTAA AATCATCAAT TTGCTTTTTA AAGATGTTAA AGTCCAAGTG 480GATGGCAACG CCCACTATTC ACCCAAAGCC AGGAAAATGG CGTTCAATTT GATTGTCAAG 540CCCTTAGTTG AACCCAGCGC TGCAATTTAT TTGCAAGGGC TAACCGATTT AAAAACCATA 600GAATTAAAAA TTAACACTTC TCCAATGAAA AGCCTAGCGT TTTTAAAGCC TCTTTTCCAA 660CGCCAATCGC AAAAAAATTT AAAAACGTGG ATTTTTGACA AGATCCAATT TGCCAGCTTT 720AAGATTGATA ACGCTTTAAT CAAGGCTAAT TTCACTCCTA GCGAGTTTAT CCCATCGCTT 780TTGGAAAATT CTGTAGTTAA AGCCACTTTG ATTAAGCCTT CAGTCGTTTT TAATGATGGC 840TTATCGCCCA TTAAAATGGA TAAAACCGAA TTGATTTTCA AAAACAAACA GCTCCTCATA 900CAGCCCCAAA AAATCACTTA TGAAACCATG GAATTAACCG GCTCTTACGC CACTTTTTCC 960AATTTGTTAG AAGCCCCTAA GTTGGAGGTT TTTTTAAAAA CGACCCCTAA TTATTATGGC 1020GATAGCATTA AGGATTTATT GAGCGCTTAT AAAGTCGTTT TACCTTTGGA TAAAATCAGC 1080ATGCCATCTA GCGCGGATTT GAAGCTCACT TTGCAATTCT TAAAAAACAC CGCCCCCTTA 1140TTTAGCGTTC AAGGCAGCGT TAATTTGCAA GAAGGCACTT TCTCGCTCTA TAATATCCCC 1200CTTTACACGC AAAGCGCTCA AATCAATTTG GACATCGCCC AAGAATACCA ATACATCTAC 1260ATAGACACGA TCCACACGCG CTATGCAAAC ATGCTGGATT TAGACGCTAA AATCGCTTTA 1320GATTTAGGTC AAAAAAACCT TTCTTTGGAT TCTTTAGTCC ATAAAATCCA AGTCAATACC 1380AATAACAATA TCAACATGCG CTCTTATGAT CCCAATAACA CTCAAGAAGA TCCGCAAACT 1440AACTTTACTT TGGATCTAAA AAGCTTGCAT TCTATCATTC AAGAGGGTGA AAATTCAGAA 1500GTTTTTAGAA GAAAAATCAT AGACACCATT AAAGCCCAAA GCGAAGATAA ATTCACTAAA 1560GATGTTTTTT ACGCCACAGG AGACACTCTC AAAAGCCTGT CGTTGAGTTT TGATTTTTCC 1620AACCCCGATC ACATACAATG GAGCGTGCCA CAACTCTTAT TAGAAGGCGA ATTTAAAGAT 1680AACGCCTATA CTTTTAAGAT CAAAGATTTG AAAAAGATCA AGCCCTATTC CCCCATTATG 1740GACTATATTG CCCTAAAAGA CGGCTCTTTA GAGGTTTCTA CGAGCGATTT TGTCAATATT 1800GATTTTTTTG CTAAAGATTT GAAAATCAAC CTCCCCATTT ATAGGAGCGA TGGATCGCAT 1860TTTGATTCTT TTTCTTTATT TGGCTCTATC AATAAAGATG AAATTTCTGT CTATACTCCA 1920AGCAAAAGCA TATCCATAAA AGTTAAGGGG GATCAAAAGG ATATTACCCT TAATAACATT 1980GATTTGAGTA TTGATGATTT CTTGGATAGT AAAATGCCAG CTATTGCGGG ATTATTCTCA 2040AAAGAACGAA AAGAAAAGCC TAGCTCTAAA GAAATCCAAG ATGAAGATGT TTTCATTAGC 2100GCCAAACAAC GCTATGAAAA AGCCCACAAA ATTATCCCCA TCTCTACACG CATCCATGCT 2160AAAGATGTCG TGCTGATCTA TAAAAAAATG CCTTTTCCTT TAGAAAATCT TGATATTGTC 2220GCTCAAGACG ATAGGGTGAA AATTGATGGC AATTATAAAA ACGCCATGAT CATGGCGGAT 2280TTAGTGCATG GGGCTTTGTA TCTTAAGGCT CATAATTTTA GCGGGGATTA TATCAACACC 2340ATTCTTCAAA AAGATTTCGT AGAAGGAGGC TTATTCACGC TTATTGGGGC TCTTGAAGAT 2400CAGGTTTTCA ATGGCGAATT GAAATTCCAA AACACAAGCT TAAAGAATTT CGCCCTCATG 2460CAAAACATGG TCAATCTCAT CAACACCATT CCCTCCCTCA TTGTCTTTAG AAACCCTCAT 2520TTAGGGGCTA ATGGCTATCA AATCAAAACC GGCTCCGTTG TGTTTGGGAT CACTAAAGAA 2580TATTTAGGGT TAGAAAAAAT TGATCTTGTC GGCAAAACGC TTGATATTGC TGGCAATGGA 2640ATCATTGAAT TAGACAAAAA CAAATTAGAT TTAAACTTAG AAGTTTCCAC TATCAAGGCT 2700TTGAGTAATG TCTTAAATAA AATCCCTATC GTGGGCTATC TCGTTTTAGG AAAAGGAGGT 2760AAAATCACCA CTAACGTGAA TGTCAAAGGC ACGTTGGATA AGCCTAAAAC CCAAGTAACT 2820TTAGCGTCAG ATATTATCCA AGCGCCTTTT AAAATCTTAC GCCGTATTTT CACGCCTATT 2880GACATCATCG TGGATGAAGT CAAGAAAAAC ATTGATTCAA AAAGGAAATT AAAATGA 2937 ( 2 ) SEQ ID NO:50： ( ⅰ ) ：
(A) length: 1434 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1434 ( ⅹⅰ ) ：SEQ ID NO:50:ATGAATACTA TTATAAGATA TGCGAGTTTA TGGGGCTTGT GTATTACTCT AACTCTAGCG 60CAAACCCCCT CTAAAACCCC TGATGAAATC AAGCAAATCC TTAACAATTA TAGCCATAAG 120AATTTAAAGC TCATTGATCC GCCGACAAGT TCTTTAGAAG CGACACCGGG TTTTTTACCC 180TCGCCTAAAG AAACAGCGAC CACGATCAAT CAAGAGATCG CTAAATACCA TGAAAAAAGC 240GATAAAGCCG CTTTGGGGCT TTATGAATTG CTAAAGGGGG CTACCACCAA TCTCAGTTTG 300CAAGCGCAAG AACTCAGTGT CAAGCAAGCG ATGAAGAACC ACACCATCGC CAAAGCGATG 360TTTTTGCCTA CTTTGAACGC GAGTTATAAT TTTAAAAATG AAGCTAGGGA TACTCCAGAA 420TATAAGCATT ATAACACCCA ACAACTCCAA GCTCAAGTCA CATTGAATGT GTTTAATGGC 480TTTAGCAATG TGAATAATGT CAAAGAAAAG TCTGCGACTT ACCGATCCAC TGTGGCTAAT 540TTAGAATATA GCCGCCAAAG CGTGTATTTG CAAGTGGTGC AACAATACTA CGAGTATTTT 600AACAATCTCG CTCGCATGAT CGCTTTGCAA AAGAAATTAG AGCAAATCCA AACGGACATT 660AAAAGGGTTA CTAAGCTCTA TGACAAAGGG CTGACCACGA TTGATGATTT ACAAAGCTTA 720AAAGCGCAAG GGAATTTGAG CGAATACGAT ATTTTGGACA TGCAATTTGC TTTGGAGCAA 780AACCGCTTGA CTTTAGAATA CCTCACTAAC CTCAGTGTGA AAAATTTGAA AAAGACCACG 840ATTGATGCGC CTAATTTGCA ATTAAGAGAA AGGCAGGATT TGGTTTCTTT AAGGGAGCAG 900ATTTCTGCAC TCAGATACCA AAACAAGCAA CTCAATTATT ACCCCAAGAT AGATGTGTTT 960GACTCATGGC TTTTTTGGAT CCAAAAACCC GCTTATGCCA CAGGGCGTTT TGGGAATTTC 1020TACCCAGGTC AGCAAAATAC GGCTGGGGTT ACTGCGACTT TGAATATTTT TGATGATATA 1080GGGTTGAGCT TGCAAAAACA ATCCATCATG CTAGGCCAAT TAGCGAATGA AAAGAATTTA 1140GCGTATAAAA AATTGGAGCA AGAAAAAGAC GAACAGCTTT ACAGAAAGTC GCTTGATATT 1200GCCAGAGCTA AGATTGAATC TTCAAAGGCT AGTTTGGATG CGGCCAATCT TTCTTTTGCC 1260AATATTAAAA GGAAATACGA CGCTAATTTA GTGGATTTCA CTACCTATTT AAGGGGCTTA 1320ACCACGCGCT TTGATGCAGA AGTGGCTTAC AATTTAGCGC TCAACAATTA CGAAGTGCAA 1380AAAGCCAATT ACATTTTTAA CAGCGGGCAT AAAATAGACG ACTATGTGCA TTAA 1434 ( 2 ) SEQ ID NO:51： ( ⅰ ) ：
(A) length: 1239 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1239 ( ⅹⅰ ) ：SEQ ID NO:51:ATGCTATCTT TTATAAGCGC GTTTGATAAA AGGGGCGTTT CAATACGCCT TCTAACAGCC 60TTGTTACTGC TTTTTAGTTT GGGTTTGGCT AAAGATTTAG AAATCCAAAC TTTTGTGGCT 120AAATACCTTT CTAAAAATCA AAAAATACAA GCCCTACAGG AGCAAATTGA CGCTTTAGAT 180TCTCAAGAAA AAGTCGTTAG CAAATGGGAT AACCCTATTT TGTATTTAGG CTATAACAAC 240GCTAACGTGA GCGATTTTTT CAGGCTGGAT AGCACCTTAA TGCAAAACAT GAGCTTGGGT 300TTGTCTCAAA AAGTGGATTT AAATGGTAAA AAACTCACGC AGTCTAAAAT GATCAATTTA 360GAAAAACAAA AAAAAATATT AGAGCTTAAA AAAACCAAGC AGCAATTGGT GATTAATTTA 420ATGATAAACG GCATTGAAAA CTATAAAAAC CAACAAGAAA TAGAGCTTTT AAACACAGCG 480ATTAAAAATT TAGAAAACAC CCTCTATCAA GCCAACCATT CCAGTTCGCC CGATTTAATA 540GCGATCGCCA AGTTAGAAAT TTTAAAATCG CTATTAGAAA TCCAAAAAAA CGATTTAGAA 600GTAGCGCTCT CTAGCAGCCA TTATTCCATG GGCGAATTGA CTTTTAAAGA AAACGAGATT 660TTAAGCATTG CCCCTAAAAA TTTTGAATTC AATAACGAGC AAGAGCTGCA TAACATTAGC 720GCCACTAATT ACGATATTGC GATCGCCAGG CTTGATGAAG AAAAAGCACA AAAAGACATC 780ACTCTGGCTA AAAAAAGCTT TTTAGAAGAC ATAAACGTTA CCGGGGTGTA TTATTTCCGC 840TCCAAACAAT ACTATAACTA CGACATGTTT AGCGTCGCTT TGTCTATCCC TTTACCTCTT 900TATGGCAAGC AGGCTAAATT AGTGGAGCAA AAGAAAAAAG AAAGCTTGGC GTTTAAAAGC 960GAAGTGGAAA ACGCCAAAAA CAAAACGCGC CACCTGGCCC TAAAACTCCT TAAAAAATTA 1020GAAACCTTGC AAAAAAACCT GGAATCGATC AATAAAATCA TCAAACAGAA TGAAAAAATC 1080GCGCAAATTT ATGCGCTTGA TTTGAAAACT AATGGCGATT ACAACGCTTA TTACAACGCC 1140TTGAATGACA AAATCACTAT TCAAATCACC CAGCTTGAAA CCTTAAGCGC TCTAAATAGT 1200GCTTATTTGT CCTTACAAAA TCTCAAAGGA TTAGAATGA 1239 ( 2 ) SEQ ID NO:52： ( ⅰ ) ：
(A) length: 414 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..414 (ⅹ ⅰ) sequence description: the data of SEQ ID NO:52:ATGCGTATAG TTAGAAATTT ATTTCTTGTA TCGTTTGTGG CGTATAGTAG TGCGTTCGCA 60GCGGATTTAG AAACCGGAAC CAAAAACGAC AAAAAGAGCG GTAAAAAATT TTACAAACTC 120CATAAAAACC ATGGCTCAGA AACCGAGACT AAAAACGATA AAAAGCTTTA TGATTTCACT 180AAAAATAGCG GATTAGAAGG CGTGGATTTA GAAAAAAGCC CTAACCTTAA AAGCCATAAA 240AAAAGCGATA AAAAGTTTTA TAAACAACTC GCTAAAAACA ATATCGCTGA AGGGGTGAGC 300ATGCCGATTG TGAATTTCAA TAAAGCCCTA TCTTTTGGGC CTTATTTTGA AAGGACTAAA 360AGCAAAAAAA CCCAATACAT GGACGGCGGG TTGATGATGC ACATCCGTTT TTAA 414 (2) SEQ ID NO:53: (ⅰ) sequence signature:
(A) length: 930 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..930 ( ⅹⅰ ) ：SEQ ID NO:53:TTGATGCCAC AAAACCAGCT TGTGATCACC ATCATTGATG AATCAGGCTC TAAGCAACTC 60AAATTTTCTA AAAATTTAAA ACGCAACCTC ATCATTTCTG TTGTCATTCT TTTATTGATC 120GTGGGGCTTG GCGTGGGGTT TTTAAAATTT TTAATCGCTA AAATGGATAC GATGACAAGC 180GAGAGGAATG CGGTTTTAAG GGATTTTAGG GGTTTGTATC AAAAAAATTA CGCCCTAGCG 240AAAGAGATTA AAAACAAGCG AGAAGAGCTT TTTATTGTGG GGCAAAAGAT CCGTGGGCTA 300GAATCCTTGA TTGAAATCAA AAAGGGGGCT AATGGGGGAG GGCATCTCTA TGATGAAGTG 360GATTTAGAAA ATTTGAGCTT AAATCAAAAA CATTTAGCAC TCATGCTCAT TCCTAATGGC 420ATGCCCCTAA AAACTTATAG CGCTATCAAA CCCACTAAAG AAAGGAACCA CCCCATTAAA 480AAGATTAAGG GCGTTGAATC CGGGATCGAT TTTATCGCGC CATTGAACAC GCCTGTGTAT 540GCGAGCGCTG ATGGGATTGT GGATTTTGTG AAGACTCGTT CTAATGCGGG GTATGGGAAC 600TTGGTGCGCA TTGAACATGC GTTTGGTTTC AGCTCCATTT ATACGCACTT AGATCATGTC 660AATGTGCAGC CTAAAAGCTT CATCCAAAAA GGGCAGTTGA TTGGCTATAG CGGGAAGAGC 720GGTAATAGCG GCGGCGAAAA ATTGCATTAT GAAGTGCGGT TTTTGGGTAA AATTTTAGAC 780GCAGAAAAAT TCCTAGCATG GGATTTGGAT CATTTTCAAA GCGCTTTAGA AGAAAATAAA 840TTTATTGAAT GGAAGAATCT GTTTTGGGTT TTAGAAGACA TCGTCCAGCT CCAAGAGCAT 900GTGGATAAAG ACACCTTAAA AGGTCAGTAG 930 ( 2 ) SEQ ID NO:54： ( ⅰ ) ：
(A) length: 999 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..999 ( ⅹⅰ ) ：SEQ ID NO:54:GTGCTATATT TTTTAACCAG TTTATTTATT TGCTCTTTGA TTGTTTTGTG GTCTAAAAAA 60TCCATGCTCT TTGTGGATAA CGCTAATAAA ATCCAAGGCT TCCATCATGC AAGAACCCCA 120CGAGCCGGGG GGCTTGGGAT CTTTCTTTCT TTTGCGTTGG CTTGTTATCT TGAACCTTTT 180GAGATGCCTT TTAAGGGGCC TTTTGTTTTC TTAGGGCTAT CGCTAGTGTT TTTGAGCGGT 240TTTTTAGAAG ACATTAACCT TTCATTAAGC CCCAAAATAC GCCTTATTTT GCAAGCTGTA 300GGGGTCGTTT GCATCA TTTC ATCAACGCCT TTAGTGGTGA GCGATTTTTC GCCCCTTTT 360AGCTTGCCTT ATTTCATCGC TTTTTTATTC GCTATTTTTA TGCTGGTGGG TATCAGTAAC 420GCTATTAATA TCATTGACGG GTTTAACGGG CTTGCATCTG GGATTTGCGC GATCGCGCTT 480TTAGTCATTC ATTATATAGA CCCTAGCAGT TTGTCTTGTT TGCTCGCTTA CATGGTGCTT 540GGGTTTATGG TGTTAAATTT CCCTTCAGGA AAGATTTTTT TAGGCGATGG GGGGGCGTAT 600TTTTTGGGTT TGGTGTGCGG GATTTCTCTC TTGCATTTGA GTTTGGAGCA AAAAATCAGC 660GTGTTTTTTG GGCTCAATTT AATGCTTTAT CCGGTCATAG AGGTGCTTTT TAGTATCCTT 720AGGCGCAAAA TAAAACGCCA GAAAGCCACC ATGCCGGATA ATTTGCATTT GCACACCCTT 780TTATTTAAAT TCTTGCAACA ACGCTCTTTC AATTACCCTA ACCCTTTATG CGCGTTTATC 840CTTATTCTAT GCAACCTGCC TTTTATTTTA ATAAGCGTTT TGTTTCGCTT GGACGCTTAT 900GCGCTCATTG TGATTAGCCT AGTCTTTATC GCATGCTATT TAATAGGCTA TGCTTATTTG 960AATAGGCAAG TTTGCGCTTT AGAAAAGCGG GCGTTTTTAA 999 ( 2 ) SEQ ID NO:55： ( ⅰ ) ：
(A) length: 816 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..816 ( ⅹⅰ ) ：SEQ ID NO:55:ATGAACATAT TCAAGCGTAT TATTTGCGTA ACCGCTATTG TTTTAGGTTT TTTTAACCTT 60TTAGACGCCA AACACCACAA AGAAAAAAAA GAAGACCACA AAATCACTCG TGAGCTTAAA 120GTGGGCGCTA ACCCTGTGCC GCATGCGCAA ATCTTGCAAT CAGTTGTGGA TGATTTGAAA 180GAGAAAGGGA TCAAATTAGT GATCGTGTCT TTTACGGATT ATGTGTTGCC TAATTTAGCG 240CTCAATGACG GCTCTTTAGA CGCGAATTAC TTCCAGCACC GCCCTTATTT GGATCGGTTT 300AATTTGGACA GAAAAATGCA CCTTGTTGGT TTGGCCAATA TCCATGTGGA GCCTTTAAGA 360TTTTATTCTC AAAAAATCAC AGACATTAAA AACCTTAAAA AAGGCTCAGT GATTGCTGTG 420CCAAATGATC CGGCCAATCA AGGCAGGGCG TTGATTTTAC TCCATAAACA AGGCCTTATC 480GCTCTCAAAG ACCCAAGCAA TCTATACGCT ACGGAGTTTG ATATTGTCAA AAATCCTTAC 540AACATCAAAA TCAAACCCCT AGAAGCTGCG TTATTGCCTA AGGTTTTAGG GGATGTGGAT 600GGGGCTATCA TAACAGGGAA TTATGCCTTG CAAGCAAAAC TCACCGGAGC CTTATTTTCA 660GAAGATAAGG ACTCGCCTTA TGCTAATCTT GTAGCCTCTC GTGAGGATAA TGCGCAAGAT 720GAAGCGATAA AAGCGTTGAT TGAAGCCTTA CAGAGCGAAA AGACCAGGAA ATTCATTTTG 780GATACCTATA AGGGGGCGAT TATCCCGGCT TTTAA 816 ( 2 ) SEQ ID NO:56： ( ⅰ ) ：
(A) length: 951 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅵ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..951 ( ⅹⅰ ) ：SEQ ID NO:56:ATGCAAGAAT TCAGTTTGTG GTGCGATTTT ATAGAAAGGG ATTTTTTAGA AAACGATTTT 60TTAAAGCTCA TCAATAAGGG GGCTATTTGC GGGGCGACGA GTAACCCTAG TTTGTTTTGC 120GAAGCGATCA CAAAAAGCGC GTTTTATCAA GATGAAATCG CTAAACTCAA AGGCAAAAAA 180GCTAAAGAAA TTTATGAAAC TCTGGCACTA AAGGATATTT TACAAGCCTC TAGCGCGTTA 240ATGCCTTTGT ATGAAAAAGA CCCTAACAAC GGCTACATCA GCCTAGAAAT TGACCCCTTT 300TTAGAAGACG ATGCGATTAA AAGCATTGAT GAAGCCAAGC GGTTATTCAA AACATTAAAC 360CGCCCCAATG TGATGATTAA AGTCCCGGCG AGTGAAAGCG CTTTTGAAGT CATTAGCGCT 420CTGGCTCAAG CCTCTATCCC CATTAATGTA ACTTTAGTCT TTTCGCCTAA AATTGCCGGT 480GAAATCGCTC AAATCTTAGC CAAAGAAGCA CGAAAAAGAG CGGTCATTAG CGTGTTTGTC 540TCACGATTTG ACAAAGAAAT AGACCCACTA GTGCCACAAA ATTTGCAAGC TCAAAGTGGG 600ATCATGAACG CTACCGAGTG TTATTATCAA ATCAACCAGC ATGCTAATAA GCTAATAAGC 660ACCCTTTTTG CATCCACCGG CGTTAAATCT AATTCTTTAG CTAAAGATTA CTACATTAAA 720GCGCTGTGTT TTAAAAACTC TATCAACACA GCCCCCCTAG ACGCCCTAAA CGCTTATTTG 780CTTGACCCAA ACACCGAGTG TCAAACCCCT TTAAAAATCA CAGAAATTGA AGCGTTCAAA 840AAAGAATTAA AAACGCACAA TATTGATTTA GAAAACACCG CCCAAAAACT CCTTAAAGAA 900GGCTTGATAG CGTTCAAACA ATCCTTTGAA AAGCTTTTAA GCAGTTTTTG A 951 ( 2 ) SEQ ID NO:57： ( ⅰ ) ：
(A) length: 783 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..783 ( ⅹⅰ ) ：SEQ ID NO:57:ATGAAAACAA ATGGTCATTT TAAGGATTTT GCATGGAAAA AATGCTTTTT AGGCGCGAGC 60GTGGTGGCTT TATTAGTGGG GTGTAGCCCG CATATTATTG AAACCAATGA AGTTGCTTTG 120AAATTGAATT ACCATCCAGC TAGCGAGAAA GTTCAAGCGT TAGATGAAAA GATTTTACTT 180TTAAGGCCAG CTTTCCAATA CAGCGATAAT ATTGCTAAAG AGTATGAAAA CAAATTCAAG 240AATCAAACCA CGCTTAAAGT TGAAGAGATC TTGCAAAATC AGGGCTATAA GGTTATTAAT 300GTGGATAGCA GCGATAAAGA CGATTTTTCT TTTGCGCAAA AAAAAGAAGG GTATTTGGCT 360GTCGCTATGA ATGGCGAAAT TGTTTTACGC CCCGATCCTA AAAGGACCAT ACAGAAAAAA 420TCAGAACCCG GGTTATTATT CTCCACTGGT TTGGATAAAA TGGAAAGGGT TTTAATCCCG 480GCTGGGTTTG TCAAGGTTAC CATACTAGAG CCTATGAGTG GGGAATCTTT GGATTCTTTT 540ACGATGGATT TGAGCGAGTT GGACATCCAA GAAAAATTCT TAAAAACCAC CCATTCAAGC 600CATAGCGGAG GGTTAGTTAG CACTATGGTT AAGGGGACGG ATAATTCTAA TGACGCAATT 660AAGAGCGCTT TGAATAAGAT TTTTGCAAGT ATCATGCAAG AAATGGATAA GAAACTCACT 720CAAAGGAATT TAGAATCTTA TCAAAAAGAC GCCAAGGAAT TAAAAAACAA GAGAAACCGA 780TAA 783 ( 2 ) SEQ ID NO:58： ( ⅰ ) ：
(A) length: 4149 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..4149 ( ⅹⅰ ) ：SEQ ID NO:58:TTGAATTTTA ATAACCTTAC GGCTAATGGG GCGTTAAATT TTAATGGTTA TGCGCCCTCT 60TTAACTAAGG CTTTAATGAA TGTCAGCGGG CAGTTTGTTT TAGGGAATAA TGGGGATATT 120AATTTATCTG ACATCAATAT CTTTGACAAC ATCACAAAAT CTGTAACTTA CAACATCTTA 180AACGCTCAAA AAGGGATTAC TGGCATTAGT GGGGCTAATG GCTATGAAAA AATCCTTTTT 240TATGGCATGA AAATCCAAAA CGCTACCTAT AGCGATAATA ACAACATCCA AACTTGGTCG 300TTTATAAACC CTCTCAATTC TTCTCAAATC ATTCAAGAGA GCATTAAAAA TGGGGATCTA 360ACCATAGAAG TTTTAAATAA CCCTAACTCG GCTTCCAACA CTATTTTTAA TATCGCTCCT 420GAGCTTTATA ATTACCAAGA TTCTAAGCAA AATCCTACCG GCTATAGCTA TGATTATAGC 480GACAATCAAG CAGGCACTTA TTACTTGACA AGCAACATTA AAGGTCTTTT CACCCCTAAA 540GGCTCTCAAA CGCCTCAAAC CCCAGGCACT TATAGCCCAT TTAACCAGCC TTTGAATAGT 600TTGAATATCT ACAATAAGGG TTTTTCTAGC GAGAATTTAA AAACGCTTTT AGGGATCCTT 660TCTCAAAATT CCGCCACCTT AAAAGAAATG ATTGAATCCA ACCAACTAGA CAATATCACT 720AACATTAATG AAGTGTTGCA ACTCTTAGAT AAGATTAAAA TCACCCAAGC GCAAAAGCAA 780GCGCTCCTAG AAACGATCAA CCATTTGACT GACAACATCA ATCAAACCTT TAATAACGGG 840AATCTCGTTA TAGGCGCTAC CCAAGATAAT GTTACAAACT CTACTAGCTC TATATGGTTT 900GGGGGCAATG GCTATAGCAG CCCTTGCGCG CTAGATAGCG CCACTTGTTC TTCTTTTAGA 960AACACTTACT TGGGGCAATT ATTAGGCTCA ACTTCCCCTT ATTTAGGCTA CATTAACGCT 1020GATTTTAAAG CTAAAAGCAT TTATATTACC GGGACAATTG GAAGTAGTAA CGCTTTTGAA 1080AGCGGAGGGA GCGCGGATGT AACCTTTCAA AGCGCTAATA ACTTAGTGTT GAATAAAGCT 1140AACATAGAAG CTCAAGCCAC AGACAATATC TTTAATCTTT TGGGTCAAGA AGGGATTGAT 1200AAAATCTTTA ATCAGGGGAA TTTAGCGAAT GTTCTTAGTC AAATGGCTAT GGAAAAAATC 1260AAGCAAGCCG GCGGTTTAGG GAACTTTATA GAAAACGCTC TAAGCCCTTT GAGTAAGGAA 1320TTACCCGCTA GCTTGCAAGA TGAAACCTTA GGCCAACTTA TAGGTCAAAA TAACTTAGAT 1380GATTTATTGA ATAATAGTGG AGTCATGAAT GAAATCCAAA ACATTATCAG TCAAAAACTA 1440AGCATTTTTG GCAATTTTGT TACCCCATCC ATCATAGAAA ACTACCTTGC TAAGCAGTCT 1500TTAAAAAGCA TGCTAGACGA TAAAGGGCTT TTGAATTTTA TCGGTGGGTA TATAGACGCT 1560TCTGAATTAA GCTCTATTTT AGGCGTGATT TTAAAGGATA TTACTAACCC CCCTACAAGC 1620CTGCAAAAAG ACATTGGTGT GGTAGCGAAC GACTTGTTGA ACGAGTTTTT AGGACAAGAT 1680GTTGTCAAAA AGCTAGAAAG TCAAGGCTTG GTGAGTAATA TCATCAATAA TGTTATTTCT 1740CAAGGCGGGT TGAGCGGCGT TTATAATCAA GGTTTAGGGA GCGTGTTGCC GCCCTCTTTA 1800CAAAACGCGC TCAAAGAAAA CGATTTAGGC ACTCTTTTAT CGCCTAGAGG CTTGCATGAT 1860TTTTGGCAAA AAGGGTATTT TAACTTTTTA AGCAATGGCT ATGTTTTTGT CAATAACAGC 1920TCTTTTAGTA ACGCTACTGG GGGTAGTTTG AATTTTGTCG CCAACAAGTC TATTATCTTT 1980AATGGCGATA ATACGATTGA CTTTAGCAAG TATCAAGGCG CATTGATTTT TGCTTCTAAT 2040GGTGTTTCTA ATATCAATAT CACCACCCTA AACGCCACTA ATGGCTTAAG CCTTAATGCG 2100GGTTTGAATA ATGTGAGCGT TCAAAAAGGA GAAATTTGTA TCAATTTAGC CAATTGCCCT 2160ACAACCAAAA ACAGCTCTCC TGCAAACTCT AGCGTAACCC CCACTAATGA GTCTTTAAGC 2220GTGCACGCTA ATAATTTCAC TTTCTTAGGC ACAATCATCT CTAATGGGGC TATTGATTTG 2280TCTCAAGTAA CAAATAATAG CGTTATAGGC ACGCTCAATC TCAATGAAAA TGCGACCTTG 2340CAAGCTAATA ATTTAACGAT CACCAACGCT TTTAACAACG CCTCTAACTC TACGGCTAAT 2400ATTGATGGTA ATTTCACCTT AAACCAACAA GCGACTTTAA GCACTAACGC TAGTGGTTTG 2460AATGTCATGG GGAATTTTAA TAGCTATGGC GATTTGGTGT TTAACCTCAG TCATTCAGTT 2520AGTCATGCTA TTATCAATAC TCAAGGCACA GCGACGATCA TGGCCAATAA TAACCCTTTG 2580ATCCAATTCA ACGCTTCTTC AAAAGAAGTG GGTACTTACA CGCTGATTGA TAGCGCTAAA 2640GCCATTTATT ACGGGTATAA CAACCAAATC ACAGGAGGCA GTAGCCTGGA TAATTACCTT 2700AAGCTTTATG CGCTCATTGA TATTAATGGC AAGCACATGG TGATGACTGA CAACGGCTTA 2760ACCTATAACG GGCAAGCCGT GAGCGTTAAA GATGGCGGTT TAGTTGTAGG CTTTAAGGAC 2820TCTCAAAATC AATACATTTA CACTTCCATT CTTTATAATA AAGTGAAAAT CGCTGTTTCT 2880AATGATCCTA TCAATAACCC ACAAGCCCCC ACTTTAAAAC AATATATCGC TCAAATTCAG 2940GGCGTTCAAA GCGTGGATAG CATCGATCAA GCTGGGGGAA ATCAAGCGAT TAATTGGCTC 3000AATAAAATCT TTGAAACTAA AGGAAGCCCT TTATTCGCTC CCTATTATCT AGAGAGCCAC 3060TCCACAAAAG ATTTAACCAC GATCGCTGGA GATATTGCTA ACACTTTAGA AGTCATCGCT 3120AACCCTAATT TTAAAAATGA CGCCACTAAT ATTTTACAGA TCAACACCTA CACGCAGCAA 3180ATGAGTCGTT TAGCCAAGCT CTCTGACACT TCAACTTTCG CCCGTTCTGA TTTCTTAGAA 3240CGCTTAGAAG CCCTTAAAAA CAAGCGATTC GCTGATGCGA TCCCTAACGC TATGGATGTG 3300ATTTTAAAAT ACTCTCAAAG GAATAGAGTT AAAAATAATG TGTGGGCGAC AGGAGTTGGA 3360GGGGCTAGTT TCATTAGTGG AGGTACTGGA ACTTTATATG GTATCAATGT AGGGTATGAT 3420AGGTTTATTA AGGGCGTGAT TGTGGGAGGT TATGCCGCTT ATGGGTATAG CGGGTTCCAT 3480GCAAACATCA CTCAATCAGG CTCTAGCAAT GTCAATGTGG GCGTTTATAG CCGAGCGTTT 3540ATCAAAAGAA GCGAGCTAAC CATGAGCTTG AATGAGACTT GGGGATACAA TAAAACTTTC 3600ATCAACTCCT ATGACCCCCT ACTCTCAATC ATCAATCAGT CTTACAGATA CGACACTTGG 3660ACGACTGACG CTAAAATCAA TTATGGCTAT GATTTCATGT TTAAAGATAA AAGCGTTATT 3720TTTAAACCCC AAGTAGGCTT AAGCTATTAT TACATTGGTT TGTCTGGTTT AAGGGGCATT 3780ATGGATGATC CTATTTACAA CCAATTCAGA GCCAATGCTG ACCCTAATAA AAAATCCGTT 3840CTAACGATCA ATTTTGCCCT AGAAAGTCGG CATTATTTCA ATAAAAACTC TTATTATTTT 3900GTGATTGCGG ATGTGGGCAG AGACTTATTC ATTAATTCTA TGGGGGATAA AATGGTGCGT 3960TTCATCGGTA ATAACACCCT AAGCTATAGA GATGGTGGCA GATACAACAC TTTTGCTAGC 4020ATTATCACAG GCGGGGAGAT AAGATTGTTC AAAACCTTTT ATGTGAATGC GGGCATAGGG 4080GCTAGGTTTG GGCTTGATTA TAAAGATATT AATATTACCG GAAATATTGG TATGCGCTAT 4140GCTTTTTAA 4149 ( 2 ) SEQ ID NO:59： ( ⅰ ) ：
(A) length: 789 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..789 ( ⅹⅰ ) ：SEQ ID NO:59:ATGAAAAAAA TTGGTTTGAG CTTGTGTTTG GTTTTGAGTT TGGGTTTTTT AAAAGCCCAT 60GAAGTGAGCG CTGAAGAGAT TGCGGATATT TTCTACAAAC TCAACGCCAA AGAGCCTAAA 120ATGAAAATCA ACCACACGAA GGGGTTTTGC GCTAAAGGCG TGTTCCTCCC TAACCCGCAA 180GCAAGAGAGG ATTTAGAGGT GCCACTACTC AATGAAAAAG AAATCCCTGC GTCTGTAAGG 240TATTCTTTAG GGGGCGTGGC GATGGACGAT AAAAGCAAGG TTAGGGGAAT GGCGTTAAAA 300CTAGAAAATC AAAACGCTAG TTGGACAATG GTGATGCTCA ATACAGAAAT CAATTTTGCC 360AAAAACCCTG AAGAATTCGC CCAATTTTTT GAAATGAGAC TTCCTAAAAA TGGCAAGGTA 420GATGAAGCAA GAATCAAAAA GCTTTACGAA GAAGTCCCCT CTTATAGGAA TTTTGCCGCC 480TATATGAAAA CGATAGGGAT TAGCTCAAGC GTGGCTAATA CGCCTTATTA TAGCGTGCAT 540GCGTTCAAGT TTAAAGATAA GAAAGAAAAA TTATTGCCTG CGAGGTGGAA ATTTGTGCCT 600AAAGAGGGCG TTAAATACTT AAATCCTCAA GAATTAAAGC AAAAAGATTC AAATTATCTG 660CTCTCTTCAT TCCAACAACA CCTTAAAAAT AAACCCATAG AATACCAAAT GTATTTGGTG 720TTTGCGAATC AAAATGATGC CACCAACGAC ACGACCGCGC TTTGGAAAGG CAGCATAAGG 780AATTATTAG 789 ( 2 ) SEQ ID NO:60： ( ⅰ ) ：
(A) length: 741 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..741 ( ⅹⅰ ) ：SEQ ID NO:60:ATGAAACAAT TTAAAAAGAA ACCAAAAAAG ATAAAACGAT CGCATCAAAA TCAAAAAACA 60ATCTTAAAGC GTCCTTTATG GCTTATGCCT TTACTGATTG GCGGGTTTGC TAGTGGGGTG 120TATGCGGATG GAACAGACAT TTTGGGGCTT AGTTGGGGGG AAAAAAGCCA AAAGGTATGC 180GTGCATCGTC CATGGTATGC TATATGGAGT TGCGATAAAT GGGAGGAAAA AACACAACAA 240TTTACAGGAA ACCAACTCAT CACAAAAACT TGGGCAGGGG GTAATGCGGC TAACTACTAC 300CACTCTCAAA ACAACCAAGA CATCACAGCC AATTTAAAAA ATGATAACGG CACTTATTTT 360TTAAGCGGTC TGTATAACTA CACCGGAGGG GAATATAATG GGGGGAATTT AGACATTGAA 420TTAGGCAGTA ACGCTACTTT TAATCTAGGT GCGAGTAGTG GGAATAGCTT CACTTCTTGG 480TATCCTAATG GGCATACTGA TGTTACTTTT AGCGCTGGGA CTATCAATGT GAATAACAGC 540GTAGAAGTGG GCAATCGTGT GGGATCGGGA GCTGGCACGC ACACCGGCAC AGCCACTTTA 600AACTTGAACG CTAATAAGGT TACTATCAAT TCCAATATCA GCGCGTATAA AACTTCGCAA 660GTGAATGTAG GCAATGCTAA CAGCGTTATT ACCATTAATT CGGTTTCTTT AAATGGGGAA 720TACTTGCAGT TCTTTAGCTA G 741 ( 2 ) SEQ ID NO:61： ( ⅰ ) ：
(A) length: 738 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..738 ( ⅹⅰ ) ：SEQ ID NO:61:ATGATAAAAA AGACCCTTGC ATCGGTTTTA TTAGGATTGA GTTTGATGAG TGTGTTAAAT 60GCCAAAGAAT GCGTTTCGCC CATAACAAGA AGCGTTAAGT ATCATCAGCA AAGTGCTGAG 120ATCAGAGCCT TGCAATTACA AAGTTACAAA ATGGCGAAAA TGGCGCTAGA CAATAACCTT 180AAGCTCGTTA AAGACAAAAA GCCAGCCGTC ATCTTGGATT TAGATGAAAC CGTTTTGAAC 240ACTTTTGATT ATGCGGGCTA TTTAGTCAAA AACTGCATTA AATACACCCC AGAAACTTGG 300GATAAATTTG AAAAAGAAGG CTCTCTTACG CTCATTCCTG GAGCGCTAGA CTTTTTAGAA 360TACGCTAATT CTAAGGGCGT TAAGATTTTT TACATTTCTA ACCGCACCCA AAAAAATAAG 420GCATTCACTT TAAAAACGCT CAAAAGCTTT AAGCTCCCCC AAGTGAGTGA AGAATCCGTT 480TTGTTAAAGG AAAAAGGCAA GCCTAAAGCC GTTAGGCGGG AGTTAGTCGC TAAGGATTAT 540GCGATTGTTT TACAAGTGGG CGACACTTTG CATGATTTTG ACGCCATTTT TGCTAAAGAC 600GCTAAAAACA GCCAAGAACA ACAAGCCAAA GTCTTGCAAA ACGCTCAAAA ATTCGGCACA 660GAATGGATCA TTTTACCCAA CTCTCTTTAT GGCACATGGG AAGATGGGCC TATAAAAGCA 720TGGCAAAATA AAAAATAA 738 ( 2 ) SEQ ID NO:62： ( ⅰ ) ：
(A) length: 867 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..867 ( ⅹⅰ ) ：SEQ ID NO:62:TTGTGGTGTT TAAAAACCCC TATCATAGGG CATGGCATGA AGAAAAAAGC AAAAGTCTTT 60TGGTGTTGTT TTAAAATGAT TCGTTGGTTG TATTTGGCGG TCTTTTTTTT GTTGAGCGTA 120TCAGACGCTA AAGAAATCGC TATGCAACGA TTTGACAAAC AAAACCATAA GATTTTTGAA 180ATCCTTGCGG ATAAAGTGAG CGCCAAAGAC AATGTGATAA CCGCCTCAGG GAATGCGATC 240CTATTGAATT ATGACGTGTA TATTCTAGCG GATAAGGTGC GTTATGACAC CAAGACTAAA 300GAAGCGTTAT TAGAAGGCAA TATTAAGGTT TATAGGGGCG AGGGCTTGCT CGTTAAAACC 360GATTATGTGA AATTGAGTTT GAACGAAAAA TATGAGATCA TTTTCCCCTT TTATGTCCAA 420GACAGCGTGA GCGGGATTTG GGTGAGCGCG GATATTGCTA GCGGGAAGGA TCAAAAATAT 480AAGATTAAAA ACATGAGCGC TTCAGGGTGC AGCATTGACA ACCCCATTTG GCATGTCAAT 540GCGACTTCAG GCTCATTTAA CATGCAAAAA TCGCATTTGT CAATGTGGAA TCCTAAGATT 600TATGTCGGCG ATATTCCTGT ATTGTATTTG CCCTATATTT TCATGTCCAC GAGCAATAAA 660AGAACTACCG GGTTTTTATA CCCTGAGTTT GGCACTTCCA ACTTAGACGG CTTTATTTAT 720TTGCAACCCT TTTATTTAGC CCCCAAAAAC TCATGGGATA TGACCTTTAC CCCACAAATC 780CGTTACAAAA GGGGTTTTGG CTTGAATTTT GAAGCGCGCT ACATCAACTC TAAGACGCAG 840GTTTTTATTC AATGCGCGCT ATTTTAG 867 ( 2 ) SEQ ID NO:63： ( ⅰ ) ：
(A) length: 387 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..387 (ⅹ ⅰ) sequence description: the data of SEQ ID NO:63:TTGATGTTTA AAAAAATGTG TTTGAGCCTG CTAATGATAA GCGGTGTTTG TGTGGGGGCA 60AAGGATTTGG ATTTCAAGCT GGATTATCGC GCGACTGGGG GGAAATTCAT GGGGAAAATG 120ACGGACTCTA GTCTTTTAAG TATCACTTCT ATGAACGATG AACCGGTGGT GATTAAAAAC 180CTTATTGTCA ATAGGGGAAA TTCATGCGAA GCGACTAAAA AAGTAGAACC CAAATTTGGC 240GATAAGTTTA AAAAAGAAAA ACTCTTTGAT CATGAATTAA AATACTCGCA ACAGATATTT 300TACCGCCTGG ATTGCAAGCC TAACCAATTG TTAGAAGTTA AAATCATCAC GGACAAGGGC 360GAATATTACC ATAAATTTTC CAAATAG 387 (2) SEQ ID NO:64: (ⅰ) sequence signature:
(A) length: 510 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..510 ( ⅹⅰ ) ：SEQ ID NO:64:ATGCAAGCGT TAAAATCATT GCTTGAAGTG ATTACAAAAC TCCAGAATCT AGGCGGCTAT 60TTGATGCATA TAGCTATTTT CATCATTTTT ATTTGGATTG GAGGGCTTAA GTTTGTGCCT 120TACGAAGCTG AAGGGATCGC CCCTTTTGTG GCCAACTCCC CTTTCTTTTC TTTCATGTAT 180AAATTTGAAA AACCTGCATA CAAACAACAC AAAATGTCTG AATCCCAATC CATGCAAGAA 240GAAATGCAAG ATAACCCTAA AATCGTTGAA AACAAAGAAT GGCATAAAGA AAACCGCACT 300TATTTAGTGG CTGAAGGTTT AGGGATTACG ATCATGATCC TAGGCATTTT GGTGCTTTTG 360GGGCTTTGGA TGCCTTTAAT GGGCGTAGTT GGGGGCTTGC TTGTCGCTGG AATGACGATC 420ACCACCCTAT TCTTTTTTAT TCACAACGCC AGAAGTGTTT GTCAATCAGC ATTTCCCATG 480GCTTTCTGGG GCTGGAAGGC TAGTGGTTAA 510 ( 2 ) SEQ ID NO:65： ( ⅰ ) ：
(A) length: 1464 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..1464 ( ⅹⅰ ) ：SEQ ID NO:65:ATGATTGAAT GGATGCAAAA TCATAGAAAG TATTTAGTGG TTACGATATG GATAAGCACG 60ATCGCTTTTA TTGCCGCCGG AATGATAGGT TGGGGGCAAT ACAGCTTTTC TTTAGATAGC 120GATAGCGCTG CCAAAGTGGG ACAGATTAAG ATTTCTCAAG AAGAATTAGC CCAAGAATAC 180CGCCGCCTTA AAGACGCCTA TGCTGAGTCT ATCCCTGATT TTAAAGAACT CACCGAAGAT 240CAAATCAAAG CCATGCATTT AGAAAAAAGC GCGCTAGATT CGCTCATCAA TCAAGCTTTA 300TTGAGGAATT TCGCTTTAGA TTTAGGGCTT GGTGCTACCA AGCAAGAAGT GGCCAAAGAG 360ATCAGAAAAA CGAACGTTTT TCAAAAAGAT GGCGTTTTTG ATGAAGAATT GTATAAAAAT 420ATCTTAAAAC AAAGCCATTA CCGCCCCAAG CATTTTGAAG AAAGCGTTGA AAGGCTTTTA 480ATCCTTCAAA AAATCAGCGC TCTATTCCCC AAAACCACCA CCCCTTTGGA GCAATCCAGT 540CTATCGCTTT GGGCAAAATT GCAAGACAAA TTAGACATTC TTATCCTAAA TCCTAATGAT 600GTTAAAATCT CTCTCAATGA AGAAGAGATG AAAAAATATT ATGAAAACCA TAGAAAGGAT 660TTTAAAAAGC CCACAAGCTT TAAAACACGC TCTTTATATT TTGACGCTAG TTTAGAAAAA 720ACTGATTTGA AAGAGTTGGA GGAATACTAC CATAAAAACA AGGTGTCTTA TTTGGACAAA 780GAGGGGAAAT TACAGGATTT TAAAAGCGTT CAAGAGCAAG TCAAGCATGA TTTAAACATG 840CAAAAGGCGA ATGAAAAAGC CTTAAGGAGC TATATCGCTC TAAAAAAGGG GAACGCACAA 900AACTACACCA CGCAAGATTT TGAAAAAAAC AACTCCCCCT ATACTGCTGA AATCACGCAA 960AAACTCACCG CTCTCAAGCC CCTTGAAGTC CTAAAACCAG AGCCTTTTAA AGATGGTTTT 1020ATCGTGGTGC AGCTTGTCTC TCAAATTAAA GACGAATTGC AAAATTTTGA TGAAGCCAAA 1080AGCGCTCTTA AAACCCGTCT GACTCAAGAA AAAACCCTTA TGGCGTTGCA AACTTTAGCT 1140AAAGAAAAGC TTAAGGATTT TAAAGGGAAA AGCGTGGGTT ATGTAAGCCC TAATTTTGGA 1200GGCACTATCA GTGAACTTAA CCAAGAAGAG AGCGCGAAGT TTATCAACAC CCTTTTTAAC 1260CGCCAGGAAA AAAAAGGGTT TGTAACCATA GGTAATAAAG TGGTGCTTTA TCAAATCACA 1320GAGCAAAATT TCAATCACCC CTTTAGTGCA GAAGAAAACC AATACATGCA GCGTTTAGTC 1380AATAACACTA AAACGGATTT TTTTGATAAA GCGTTGATAG AAGAATTGAA AAAACGCTAT 1440AAGATAGTCA AATACATTCA ATAA 1464 ( 2 ) SEQ ID NO:66： ( ⅰ ) ：
(A) length: 429 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
( B ) ：1..429 ( ⅹⅰ ) ：SEQ ID NO:66:ATGAAAACGA ACTTTTATAA AATTAAATTA CTATTTGCTT GGTGTCTTAT CATTGGCATG 60TTTAACGCTC CGCTTAACGC TGACCAAAAC ACGGATATAA AAGATATTAG TCCTGAAGAT 120ATGGCGCTAA ATAGCGTGGG GCTTGTTTCT AGAGATCAGC TAAAAATAGA GATCCCTAAA 180GAAACCCTAG AGCAAAAAGT GGCCATACTC AATGACTATA ATGATAAGAA TGTTAATATC 240AAGTTTGACG ACATAAGTTT AGGGAGTTTC CAACCTAATG ATAATCTAGG TATCAATGCG 300ATGTGGGGCA TTCAAAATCT TCTCATGAGC CAAATGATGA GCAATTACGG TCCAAACAAT 360TCTTTCATGT ATGGCTATGC GCCAACATAC TCAGATTCAT CGTTTTTACC ACCGATCTTA 420GGGTATTAA 429 ( 2 ) SEQ ID NO:67： ( ⅰ ) ：
(A) length: 627 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular (ⅱ) molecule type: DNA (genome) (ⅲ) supposes: deny (ⅳ) antisense: (ⅵ) do not originate:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..627
( ⅹⅰ ) ：SEQ ID NO:67:TTGATCAACA ATAATAATAA CAATAAAAAA CTGAGAGGCT TTTTTTTGAA AGTTCTCTTA 60AGTCTCGTTG TTTTCAGTTC GTATGGGTCA GCAAATGACG ATAAAGAAGC CAAAAAAGAA 120GCGCTAGAAA AAGAAAAAAA CACTCCCAAT GGGCTTGTTT ATACGAATTT AGATTTTGAT 180AGTTTTAAAG CGACTATCAA AAATTTGAAA GACAAGAAAG TAACTTTCAA AGAAGTCAAT 240CCCGATATTA TCAAAGATGA AGTTTTTGAC TTCGTGATTG TCAATAGAGT CCTTAAAAAA 300ATAAAGGATT TGAAGCATTA CGATCCAGTT ATTGAAAAAA TCTTTGATGA AAAGGGTAAA 360GAAATGGGAT TGAATGTAGA ATTACAGATC AATCCTGAAG TGAAAGACTT TTTTACTTTC 420AAAAGCATCA GCACGACCAA CAAACAACGC TGCTTTCTAT CATTGCACGG AGAAACAAGA 480GAAATTTTAT GCGATGATAA GCTATATAAT GTTTTATTGG CCGTATTCAA TTCTTATGAT 540CCTAATGATC TTTTGAAACA CATTAGCACC ATAGAGTCTC TCAAAAAAAT CTTTTATACG 600ATTACATGTG AAGCGGTATA TCTATAA 627 ( 2 ) SEQ ID NO:68：
(ⅰ) sequence signature:
(A) length: 738 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..738
( ⅹⅰ ) ：SEQ ID NO:68:ATGGCAGGCA CACAAGCTAT ATATGAATCA TCTTCTGCAG GATTCTTATC GCAAGTCTCC 60TCAATCATCT CAAGCACAAG TGGTGTCGCA GGGCCATTTG CAGGAATAGT AGCGGGCGCT 120ATGACAGCAG CGATTATTCC TATTGTTGTG GGATTTACTA ATCCGCAAAT GACCGCTATC 180ATGACCCAAT ACAATCAAAG CATCGCTGAA GCTGTAAGCG TGCCTATGAA AGCCGCTAAC 240CAACAATACA ACCAATTGTA TCAAGGTTTT AACGATCAAA GCATGGCTGT GGGGAACAAT 300ATCTTAAATA TCAGCAAATT AACAGGGGAA TTTAACGCGC AAGGCAACAC GCAAAGCGCG 360CAAATTAGTG CTGTCAATAG TCAGATTGCA AGCATTTTAG CGAGTAACAC TACCCCTAAA 420AATCCTAGCG CTATTGAAGC TTATGCGACG AATCAAATCG CTGTTCCTAG CGTGCCAACA 480ACGGTTGAAA TGATGAGCGG TATATTAGGC AATATTACAA GCGCAGCACC AAAATACGCC 540CTAGCTCTAC AAGAGCAACT GCGTTCTCAA GCAAGCAACA GCTCAATGAA TGATACAGCC 600GATTCCCTTG ATAGCTGTAC CGCTTTAGGC GCACTTGTTG GCTCATCAAA AGTGTTTTTC 660AGTTGCATGC AAATTTCTAT GACTCCTATG AGTGTTTCTA TGCCCACTGT TATGCCAAAT 720ACCAGCGGTT GCCACTAA 738 ( 2 ) SEQ ID NO:69：
(ⅰ) sequence signature:
(A) length: 1104 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..1104
( ⅹⅰ ) ：SEQ ID NO:69:ATGATTAAAA GCGTAGAGAT TGAAAATTAC AAAAATTTTG AGCACCTTAA AATGGAAAAT 60TTTAAACTCA TCAACTTTTT TACCGGTCAA AACGATGCGG GTAAAACCAA TCTTTTAGAA 120GCTCTTTATA CCAACACAGG CCTTTGTGAT CCTACTGCCA ATCAAGTCAG TCTTCCTCCT 180GAACATGCCG TGAATATTAG TGAATTCAGA AAAATCAAAC TCGATGCCGA CAACCTAAAA 240ACCTTTTTTT ATCAAGGAAA CACCGCTAAT CCCATTAGTA TCCGCACTGA ATTTGAACAT 300GCTACTATCC CTCTTACTAT CCAATACCCC ACACAAACCA GTTACAGCAA AGACATCAAT 360TTGAATAGCG ATGATGCTCA TATGACAAAC CTTATAAACA CAACAATAAC GAAGCCACAG 420CTCCAATTTT CCTACAATCC ATCCCTTTCC CCCATGACAA TGACTTATGA ATTTGAAAGG 480CAAAACCTAG GTTTAATCCA TTCTAATTTA GATAAAATCG CTCAAACCTA TAAAGAAAAT 540GCGATGTTTA TTCCTATAGA ATTATCTATT GTTAATTCTC TTAAAGCATT GGAAAATTTA 600CAATTAGCAA GCAAAGAAAA AGAATTGATT GAAATCCTAC AATGTTTCAA CCCTAATATT 660TTAAATGCTA ATACAATAAG AAAGTCTGTC TATATCCAAA TCAAAGATGA AAACACACCG 720CTAGAAGAAA GTCCCAAAAG GCTTTTAAAT TTGTTTGGTT GGGGTTTTAT CAAATTCTTT 780ATTATGGTGA GCATTCTTAT AGACAATCGT GTCAAGTATC TTTTTATTGA TGAAATAGAA 840AGCGGTTTGC ACCATACAAA AATGCAAGAG TTTTTAAAAG CTCTGTTTAA GTTAGCTCAA 900AAATTACAGA TTCAAATTTT TGCCACCACG CACAATAAGG AATTTTTATT AAACGCCATC 960AACACGATAT CCGATAATGA AACGGGAGTT TTTAAAGACA TAGCCTTGTT TGAGCTTGAA 1020AAAGAAAGCG CTTCTGGCTT TATCAGACAC AGCTATTCTA TGCTAGAAAA AGCGCTTTAT 1080AGGGGTATGG AGGTTAGAGG CTGA 1104 ( 2 ) SEQ ID NO:70：
(ⅰ) sequence signature:
(A) length: 1230 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..1230
( ⅹⅰ ) ：SEQ ID NO:70:ATGTCCTTGA TTAGAGTGAA TGGGGAAGCT TTTAAACTCT CTTTGGAAAG TTTAGAAGAA 60GATCCTTTTG AAACTAAAGA AACGCTAGAA ACGCTAGAAA CGCTTATCAA ACAAACGAGC 120GTTGTTTTAT TGGCCGCTGG GGAGTCTAAG CGTTTTTCTC GTGCGATTAA AAAGCAGTGG 180CTACGCTCTC ACCACACCCC CTTATGGCTC AGCGTGTATG AAAGCTTTAA AGAAGCCCTA 240GACTTTAAGG AAGTCATTCT AGTTGTAAGC GAATTGGATT ATGTTTATAT CCAACGCCAT 300TACCCCAAAA TCAAGCTTGT AAAAGGCGGG GCATCAAGGC AAGAATCCGT GCGTAACGCT 360TTGAAAGTAA TTGATAGCAC TTACACGATC ACCAGCGATG TGGCTAGGGG TTTAGCGAAT 420ATGGAAGCGC TTAAAAGCTT GTTTTTAACC CTCCAACAAA CGAGCCATTA TTGCATCGCC 480CCTTACTTGC CTTGCTATGA CACAGCGATC TATTATAACG AGGCTTTAGA TAGAGAAGCG 540ATCAAACTCA TTCAAACCCC GCAATTAAGC CACACCAAAA CGCTCCAATC AGCCCTAAAC 600CAAGGGGGTT TTAAAGATGA AAGCAGCGCG ATTTTACAAG CTTTCCCTAA CTCTGTGAGC 660TATATTGAAG GCAGTAAGGA TTTGCACAAA CTCACCACAA GCGGCGATTT AAAGTTTTTT 720ACGCCTTTTT TTAACCCAGC AAAGGACACT TTTATAGGCA TGGGTTTTGA TACGCATGCG 780TTCATTAAAG ATAAGCCTAT GGTTTTAGGG GGGGTTGTTT TGGATTGCGA GTTTGGGTTA 840AAGGCTCATA GCGATGGCGA TGCTTTATTG CATGCGGTTA TTGATGCGAT TTTAGGAGCG 900ATTAAAGGGG GGGATATTGG CGAATGGTTC CCTGATAATG ACCCCAAATA CAAAAACGCC 960TCTTCTAAAG AGCTTTTAAA AATCGTGTTG GATTTTTCTC AAAGCATTGG GTTTGAATTG 1020CTTGAAATGG GAGCGACCAT CTTTAGCGAA ATCCCTAAAA TCACTCCTTA CAAACCGGCG 1080ATTTTAGAGA ATTTGAGCCA ACTTTTGGGT TTAGAAAAAT CTCAAATCAG CTTGAAAGCC 1140ACTACAATGG AAAAAATGGG GTTCATTGGC AAACAAGAAG GGCTGTTAGT CCAAGCGCAT 1200GTGAGCATGC GTTATAAACA AAAACTTTAA 1230 ( 2 ) SEQ ID NO:71：
(ⅰ) sequence signature:
(A) length: 813 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..813
( ⅹⅰ ) ：SEQ ID NO:71:ATGAAAAAGT TTGTAGCTTT AGGGCTTCTA TCCGCGGTTT TAAGCTCTTC GTTGTTAGCC 60GAAGGTGATG GTGTTTATAT AGGGACTAAT TATCAGCTTG GACAAGCCCG TTTGAATAGC 120AATATTTATA ATACAGGGGA TTGCACAGGG AGTGTTGTAG GTTGCCCCCC AGGTCTTACC 180GCTAATAAGC ATAATCCAGG AGGCACCAAT ATCAATTGGC ACTCCAAATA CGCTAATGGG 240GCTTTGAATG GTTTTGGGTT GAATGTGGGT TATAAGAAAT TCTTCCAATT CAAGTCGCTA 300GATATGACAA GCAAGTGGTT TGGTTTTAGA GTGTATGGGC TTTTTGATTA CGGGCATGCC 360GATTTAGGTA AACAAGTTTA TGCACCTAAT AAAATCCAGT TGGATATGGT CTCTTGGGGT 420GTGGGGAGCG ATTTGTTAGC TGATATTATT GATAAAGACA ACGCTTCTTT TGGTATTTTT 480GGTGGGGTCG CTATCGGCGG TAACACTTGG AAAAGCTCTG CAGCAAACTA TTGGAAAGAG 540CAAATCATTG AAGCCAAAGG TCCTGATGTT TGTACCCCTA CTTATTGTAA CCCTAATGCC 600CCTTATAGCA CCAACACTTC AACCGTCGCT TTTCAAGTGT GGTTGAATTT TGGGGTGAGA 660GCCAATATCT ACAAGCATAA TGGCGTGGAA TTTGGCGTGA GAGTGCCGCT ACTCATCAAT 720AAATTTTTGA GCGCGGGTCC TAACGCTACT AACCTTTATT ACCATTTGAA ACGGGATTAT 780TCGCTTTATT TGGGGTATAA CTACACTTTT TAA 813 ( 2 ) SEQ ID NO:72：
(ⅰ) sequence signature:
(A) length: 1317 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..1317
( ⅹⅰ ) ：SEQ ID NO:72:ATGGCTTACA AACCTAACAA AAAGAAGTTA AAAGAATTAA GAGAGCAACC GAATTTATTT 60AGCATCTTAG ATAAGGGCGA TGTTGCAACA AACAATCCTG TTGAAGAGTC AGACAAGGCC 120AATAAAATAC AAGAGCCACT CCCTTATGTC GTGAAAACGC AAATCAATAA AGCAAGCATG 180ATTTCTAGAG ATCCTATTGA ATGGGCAAAG TATTTAAGCT TTGAAAAACG AGTCTATAAG 240GATAATAGTA AAGAAGATGT CAATTTCTTT GCCAATGGTG AGATAAAAGA AAGTTCTCGT 300GTTTATGAAG CGAATAAAGA AGGGTTTGAA AGGCGCATCA CTAAAAGATA CGATCTGATT 360GATAGAAATA TTGATAGAAA TAGAGAATTT TTTATAAAAG AAATTGAAAT TCTAACCCAC 420ACAAACAGCT TAAAAGAATT GAAAGAGCAA GGGTTAGAAA TCCAATTGAC CCACCATAAT 480GAAACGCATA AGAAAGCCTT AGAAAATGGC AATGAAATCG TTAAAGAATA CGACCATCTT 540AAAGATATTT ACCAAGAAGT AGAAAGAACA AAAGATGGTG GATTGGTAAG AGAAATAATC 600CCCAGTATTT CTAGCGCTGA GTATTTCAAG CTTTACAACA AACTGCCTTT TGAATCAATA 660AACAATGAAA ATACCAAACT GAATACTAAC GACAATGAAG AAGTTAAAAA ACTAGAATTT 720GAATTAGCTA AAGAAGTGCA TATTTTAATC CTAGAGCAAC AATTGCTTTC AGCAACAAAT 780TATTATTCTT GGATAGATAA AGATGATAAT GCGAATTTTG CTTGGAAAAT GCATAGGCTT 840ATCAATGAAA ATAAACTCAA AGAAAACCAT CTCAGCGCCA ATAACGCTAA TAAGATTAAG 900CAATTTTTCT TTAATAATGG TTCTATTTTA GGCTGGACTA AAGAAGAACA AAGCGCTATA 960CAAGAAAACA GAGATTATTC TTTAAGAAGC GCTCTTTTAA GTTTAGAAGA AATCGCTCAA 1020GCAAAAATTG AATTGCAAAA ATACTATGAA AGCGTTTATG TTAATGGTGA TGGGAATAAA 1080AGAGAAATCA AGCCTTTTAA AGAAATTTTA AGAGACACCA ACAATTTTGA AAAAGCTTAT 1140AAGGAGCGTT ATGACAAATT GGTAAGCTTG AGTGCAGCAA TCATTCAAGC TAAAGAGGGT 1200GGTAATGAGC GACCAAATTC TAGTGCAAAT AACAATAACC CTATTAAAAA TACAATAGAG 1260ACTAATACTT CTAACAATAT TATTCAAAAT AATGATAATA TAATCATCCA AATTTAA 1317 ( 2 ) SEQ ID NO:73：
(ⅰ) sequence signature:
(A) length: 648 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..648
( ⅹⅰ ) ：SEQ ID NO:73:ATGCAAGCGT TAAAATCATT GCTTGAAGTG ATTACAAAAC TCCAGAATCT AGGCGGCTAT 60TTGATGCATA TAGCTATTTT CATCATTTTT ATTTGGATTG GAGGGCTTAA GTTTGTGCCT 120TACGAAGCTG AAGGGATCGC CCCTTTTGTG GCCAACTCCC CTTTCTTTTC TTTCATGTAT 180AAATTTGAAA AACCTGCATA CAAACAACAC AAAATGTCTG AATCCCAATC CATGCAAGAA 240GAAATGCAAG ATAACCCTAA AATCGTTGAA AACAAAGAAT GGCATAAAGA AAACCGCACT 300TATTTAGTGG CTGAAGGTTT AGGGATTACG ATCATGATCC TAGGCATTTT GGTGCTTTTG 360GGGCTTTGGA TGCCTTTAAT GGGCGTAGTT GGGGGCTTGC TTGTCGCTGG AATGACGATC 420ACCACCCTAT CTTTTTTATT CACAACGCCA GAAGTGTTTG TCAATCAGCA TTTCCCATGG 480CTTTCTGGGG CTGGAAGGCT AGTGGTTAAA GACTTGGCGT TATTTGCTGG AGGCTTGTTT 540GTGGCCGGAT TTGATGCGAA ACGCTATTTG GAGGGTAAAG GGTTTTGCTT GATGGACCGC 600TCATCGGTAG GGATTAAAAC TAAATGCTCT AGCGGGTGTT GCTCTTAA 648 ( 2 ) SEQ ID NO:74：
(ⅰ) sequence signature:
(A) length: 186 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅳ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..186
(ⅹ ⅰ) sequence description: SEQ ID NO:74:Met Ile Lys Arg Ile Ala Cys Ile Leu Ser Leu Ser Ala Ser Leu Ala1 5 10 15Leu Ala Gly Glu Val Asn Gly Phe Phe Met Gly Ala Gly Tyr Gln Gln
20??????????????????25??????????????????30Gly?Arg?Tyr?Gly?Pro?Tyr?Asn?Ser?Asn?Tyr?Ser?Asp?Trp?Arg?His?Gly
35??????????????????40??????????????????45Asn?Asp?Leu?Tyr?Gly?Leu?Asn?Phe?Lys?Leu?Gly?Phe?Val?Gly?Phe?Ala
50??????????????????55??????????????????60Asn?Lys?Trp?Phe?Gly?Ala?Arg?Val?Tyr?Gly?Phe?Leu?Asp?Trp?Phe?Asn65??????????????????70??????????????????75??????????????????80Thr?Ser?Gly?Thr?Glu?His?Thr?Lys?Thr?Asn?Leu?Leu?Thr?Tyr?Gly?Gly
85??????????????????90??????????????????95Gly?Gly?Asp?Leu?Ile?Val?Asn?Leu?Ile?Pro?Leu?Asp?Lys?Phe?Ala?Leu
100?????????????????105?????????????????110Gly?Leu?Ile?Gly?Gly?Val?Gln?Lau?Ala?Gly?Asn?Thr?Trp?Met?Phe?Pro
115?????????????????120?????????????????125Tyr?Asp?Val?Asn?Gln?Thr?Arg?Phe?Gln?Phe?Leu?Trp?Asn?Leu?Gly?Gly
130?????????????????135?????????????????140Arg?Met?Arg?Val?Gly?Asp?Arg?Ser?Ala?Phe?Glu?Ala?Gly?Val?Lys?Phe145?????????????????150?????????????????155?????????????????160Pro?Met?Val?Asn?Gln?Gly?Ser?Lys?Asp?Val?Gly?Leu?Ile?Arg?Tyr?Tyr
165?????????????????170?????????????????175Ser?Trp?Tyr?Val?Asp?Tyr?Val?Phe?Thr?Phe
The data of 180 185 (2) SEQ ID NO:75:
(ⅰ) sequence signature:
(A) length: 116 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..116
(ⅹ ⅰ) sequence description: SEQ ID NO:75:Leu Met Arg Ile Ile Ile Arg Leu Leu Ser Phe Lys Met Asn Ala Phe1 5 10 15Leu Lys Leu Ala Leu Ala Ser Leu Met Gly Gly Leu Trp Tyr Ala Phe
20??????????????????25??????????????????30Asn?Gly?Glu?Gly?Ser?Glu?Ile?Val?Ala?Ile?Gly?Ile?Phe?Val?Leu?Ile
35??????????????????40??????????????????45Leu?Phe?Val?Phe?Phe?Ile?Arg?Pro?Val?Ser?Phe?Gln?Asp?Pro?Glu?Lys
50??????????????????55??????????????????60Arg?Glu?Glu?Tyr?Ile?Glu?Arg?Leu?Lys?Lys?Asn?His?Glu?Arg?Lys?Met65??????????????????70??????????????????75??????????????????80Ile?Leu?Gln?Asp?Lys?Gln?Lys?Glu?Glu?Gln?Met?Arg?Leu?Tyr?Gln?Ala
85??????????????????90??????????????????95Lys?Lys?Glu?Arg?Glu?Ser?Arg?Gln?Lys?Gln?Asp?Leu?Lys?Glu?Gln?Met
100?????????????????105?????????????????110Lys?Lys?Tyr?Ser
The data of 115 (2) SEQ ID NO:76:
(ⅰ) sequence signature:
(A) length: 345 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..345
(ⅹ ⅰ) sequence description: SEQ ID NO:76:Met Val Lys His Tyr Leu Phe Met Ala Val Ser Gln Val Phe Phe Ser1 5 10 15Phe Phe Leu Val Leu Phe Phe Ile Ser Ser Ile Val Leu Leu Ile Ser
20??????????????????25??????????????????30Ile?Ala?Ser?Val?Thr?Leu?Val?Ile?Lys?Val?Ser?Phe?Leu?Asp?Leu?Val
35??????????????????40??????????????????45Gln?Leu?Phe?Leu?Tyr?Ser?Leu?Pro?Gly?Thr?Ile?Phe?Phe?Ile?Leu?Pro
50??????????????????55??????????????????60Ile?Thr?Phe?Phe?Ala?Ala?Cys?Ala?Leu?Gly?Leu?Ser?Arg?Leu?Ser?Tyr65??????????????????70??????????????????75??????????????????80Asp?His?Glu?Leu?Leu?Val?Phe?Phe?Ser?Leu?Gly?Val?Ser?Pro?Lys?Lys
85??????????????????90??????????????????95Met?Thr?Lys?Ala?Phe?Val?Pro?Leu?Ser?Leu?Leu?Val?Ser?Ala?Ile?Leu
100?????????????????105?????????????????110Leu?Ala?Phe?Ser?Leu?Ile?Leu?Ile?Pro?Thr?Ser?Lys?Ser?Ala?Tyr?Tyr
115?????????????????120?????????????????125Gly?Phe?Leu?Arg?Gln?Lys?Lys?Asp?Lys?Ile?Asp?Ile?Asn?Ile?Arg?Ala
130?????????????????L35?????????????????140Gly?Glu?Phe?Gly?Gln?Lys?Leu?Gly?Asp?Trp?Leu?Val?Tyr?Val?Asp?Lys145?????????????????150?????????????????155?????????????????160Thr?Glu?Asn?Asn?Ser?Tyr?Asp?Asn?Leu?Val?Leu?Phe?Ser?Asn?Lys?Ser
165?????????????????170?????????????????175Leu?Ser?Gln?Glu?Ser?Phe?Ile?Leu?Ala?Gln?Lys?Gly?Asn?Ile?Asn?Asn
180?????????????????185?????????????????190Gln?Asn?Gly?Val?Phe?Glu?Leu?Asn?Leu?Tyr?Asn?Gly?His?Ala?Tyr?Phe
195?????????????????200?????????????????205Thr?Gln?Gly?Asp?Lys?Met?Arg?Lys?Val?Asp?Phe?Glu?Glu?Leu?His?Leu
210?????????????????215?????????????????220Arg?Asn?Lys?Leu?Lys?Ser?Phe?Asn?Ser?Asn?Asp?Ala?Ala?Tyr?Leu?Gln225?????????????????230?????????????????235?????????????????240Gly?Thr?Asp?Tyr?Leu?Gly?Tyr?Trp?Lys?Lys?Ala?Phe?Gly?Lys?Asn?Ala
245?????????????????250?????????????????255Asn?Lys?Asn?Gln?Lys?Arg?Arg?Phe?Ser?Gln?Ala?Ile?Leu?Val?Ser?Leu
260?????????????????265?????????????????270Phe?Pro?Leu?Ala?Ser?Val?Phe?Leu?Ile?Pro?Leu?Phe?Gly?Ile?Ala?Asn
275?????????????????280?????????????????285Pro?Arg?Phe?Lys?Thr?Asn?Trp?Ser?Tyr?Phe?Tyr?Val?Leu?Gly?Ala?Val
290?????????????????295?????????????????300Gly?Val?Tyr?Phe?Leu?Met?Val?His?Val?Ile?Ser?Thr?Asp?Leu?Phe?Leu305?????????????????310?????????????????315?????????????????320Met?Thr?Phe?Phe?Phe?Pro?Phe?Ile?Trp?Ala?Phe?Ile?Ser?Tyr?Leu?Leu
325?????????????????330?????????????????335Phe?Arg?Lys?Phe?Ile?Leu?Lys?Arg?Tyr
The data of 340 345 (2) SEQ ID NO:77:
(ⅰ) sequence signature:
(A) length: 276 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..276
(ⅹ ⅰ) sequence description: SEQ ID NO:77:Met Lys Lys Lys Ala Lys Val Phe Trp Cys Cys Phe Lys Met Ile Arg1 5 10 15Trp Leu Tyr Leu Ala Val Phe Phe Leu Leu Ser Val Ser Asp Ala Lys
20??????????????????25??????????????????30Glu?Ile?Ala?Met?Gln?Arg?Phe?Asp?Lys?Gln?Asn?His?Lys?Ile?Phe?Glu
35??????????????????40??????????????????45Ile?Leu?Ala?Asp?Lys?Val?Ser?Ala?Lys?Asp?Asn?Val?Ile?Thr?Ala?Ser
50??????????????????55??????????????????60Gly?Asn?Ala?Ile?Leu?Leu?Asn?Tyr?Asp?Val?Tyr?Ile?Leu?Ala?Asp?Lys65??????????????????70??????????????????75??????????????????80Val?Arg?Tyr?Asp?Thr?Lys?Thr?Lys?Glu?Ala?Leu?Leu?Glu?Gly?Asn?Ile
85??????????????????90??????????????????95Lys?Val?Tyr?Arg?Gly?Glu?Gly?Leu?Leu?Val?Lys?Thr?Asp?Tyr?Val?Lys
100?????????????????105?????????????????110Leu?Ser?Leu?Asn?Glu?Lys?Tyr?Glu?Ile?Ile?Phe?Pro?Phe?Tyr?Val?Gln
115?????????????????120?????????????????125Asp?Ser?Val?Ser?Gly?Ile?Trp?Val?Ser?Ala?Asp?Ile?Ala?Ser?Gly?Lys
130?????????????????135?????????????????140Asp?Gln?Lys?Tyr?Lys?Ile?Lys?Asn?Met?Ser?Ala?Ser?Gly?Cys?Ser?Ile145?????????????????150?????????????????155?????????????????160Asp?Asn?Pro?Ile?Trp?His?Val?Asn?Ala?Thr?Ser?Gly?Ser?Phe?Asn?Met
165?????????????????170?????????????????175Gln?Lys?Ser?His?Leu?Ser?Met?Trp?Asn?Pro?Lys?Ile?Tyr?Val?Gly?Asp
180?????????????????185?????????????????190Ile?Pro?Val?Leu?Tyr?Leu?Pro?Tyr?Ile?Phe?Met?Ser?Thr?Ser?Asn?Lys
195?????????????????200?????????????????205Arg?Thr?Thr?Gly?Phe?Leu?Tyr?Pro?Glu?Phe?Gly?Thr?Ser?Asn?Leu?Asp
210?????????????????215?????????????????220Gly?Phe?Ile?Tyr?Leu?Gln?Pro?Phe?Tyr?Leu?Ala?Pro?Lys?Asn?Ser?Trp225?????????????????230?????????????????235?????????????????240Asp?Met?Thr?Phe?Thr?Pro?Gln?Ile?Arg?Tyr?Lys?Arg?Gly?Phe?Gly?Leu
245?????????????????250?????????????????255Asn?Phe?Glu?Ala?Arg?Tyr?Ile?Asn?Ser?Lys?Thr?Gln?Val?Phe?Ile?Gln
260?????????????????265?????????????????270Cys?Ala?Leu?Phe
The data of 275 (2) SEQ ID NO:78:
(ⅰ) sequence signature:
(A) length: 224 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..224
(ⅹ ⅰ) sequence description: SEQ ID NO:78:Met Ile Arg Leu Lys Gly Leu Asn Lys Thr Leu Lys Thr Ser Leu Leu1 5 10 15Ala Gly Val Leu Leu Gly Ala Thr Ala Pro Leu Met Ala Lys Pro Leu
20??????????????????25??????????????????30Leu?Ser?Asp?Glu?Asp?Leu?Leu?Lys?Arg?Val?Lys?Leu?His?Asn?Ile?Lys
35??????????????????40??????????????????45Glu?Asp?Thr?Leu?Thr?Ser?Cys?Asn?Ala?Lys?Val?Asp?Gly?Ser?Gln?Tyr
50??????????????????55??????????????????60Leu?Asn?Ser?Gly?Trp?Asn?Leu?Ser?Lys?Glu?Phe?Pro?Gln?Glu?Tyr?Arg65??????????????????70??????????????????75??????????????????80Glu?Lys?Ile?Phe?Glu?Cys?Val?Glu?Glu?Glu?Lys?His?Lys?Gln?Ala?Leu
85??????????????????90??????????????????95Asn?Leu?Ile?Asn?Lys?Glu?Asp?Thr?Lys?Asp?Lys?Glu?Glu?Leu?Ala?Lys
100?????????????????105?????????????????110Lys?Ile?Lys?Glu?Ile?Lys?Glu?Lys?Ala?Lys?Val?Leu?Arg?Gln?Lys?Phe
115?????????????????120?????????????????125Met?Ala?Phe?Glu?Met?Lys?Glu?His?Ser?Lys?Glu?Phe?Pro?Asn?Lys?Lys
130?????????????????135?????????????????140Gln?Leu?Gln?Thr?Met?Leu?Glu?Asn?Ala?Phe?Asp?Asn?Gly?Ala?Glu?Ser145?????????????????150?????????????????155?????????????????160Phe?Ile?Asp?Asp?Trp?His?Glu?Arg?Phe?Gly?Gly?Ile?Ser?Arg?Glu?Asn
165?????????????????170?????????????????175Thr?Tyr?Lys?Ala?Leu?Gly?Ile?Lys?Glu?Tyr?Set?Asp?Glu?Gly?Lys?Ile
180?????????????????185?????????????????190Leu?Pro?Leu?Ala?Lys?Glu?Val?Ile?Leu?Asp?Asn?Ile?Lys?Lys?Ile?Leu
195?????????????????200?????????????????205Lys?Lys?Ala?Leu?Met?Ile?Leu?Asp?Asn?Pro?Tyr?Leu?Leu?Trp?Leu?Val
The data of 210 215 220 (2) SEQ ID NO:79:
(ⅰ) sequence signature:
(A) length: 429 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..429
(ⅹ ⅰ) sequence description: SEQ ID NO:79:Met Pro Tyr Ala Leu Arg Lys Arg Phe Phe Lys Arg Leu Leu Leu Phe1 5 10 15Phe Leu Ile Val Cys Met Ile Asn Leu His Ala Lys Ser Tyr Leu Phe
20??????????????????25??????????????????30Ser?Pro?Leu?Pro?Pro?Ala?His?Gln?Gln?Ile?Ile?Lys?Thr?Glu?Pro?Cys
35??????????????????40???????????????????45Ser?Leu?Glu?Cys?Leu?Lys?Asp?Leu?Met?Leu?Gln?Asn?Gln?Ile?Phe?Ser
50??????????????????55??????????????????60Phe?Val?Ser?Gln?Tyr?Asp?Asp?Asn?Asn?Gln?Asp?Glu?Ser?Leu?Lys?Thr65??????????????????70??????????????????75??????????????????80Tyr?Tyr?Lys?Asp?Ile?Leu?Asn?Lys?Leu?Asn?Pro?Val?Phe?lle?Ala?Ser
85??????????????????90??????????????????95Gln?Thr?Pro?Ala?Lys?Glu?Ser?Tyr?Glu?Pro?Lys?Ile?Glu?Leu?Ala?Ile
100?????????????????105?????????????????110Leu?Leu?Pro?Lys?Lys?Val?Val?Gly?Arg?Tyr?Ala?Ile?Leu?Val?Met?Asn
115?????????????????120?????????????????125Thr?Leu?Leu?Ala?Tyr?Leu?Asn?Thr?Arg?Asn?Asn?Asp?Phe?Asn?Ile?Gln
130?????????????????135?????????????????140Val?Phe?Asp?Ser?Asp?Glu?Glu?Ser?Pro?Glu?Lys?Leu?Glu?Glu?Thr?Tyr145?????????????????150?????????????????155?????????????????160Lys?Glu?Ile?Glu?Lys?Glu?Lys?Phe?Pro?Phe?Ile?Ile?Ala?Leu?Leu?Thr
165?????????????????170?????????????????175Lys?Glu?Gly?Val?Glu?Asn?Leu?Leu?Gln?Asn?Thr?Thr?Ile?Asn?Thr?Pro
180?????????????????185?????????????????190Thr?Tyr?Val?Pro?Thr?Val?Asn?Lys?Thr?Gln?Leu?Glu?Asn?His?Thr?Glu
195?????????????????200?????????????????205Leu?Ser?Leu?Ser?Glu?Arg?Leu?Tyr?Phe?Gly?Gly?Ile?Asp?Tyr?Lys?Glu
210?????????????????215?????????????????220Gln?Leu?Gly?Met?Leu?Ala?Thr?Phe?Ile?Ser?Pro?Asn?Ser?Pro?Val?Ile225?????????????????230?????????????????235?????????????????240Glu?Tyr?Asp?Asp?Asp?Gly?Leu?Ile?Gly?Glu?Arg?Leu?Arg?Gln?Ile?Thr
245?????????????????250?????????????????255Glu?Ser?Leu?Asn?Val?Glu?Val?Lys?His?Gln?Glu?Asn?Ile?Ser?Tyr?Lys
260?????????????????265?????????????????270Gln?Ala?Thr?Ser?Phe?Ser?Lys?Asn?Phe?Arg?Lys?His?Asp?Ala?Phe?Phe
275?????????????????280?????????????????285Lys?Asn?Ser?Thr?Leu?Ile?Leu?Asn?Thr?Pro?Thr?Thr?Lys?Ser?Gly?Leu
290?????????????????295?????????????????300Ile?Leu?Ser?Gln?Ile?Gly?Leu?Leu?Glu?Tyr?Lys?Pro?Leu?Lys?Ile?Leu305?????????????????310?????????????????315?????????????????320Ser?Thr?Gln?Ile?Asn?Phe?Asn?Pro?Ser?Leu?Leu?Leu?Leu?Thr?Gln?Pro
325?????????????????330?????????????????335Lys?Asp?Arg?Lys?Asn?Leu?Phe?Ile?Val?Asn?Ala?Leu?Gln?Asn?Ser?Asp
340?????????????????345?????????????????350Glu?Thr?Leu?Ile?Glu?Tyr?Ala?Ser?Leu?Leu?Glu?Ser?Asp?Leu?Arg?His
355?????????????????360?????????????????365Asp?Trp?Val?Asn?Tyr?Ser?Ser?Ala?Ile?Gly?Leu?Glu?Met?Phe?Leu?Asn
370?????????????????375?????????????????380Thr?Leu?Asp?Pro?His?Phe?Lys?Lys?Ser?Phe?Gln?Glu?Ser?Leu?Glu?Asp385?????????????????390?????????????????395?????????????????400Asn?Gln?Val?Arg?Tyr?His?Asn?Gln?Ile?Tyr?Gln?Ala?Leu?Gly?Tyr?Ser
405?????????????????410?????????????????415Phe?Glu?Pro?Ile?Lys?Asn?Glu?Ser?Glu?Thr?Lys?Lys?Glu
The data of 420 425 (2) SEQ ID NO:80:
(ⅰ) sequence signature:
(A) length: 455 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..455
(ⅹ ⅰ) sequence description: SEQ ID NO:80:Val Leu Lys Phe Gln Lys Leu Pro Leu Leu Phe Val Ser Ile Leu Tyr1 5 10 15Asn Gln Ser Pro Leu Leu Ala Phe Asp Tyr Lys Phe Ser Gly Val Ala
20??????????????????25??????????????????30Glu?Ser?Val?Ser?Lys?Val?Gly?Phe?Asn?His?Ser?Lys?Leu?Asn?Ser?Lys
35??????????????????40??????????????????45Glu?Gly?Ile?Phe?Pro?Thr?Ala?Thr?Phe?Val?Thr?Ala?Thr?Ile?Lys?Leu
50??????????????????55??????????????????60Gln?Val?Asp?Ser?Asn?Leu?Leu?Pro?Lys?Asn?Ile?Glu?Lys?His?Ser?Leu65??????????????????70??????????????????75??????????????????80Lys?Ile?Gly?Val?Gly?Gly?Ile?Leu?Gly?Ala?Leu?Ala?Tyr?Asp?Ser?Thr
85??????????????????90??????????????????95Lys?Thr?Leu?Ile?Asp?Gln?Ala?Thr?His?Gln?Ile?Tyr?Gly?Ser?Glu?Leu
100?????????????????105?????????????????110Phe?Tyr?Leu?Ile?Gly?Arg?Trp?Trp?Gly?Phe?Leu?Gly?Asn?Ala?Pro?Trp
115?????????????????120?????????????????125Lys?Asp?Ser?Leu?Ile?Glu?Ser?Asp?Ala?His?Thr?Arg?Asn?Tyr?Val?Leu
130?????????????????135?????????????????140Tyr?Asn?Ser?Tyr?Leu?Phe?Tyr?Sar?Tyr?Gly?Asp?Lys?Phe?His?Leu?Lys145?????????????????150?????????????????155?????????????????160Leu?Gly?Arg?Tyr?Leu?Ser?Asn?Met?Asp?Phe?Met?Ser?Ser?Tyr?Thr?Gln
165?????????????????170?????????????????175Gly?Phe?Glu?Leu?Asp?Tyr?Lys?Ile?Asn?Ser?Lys?Ile?Ala?Leu?Lys?Trp
180?????????????????185?????????????????190Phe?Ser?Ser?Phe?Gly?Arg?Ala?Leu?Ala?Phe?Gly?Gln?Trp?Ile?Arg?Asp
195?????????????????200?????????????????205Trp?Tyr?Ala?Pro?Ile?Val?Thr?Glu?Asp?Gly?Arg?Lys?Glu?Val?Tyr?Asp
210?????????????????215?????????????????220Gly?Ile?His?Ala?Ala?Gln?Leu?Tyr?Phe?Ser?Ser?Lys?His?Val?Gln?Val225?????????????????230?????????????????235?????????????????240Met?Pro?Phe?Ala?Tyr?Phe?Ser?Pro?Lys?Ile?Tyr?Gly?Ala?Pro?Gly?Val
245?????????????????250?????????????????255Lys?Ile?His?Ile?Asp?Ser?Asn?Pro?Lys?Phe?Lys?Gly?Leu?Gly?Leu?Arg
260?????????????????265?????????????????270Ala?Gln?Thr?Thr?Ile?Asn?Val?Ile?Phe?Pro?Val?Tyr?Ala?Lys?Asp?Leu
275?????????????????280?????????????????285Tyr?Asp?Val?Tyr?Trp?Arg?Asn?Ser?Lys?Ile?Gly?Glu?Trp?Gly?Ala?Ser
290?????????????????295?????????????????300Leu?Leu?Ile?His?Gln?Arg?Phe?Asp?Tyr?Asn?Glu?Phe?Asn?Phe?Gly?Phe305?????????????????310?????????????????315?????????????????320Gly?Tyr?Tyr?Gln?Asn?Phe?Gly?Asn?Ala?Asn?Ala?Arg?Ile?Gly?Trp?Tyr
325?????????????????330?????????????????335Gly?Asn?Pro?Ile?Pro?Phe?Asn?Tyr?Arg?Asn?Asn?Ser?Val?Tyr?Gly?Gly
340?????????????????345?????????????????350Val?Phe?Ser?Asn?Ala?Ile?Thr?Ala?Asp?Ala?Val?Ser?Gly?Tyr?Val?Phe
355?????????????????360?????????????????365Gly?Gly?Gly?Val?Tyr?Arg?Gly?Phe?Leu?Trp?Gly?Ile?Leu?Gly?Arg?Tyr
370?????????????????375?????????????????380Thr?Tyr?Ala?Thr?Arg?Ala?Ser?Glu?Arg?Ser?Ile?Asn?Leu?Asn?Leu?Gly385?????????????????390?????????????????395?????????????????400Tyr?Lys?Trp?Gly?Ser?Phe?Ala?Arg?Val?Asp?Val?Asn?Leu?Glu?Tyr?Tyr
405?????????????????410?????????????????415Val?Val?Ser?Met?His?Asn?Gly?Tyr?Arg?Leu?Asp?Tyr?Leu?Thr?Gly?Pro
420?????????????????425?????????????????430Phe?Asn?Lys?Ala?Phe?Lys?Ala?Asp?Ala?Gln?Asp?Arg?Ser?Asn?Leu?Met
435?????????????????440?????????????????445Val?Ser?Met?Lys?Phe?Phe?Phe
The data of 450 455 (2) SEQ ID NO:81:
(ⅰ) sequence signature:
(A) length: 282 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..282
(ⅹ ⅰ) sequence description: SEQ ID NO:81:Met Gly Cys Ser Phe Ile Phe Lys Lys Val Arg Val Tyr Ser Lys Met1 5 10 15Leu Val Ala Leu Gly Leu Ser Ser Val Leu Ile Gly Cys Ala Met Asn
20??????????????????25??????????????????30Pro?Sar?Ala?Glu?Thr?Lys?Lys?Pro?Asn?Asp?Ala?Lys?Asn?Gln?Gln?Pro
35??????????????????40??????????????????45Val?Gln?Thr?His?Glu?Arg?Met?Thr?Thr?Ser?Ser?Glu?His?Val?Thr?Pro
50??????????????????55??????????????????60Leu?Asp?Phe?Asn?Tyr?Pro?Val?His?Ile?Val?Gln?Ala?Pro?Gln?Asn?His65??????????????????70??????????????????75??????????????????80His?Val?Val?Gly?Ile?Leu?Met?Pro?Arg?Ile?Gln?Val?Ser?Asp?Asn?Leu
85??????????????????90??????????????????95Lys?Pro?Tyr?Ile?Asp?Lys?Phe?Gln?Asp?Ala?Leu?Ile?Asn?Gln?Ile?Gln
100?????????????????105?????????????????110Thr?Ile?Phe?Glu?Lys?Arg?Gly?Tyr?Gln?Val?Leu?Arg?Phe?Gln?Asp?Glu
115?????????????????120?????????????????125Lys?Ala?Leu?Asn?Val?Gln?Asp?Lys?Lys?Lys?Ile?Phe?Ser?Val?Leu?Asp
130?????????????????135?????????????????140Leu?Lys?Gly?Trp?Val?Gly?Ile?Leu?Glu?Asp?Leu?Lys?Met?Asn?Leu?Lys145?????????????????150?????????????????155?????????????????160Asp?Pro?Asn?Ser?Pro?Asn?Leu?Asp?Thr?Leu?Val?Asp?Gln?Ser?Ser?Gly
165?????????????????170?????????????????175Ser?Val?Trp?Phe?Asn?Phe?Tyr?Glu?Pro?Glu?Ser?Asn?Arg?Val?Val?His
180?????????????????185?????????????????190Asp?Phe?Ala?Val?Glu?Val?Gly?Thr?Phe?Gln?Ala?Ile?Thr?Tyr?Thr?Tyr
195?????????????????200?????????????????205Thr?Ser?Thr?Asn?Asn?Ala?Ser?Gly?Gly?Phe?Asn?Ser?Ser?Lys?Ser?Val
210?????????????????215?????????????????220Ile?His?Glu?Asn?Leu?Asp?Lys?Asn?Arg?Glu?Asp?Ala?Ile?His?Lys?Ile225?????????????????230?????????????????235?????????????????240Leu?Asn?Arg?Met?Tyr?Ala?Val?Val?Met?Lys?Lys?Ala?Val?Thr?Glu?Leu
245?????????????????250?????????????????255Thr?Lys?Glu?Asn?Ile?Ala?Lys?Tyr?Arg?Asp?Ala?Ile?Asp?Arg?Met?Lys
260?????????????????265?????????????????270Gly?Phe?Lys?Ser?Ser?Met?Pro?Gln?Lys?Lys
The data of 275 280 (2) SEQ ID NO:82:
(ⅰ) sequence signature:
(A) length: 280 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..280
(ⅹ ⅰ) sequence description: SEQ ID NO:82:Met Lys Leu Arg Ala Ser Val Leu Ile Gly Val Ala Ile Leu Cys Leu1 5 10 15Ile Leu Ser Ala Cys Ser Asn Tyr Ala Lys Lys Val Val Lys Gln Lys
20??????????????????25??????????????????30Asn?His?Val?Tyr?Thr?Pro?Val?Tyr?Asn?Glu?Leu?Ile?Glu?Lys?Tyr?Ser
35??????????????????40??????????????????45Glu?Ile?Pro?Leu?Asn?Asp?Lys?Leu?Lys?Asp?Thr?Pro?Phe?Met?Val?Gln
50??????????????????55??????????????????60Val?Lys?Leu?Pro?Asn?Tyr?Lys?Asp?Tyr?Leu?Leu?Asp?Asn?Lys?Gln?Val65??????????????????70??????????????????75??????????????????80Val?Leu?Thr?Phe?Lys?Leu?Val?His?His?Ser?Lys?Lys?Ile?Thr?Leu?Ile
85??????????????????90??????????????????95Gly?Asp?Ala?Asn?Lys?Ile?Leu?Gln?Tyr?Lys?Asn?Tyr?Phe?Gln?Ala?Asn
100?????????????????105?????????????????110Gly?Ala?Arg?Ser?Asp?Ila?Asp?Phe?Tyr?Leu?Gln?Pro?Thr?Leu?Asn?Gln
115?????????????????120?????????????????125Lys?Gly?Val?Val?Met?Ile?Ala?Ser?Asn?Tyr?Asn?Asp?Asn?Pro?Asn?Asn
130?????????????????135?????????????????140Lys?Glu?Lys?Pro?Gln?Thr?Phe?Asp?Val?Leu?Gln?Gly?Ser?Gln?Pro?Met145?????????????????150?????????????????155?????????????????160Leu?Gly?Ala?Asn?Thr?Lys?Asn?Leu?His?Gly?Tyr?Asp?Val?Ser?Gly?Ala
165?????????????????170?????????????????175Asn?Asn?Lys?Gln?Val?Ile?Asn?Glu?Val?Ala?Arg?Glu?Lys?Ala?Gln?Leu
180?????????????????185?????????????????190Glu?Lys?Ile?Asn?Gln?Tyr?Tyr?Lys?Thr?Leu?Leu?Gln?Asp?Lys?Glu?Gln
195?????????????????200?????????????????205Glu?Tyr?Thr?Thr?Arg?Lys?Asn?Asn?Gln?Arg?Glu?Ile?Leu?Glu?Thr?Leu
210?????????????????215?????????????????220Ser?Asn?Arg?Ala?Gly?Tyr?Gln?Met?Arg?Gln?Asn?Val?Ile?Ser?Ser?Glu225?????????????????230?????????????????235?????????????????240Ile?Phe?Lys?Asn?Gly?Asn?Leu?Asn?Met?Gln?Ala?Lys?Glu?Glu?Glu?Val
245?????????????????250?????????????????255Arg?Glu?Lys?Leu?Gln?Glu?Glu?Arg?Glu?Asn?Glu?Tyr?Leu?Arg?Asn?Gln
260?????????????????265?????????????????270Ile?Arg?Ser?Leu?Leu?Ser?Gly?Lys
The data of 275 280 (2) SEQ ID NO:83:
(ⅰ) sequence signature:
(A) length: 393 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..393
(ⅹ ⅰ) sequence description: SEQ ID NO:83:Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala1 5 10 15Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu
20??????????????????25??????????????????30Leu?Glu?Gly?Thr?Gln?Thr?Gln?Glu?Lys?Arg?His?Thr?Thr?Thr?Lys?Asn
35??????????????????40??????????????????45Thr?Tyr?Ala?Thr?Tyr?Asn?Tyr?Leu?Pro?Thr?Asp?Thr?Ile?Leu?Lys?Arg
50??????????????????55??????????????????60Ala?Ala?Asn?Leu?Phe?Thr?Asn?Ala?Glu?Ala?Ile?Ser?Lys?Leu?Lys?Phe65??????????????????70??????????????????75??????????????????80Ser?Ser?Leu?Set?Pro?Val?Arg?Val?Leu?Tyr?Met?Tyr?Asn?Gly?Gln?Leu
85??????????????????90??????????????????95Thr?Ile?Glu?Asn?Phe?Leu?Pro?Tyr?Asn?Leu?Asn?Asn?Val?Lys?Leu?Ser
100?????????????????105?????????????????110Phe?Thr?Asp?Ala?Gln?Gly?Asn?Val?Ile?Asp?Leu?Gly?Val?Ile?Glu?Thr
115?????????????????120?????????????????125Ile?Pro?Lys?His?Ser?Lys?Ile?Val?Leu?Pro?Gly?Glu?Ala?Phe?Asp?Ser
130?????????????????135?????????????????140Leu?Lys?Ile?Asp?Pro?Tyr?Thr?Leu?Phe?Leu?Pro?Lys?Ile?Glu?Ala?Thr145?????????????????150?????????????????155?????????????????160Ser?Thr?Ser?Ile?Ser?Asp?Ala?Asn?Thr?Gln?Arg?Val?Phe?Glu?Thr?Leu
165?????????????????170?????????????????175Asn?Lys?Ile?Lys?Thr?Asn?Leu?Val?Val?Asn?Tyr?Arg?Asn?Glu?Asn?Lys
180?????????????????185?????????????????190Phe?Lys?Asp?His?Glu?Asn?His?Trp?Glu?Ala?Phe?Thr?Pro?Gln?Thr?Ala
195?????????????????200?????????????????205Glu?Glu?Phe?Thr?Asn?Leu?Met?Leu?Asn?Met?Ile?Ala?Val?Leu?Asp?Ser
210?????????????????215?????????????????220Gln?Ser?Trp?Gly?Asp?Ala?Ile?Leu?Asn?Ala?Pro?Phe?Glu?Phe?Thr?Asn225?????????????????230?????????????????235?????????????????240Ser?Pro?Thr?Asp?Cys?Asp?Asn?Asp?Pro?Ser?Lys?Cys?Val?Asn?Pro?Gly
245?????????????????250?????????????????255Thr?Asn?Gly?Leu?Val?Asn?Ser?Lys?Val?Asp?Gln?Lys?Tyr?Val?Leu?Asn
260?????????????????265?????????????????270Lys?Gln?Asp?Ile?Val?Asn?Lys?Phe?Lys?Asn?Lys?Ala?Asp?Leu?Asp?Val
275?????????????????280?????????????????285Ile?Val?Leu?Lys?Asp?Ser?Gly?Val?Val?Gly?Leu?Gly?Ser?Asp?Ile?Thr
290?????????????????295?????????????????300Pro?Ser?Asn?Asn?Asp?Asp?Gly?Lys?His?Tyr?Gly?Gln?Leu?G1y?Val?Val305?????????????????310?????????????????315?????????????????320Ala?Ser?Ala?Leu?Asp?Pro?Lys?Lys?Leu?Phe?Gly?Asp?Asn?Leu?Lys?Thr
325?????????????????330?????????????????335Ile?Asn?Leu?Glu?Asp?Leu?Arg?Thr?Ile?Leu?His?Glu?Phe?Ser?His?Thr
340?????????????????345?????????????????350Lys?Gly?Tyr?Gly?His?Asn?Gly?Asn?Met?Thr?Tyr?Gln?Arg?Val?Pro?Val
355?????????????????360?????????????????365Thr?Lys?Asp?G1y?Gln?Val?Glu?Lys?Asp?Ser?Asn?Gly?Lys?Pro?Lys?Asp
The data of 370 375 380Ser Asp Gly Leu Pro Tyr Asn Val Cys385,390 (2) SEQ ID NO:84:
(ⅰ) sequence signature:
(A) length: 270 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..270
(ⅹ ⅰ) sequence description: SEQ ID NO:84:Met Lys Lys Phe Val Ala Leu Gly Leu Leu Ser Ala Val Leu Ser Ser1 5 10 15Ser Leu Leu Ala Glu Gly Asp Gly Val Tyr Ile Gly Thr Asn Tyr Gln
20??????????????????25??????????????????30Leu?Gly?Gln?Ala?Arg?Leu?Asn?Ser?Asn?Ile?Tyr?Asn?Thr?Gly?Asp?Cys
35??????????????????40??????????????????45Thr?Gly?Ser?Val?Val?Gly?Cys?Pro?Pro?Gly?Leu?Thr?Ala?Asn?Lys?His
50??????????????????55??????????????????60Asn?Pro?Gly?Gly?Thr?Asn?Ile?Asn?Trp?His?Ser?Lys?Tyr?Ala?Asn?Gly65??????????????????70??????????????????75??????????????????80Ala?Leu?Asn?Gly?Phe?Gly?Leu?Asn?Val?Gly?Tyr?Lys?Lys?Phe?Phe?Gln
85??????????????????90??????????????????95Phe?Lys?Ser?Leu?Asp?Met?Thr?Ser?Lys?Trp?Phe?Gly?Phe?Arg?Val?Tyr
100?????????????????105?????????????????110Gly?Leu?Phe?Asp?Tyr?Gly?His?Ala?Asp?Leu?Gly?Lys?Gln?Val?Tyr?Ala
115?????????????????120?????????????????125Pro?Asn?Lys?Ile?Gln?Leu?Asp?Met?Val?Ser?Trp?Gly?Val?Gly?Ser?Asp
130?????????????????135?????????????????140Leu?Leu?Ala?Asp?Ile?Ile?Asp?Lys?Asp?Asn?Ala?Ser?Phe?Gly?Ile?Phe145?????????????????150?????????????????155?????????????????160Gly?Gly?Val?Ala?Ile?Gly?Gly?Asn?Thr?Trp?Lys?Ser?Ser?Ala?Ala?Asn
165?????????????????170?????????????????175Tyr?Trp?Lys?Glu?Gln?Ile?Ile?Glu?Ala?Lys?Gly?Pro?Asp?Val?Cys?Thr
180?????????????????185?????????????????190Pro?Thr?Tyr?Cys?Asn?Pro?Asn?Ala?Pro?Tyr?Ser?Thr?Asn?Thr?Ser?Thr
195?????????????????200?????????????????205Val?Ala?Phe?Gln?Val?Trp?Leu?Asn?Phe?Gly?Val?Arg?Ala?Asn?Ile?Tyr
210?????????????????215?????????????????220Lys?His?Asn?Gly?Val?Glu?Phe?Gly?Val?Arg?Val?Pro?Leu?Leu?Ile?Asn225?????????????????230?????????????????235?????????????????240Lys?Phe?Leu?Ser?Ala?Gly?Pro?Asn?Ala?Thr?Asn?Leu?Tyr?Tyr?His?Leu
245?????????????????250?????????????????255Lys?Arg?Asp?Tyr?Ser?Leu?Tyr?Leu?Gly?Tyr?Asn?Tyr?Thr?Phe
The data of 260 265 270 (2) SEQ ID NO:85:
(ⅰ) sequence signature:
(A) length: 140 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..140
(ⅹ ⅰ) sequence description: SEQ ID NO:85:Met His Pro Ile Met Phe Ala Tyr Ile Ala Asn Ala Leu Ala Gln Ala1 5 10 15Arg Lys Ile Asn Gly Thr Leu Cys Met Ala Phe Gln Lys Ile Ser Gln
20??????????????????25??????????????????30Val?Lys?Glu?Leu?Gly?Ile?Asp?Lys?Ala?Lys?Ser?Leu?Ile?Gly?Asn?Leu
35??????????????????40??????????????????45Ser?Gln?Val?Ile?Ile?Tyr?Pro?Thr?Lys?Asp?Thr?Asp?Glu?Leu?Ile?Glu
50??????????????????55??????????????????60Cys?Gly?Val?Pro?Leu?Ser?Asp?Ser?Glu?Ile?Asn?Phe?Leu?His?Asn?Thr65??????????????????70??????????????????75??????????????????80Asp?Met?Arg?Ala?Arg?Gln?Val?Leu?Val?Lys?Asn?Ile?Val?Thr?Asn?Ala
85??????????????????90??????????????????95Ser?Ala?Phe?Ile?Glu?Ile?Asp?Leu?Lys?Lys?Ile?Cys?Lys?Asn?Tyr?Phe
100?????????????????105?????????????????110Ile?Phe?Leu?Ile?Ala?Met?Leu?Val?Ile?Glu?Lys?Ser?Ser?Met?Ile?Leu
115?????????????????120?????????????????125Lys?Lys?Gln?Thr?Lys?Lys?Leu?Ile?Arg?Lys?Ser?Ile
The data of 130 135 140 (2) SEQ ID NO:86:
(ⅰ) sequence signature:
(A) length: 256 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..256
(ⅹ ⅰ) sequence description: SEQ ID NO:86:Met Leu Gly Ser Val Lys Lys Ala Val Phe Arg Val Leu Cys Leu Gly1 5 10 15Ala Leu Cys Leu Cys Gly Gly Leu Met Ala Glu Gln Asp Pro Lys Glu
20??????????????????25??????????????????30Leu?Ile?Phe?Ser?Gly?Ile?Thr?Ile?Tyr?Thr?Asp?Lys?Asn?Phe?Thr?Arg
35??????????????????40??????????????????45Ala?Lys?Lys?Tyr?Phe?Glu?Lys?Ala?Cys?Lys?Ser?Asn?Asp?Ala?Asp?Gly
50??????????????????55??????????????????60Cys?Ala?Ile?Leu?Arg?Glu?Val?Tyr?Ser?Ser?Gly?Lys?Ala?Ile?Ala?Arg65??????????????????70??????????????????75??????????????????80Glu?Asn?Ala?Arg?Glu?Ser?Ile?Glu?Lys?Ala?Leu?Glu?His?Thr?Ala?Thr
85??????????????????90??????????????????95Ala?Lys?Val?Cys?Lys?Leu?Asn?Asp?Ala?Glu?Lys?Cys?Lys?Asp?Leu?Ala
100?????????????????105?????????????????110Glu?Phe?Tyr?Phe?Asn?Val?Asn?Asp?Leu?Lys?Asn?Ala?Leu?Glu?Tyr?Tyr
115?????????????????120?????????????????125Ser?Lys?Ser?Cys?Lys?Leu?Asn?Asn?Val?Glu?Gly?Cys?Met?Leu?Ser?Ala
130?????????????????135?????????????????140Thr?Phe?Tyr?Asn?Asp?Met?Ile?Lys?Gly?Leu?Lys?Lys?Asp?Lys?Lys?Asp145?????????????????150?????????????????155?????????????????160Leu?Glu?Tyr?Tyr?Ser?Lys?Ala?Cys?Glu?Leu?Asn?Asn?Gly?Gly?Gly?Cys
165?????????????????170?????????????????175Ser?Lys?Leu?Gly?Gly?Asp?Tyr?Phe?Phe?Gly?Glu?Gly?Val?Thr?Lys?Asp
180?????????????????185?????????????????190Phe?Lys?Lys?Ala?Phe?Glu?Tyr?Ser?Ala?Lys?Ala?Cys?Glu?Leu?Asn?Asp
195?????????????????200?????????????????205Ala?Lys?Gly?Cys?Tyr?Ala?Leu?Ala?Ala?Phe?Tyr?Asn?Glu?Gly?Lys?Gly
210?????????????????215?????????????????220Val?Ala?Lys?Asp?Glu?Lys?Gln?Thr?Thr?Glu?Asn?Leu?Glu?Lys?Ser?Cys225?????????????????230?????????????????235?????????????????240Lys?Leu?Gly?Leu?Lys?Glu?Ala?Cys?Asp?Ile?Leu?Lys?Glu?Gln?Lys?Gln
The data of 245 250 255 (2) SEQ ID NO:87:
(ⅰ) sequence signature:
(A) length: 242 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..242
(ⅹ ⅰ) sequence description: SEQ ID NO:87:Met Lys Lys Phe Phe Ser Gln Ser Leu Leu Ala Leu Ile Ile Ser Met1 5 10 15Asn Ala Val Ser Gly Met Asp Gly Asn Gly Val Phe Leu Gly Ala Gly
20??????????????????25??????????????????30Tyr?Leu?Gln?Gly?Gln?Ala?Gln?Met?His?Ala?Asp?Ile?Asn?Ser?Gln?Lys
35??????????????????40??????????????????45Gln?Ala?Thr?Asn?Ala?Thr?Ile?Lys?Gly?Phe?Asp?Ala?Leu?Leu?Gly?Tyr
50??????????????????55??????????????????60Gln?Phe?Phe?Phe?Glu?Lys?His?Phe?Gly?Leu?Arg?Leu?Tyr?Gly?Phe?Phe65??????????????????70??????????????????75??????????????????80Asp?Tyr?Ala?His?Ala?Asn?Ser?Ile?Lys?Leu?Lys?Asn?Pro?Asn?Tyr?Asn
85??????????????????90??????????????????95Ser?Glu?Ala?Ala?Gln?Val?Ala?Ser?Gln?Ile?Leu?Gly?Lys?Gln?Glu?Ile
100?????????????????105?????????????????110Asn?Arg?Leu?Thr?Asn?Ile?Ala?Asp?Pro?Arg?Thr?Phe?Glu?Pro?Asn?Met
115?????????????????120?????????????????125Leu?Thr?Tyr?Gly?Gly?Ala?Met?Asp?Val?Met?Val?Asn?Val?Ile?Asn?Asn
130?????????????????135?????????????????140Gly?Ile?Met?Ser?Leu?Gly?Ala?Phe?Gly?Gly?Ile?Gln?Leu?Ala?Gly?Asn145?????????????????150?????????????????155?????????????????160Ser?Trp?Leu?Met?Ala?Thr?Pro?Ser?Phe?Glu?Gly?Ile?Leu?Val?Glu?Gln
165?????????????????170?????????????????175Ala?Leu?Val?Ser?Lys?Lys?Ala?Thr?Ser?Phe?Gln?Phe?Leu?Phe?Asn?Val
180??????????????????185?????????????????190Gly?Ala?Arg?Leu?Arg?Ile?Leu?Lys?His?Ser?Ser?Ile?Glu?Ala?Gly?Val
195?????????????????200?????????????????205Lys?Phe?Pro?Met?Leu?Lys?Lys?Asn?Pro?Tyr?Ile?Thr?Ala?Lys?Asn?Leu
The data of 210 215 220Asp Ile Gly Phe Arg Arg Val Tyr Ser Trp Tyr Val Asn Tyr Val Phe225,230 235 240Thr Phe (2) SEQ ID NO:88:
(ⅰ) sequence signature:
(A) length: 267 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..267
(ⅹ ⅰ) sequence description: SEQ ID NO:88:Met Asn Tyr Pro Asn Leu Pro Asn Ser Ala Leu Glu Ile Ser Glu Gln1 5 10 15Pro Glu Val Lys Glu Ile Thr Asn Glu Leu Leu Lys Gln Leu Gln Asn
20??????????????????25??????????????????30Ala?Leu?Arg?Ser?Asn?Ala?His?Phe?Ser?Glu?Gln?Val?Glu?Leu?Ser?Leu
35??????????????????40??????????????????45Lys?Cys?Ile?Val?Arg?Ile?Leu?Glu?Val?Leu?Leu?Ser?Leu?Asp?Phe?Phe
50??????????????????55??????????????????60Lys?Asn?Ala?Asn?Glu?Ile?Asp?Ser?Ser?Leu?Arg?Asn?Ser?Ile?Glu?Trp65??????????????????70??????????????????75??????????????????80Leu?Thr?Asn?Ala?Gly?Glu?Ser?Leu?Lys?Leu?Lys?Met?Lys?Glu?Tyr?Glu
85??????????????????90??????????????????95Arg?Phe?Phe?Ser?Glu?Phe?Asn?Thr?Ser?Met?His?Ala?Asn?Glu?Gln?Glu
100?????????????????105?????????????????110Val?Thr?Asn?Thr?Leu?Asn?Ala?Asn?Ala?Glu?Asn?Ile?Lys?Ser?Glu?Ile
115?????????????????120?????????????????125Lys?Lys?Leu?Glu?Asn?Gln?Leu?Ile?Glu?Thr?Thr?Thr?Arg?Leu?Leu?Thr
130?????????????????135?????????????????140Ser?Tyr?Gln?Ile?Phe?Leu?Asn?Gln?Ala?Arg?Asp?Asn?Ala?Asn?Asn?Gln145?????????????????150?????????????????155?????????????????160Ile?Thr?Lys?Asn?Lys?Thr?Gln?Ser?Leu?Glu?Ala?Ile?Thr?Gln?Ala?Lys
165?????????????????170?????????????????175Asn?Asn?Ala?Asn?Asn?Glu?Ile?Set?Asn?Asn?Gln?Thr?Gln?Ala?Ile?Thr
180?????????????????185?????????????????190Asn?Ile?Thr?Glu?Ala?Lys?Thr?Asn?Ala?Asn?Asn?Glu?Ile?Ser?Asn?Asn
195?????????????????200?????????????????205Gln?Thr?Gln?Ala?Ile?Thr?Asn?Ile?Asn?Glu?Ala?Lys?Glu?Ser?Ala?Thr
210?????????????????215?????????????????220Thr?Gln?Ile?Asn?Ala?Asn?Lys?Gln?Glu?Ala?Ile?Asn?Asn?Ile?Thr?Gln225?????????????????230?????????????????235?????????????????240Glu?Lys?Thr?Gln?Ala?Thr?Ser?Glu?Ile?Thr?Glu?Ala?Lys?Lys?Thr?Asp
245?????????????????250?????????????????255His?Tyr?Gln?Asn?Ile?Asp?Phe?Phe?Glu?Phe?Glu
The data of 260 265 (2) SEQ ID NO:89:
(ⅰ) sequence signature:
(A) length: 544 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..544
(ⅹ ⅰ) sequence description: SEQ ID NO:89:Val Ile Glu Thr Ile Pro Lys His Ser Lys Ile Val Leu Pro Gly Glu1 5 10 15Ala Phe Asp Ser Leu Lys Glu Ala Phe Asp Lys Ile Asp Pro Tyr Thr
20??????????????????25??????????????????30Phe?Phe?Phe?Pro?Lys?Phe?Glu?Ala?Thr?Ser?Thr?Ser?Ile?Ser?Asp?Thr
35??????????????????40??????????????????45Asn?Thr?Gln?Arg?Val?Phe?Glu?Thr?Leu?Asn?Asn?Ile?Lys?Thr?Asn?Leu
50??????????????????55??????????????????60Ile?Met?Lys?Tyr?Ser?Asn?Glu?Asn?Pro?Asn?Asn?Phe?Asn?Thr?Cys?Pro65??????????????????70??????????????????75??????????????????80Tyr?Asn?Asn?Asn?Gly?Asn?Thr?Lys?Asn?Asp?Cys?Trp?Gln?Asn?Phe?Thr
85??????????????????90??????????????????95Pro?Gln?Thr?Ala?Glu?Glu?Phe?Thr?Asn?Leu?Met?Leu?Asn?Met?Ile?Ala
100?????????????????105?????????????????110Val?Leu?Asp?Ser?Gln?Ser?Trp?Gly?Asp?Ala?Ile?Leu?Asn?Ala?Pro?Phe
115?????????????????120?????????????????125Glu?Phe?Thr?Asn?Ser?Ser?Thr?Asp?Cys?Asp?Ser?Asp?Pro?Ser?Lys?Cys
130?????????????????135?????????????????140Val?Asn?Pro?Gly?Val?Asn?Gly?Arg?Val?Asp?Thr?Lys?Val?Asp?Gln?Gln145?????????????????150?????????????????155?????????????????160Tyr?Ile?Leu?Asn?Lys?Gln?Gly?Ile?Ile?Asn?Asn?Phe?Arg?Lys?Lys?Ile
165?????????????????170?????????????????175Glu?Ile?Asp?Ala?Val?Val?Leu?Lys?Asn?Ser?Gly?Val?Val?Gly?Leu?Ala
180?????????????????185?????????????????190Asn?Gly?Tyr?Gly?Asn?Asp?Gly?Glu?Tyr?Gly?Thr?Leu?Gly?Val?Glu?Ala
195?????????????????200?????????????????205Tyr?Ala?Leu?Asp?Pro?Lys?Lys?Leu?Phe?Gly?Asn?Asp?Leu?Lys?Thr?Ile
210?????????????????215?????????????????220Asn?Leu?Glu?Asp?Leu?Arg?Thr?Ile?Leu?His?Glu?Phe?Ser?His?Thr?Lys225?????????????????230?????????????????235?????????????????240Gly?Tyr?Gly?His?Asn?Gly?Asn?Met?Thr?Tyr?Gln?Arg?Val?Pro?Val?Thr
245?????????????????250?????????????????255Lys?Asp?Gly?Gln?Val?Glu?Lys?Asp?Ser?Asn?Gly?Lys?Pro?Lys?Asp?Ser
260?????????????????265?????????????????270Asp?Gly?Leu?Pro?Tyr?Asn?Val?Cys?Ser?Leu?Tyr?Gly?Gly?Ser?Asn?Gln
275?????????????????280?????????????????285Pro?Ala?Phe?Pro?Ser?Asn?Tyr?Pro?Asn?Ser?Ile?Tyr?His?Asn?Cys?Ala
290?????????????????295?????????????????300Asp?Val?Pro?Ala?Gly?Phe?Leu?Gly?Val?Thr?Ala?Ala?Val?Trp?Gln?Gln305?????????????????310?????????????????315?????????????????320Leu?Ile?Asn?Gln?Asn?Ala?Leu?Pro?Ile?Asn?Tyr?Ala?Asn?Leu?Gly?Ser
325?????????????????330?????????????????335Gln?Thr?Asn?Tyr?Asn?Leu?Asn?Ala?Ser?Leu?Asn?Thr?Gln?Asp?Leu?Ala
340?????????????????345?????????????????350Asn?Ser?Met?Leu?Ser?Thr?Ile?Gln?Lys?Thr?Phe?Val?Thr?Ser?Ser?Val
355?????????????????360?????????????????365Thr?Asn?His?His?Phe?Ser?Asn?Ala?Ser?Gln?Ser?Phe?Arg?Ser?Pro?Ile
370?????????????????375?????????????????380Leu?Gly?Val?Asn?Ala?Lys?Ile?Gly?Tyr?Gln?Asn?Tyr?Phe?Asn?Asp?Phe385?????????????????390?????????????????395?????????????????400Ile?Gly?Leu?Ala?Tyr?Tyr?Gly?Ile?Ile?Lys?Tyr?Asn?Tyr?Ala?Lys?Ala
405?????????????????410?????????????????415Val?Asn?Gln?Lys?Val?Gln?Gln?Leu?Ser?Tyr?Gly?Gly?Gly?Ile?Asp?Leu
420?????????????????425?????????????????430Leu?Leu?Asp?Phe?Ile?Thr?Thr?Tyr?Ser?Asn?Lys?Asn?Ser?Pro?Thr?Gly
435?????????????????440?????????????????445Ile?Gln?Thr?Lys?Arg?Asn?Phe?Ser?Ser?Ser?Phe?Gly?Ile?Phe?Gly?Gly
450?????????????????455?????????????????460Leu?Arg?Gly?Leu?Tyr?Asn?Ser?Tyr?Tyr?Val?Leu?Asn?Lys?Val?Lys?Gly465?????????????????470?????????????????475?????????????????480Ser?Gly?Asn?Leu?Asp?Val?Ala?Thr?Gly?Leu?Asn?Tyr?Arg?Tyr?Lys?His
485?????????????????490?????????????????495Ser?Lys?Tyr?Ser?Val?Gly?Ile?Ser?Ile?Pro?Leu?Ile?Gln?Arg?Lys?Ala
500?????????????????505?????????????????510Ser?Val?Val?Ser?Ser?Gly?Gly?Asp?Tyr?Thr?Asn?Ser?Phe?Val?Phe?Asn
515?????????????????520?????????????????525Glu?Gly?Ala?Ser?His?Phe?Lys?Val?Phe?Phe?Asn?Tyr?G1y?Gly?Cys?Phe
The data of 530 535 540 (2) SEQ ID NO:90:
(ⅰ) sequence signature:
(A) length: 356 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..356
(ⅹ ⅰ) sequence description: SEQ ID NO:90:Leu Met Lys Ser Ile Leu Leu Phe Met Ile Phe Val Val Cys Gln Leu1 5 10 15Glu Gly Lys Lys Phe Ser Gln Asp Asn Phe Lys Val Asp Tyr Asn Tyr
20??????????????????25??????????????????30Tyr?Leu?Arg?Lys?Gln?Asp?Leu?His?Ile?Ile?Lys?Thr?Gln?Asn?Asp?Leu
35??????????????????40??????????????????45Ser?Asn?Ala?Trp?Tyr?Leu?Pro?Pro?Gln?Lys?Ala?Pro?Lys?Glu?His?Ser
50??????????????????55??????????????????60Trp?Val?Asp?Phe?Ala?Lys?Lys?Tyr?Leu?Asn?Met?Met?Asp?Tyr?Leu?Gly65??????????????????70??????????????????75??????????????????80Thr?Tyr?Phe?Leu?Pro?Phe?Tyr?His?Ser?Phe?Thr?Pro?Ile?Phe?Gln?Trp
85??????????????????90??????????????????95Tyr?His?Pro?Asn?Ile?Asn?Pro?Tyr?Gln?Arg?Asn?Glu?Phe?Lys?Phe?Gln
100?????????????????105?????????????????110Ile?Ser?Phe?Arg?Val?Pro?Val?Phe?Arg?His?Ile?Leu?Trp?Thr?Lys?Gly
115?????????????????120?????????????????125Thr?Leu?Tyr?Leu?Ala?Tyr?Thr?Gln?Thr?Asn?Trp?Phe?Gln?Ile?Tyr?Asn
130?????????????????135?????????????????140Asp?Pro?Gln?Ser?Ala?Pro?Met?Arg?Met?Ile?Asn?Phe?Met?Pro?Glu?Leu145?????????????????150?????????????????155?????????????????160Ile?Tyr?Val?Tyr?Pro?Ile?Asn?Phe?Lys?Pro?Phe?Gly?Gly?Lys?Ile?Gly
165?????????????????170?????????????????175Asn?Phe?Ser?Glu?Ile?Trp?Ile?Gly?Trp?Gln?His?Ile?Ser?Asn?Gly?Val
180?????????????????185?????????????????190Gly?Gly?Ala?Gln?Cys?Tyr?Gln?Pro?Phe?Asn?Lys?Glu?Gly?Asn?Pro?Glu
195?????????????????200?????????????????205Asn?Gln?Phe?Pro?Gly?Gln?Pro?Val?Ile?Val?Lys?Asp?Tyr?Asn?Gly?Gln
210?????????????????215?????????????????220Lys?Asp?Val?Arg?Trp?Gly?Gly?Cys?Xaa?Ser?Val?Xaa?Xaa?Gly?Asn?Xaa225?????????????????230?????????????????235?????????????????240Leu?Cys?Phe?Val?Leu?Val?Trp?Glu?Lys?Gly?Gly?Leu?Lys?Ile?Met?Val
245?????????????????250?????????????????255Ala?Tyr?Trp?Pro?Tyr?Val?Pro?Tyr?Asp?Gln?Ser?Asn?Pro?Gln?Leu?Ile
260?????????????????265?????????????????270Asp?Tyr?Met?Gly?Tyr?Gly?Asn?Ala?Lys?Ile?Asp?Tyr?Arg?Arg?Gly?Arg
275?????????????????280?????????????????285His?His?Phe?Glu?Leu?Gln?Leu?Tyr?Asp?Ile?Phe?Thr?Gln?Tyr?Trp?Arg
290?????????????????295?????????????????300Tyr?Asp?Arg?Trp?His?Gly?Ala?Phe?Arg?Leu?Gly?Tyr?Thr?Tyr?Arg?Ile305?????????????????310?????????????????315?????????????????320Asn?Pro?Phe?Val?Gly?Ile?Tyr?Ala?Gln?Trp?Phe?Asn?Gly?Tyr?Gly?Asp
325?????????????????330?????????????????335Gly?Leu?Tyr?Glu?Tyr?Asp?Val?Phe?Ser?Asn?Arg?Ile?Gly?Val?Gly?Ile
340?????????????????345?????????????????350Arg?Leu?Asn?Pro
The data of 355 (2) SEQ ID NO:91:
(ⅰ) sequence signature:
(A) length: 675 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..675
(ⅹ ⅰ) sequence description: SEQ ID NO:91:Leu Ser Lys Gly Leu Ser Ile Gly Asn Lys Ile Ile Leu Cys Val Ala1 5 10 15Leu Ile Val Ile Val Cys Val Ser Ile Leu Gly Val Ser Leu Asn Ser
20??????????????????25??????????????????30Arg?Val?Lys?Glu?Ile?Leu?Lys?Glu?Ser?Ala?Leu?His?Ser?Met?Gln?Asp
35??????????????????40??????????????????45Ser?Leu?His?Phe?Lys?Val?Lys?Glu?Val?Gln?Ser?Val?Leu?Glu?Asn?Thr
50??????????????????55??????????????????60Tyr?Thr?Ser?Met?Gly?Ile?Val?Lys?Glu?Met?Leu?Pro?Glu?Asp?Thr?Lys65??????????????????70??????????????????75??????????????????80Arg?Glu?Ile?Lys?Ile?Gln?Leu?Leu?Lys?Asn?Phe?Ile?Leu?Ala?Asn?Ser
85??????????????????90??????????????????95His?Val?Ala?Gly?Val?Ser?Met?Phe?Phe?Lys?Asp?Arg?Glu?Asp?Leu?Arg
100?????????????????105?????????????????110Leu?Thr?Leu?Leu?Arg?Asp?Asn?Asp?Thr?Ile?Lys?Leu?Met?Glu?Asn?Pro
115?????????????????120?????????????????125Ser?Leu?Gly?Ser?Asn?Pro?Leu?Ala?Gln?Lys?Ala?Met?Lys?Asn?Lys?Glu
130?????????????????135?????????????????140Ile?Ser?Lys?Ser?Leu?Pro?Tyr?Tyr?Arg?Lys?Met?Pro?Asn?Gly?Ala?Glu145?????????????????150?????????????????155?????????????????160Val?Tyr?Gly?Val?Asp?Ile?Leu?Leu?Pro?Leu?Phe?Lys?Glu?Asn?Thr?Gln
165?????????????????170?????????????????175Glu?Val?Val?Gly?Val?Leu?Met?Ile?Phe?Phe?Ser?Ile?Asp?Ser?Phe?Ser
180?????????????????185?????????????????190Asn?Glu?Ile?Thr?Lys?Asn?Arg?Ser?Asp?Leu?Phe?Leu?Ile?Gly?Val?Lys
195?????????????????200?????????????????205Gly?Lys?Val?Leu?Leu?Ser?Ala?Asn?Lys?Ser?Leu?Gln?Asp?Lys?Ser?Ile
210?????????????????215?????????????????220Thr?Glu?Ile?Tyr?Lys?Ser?Val?Pro?Lys?Ala?Thr?Asn?Glu?Val?Met?Ala225?????????????????230?????????????????235?????????????????240Ile?Leu?Glu?Asn?Gly?Ser?Lys?Ala?Thr?Leu?Glu?Tyr?Leu?Asp?Pro?Phe
245?????????????????250?????????????????255Ser?His?Lys?Glu?Asn?Phe?Leu?Ala?Val?Glu?Thr?Phe?Lys?Met?Leu?Gly
260?????????????????265?????????????????270Lys?Thr?Glu?Ser?Lys?Asp?Asn?Leu?Asn?Trp?Met?Ile?Ala?Leu?Ile?Ile
275?????????????????280?????????????????285Glu?Lys?Asp?Lys?Val?Tyr?Glu?Gln?Val?Gly?Ser?Val?Arg?Phe?Val?Val
290?????????????????295?????????????????300Val?Ala?Ala?Ser?Ala?Ile?Met?Val?Leu?Ala?Leu?Ile?Ile?Ala?Ile?Thr305?????????????????310?????????????????315?????????????????320Leu?Leu?Met?Arg?Ala?Ile?Val?Ser?Asn?Arg?Leu?Glu?Val?Val?Ser?Ser
325?????????????????330?????????????????335Thr?Leu?Ser?His?Phe?Phe?Lys?Leu?Leu?Asn?Asn?Gln?ALa?His?Ser?Ser
340?????????????????345?????????????????350Asp?Ile?Lys?Leu?Val?Glu?Ala?Arg?Ser?Asn?Asp?Glu?Leu?Gly?Arg?Met
355?????????????????360?????????????????365Gln?Thr?Ala?Ile?Asn?Lys?Asn?Ile?Leu?Gln?Thr?Gln?Lys?Thr?Met?Gln
370?????????????????375?????????????????380Glu?Asp?Arg?Gln?Ala?Val?Gln?Asp?Thr?Ile?Lys?Val?Val?Ser?Asp?Val385?????????????????390?????????????????395?????????????????400Lys?Ala?Gly?Asn?Phe?Ala?Val?Arg?Ile?Thr?Ala?Glu?Pro?Ala?Ser?Pro
405?????????????????410?????????????????415Asp?Leu?Lys?Glu?Leu?Arg?Asp?Ala?Leu?Asn?Gly?Ile?Met?Asp?Tyr?Leu
420?????????????????425?????????????????430Gln?Glu?Ser?Val?Gly?Thr?His?Met?Pro?Ser?Ile?Phe?Lys?Ile?Phe?Glu
435?????????????????440?????????????????445Ser?Tyr?Ser?Gly?Leu?Asp?Phe?Arg?Gly?Arg?Ile?Gln?Asn?Ala?Ser?Gly
450?????????????????455?????????????????460Arg?Val?Glu?Leu?Val?Thr?Asn?Ala?Leu?Gly?Gln?Glu?Ile?Gln?Lys?Met465?????????????????470?????????????????475?????????????????480Leu?Glu?Thr?Ser?Ser?Asn?Phe?Ala?Lys?Asp?Leu?Ala?Asn?Asp?Ser?Ala
485?????????????????490?????????????????495Asn?Leu?Lys?Glu?Cys?Val?Gln?Asn?Leu?Glu?Lys?Ala?Ser?Asn?Ser?Gln
500?????????????????505?????????????????510His?Lys?Ser?Leu?Met?Glu?Thr?Ser?Lys?Thr?Ile?Glu?Asn?Ile?Thr?Thr
515?????????????????520?????????????????525Ser?Ile?Gln?Gly?Val?Ser?Ser?Gln?Ser?Glu?Ala?Met?Ile?Glu?Gln?Gly
530?????????????????535?????????????????540Lys?Asp?Ile?Lys?Ser?Ile?Val?Glu?Ile?Ile?Arg?Asp?Ile?Ala?Asp?Gln545?????????????????550?????????????????555?????????????????560Thr?Asn?Leu?Leu?Ala?Leu?Asn?Ala?Ala?Ile?Glu?Ala?Ala?Arg?Ala?Gly
565?????????????????570?????????????????575Glu?His?Gly?Arg?Gly?Phe?Ala?Val?Val?Ala?Asp?Glu?Val?Arg?Lys?Leu
580?????????????????585?????????????????590Ala?Glu?Arg?Thr?Gln?Lys?Ser?Leu?Ser?Glu?Ile?Glu?Ala?Asn?Ile?Asn
595?????????????????600?????????????????605Ile?Leu?Val?Gln?Ser?Ile?Ser?Asp?Thr?Ser?Glu?Ser?Ile?Lys?Asn?Gln
610?????????????????615?????????????????620Val?Lys?Glu?Val?Glu?Glu?Ile?Asn?Ala?Ser?Ile?Glu?Ala?Leu?Arg?Ser625?????????????????630?????????????????635?????????????????640Val?Thr?Glu?Gly?Asn?Leu?Lys?Ile?Ala?Ser?Asp?Ser?Leu?Glu?Ile?Ser
645?????????????????650?????????????????655Gln?Glu?Ile?Asp?Lys?Val?Ser?Asn?Asp?Ile?Leu?Glu?Asp?Val?Asn?Lys
660?????????????????665?????????????????670Lys?Gln?Phe
The data of 675 (2) SEQ ID NO:92:
(ⅰ) sequence signature:
(A) length: 271 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..271
(ⅹ ⅰ) sequence description: SEQ ID NO:92:Met Asn Ile Phe Lys Arg Ile Ile Cys Val Thr Ala Ile Val Leu Gly1 5 10 15Phe Phe Asn Leu Leu Asp Ala Lys His His Lys Glu Lys Lys Glu Asp
20??????????????????25??????????????????30His?Lys?Ile?Thr?Arg?Glu?Leu?Lys?Val?Gly?Ala?Asn?Pro?Val?Pro?His
35??????????????????40??????????????????45Ala?Gln?Ile?Leu?Gln?Ser?Val?Val?Asp?Asp?Leu?Lys?Glu?Lys?Gly?Ile
50??????????????????55??????????????????60Lys?Leu?Val?Ile?Val?Ser?Phe?Thr?Asp?Tyr?Val?Leu?Pro?Asn?Leu?Ala65??????????????????70??????????????????75??????????????????80Leu?Asn?Asp?Gly?Ser?Leu?Asp?Ala?Asn?Tyr?Phe?Gln?His?Arg?Pro?Tyr
85??????????????????90??????????????????95Leu?Asp?Arg?Phe?Asn?Leu?Asp?Arg?Lys?Met?His?Leu?Val?Gly?Leu?Ala
100?????????????????105?????????????????110Asn?Ile?His?Val?Glu?Pro?Leu?Arg?Phe?Tyr?Ser?Gln?Lys?Ile?Thr?Asp
115?????????????????120?????????????????125Ile?Lys?Asn?Leu?Lys?Lys?Gly?Ser?Val?Ile?Ala?Val?Pro?Asn?Asp?Pro
130?????????????????135?????????????????140Ala?Asn?Gln?Gly?Arg?Ala?Leu?Ile?Leu?Leu?His?Lys?Gln?Gly?Leu?Ile145?????????????????150?????????????????155?????????????????160Ala?Leu?Lys?Asp?Pro?Ser?Asn?Leu?Tyr?Ala?Thr?Glu?Phe?Asp?Ile?Val
165?????????????????170?????????????????175Lys?Asn?Pro?Tyr?Asn?Ile?Lys?Ile?Lys?Pro?Leu?Glu?Ala?Ala?Leu?Leu
180?????????????????185?????????????????190Pro?Lys?Val?Leu?Gly?Asp?Val?Asp?Gly?Ala?Ile?Ile?Thr?Gly?Asn?Tyr
195?????????????????200?????????????????205Ala?Leu?Gln?Ala?Lys?Leu?Thr?Gly?Ala?Leu?Phe?Ser?Glu?Asp?Lys?Asp
210?????????????????215?????????????????220Ser?Pro?Tyr?Ala?Asn?Leu?Val?Ala?Ser?Arg?Glu?Asp?Asn?Ala?Gln?Asp225?????????????????230?????????????????235?????????????????240Glu?Ala?Ile?Lys?Ala?Leu?Ile?Glu?Ala?Leu?Gln?Ser?Glu?Lys?Thr?Arg
245?????????????????250?????????????????255Lys?Phe?Ile?Leu?Asp?Thr?Tyr?Lys?Gly?Ala?Ile?Ile?Pro?Ala?Phe
The data of 260 265 270 (2) SEQ ID NO:93:
(ⅰ) sequence signature:
(A) length: 161 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..161
(ⅹ ⅰ) sequence description: SEQ ID NO:93:Met Phe phe Lys Thr Tyr Gln Lys Leu Leu Gly Ala Ser Cys Leu Ala1 5 10 15Leu Tyr Leu Val Gly Cys Gly Asn Gly Gly Gly Gly Glu Ser Pro Val
20??????????????????25??????????????????30Glu?Met?Ile?Ala?Asn?Ser?Glu?Gly?Thr?Phe?Gln?Ile?Asp?Ser?Lys?Ala
35??????????????????40??????????????????45Asp?Ser?Ile?Thr?Ile?Gln?Gly?Val?Lys?Leu?Asn?Arg?Gly?Asn?Cys?Ala
50??????????????????55??????????????????60Val?Asn?Phe?Val?Pro?Val?Ser?Glu?Thr?Phe?Gln?Met?Gly?Val?Leu?Ser65??????????????????70??????????????????75??????????????????80Gln?Val?Thr?Pro?Ile?Ser?Ile?Gln?Asp?Phe?Lys?Asp?Met?Ala?Ser?Thr
85??????????????????90??????????????????95Tyr?Lys?Ile?Phe?Asp?Gln?Lys?Lys?Gly?Leu?Ala?Asn?Ile?Ala?Asn?Lys
100?????????????????105?????????????????110Ile?Ser?Gln?Leu?Glu?Gln?Lys?Gly?Val?MeC?MeC?Glu?Pro?Gln?Thr?Leu
115?????????????????120?????????????????125Asn?Phe?Gly?Glu?Ser?Leu?Lys?Gly?Ile?Ser?Gln?Gly?Cys?Asn?Ile?Ile
The data of 130 135 140Glu Ala Glu Ile Gln Thr Asp Lys Gly Ala Trp Thr Phe Asn Phe Asp145 150 155 160Lys (2) SEQ ID NO:94:
(ⅰ) sequence signature:
(A) length: 337 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..337
(ⅹ ⅰ) sequence description: SEQ ID NO:94:Met Ile Arg Leu Lys Gly Leu Asn lys Thr Leu Lys Thr Ser Leu Leu1 5 10 15Ala Gly Val Leu Leu Gly A la Thr Ala Pro Leu Met Ala Lys Pro Leu
20???????????????????25??????????????????30Leu?Ser?Asp?Glu?Asp?Leu?Leu?Lys?Arg?Val?Lys?Leu?His?Asn?Ile?Lys
35??????????????????40??????????????????45Glu?Asp?Thr?Leu?Thr?Ser?Cys?Asn?Ala?Lys?Val?Asp?Gly?Ser?Gln?Tyr
50??????????????????55??????????????????60Leu?Asn?Ser?Gly?Trp?Asn?Leu?Ser?Lys?Glu?Phe?Pro?Gln?Glu?Tyr?Arg65??????????????????70??????????????????75??????????????????80Glu?Lys?Ile?Phe?Glu?Cys?Val?Glu?Glu?Glu?Lys?His?Lys?Gln?Ala?Leu
85??????????????????90??????????????????95Asn?Leu?Ile?Asn?Lys?Glu?Asp?Thr?Glu?Asp?Lys?Glu?Glu?Leu?Ala?Lys
100?????????????????105?????????????????110Lys?Ile?Lys?Glu?Ile?Lys?Glu?Lys?Ala?Lys?Val?Leu?Arg?Gln?Lys?Phe
115?????????????????120?????????????????125Met?Ala?Phe?Glu?Met?Lys?Glu?His?Ser?Lys?Glu?Phe?Pro?Asn?Lys?Lys
130?????????????????135?????????????????140Gln?Leu?Gln?Thr?Met?Leu?Glu?Asn?Ala?Phe?Asp?Asn?Gly?Ala?Glu?Ser145?????????????????150?????????????????155?????????????????160Phe?Ile?Asp?Asp?Trp?His?Glu?Arg?Phe?Gly?Gly?Ile?Ser?Arg?Glu?Asn
165?????????????????170?????????????????175Thr?Tyr?Lys?Ala?Leu?Gly?Ile?Lys?Glu?Tyr?Ser?Asp?Glu?Gly?Lys?Ile
180?????????????????185?????????????????190Leu?Ala?Phe?Gly?Glu?Arg?Ser?Tyr?Ile?Arg?Gln?Tyr?Lys?Lys?Asp?Phe
195?????????????????200?????????????????205Glu?Glu?Ser?Thr?Tyr?Asp?Thr?Arg?Gln?Thr?Leu?Ser?Ala?Met?Ala?Asn
210?????????????????215?????????????????220Met?Ser?Gly?Glu?Asn?Asp?Tyr?Lys?Ile?Thr?Trp?Leu?Lys?Pro?Lys?Tyr225?????????????????230?????????????????235?????????????????240Gln?Leu?His?Ser?Ser?Asn?Asn?Ile?Lys?Pro?Leu?Met?Ser?Asn?Thr?Glu
245?????????????????250?????????????????255Leu?Leu?Asn?Met?Ile?Glu?Leu?Thr?Asn?Ile?Lys?Lys?Glu?Tyr?Val?Met
260?????????????????265?????????????????270Gly?Cys?Asn?Met?Glu?Ile?Asp?Gly?Ser?Lys?Tyr?Pro?Ile?His?Lys?Asp
275?????????????????280?????????????????285Trp?Gly?Phe?Phe?Gly?Lys?Ala?Lys?Val?Pro?Glu?Thr?Trp?Arg?Asn?Lys
290?????????????????295?????????????????300Ile?Trp?Glu?Cys?Ile?Lys?Asn?Lys?Val?Lys?Ser?Tyr?Asp?Asn?Thr?Thr305?????????????????310?????????????????315?????????????????320Ala?Glu?Ile?Gly?Ile?Val?Trp?Lys?Lys?Asn?Thr?Tyr?Ser?Ile?Ser?His
The data of 325 330 335His (2) SEQ ID NO:95:
(ⅰ) sequence signature:
(A) length: 416 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..416
(ⅹ ⅰ) sequence description: SEQ ID NO:95:Met Lys Lys Leu Val Phe Ser Met Leu Leu Cys Cys Lys Ser Val Phe1 5 10 15Ala Glu Gly Glu Thr Pro Leu Ile Val Asn Asp Pro Glu Thr His Val
20??????????????????25??????????????????30Ser?Gln?Ala?Thr?Ile?Ile?Gly?Lys?Met?Val?Asp?Ser?Ile?Lys?Arg?Tyr
35??????????????????40??????????????????45Glu?Glu?Ile?Ile?Ser?Lys?Ala?Gln?Ala?Gln?Val?Asn?Gln?Leu?Gln?Lys
50??????????????????55??????????????????60Val?Asn?Asn?Met?Ile?Asn?Thr?Thr?Asn?Ser?Leu?Ile?Ser?Ser?Ser?Ala65??????????????????70??????????????????75??????????????????80Ile?Thr?Leu?Ala?Asn?Pro?Met?Gln?Val?Leu?Gln?Asn?Ala?Gln?Tyr?Gln
85??????????????????90??????????????????95Ile?Glu?Ser?Ile?Arg?Tyr?Asn?Tyr?Glu?Asn?Leu?Lys?Gln?Ser?Ile?Glu
100?????????????????105?????????????????110Asn?Trp?Asn?Ala?Gln?Asn?Leu?Leu?Arg?Asn?Lys?Tyr?Leu?Gln?Gln?Gln
115?????????????????120?????????????????125Cys?Pro?Trp?Leu?Asn?Val?Asn?Ala?Leu?Thr?Asn?Asn?Lys?Ile?Val?Asn
130?????????????????135?????????????????140Leu?Lys?Asp?Leu?Asn?Asn?Leu?Ile?Thr?Lys?Asn?Gly?Glu?Gln?Thr?Gln145?????????????????150?????????????????155?????????????????160Thr?Ala?Arg?Asp?Val?Gln?Asn?Leu?Ile?Gln?Ser?Ile?Ser?Gly?Ser?Gly
165?????????????????170?????????????????175Tyr?Gly?Asn?Met?Gln?Ser?Leu?Ala?Gly?Glu?Leu?Ser?Gly?Arg?Ala?Trp
180?????????????????185?????????????????190Gly?Glu?Met?Leu?Cys?Lys?Met?Val?Asn?Asp?Ser?Asn?Tyr?Glu?Ser?Glu
195?????????????????200?????????????????205Gln?Ala?Leu?Leu?Ala?Thr?Gly?Asn?Asn?Pro?Glu?Glu?Gln?Lys?Arg?Arg
210?????????????????215?????????????????220Phe?Leu?Leu?Arg?Val?Lys?Lys?Lys?Val?Asn?Asp?Asn?Lys?Gln?Leu?Lys225?????????????????230?????????????????235????????????????240Asp?Lys?Leu?Asp?Pro?Phe?Leu?Lys?Arg?Leu?Asp?Val?Leu?Gln?Thr?Glu
245?????????????????250?????????????????255Phe?Gly?Val?Thr?Asp?Pro?Thr?Ala?Asn?His?Asn?Lys?Gln?Gly?Ile?His
260?????????????????265?????????????????270Tyr?Cys?Thr?Glu?Asn?Lys?Glu?Thr?Gly?Lys?Cys?Asp?Pro?Ile?Lys?Asn
275?????????????????280?????????????????285Val?Phe?Arg?Thr?Thr?Arg?Leu?Asp?Asn?Glu?Leu?Glu?Gln?Glu?Ile?Gln
290?????????????????295?????????????????300Thr?Leu?Thr?Leu?Asp?Leu?Ile?Lys?Ala?Ser?Asn?Lys?Asp?Ala?Gln?Ser305?????????????????310?????????????????315?????????????????320Gln?Ala?Tyr?Ala?Asn?Phe?Asn?Gln?Arg?Ile?Lys?Leu?Leu?Thr?Leu?Lys
325?????????????????330?????????????????335Tyr?Leu?Lys?Glu?Ile?Thr?Asn?Gln?Met?Leu?Phe?Leu?Asn?Gln?Thr?Met
340?????????????????345?????????????????350Ala?Met?Gln?Ser?Glu?Ile?Met?Thr?Asp?Asp?Tyr?Phe?Arg?Gln?Asn?Asn
355?????????????????360?????????????????365Asp?Gly?Phe?Gly?Glu?Lys?Glu?Asn?His?Ile?Asp?Lys?Gln?Leu?Thr?Gln
370?????????????????375?????????????????380Lys?Arg?Ile?Asn?Glu?Arg?Glu?Arg?Ala?Arg?Ile?Tyr?Phe?Gln?Asn?Pro385?????????????????390?????????????????395?????????????????400Asn?Val?Lys?Phe?Asp?Gln?Phe?Gly?Phe?Pro?Ile?Phe?Ser?Ile?Trp?Asp
The data of 405 410 415 (2) SEQ ID NO:96:
(ⅰ) sequence signature:
(A) length: 376 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..376
(ⅹ ⅰ) sequence description: SEQ ID NO:96:Val Asn Lys Trp Ile Lys Gly Ala Val Val Phe Val Gly Gly Phe Ala1 5 10 15Thr Ile Thr Thr Phe Ser Leu Ile Tyr His Gln Lys Pro Lys Ala Pro
20??????????????????25??????????????????30Leu?Asn?Asn?Gln?Pro?Ser?Leu?Leu?Asn?Asp?Asp?Glu?Val?Lys?Tyr?Pro
35??????????????????40??????????????????45Leu?Gln?Asp?Tyr?Thr?Phe?Thr?Gln?Asn?Pro?Gln?Pro?Thr?Asn?Thr?Glu
50??????????????????55??????????????????60Ser?Ser?Lys?Asp?Ala?Thr?Ile?Lys?Ala?Leu?Gln?Glu?Gln?Leu?Lys?Ala65??????????????????70??????????????????75??????????????????80Ala?Leu?Lys?Ala?Leu?Asn?Ser?Lys?Glu?Met?Asn?Tyr?Ser?Lys?Glu?Glu
85??????????????????90??????????????????95Thr?Phe?Thr?Ser?Pro?Pro?Met?Asp?Pro?Lys?Thr?Thr?Pro?Pro?Lys?Lys
100?????????????????105?????????????????110Asp?Phe?Ser?Pro?Lys?Gln?Leu?Asp?Leu?Leu?Ala?Ser?Arg?Ile?Thr?Pro
115?????????????????120?????????????????125Phe?Lys?Gln?Ser?Pro?Lys?Asn?Tyr?Glu?Glu?Asn?Leu?Ile?Phe?Pro?Val
130?????????????????135?????????????????140Asp?Asn?Pro?Asn?Gly?Ile?Asp?Ser?Phe?Thr?Asn?Leu?Lys?Glu?Lys?Asp145?????????????????150?????????????????155?????????????????160Ile?Ala?Thr?Asn?Glu?Asn?Lys?Leu?Leu?Arg?Thr?Ile?Thr?Ala?Asp?Lys
165?????????????????170?????????????????175Met?Ile?Pro?Ala?Phe?Leu?Ile?Thr?Pro?Ile?Ser?Ser?Gln?Ile?Ala?Gly
180?????????????????185?????????????????190Lys?Val?Ile?Ala?Gln?Val?Glu?Ser?Asp?Ile?Phe?Ala?Ser?Met?Gly?Lys
195?????????????????200?????????????????205Ala?Val?Leu?Ile?Pro?Lys?Gly?Ser?Lys?Val?Ile?Gly?Tyr?Tyr?Ser?Asn
210?????????????????215?????????????????220Asn?Asn?Lys?Met?Gly?Glu?Tyr?Arg?Leu?Asp?Ile?Val?Trp?Ser?Arg?Ile225?????????????????230?????????????????235?????????????????240Ile?Thr?Pro?His?Gly?Ile?Asn?Ile?Met?Leu?Thr?Asn?Ala?Lys?Gly?Ala
245?????????????????250?????????????????255Asp?Ile?Lys?Gly?Tyr?Asn?Gly?Leu?Val?Gly?Glu?Leu?Ile?Glu?Arg?Asn
260?????????????????265?????????????????270Phe?Gln?Arg?Tyr?Gly?Val?Pro?Leu?Leu?Leu?Ser?Thr?Leu?Thr?Asn?Gly
275?????????????????280?????????????????285Leu?Leu?Ile?Gly?Ile?Thr?Ser?Ala?Leu?Asn?Asn?Arg?Gly?Asn?Lys?Glu
290?????????????????295?????????????????300Glu?Val?Thr?Asn?Phe?Phe?Gly?Asp?Tyr?Leu?Leu?Leu?Gln?Leu?Met?Arg305?????????????????310?????????????????315?????????????????320Gln?Ser?Gly?Met?Gly?Ile?Asn?Gln?Val?Val?Asn?Gln?Ile?Leu?Arg?Asp
325?????????????????330?????????????????335Lys?Ser?Lys?Ile?Ala?Pro?Ile?Val?Val?Ile?Arg?Glu?Gly?Ser?Arg?Val
340?????????????????345?????????????????350Phe?Ile?Ser?Pro?Asn?Thr?Asp?Ile?Phe?Phe?Pro?Ile?Pro?Arg?Glu?Asn
355?????????????????360?????????????????365Glu?Val?Ile?Ala?Glu?Phe?Leu?Lys
The data of 370 375 (2) SEQ ID NO:97:
(ⅰ) sequence signature:
(A) length: 916 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..916
(ⅹ ⅰ) sequence description: SEQ ID NO:97:Val Asp Leu Arg Ile Gln Ser Lys Glu Val Ser His Asn Leu Lys Glu1 5 10 15Leu Ser Lys Thr Leu Ile Ser Tyr Pro Phe Glu Lys His Val Glu Ala
20??????????????????25??????????????????30Leu?Gly?Glu?Gln?Cys?Ser?Asn?Phe?Val?Ser?Ile?Pro?Ile?Asn?Asn?Asp
35??????????????????40??????????????????45Asp?Tyr?Ser?ASn?Ile?Cys?Thr?Phe?Val?Ser?Asp?Phe?Ile?Asn?Leu?Ile
50??????????????????55??????????????????60Ala?Ser?Tyr?Asn?Leu?Leu?Glu?Ser?Phe?Leu?Asp?Phe?Tyr?Lys?Asp?Lys65??????????????????70??????????????????75??????????????????80Leu?Lys?Leu?Ser?Glu?Leu?Val?Thr?Glu?Tyr?Ala?Asn?Val?Thr?Asn?Asn
85??????????????????90??????????????????95Leu?Leu?Phe?Lys?Lys?Leu?Ile?Lys?His?Leu?Ser?Gly?Asn?Asn?Gln?Leu
100?????????????????105?????????????????110Val?Lys?Asn?Phe?Tyr?Gln?Cys?Ile?Arg?Glu?Ile?Ile?Lys?Tyr?Asn?Ala
115?????????????????120?????????????????125Pro?Asn?Lys?Glu?Tyr?Lys?Pro?Asn?Gln?Phe?Phe?Ile?Ile?Gly?Lys?Gly
130?????????????????135?????????????????140Lys?Gln?Lys?Gln?Leu?Ala?Lys?Ile?Tyr?Ser?His?Leu?Lys?Glu?Leu?Ser145?????????????????150?????????????????155?????????????????160Ala?Ser?Glu?Ile?Lys?Pro?Gln?Asp?Met?Glu?Asp?Ile?Leu?Lys?Lys?Leu
165?????????????????170?????????????????175Glu?Glu?Leu?Asp?Lys?Ile?Phe?Lys?Thr?Thr?Asp?Phe?Thr?Lys?Phe?Thr
180?????????????????185?????????????????190Pro?Lys?Thr?Glu?Ile?Lys?Asp?Ile?Ile?Lys?Glu?Ile?Asp?Glu?Lys?Tyr
195?????????????????200?????????????????205Pro?Ile?Asn?Glu?Asn?Phe?Lys?Arg?Gln?Phe?Asn?Glu?Phe?Glu?Ser?Asn
210?????????????????215?????????????????220Ile?Glu?Lys?His?Asp?Glu?Ile?Lys?Lys?Asp?Phe?Glu?Arg?Asn?Lys?Glu225?????????????????230?????????????????235?????????????????240Ser?Leu?Ile?Arg?Glu?Ile?Glu?Asn?His?Cys?Lys?Asn?Glu?Cys?Asn?Ser
245?????????????????250?????????????????255Glu?Glu?Glu?Pro?Glu?Tyr?Lys?Ile?Asn?Asp?Leu?Leu?Lys?Asn?Ile?Gln
260?????????????????265?????????????????270Gln?Ile?Cys?Lys?Asn?Tyr?Ile?Glu?Ser?His?Ala?Val?Asn?Asp?Val?Ser
275?????????????????280?????????????????285Lys?Asp?Ile?Lys?Ser?Met?Met?Cys?Gln?Phe?Tyr?Leu?Lys?Gln?Ile?Asp
290?????????????????295?????????????????300Leu?Leu?Val?Asn?Ser?Glu?Ile?Val?Arg?Tyr?Arg?Tyr?Ser?Asn?Leu?Phe305?????????????????310?????????????????315?????????????????320Glu?Pro?Ile?Gln?Arg?Ser?Leu?Trp?Glu?Ser?Ile?Lys?Ile?Leu?Asp?Asn
325?????????????????330?????????????????335Glu?Ser?Gly?Ile?Tyr?Leu?Phe?Pro?Lys?Asn?Ile?Gly?Glu?Ile?Lys?Asp
340?????????????????345?????????????????350Lys?Phe?Glu?Ala?Asn?Lys?Glu?Lys?Phe?Lys?Gln?Ser?Lys?Asn?Val?Ser
355?????????????????360?????????????????365Glu?Phe?Ala?Glu?Tyr?Cys?Arg?Glu?Cys?Asn?Pro?Tyr?Thr?Ala?Phe?Asn
370?????????????????375?????????????????380Phe?His?Leu?Asn?Ile?Asn?Asn?Gly?Leu?Ser?His?Gln?Phe?Glu?Lys?Phe385?????????????????390?????????????????395?????????????????400Val?Pro?Ile?Met?Lys?Glu?Tyr?Lys?Glu?Pro?Lys?Ile?Thr?Asp?Asn?Asp
405?????????????????410?????????????????415Leu?Glu?Ala?Ile?Ser?Thr?Lys?Glu?Thr?Gly?Leu?Ala?Ser?Gln?Leu?Ser
420?????????????????425?????????????????430Gly?His?Trp?Phe?Phe?Gln?Leu?Ser?Leu?Phe?Asn?Lys?Thr?Asn?Pne?Asn
435?????????????????440?????????????????445Pro?Asn?Lys?Ile?Trp?Ile?Pro?Leu?Glu?Phe?Asn?Lys?Arg?Ser?Lys?Ile
450?????????????????455?????????????????460Lys?Phe?Asp?Lys?Asp?Leu?Glu?Ile?Tyr?Phe?Asp?Ser?His?Glu?Ser?Phe465?????????????????470?????????????????475?????????????????480Asn?Ile?Ser?Lys?Lys?Tyr?Leu?Gln?Glu?Ile?Asp?Gln?Glu?Ser?Leu?Lys
485?????????????????490?????????????????495Lys??Ile?Lys?Gln?Ser?Lys?Asp?Phe?Phe?Ser?Ile?Gln?Lys?Ile?Glu?Ser
500?????????????????505?????????????????510Lys?His?Asp?Asn?Asn?Asp?Ile?Leu?Gln?Leu?Glu?Phe?Phe?Glu?Asn?Asp
515?????????????????520?????????????????525Thr?Ser?Phe?Leu?Phe?Ala?Lys?Gly?Ser?Phe?Ala?Glu?Ile?Leu?Glu?Tyr
530?????????????????535?????????????????540Ash?Met?Gln?Leu?Lys?Ile?Asp?Ser?Leu?Ile?Thr?Lys?Glu?Phe?Asn?Lys545?????????????????550?????????????????555?????????????????560Leu?Leu?Ala?Ile?Val?Gln?Asp?Ser?Pro?Gln?Asp?Ser?Tyr?Gln?Leu?Lys
565?????????????????570?????????????????575Ile?Arg?Val?Arg?His?Asn?Asn?Lys?Leu?Pro?Arg?Glu?Lys?Tyr?Thr?Glu
580?????????????????585?????????????????590His?Glu?Ile?Lys?Leu?Glu?Val?Tyr?Asp?Cys?Arg?Lys?Ser?His?Asp?His
595?????????????????600?????????????????605Asn?Glu?Pro?Ile?Ile?Leu?Ser?Gln?Gln?Ser?Thr?G1y?Phe?Gln?Trp?Ala
610?????????????????615?????????????????620Phe?Asn?Phe?Met?Phe?Gly?Phe?Leu?Tyr?Asn?Val?Gly?Ser?His?Phe?Ser625?????????????????630?????????????????635?????????????????640Phe?Asn?His?Asn?Ile?Ile?Tyr?Val?Met?Asp?Glu?Pro?Ala?Thr?His?Leu
645?????????????????650?????????????????655Ser?Val?Pro?Ala?Arg?Lys?Glu?Phe?Arg?Lys?Phe?Leu?Lys?Glu?Tyr?Ala
660?????????????????665?????????????????670His?Lys?Asn?His?Val?Thr?Phe?Val?Leu?Ala?Thr?His?Asp?Pro?Phe?Leu
675?????????????????680?????????????????685Val?Asp?Thr?Asp?His?Leu?Asp?Glu?Ile?Arg?Ile?Val?Glu?Lys?Glu?Thr
690?????????????????695?????????????????700Glu?Gly?Ser?Val?Ile?Lys?Asn?His?Phe?Asn?Tyr?Pro?Leu?Asn?Asn?Ala705?????????????????710?????????????????715?????????????????720Ser?Lys?Asp?Ser?Asp?Ala?Leu?Asp?Lys?Ile?Lys?Arg?Ser?Leu?Gly?Val
725?????????????????730?????????????????735Gly?Gln?His?Val?Phe?His?Asn?Pro?Gln?Lys?His?Arg?Ile?Ile?Phe?Val
740?????????????????745?????????????????750Glu?Gly?Ile?Thr?Asp?Tyr?Cys?Tyr?Leu?Ser?Ala?Phe?Lys?Leu?Tyr?Leu
755?????????????????760?????????????????765Arg?Tyr?Lys?Glu?Tyr?Lys?Asp?Asn?Pro?Ile?Pro?Phe?Thr?Phe?Leu?Pro
770?????????????????775?????????????????780Ile?Ser?Gly?Leu?Lys?Asn?Asp?Ser?Asn?Asp?Met?Lys?Glu?Thr?Ile?Glu785?????????????????790?????????????????795?????????????????800Lys?Leu?Cys?Glu?Leu?Asp?Asn?His?Pro?Ile?Val?Leu?Thr?Asp?Asp?Asp
805?????????????????810?????????????????815Arg?Lys?Cys?Val?Phe?Asn?Gln?Gln?Ala?Thr?Ser?Glu?Arg?Phe?Lys?Arg
820?????????????????825?????????????????830Ala?Asn?Glu?Glu?Met?His?Asp?Pro?Ile?Thr?Ile?Leu?Gln?Leu?Ser?Asp
835?????????????????840?????????????????845Cys?Asp?Arg?His?Phe?Lys?Gln?Ile?Glu?Asp?Cys?Phe?Ser?Ala?Asn?Asp
850?????????????????855?????????????????860Arg?Asn?Lys?Tyr?Ala?Lys?Asn?Lys?Gln?Met?Glu?Leu?Ser?Met?Ala?Phe865?????????????????870?????????????????875?????????????????880Lys?Thr?Arg?Leu?Leu?Tyr?Gly?Gly?Glu?Asp?Ala?Ile?Glu?Lys?Gln?Thr
885?????????????????890?????????????????895Lys?Arg?Asn?Phe?Leu?Lys?Leu?Pha?Lys?Trp?Ile?Ala?Trp?Ala?Thr?Asn
900?????????????????905?????????????????910Leu?Ile?Lys?Asn
The data of 915 (2) SEQ ID NO:98:
(ⅰ) sequence signature:
(A) length: 176 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..176
(ⅹ ⅰ) sequence description: SEQ ID NO:98:Met Thr Ala Met Met Arg Tyr Phe His Ile Tyr Ala Thr Thr Phe Phe1 5 10 15Phe Pro Leu Ala Leu Leu Phe Ala Val Ser Gly Leu Ser Leu Leu Phe
20??????????????????25??????????????????30Lys?Ala?Arg?Gln?Asp?Thr?Gly?Ala?Lys?Ile?Lys?Glu?Trp?Val?Leu?Glu
35??????????????????40??????????????????45Lys?Ser?Leu?Lys?Lys?Glu?Glu?Arg?Leu?Asp?Phe?Leu?Lys?Gly?Phe?Ile
50??????????????????55??????????????????60Lys?Glu?Ash?His?Ile?Ala?Met?Pro?Lys?Lys?Ile?Glu?Pro?Arg?Glu?Tyr65??????????????????70??????????????????75??????????????????80Arg?Gly?Ala?Leu?Val?Ile?Gly?Thr?Pro?Leu?Tyr?Glu?Ile?Asn?Leu?Glu
85??????????????????90??????????????????95Thr?Lys?Gly?Thr?Gln?Thr?Lys?Ile?Lys?Thr?Ile?Glu?Arg?Gly?Phe?Leu
100?????????????????105?????????????????110Gly?Ala?Leu?Ile?Met?Leu?His?Lys?Ala?Lys?Val?Gly?Ile?Val?Phe?Gln
115?????????????????120?????????????????125Ala?Leu?Leu?Gly?Ile?Phe?Cys?Val?Phe?Leu?Leu?Leu?Phe?Tyr?Leu?Ser
130?????????????????135?????????????????140Ala?Phe?Leu?Met?Val?Ala?Phe?Lys?Asp?Thr?Lys?Arg?Met?Phe?Ile?Ser145?????????????????150?????????????????155?????????????????160Val?Leu?Ile?Gly?Ser?Val?Val?Phe?Phe?Gly?Ala?Ile?Tyr?Trp?Ser?Leu
The data of 165 170 175 (2) SEQ ID NO:99:
(ⅰ) sequence signature:
(A) length: 222 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..222
(ⅹ ⅰ) sequence description: SEQ ID NO:99:Met Phe Lys Asn Ala Leu Asn Ile Gln Asp Phe Ser Phe Lys Asn His1 5 10 15Thr Ser Thr Ala Ile Ile Gly Thr Asn Gly Ala Gly Lys Ser Thr Leu
20??????????????????25??????????????????30Ile?Asn?Thr?Ile?Leu?Gly?Ile?Arg?Ser?Asp?Tyr?Asn?Phe?Lys?Ala?Gln
35??????????????????40??????????????????45Asn?Asn?Asn?Ile?Pro?Tyr?His?Asp?Asn?Val?Ile?Pro?Gln?Arg?Lys?Gln
50??????????????????55??????????????????60Leu?Gly?Val?Val?Ser?Asn?Leu?Phe?Asn?Tyr?Pro?Pro?Gly?Leu?Asn?Ala65??????????????????70??????????????????75??????????????????80Asn?Asp?Leu?Phe?Lys?Phe?Tyr?Gln?Phe?Phe?His?Lys?Asn?Cys?Thr?Leu
85??????????????????90??????????????????95Asp?Leu?Phe?Glu?Lys?Asn?Leu?Leu?Asn?Lys?Thr?Tyr?Glu?His?Leu?Ser
100?????????????????105?????????????????110Asp?Gly?Gln?Lys?Gln?Arg?Leu?Lys?Ile?Asp?Leu?Ala?Leu?Ser?His?His
115?????????????????120?????????????????125Pro?Gln?Leu?Val?Ile?Met?Asp?Glu?Pro?Glu?Thr?Ser?Leu?Glu?Gln?Asn
130?????????????????135?????????????????140Ala?Leu?Ile?Arg?Leu?Ser?Asn?Leu?Ile?Ser?Leu?Arg?Asn?Thr?Gln?Gln145?????????????????150?????????????????155?????????????????160Leu?Thr?Ser?Ile?Ile?Ala?Thr?His?Asp?Pro?Ile?Val?Leu?Asp?Ser?Cys
165?????????????????170?????????????????175Glu?Trp?Val?Leu?Leu?Leu?Lys?Asn?Gly?Asn?Ile?Ala?Gln?Tyr?Lys?Pro
180?????????????????185?????????????????190Leu?Asn?Ser?Ile?Leu?Lys?Ser?Val?Ala?Lys?Thr?Phe?Asn?Phe?Lys?Glu
195?????????????????200?????????????????205Lys?Pro?Thr?Thr?Lys?Asp?Leu?Leu?Ala?Leu?Leu?Lys?Asp?Ile
The data of 210 215 220 (2) SEQ ID NO:100:
(ⅰ) sequence signature:
(A) length: 406 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..406
(ⅹ ⅰ) sequence description: SEQ ID NO:100:Met Tyr Ala Ala His Pro Ile Lys Pro Ile Lys Ala Pro Lys Leu Lys1 5 10 15Ser Gln Phe Leu Arg Arg Val Phe Val Gly Ala Ser Ile Arg Arg Trp
20??????????????????25??????????????????30Asn?Asp?Gln?Ala?Cys?Pro?Leu?Glu?Phe?Val?Glu?Leu?Asp?Lys?Gln?Ala
35??????????????????40??????????????????45His?Lys?Ala?Met?Ile?Ala?Tyr?Leu?Leu?Ala?Lys?Asp?Leu?Lys?Asp?Arg
50??????????????????55??????????????????60Gly?Lys?Asp?Leu?Asp?Leu?Asp?Leu?Leu?Ile?Lys?Tyr?Phe?Cys?Phe?Glu65??????????????????70??????????????????75??????????????????80Phe?Leu?Glu?Arg?Leu?Val?Leu?Thr?Asp?Ile?Lys?Pro?Pro?Ile?Phe?Tyr
85??????????????????90??????????????????95Ala?Leu?Gln?Gln?Thr?His?Ser?Lys?Glu?Leu?Ala?Ser?Tyr?Val?Ala?Gln
100?????????????????105?????????????????110Ser?Leu?Gln?Asp?Glu?Ile?Ser?Ala?Tyr?Phe?Ser?Leu?Glu?Glu?Leu?Lys
115?????????????????120?????????????????125Glu?Tyr?Leu?Ser?His?Arg?Pro?Gln?Ile?Leu?Glu?Thr?Gln?Ile?Leu?Glu
130?????????????????135?????????????????140Ser?Ala?His?Phe?Tyr?Ala?Ser?Lys?Trp?Glu?Phe?Asp?Ile?Ile?Tyr?His145?????????????????150?????????????????155?????????????????160Phe?Asn?Pro?Asn?Met?Tyr?Gly?Val?Lys?Glu?Ile?Lys?Asp?Lys?Ile?Asp
165?????????????????170?????????????????175Lys?Gln?Leu?His?Asn?Asn?Asp?His?Leu?Phe?Glu?Gly?Leu?Phe?Gly?Glu
180?????????????????185?????????????????190Lys?Glu?Asp?Leu?Lys?Lys?Leu?Val?Ser?Met?Phe?Gly?Gln?Leu?Arg?Phe
195?????????????????200?????????????????205Gln?Lys?Arg?Trp?Ser?Gln?Thr?Pro?Arg?Val?Pro?Gln?Thr?Ser?Val?Leu
210?????????????????215?????????????????220Gly?His?Thr?Leu?Cys?Val?Ala?Ile?Met?Gly?Tyr?Leu?Leu?Ser?Phe?Asp225?????????????????230?????????????????235?????????????????240Leu?Lys?Ala?Cys?Lys?Ser?Met?Arg?Ile?Asn?His?Phe?Leu?Gly?Gly?Leu
245?????????????????250?????????????????255Phe?His?Asp?Leu?Pro?Glu?Ile?Leu?Thr?Arg?Asp?Ile?Ile?Thr?Pro?Ile
260?????????????????265?????????????????270Lys?Gln?Ser?Val?Ala?Gly?Leu?Asp?His?Cys?Ile?Lys?Glu?Ile?Glu?Lys
275?????????????????280?????????????????285Lys?Glu?Met?Gln?Asn?Lys?Val?Tyr?Ser?Phe?Val?Ser?Leu?Gly?Val?Gln
290?????????????????295?????????????????300Glu?Asp?Leu?Lys?Tyr?Phe?Thr?Glu?Asn?Glu?Phe?Lys?Asn?Arg?Tyr?Lys305?????????????????310?????????????????315?????????????????320Asp?Lys?Ser?His?Gln?Ile?Val?Phe?Thr?Lys?Asp?Ala?Glu?Glu?Leu?Phe
325?????????????????330?????????????????335Thr?Leu?Tyr?Asn?Ser?Asp?Glu?Tyr?Leu?Gly?Val?Cys?Gly?Glu?Leu?Leu
340?????????????????345?????????????????350Lys?Val?Cys?Asp?His?Leu?Ser?Ala?Phe?Leu?Glu?Ala?Gln?Ile?Ser?Leu
355?????????????????360?????????????????365Ser?His?Gly?Ile?Ser?Ser?Tyr?Asp?Leu?Ile?Gln?Gly?Ala?Lys?Asn?Leu
370?????????????????375?????????????????380Leu?Glu?Leu?Arg?Ser?Gln?Thr?Glu?Leu?Leu?Asp?Leu?Asp?Leu?Gly?Lys385?????????????????390?????????????????395?????????????????400Leu?Phe?Arg?Asp?Phe?Lys
The data of 405 (2) SEQ ID NO:101:
(ⅰ) sequence signature:
(A) length: 335 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..335
(ⅹ ⅰ) sequence description: SEQ ID NO:101:Val Leu Trp Val Leu Tyr Phe Leu Thr Ser Leu Phe Ile Cys Ser Leu1 5 10 15Ile Val Leu Trp Ser Lys Lys Ser Met Leu Phe Val Asp Asn Ala Asn
20??????????????????25??????????????????30Lys?Ile?Gln?Gly?Phe?His?His?Ala?Arg?Thr?Pro?Arg?Ala?Gly?Gly?Leu
35??????????????????40??????????????????45Gly?Ile?Phe?Leu?Ser?Phe?Ala?Leu?Ala?Cys?Tyr?Leu?Glu?Pro?Phe?Glu
50??????????????????55??????????????????60Met?Pro?Phe?Lys?Gly?Pro?Phe?Val?Phe?Leu?Gly?Leu?Ser?Leu?Val?Phe65??????????????????70??????????????????75??????????????????80Leu?Ser?Gly?Phe?Leu?Glu?Asp?Ile?Asn?Leu?Ser?Leu?Ser?Pro?Lys?Ile
85??????????????????90??????????????????95Arg?Leu?Ile?Leu?Gln?Ala?Val?Gly?Val?Val?Cys?Ile?Ile?Ser?Ser?Thr
100?????????????????105?????????????????110Pro?Leu?Val?Val?Ser?Asp?Phe?Ser?Pro?Leu?Phe?Ser?Leu?Pro?Tyr?Phe
115?????????????????120?????????????????125Ile?Ala?Phe?Leu?Phe?Ala?Ile?Phe?Met?Leu?Val?Gly?Ile?Ser?Asn?Ala
130?????????????????135?????????????????140Ile?Asn?Ile?Ile?Asp?Gly?Phe?Asn?Gly?Leu?Ala?Ser?Gly?Ile?Cys?Ala145?????????????????150?????????????????155?????????????????160Ile?Ala?Leu?Leu?Val?Ile?His?Tyr?Ile?Asp?Pro?Ser?Ser?Leu?Ser?Cys
165?????????????????170?????????????????175Leu?Leu?Ala?Tyr?Met?Val?Leu?Gly?Phe?Met?Val?Leu?Asn?Phe?Pro?Ser
180?????????????????185?????????????????190Gly?Lys?Ile?Phe?Leu?Gly?Asp?Gly?Gly?Ala?Tyr?Phe?Leu?Gly?Leu?Val
195?????????????????200?????????????????205Cys?Gly?Ile?Ser?Leu?Leu?His?Leu?Ser?Leu?Glu?Gln?Lys?Ile?Ser?Val
210?????????????????215?????????????????220Phe?Phe?Gly?Leu?Asn?Leu?Met?Leu?Tyr?Pro?Val?Ile?Glu?Val?Leu?Phe225?????????????????230?????????????????235?????????????????240Ser?Ile?Leu?Arg?Arg?Lys?Ile?Lys?Arg?Gln?Lys?Ala?Thr?Met?Pro?Asp
245?????????????????250?????????????????255Asn?Leu?His?Leu?His?Thr?Leu?Leu?Phe?Lys?Phe?Leu?Gln?Gln?Arg?Ser
260?????????????????265?????????????????270Phe?Asn?Tyr?Pro?Asn?Pro?Leu?Cys?Ala?Phe?Ile?Leu?Ile?Leu?Cys?Asn
275?????????????????280?????????????????285Leu?Pro?Phe?Ile?Leu?Ile?Ser?Val?Leu?Phe?Arg?Leu?Asp?Ala?Tyr?Ala
290?????????????????295?????????????????300Leu?Ile?Val?Ile?Ser?Leu?Val?Phe?Ile?Ala?Cys?Tyr?Leu?Ile?Gly?Tyr305?????????????????310?????????????????315?????????????????320Ala?Tyr?Leu?Asn?Arg?Gln?Val?Cys?Ala?Leu?Glu?Lys?Arg?Ala?Phe
The data of 325 330 335 (2) SEQ ID NO:102:
(ⅰ) sequence signature:
(A) length: 96 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..96
(ⅹ ⅰ) sequence description: SEQ ID NO:102:Met Lys Lys Val Ile Val Ala Leu Gly Val Leu Ala Phe Ala Asn Val1 5 10 15Leu Met Ala Thr Asp Val Lys Ala Leu Val Lys Gly Cys Ala Ala Cys
20??????????????????25??????????????????30His?Gly?Val?Lys?Phe?Glu?Lys?Lys?Ala?Leu?Gly?Lys?Ser?Lys?Ile?Val
35??????????????????40??????????????????45Asn?Met?Met?Ser?Glu?Lys?Glu?Ile?Glu?Glu?Asp?Leu?Met?Ala?Phe?Lys
50??????????????????55??????????????????60Ser?Gly?Ala?Asn?Lys?Asn?Pro?Val?Met?Thr?Ala?Gln?Ala?Lys?Lys?Leu65??????????????????70??????????????????75??????????????????80Ser?Asp?Glu?Asp?Ile?Lys?Ala?Leu?Ala?Lys?Tyr?Ile?Pro?Thr?Leu?Lys
The data of 85 90 95 (2) SEQ ID NO:103:
(ⅰ) sequence signature:
(A) length: 156 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..156
(ⅹ ⅰ) sequence description: SEQ ID NO:103:Met Arg Asp Phe Asn Asn Ile Gln Ile Thr Arg Leu Lys Val Arg Gln1 5 10 15Asn Ala Val Phe Glu Lys Leu Asp Leu Glu Phe Lys Asp Gly Leu Ser
20??????????????????25??????????????????30Ala?Ile?Ser?Gly?Ala?Ser?Gly?Val?Gly?Lys?Ser?Val?Leu?Ile?Ala?Ser
35??????????????????40??????????????????45Leu?Leu?Gly?Ala?Phe?Gly?Leu?Lys?Glu?Ser?Asn?Ala?Ser?Asn?Ile?Glu
50??????????????????55??????????????????60Val?Glu?Leu?Ile?Ala?Pro?Phe?Leu?Asp?Thr?Glu?Glu?Tyr?Gly?Ile?Phe65??????????????????70??????????????????75??????????????????80Arg?Glu?Asp?Glu?His?Glu?Pro?Leu?Val?Ile?Ser?Val?Ile?Lys?Lys?Glu
85??????????????????90??????????????????95Lys?Thr?Arg?Tyr?Phe?Leu?Asn?Gln?Thr?Ser?Leu?Ser?Lys?Asn?Thr?Leu
100?????????????????105?????????????????110Lys?Ala?Leu?Leu?Lys?Gly?Leu?Ile?Lys?Arg?Leu?Ser?Asn?Asp?Arg?Phe
115?????????????????120?????????????????125Ser?Gln?Asn?Glu?Leu?Asn?Asp?Ile?Leu?Met?Leu?Ser?Leu?Leu?Asp?Gly
The data of 130 135 140Tyr Ile Gln Asn Lys Asn Arg Arg Leu Ala Pro Phe145,150 155 (2) SEQ ID NO:104:
(ⅰ) sequence signature:
(A) length: 118 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..118
(ⅹ ⅰ) sequence description: SEQ ID NO:104:Val Met Leu Met Ala Ile Phe Thr Pro Tyr Ile Leu Ile Leu Lys Met1 5 10 15Met Lys Lys Ser Met Ser Leu Phe Ala Asn Met Gly Leu Glu Gln Ile
20??????????????????25??????????????????30Phe?Cys?Asn?Arg?Asp?Ile?Lys?Asp?Leu?Asn?Asp?Phe?Val?Phe?Gly?Ile
35??????????????????40??????????????????45Glu?Val?Gly?Leu?Asp?Ser?Asn?Ala?Arg?Lys?Asn?Arg?Ser?Arg?Lys?Ala
50??????????????????55??????????????????60Met?Glu?Asn?His?Leu?Ile?Gly?Leu?Phe?Val?Gln?Ala?Gln?Leu?Asn?Phe65??????????????????70??????????????????75??????????????????80Lys?Glu?Gln?Val?Asp?Ile?Arg?Glu?Phe?Glu?Asp?Leu?Arg?Gln?Ala?Phe
85??????????????????90??????????????????95Gly?Asn?Asp?Thr?Lys?Lys?Phe?Asp?Phe?Val?Ile?Phe?Ser?Lys?Glu?Lys
100?????????????????105?????????????????110Thr?Tyr?Phe?His?Arg?Ser
The data of 115 (2) SEQ ID NO:105:
(ⅰ) sequence signature:
(A) length: 355 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..355
(ⅹ ⅰ) sequence description: SEQ ID NO:105:Met Asn Ile Lys Ile Leu Lys Ile Leu Val Gly Gly Leu Phe Phe Leu1 5 10 15Ser Leu Asn Ala His Leu Trp Gly Lys Gln Asp Asn Ser Phe Leu Gly
20??????????????????25??????????????????30Ile?Gly?Glu?Arg?Ala?Tyr?Lys?Ser?Gly?Asn?Tyr?Ser?Lys?Ala?Ala?Ser
35??????????????????40??????????????????45Tyr?Phe?Lys?Lys?Ala?Cys?Asn?Asp?Gly?Val?Ser?Glu?Gly?Cys?Thr?Gln
50??????????????????55??????????????????60Leu?Gly?Ile?Ile?Tyr?Glu?Asn?Gly?Gln?Gly?Thr?Arg?Ile?Asp?Tyr?Lys65??????????????????70??????????????????75??????????????????80Lys?Ala?Leu?Glu?Tyr?Tyr?Lys?Thr?Ala?Cys?Gln?Ala?Asp?Asp?Arg?Glu
85??????????????????90??????????????????95Gly?Cys?Phe?Gly?Leu?Gly?Gly?Leu?Tyr?Asp?Glu?Gly?Leu?Gly?Thr?Ala
100?????????????????105?????????????????110Gln?Asn?Tyr?Gln?Glu?Ala?Ile?Asp?Ala?Tyr?Ala?Lys?Ala?Cys?Val?Leu
115?????????????????120?????????????????125Lys?His?Pro?Glu?Ser?Cys?Tyr?Asn?Leu?Gly?Ile?Ile?Tyr?Asp?Arg?Lys
130?????????????????135?????????????????140Ile?Lys?Gly?Asn?Ala?Ala?Gln?Ala?Val?Thr?Tyr?Tyr?Gln?Lys?Ser?Cys145?????????????????150?????????????????155?????????????????160Asn?Phe?Asp?Met?Ala?Lys?Gly?Cys?Tyr?Ile?Leu?Gly?Thr?Ala?Tyr?Glu
165?????????????????170?????????????????175Lys?Gly?Phe?Leu?Glu?Val?Lys?Gln?Ser?Asn?His?Lys?Ala?Val?Ile?Tyr
180?????????????????185?????????????????190Tyr?Leu?Lys?Ala?Cys?Arg?Leu?Asn?Glu?Gly?Gln?Ala?Cys?Arg?Ala?Leu
195?????????????????200?????????????????205Gly?Ser?Leu?Phe?Glu?Asn?Gly?Asp?Ala?Gly?Leu?Asp?Glu?Asp?Phe?Glu
210?????????????????215?????????????????220Val?Ala?Phe?Asp?Tyr?Leu?Gln?Lys?Ala?Cys?Ala?Leu?Asn?Asn?Ser?Gly225?????????????????230?????????????????235?????????????????240Gly?Cys?Ala?Ser?Leu?Gly?Ser?Met?Tyr?Met?Leu?Gly?Arg?Tyr?Val?Lys
245?????????????????250?????????????????255Lys?Asp?Pro?Gln?Lys?Ala?Phe?Asn?Tyr?Phe?Lys?Gln?Ala?Cys?Asp?Met
260?????????????????265?????????????????270Gly?Ser?Ala?Val?Ser?Cys?Ser?Arg?Met?Gly?Phe?Met?Tyr?Ser?Gln?Gly
275?????????????????280?????????????????285Asp?Thr?Val?Ser?Lys?Asp?Leu?Arg?Lys?Ala?Leu?Asp?Asn?Tyr?Glu?Arg
290?????????????????295?????????????????300Gly?Cys?Asp?Met?Gly?Asp?Glu?Val?Gly?Cys?Phe?Ala?Leu?Ala?Gly?Met305?????????????????310?????????????????315?????????????????320Tyr?Tyr?Asn?Met?Lys?Asp?Lys?Glu?Asn?Ala?Ile?Met?Ile?Tyr?Asp?Lys
325?????????????????330?????????????????335Gly?Cys?Lys?Leu?Gly?Met?Lys?Gln?Ala?Cys?Glu?Asn?Leu?Thr?Lys?Leu
340?????????????????345?????????????????350Arg?Gly?Tyr
The data of 355 (2) SEQ ID NO:106:
(ⅰ) sequence signature:
(A) length: 193 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..193
(ⅹ ⅰ) sequence description: SEQ ID NO:106:Met Lys Glu Lys Asn Phe Trp Pro Leu Gly Ile Met Ser Val Leu Ile1 5 10 15Phe Gly Leu Gly Ile Val Val Phe Leu Val Val Phe Ala Leu Lys Asn
20??????????????????25??????????????????30Ser?Pro?Lys?Asn?Asp?Leu?Val?Tyr?Phe?Lys?Gly?His?Asn?Glu?Val?Asp
35??????????????????40??????????????????45Leu?Asn?Phe?Asn?Ala?Met?Leu?Lys?Thr?Tyr?Glu?Asn?Phe?Lys?Ser?Asn
50??????????????????55??????????????????60Tyr?Arg?Phe?Ser?Val?Gly?Leu?Lys?Pro?Leu?Thr?Glu?Ser?Pro?Lys?Thr65??????????????????70??????????????????75??????????????????80Pro?Ile?Leu?Pro?Tyr?Phe?Ser?Lys?Gly?Thr?His?Gly?Asp?Lys?Lys?Ile
85??????????????????90??????????????????95Gln?Glu?Asn?Leu?Leu?Asn?Asn?Ala?Leu?Ile?Leu?Glu?Lys?Ser?Asn?Thr
100?????????????????105?????????????????110Leu?Tyr?Ala?Gln?Leu?Gln?Pro?Leu?Lys?Pro?Ala?Leu?Asp?Ser?Pro?Asn
115?????????????????120?????????????????125Ile?Gln?Val?Tyr?Leu?Ala?Phe?Tyr?Pro?Ser?Gln?Ser?Gln?Pro?Arg?Leu
130?????????????????135?????????????????140Leu?Gly?Thr?Leu?Asp?Cys?Lys?Asn?Ala?Cys?Glu?Pro?Leu?Lys?Phe?Asp145?????????????????150?????????????????155?????????????????160Leu?Leu?Glu?Gly?Asp?Lys?Val?Gly?Arg?Tyr?Lys?Ile?Leu?Phe?Lys?Phe
165?????????????????170?????????????????175Val?Phe?Lys?Ash?Lys?Glu?Glu?Leu?Ile?Leu?Glu?Gln?Leu?Ala?Phe?Phe
The data of 180 185 190Lys (2) SEQ ID NO:107:
(ⅰ) sequence signature:
(A) length: 289 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..289
(ⅹ ⅰ) sequence description: SEQ ID NO:107:Leu Gly Ile Asn Met Cys Ser Lys Lys Ile Arg Asn Leu Ile Leu Cys1 5 10 15Phe Gly Phe Ile Leu Ser Leu Cys Ala Glu Glu Asn Ile Thr Lys Glu
20??????????????????25??????????????????30Asn?Met?Thr?Glu?Thr?Asn?Thr?Thr?Glu?Glu?Asn?Thr?Pro?Lys?Asp?Ala
35??????????????????40??????????????????45Pro?Ile?Leu?Leu?Glu?Glu?Lys?Arg?Ala?Gln?Thr?Leu?Glu?Leu?Lys?Glu
50??????????????????55??????????????????60Glu?Asn?Glu?Val?Ala?Lys?Lys?Ile?Asp?Glu?Lys?Ser?Leu?Leu?Glu?Glu65??????????????????70??????????????????75??????????????????80Ile?His?Lys?Lys?Lys?Arg?Gln?Leu?Tyr?Met?Leu?Lys?Gly?Glu?Leu?His
85??????????????????90??????????????????95Glu?Lys?Asn?Glu?Ser?Ile?Leu?Phe?Gln?Gln?Met?Ala?Lys?Asn?Lys?Ser
100?????????????????105?????????????????110Gly?Phe?Phe?Ile?Gly?Val?Ile?Leu?Gly?Asp?Ile?Gly?Ile?Asn?Ala?Asn
115?????????????????120?????????????????125Pro?Tyr?Glu?Lys?Phe?Glu?Leu?Leu?Ser?Asn?Ile?Gln?Ala?Ser?Pro?Leu
130?????????????????135?????????????????140Leu?Tyr?Gly?Leu?Arg?Ser?Gly?Tyr?Gln?Lys?Tyr?Phe?Ala?Asn?Gly?Ile145?????????????????150?????????????????155?????????????????160Ser?Ala?Leu?Arg?Phe?Tyr?Gly?Glu?Tyr?Leu?Gly?Gly?Ala?Met?Lys?Gly
165?????????????????170?????????????????175Phe?Lys?Ser?Asp?Ser?Leu?Ala?Ser?Tyr?Gln?Thr?Ala?Ser?Leu?Asn?Ile
180?????????????????185?????????????????190Asp?Leu?Leu?Met?Asp?Lys?Pro?Ile?Asp?Lys?Glu?Lys?Arg?Phe?Ala?Leu
195?????????????????200?????????????????205Gly?Ile?Phe?Gly?Gly?Val?Gly?Val?Gly?Trp?Asn?Gly?Met?Tyr?Gln?Asn
210?????????????????215?????????????????220Leu?Lys?Glu?Ile?Arg?Gly?Tyr?Ser?Gln?Pro?Asn?Ala?Phe?Gly?Leu?Val225?????????????????230?????????????????235?????????????????240Leu?Asn?Leu?Gly?Val?Ser?Met?Thr?Leu?Asn?Leu?Lys?His?Arg?Phe?Glu
245?????????????????250?????????????????255Leu?Ala?Leu?Lys?Met?Pro?Pro?Leu?Lys?Glu?Thr?Ser?Gln?Thr?Phe?Leu
260?????????????????265?????????????????270Tyr?Tyr?Phe?Lys?Ser?Thr?Asn?Ile?Tyr?Tyr?Ile?Ser?Tyr?Asn?Tyr?Leu
The data of 275 280 285Leu (2) SEQ ID NO:108:
(ⅰ) sequence signature:
(A) length: 668 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..668
(ⅹ ⅰ) sequence description: SEQ ID NO:108:Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala1 5 10 15Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu
20??????????????????25??????????????????30Leu?Glu?Gly?Thr?Gln?Thr?Gln?Glu?Lys?Arg?His?Thr?Thr?Thr?Lys?Asn
35??????????????????40??????????????????45Thr?Tyr?Ala?Thr?Tyr?Asn?Tyr?Leu?Pro?Thr?Asp?Thr?Ile?Leu?Lys?Arg
50??????????????????55??????????????????60Ala?Ala?Asn?Leu?Phe?Thr?Asn?Ala?Glu?Ala?Ile?Ser?Lys?Leu?Lys?Phe65??????????????????70??????????????????75??????????????????80Ser?Ser?Leu?Ser?Pro?Val?Arg?Val?Leu?Tyr?Met?Tyr?Asn?Gly?Gln?Leu
85??????????????????90??????????????????95Thr?Ile?Glu?Asn?Phe?Leu?Pro?Tyr?Asn?Leu?Asn?Asn?Val?Lys?Leu?Ser
100?????????????????105?????????????????110Phe?Thr?Asp?Ala?Gln?Gly?Asn?Thr?Ile?Asp?Leu?Gly?Val?Ile?Glu?Thr
115?????????????????120?????????????????125Ile?Pro?Lys?His?Ser?Lys?Ile?Val?Leu?Pro?Gly?Glu?Ala?Phe?Asp?Ser
130?????????????????135?????????????????140Leu?Lys?Glu?Ala?Phe?Asp?Lys?Ile?Asp?Pro?Tyr?Thr?Leu?Phe?Leu?Pro145?????????????????150?????????????????155?????????????????160Lys?Phe?Glu?Ala?Thr?Ser?Thr?Ser?Ile?Ser?Asp?Thr?Asn?Thr?Gln?Arg
165?????????????????170?????????????????175Val?Phe?Glu?Thr?Leu?Asn?Asn?Ile?Lys?Thr?Asn?Leu?Ile?Met?Lys?Tyr
180?????????????????185?????????????????190Ser?Asn?Glu?Asn?Pro?Asn?Asn?Phe?Asn?Thr?Cys?Pro?Tyr?Asn?Asn?Asn
195?????????????????200?????????????????205Gly?Asn?Thr?Lys?Asn?Asp?Cys?Trp?Gln?Asn?Phe?Thr?Pro?Gln?Thr?Ala
210?????????????????215?????????????????220Glu?Glu?Phe?Thr?Asn?Leu?Met?Leu?Asn?Met?Ile?Ala?Val?Leu?Asp?Ser225?????????????????230?????????????????235?????????????????240Gln?Ser?Trp?Gly?Asp?Ala?Ile?Leu?Asn?Ala?Pro?Phe?Glu?Phe?Thr?Asn
245?????????????????250?????????????????255Ser?Ser?Thr?Asp?Cys?Asp?Ser?Asp?Pro?Ser?Lys?Cys?Val?Asn?Pro?Gly
260?????????????????265?????????????????270Val?Asn?Gly?Arg?Val?Asp?Thr?Lys?Val?Asp?Gln?Gln?Tyr?Ile?Leu?Asn
275?????????????????280?????????????????285Lys?Gln?Gly?Ile?Ile?Asn?Asn?Phe?Arg?Lys?Lys?Ile?Glu?Ile?Asp?Ala
290?????????????????295?????????????????300Val?Val?Leu?Lys?Asn?Ser?Gly?Val?Val?Gly?Leu?Ala?Asn?Gly?Tyr?Gly305?????????????????310?????????????????315?????????????????320Asn?Asp?Gly?Glu?Tyr?Gly?Thr?Leu?Gly?Val?Glu?Ala?Tyr?Ala?Leu?Asp
325?????????????????330?????????????????335Pro?Lys?Lys?Leu?Phe?Gly?Asn?Asp?Leu?Lys?Thr?Ile?Asn?Leu?Glu?Asp
340?????????????????345?????????????????350Leu?Arg?Thr?Ile?Leu?His?Glu?Phe?Ser?His?Thr?Lys?Gly?Tyr?Gly?His
355?????????????????360?????????????????365Asn?Gly?Asn?Met?Thr?Tyr?Gln?Arg?Val?Pro?Val?Thr?Lys?Asp?Gly?Gln
370?????????????????375?????????????????380Val?Glu?Lys?Asp?Ser?Asn?Gly?Lys?Pro?Lys?Asp?Ser?Asp?Gly?Leu?Pro385?????????????????390?????????????????395?????????????????400Tyr?Asn?Val?Cys?Ser?Leu?Tyr?Gly?Gly?Ser?Asn?Gln?Pro?Ala?Phe?Pro
405?????????????????410?????????????????415Ser?Asn?Tyr?Pro?Asn?Ser?Ile?Tyr?His?Asn?Cys?Ala?Asp?Val?Pro?Ala
420?????????????????425?????????????????430Gly?Phe?Leu?Gly?Val?Thr?Ala?Ala?Val?Trp?Gln?Gln?Leu?Ile?Asn?Gln
435?????????????????440?????????????????445Asn?Ala?Leu?Pro?Ile?Asn?Tyr?Ala?Asn?Leu?Gly?Ser?Gln?Thr?Asn?Tyr
450?????????????????455?????????????????460Asn?Leu?Asn?Ala?Ser?Leu?Asn?Thr?Gln?Asp?Leu?Ala?Asn?Ser?Met?Leu465?????????????????470?????????????????475?????????????????480Ser?Thr?Ile?Gln?Lys?Thr?Phe?Val?Thr?Ser?Ser?Val?Thr?Asn?His?His
485?????????????????490?????????????????495Phe?Ser?Asn?Ala?Ser?Gln?Ser?Phe?Arg?Ser?Pro?Ile?Leu?Gly?Val?Asn
500?????????????????505?????????????????510Ala?Lys?Ile?Gly?Tyr?Gln?Asn?Tyr?Phe?Asn?Asp?Phe?Ile?Gly?Leu?Ala
515?????????????????520?????????????????525Tyr?Tyr?Gly?Ile?Ile?Lys?Tyr?Asn?Tyr?Ala?Lys?Ala?Val?Asn?Gln?Lys
530?????????????????535?????????????????540Val?Gln?Gln?Leu?Ser?Tyr?Gly?Gly?Gly?Ile?Asp?Leu?Leu?Leu?Asp?Phe545?????????????????550?????????????????555?????????????????560Ile?Thr?Thr?Tyr?Ser?Asn?Lys?Asn?Ser?Pro?Thr?Gly?Ile?Gln?Thr?Lys
565?????????????????570?????????????????575Arg?Asn?Phe?Ser?Ser?Ser?Phe?Gly?Ile?Phe?Gly?Gly?Leu?Arg?Gly?Leu
580?????????????????585?????????????????590Tyr?Asn?Ser?Tyr?Tyr?Val?Leu?Asn?Lys?Val?Lys?Gly?Ser?Gly?Asn?Leu
595?????????????????600?????????????????605Asp?Val?Ala?Thr?Gly?Leu?Asn?Tyr?Arg?Tyr?Lys?His?Ser?Lys?Tyr?Ser
610?????????????????615?????????????????620Val?Gly?Ile?Ser?Ile?Pro?Leu?Ile?Gln?Arg?Lys?Ala?Ser?Val?Val?Ser625?????????????????630?????????????????635?????????????????640Ser?Gly?Gly?Asp?Tyr?Thr?Asn?Ser?Phe?Val?Phe?Asn?Glu?Gly?Ala?Ser
645?????????????????650?????????????????655His?Phe?Lys?Val?Phe?Phe?Asn?Tyr?Gly?Trp?Val?Phe
The data of 660 665 (2) SEQ ID NO:109:
(ⅰ) sequence signature:
(A) length: 63 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..63
(ⅹ ⅰ) sequence description: SEQ ID NO:109:Met Asn Thr Glu Ile Leu Thr Ile Met Leu Val Val Ser Val Leu Met1 5 10 15Gly Leu Val Gly Leu Ile Ala Phe Leu Trp Gly Val Lys Ser Gly Gln
20??????????????????25??????????????????30Phe?Asp?Asp?Glu?Lys?Arg?Met?Leu?Glu?Sar?Val?Leu?Tyr?Asp?Ser?Ala
25??????????????????40??????????????????45Ser?Asp?Leu?Asn?Glu?Ala?Ile?Leu?Gln?Glu?Lys?Arg?Gln?Lys?Asn
The data of 50 55 60 (2) SEQ ID NO:110:
(ⅰ) sequence signature:
(A) length: 406 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..406
(ⅹ ⅰ) sequence description: SEQ ID NO:110:Met Val Phe Phe His Lys Lys Ile Ile Leu Asn Phe Ile Tyr Ser Leu1 5 10 15Met Val Ala Phe Leu Phe His Leu Ser Tyr Gly Val Leu Leu Lys Ala
20??????????????????25??????????????????30Asp?Gly?Met?Ala?Lys?Lys?Gln?Thr?Leu?Leu?Val?Gly?Glu?Arg?Leu?Val
35??????????????????40??????????????????45Trp?Asp?Lys?Leu?Thr?Leu?Leu?Gly?Phe?Leu?Glu?Lys?Asn?His?Ile?Pro
50??????????????????55??????????????????60Gln?Lys?Leu?Tyr?Tyr?Asn?Leu?Ser?Ser?Gln?Asp?Lys?Glu?Leu?Ser?Ala65??????????????????70??????????????????75??????????????????80Glu?Ile?Gln?Ser?Asn?Val?Thr?Tyr?Tyr?Thr?Leu?Arg?Asp?Ala?Asn?Asn
85??????????????????90??????????????????95Thr?Leu?Ile?Gln?Ala?Leu?Ile?Pro?Ile?Ser?Gln?Asp?Leu?Gln?Ile?His
100?????????????????105?????????????????110Ile?Tyr?Lys?Lys?Gly?Glu?Asp?Tyr?Phe?Leu?Asp?Phe?Ile?Pro?Ile?Val
115?????????????????120?????????????????125Phe?Thr?Arg?Lys?Glu?Arg?Thr?Leu?Leu?Leu?Ser?Leu?Gln?Thr?Ser?Pro
130?????????????????135?????????????????140Tyr?Gln?Asp?Ile?Val?Lys?Ala?Thr?Asn?Asp?Pro?Leu?Leu?Ala?Asn?Gln145?????????????????150?????????????????155?????????????????160Leu?Met?Asn?Ala?Tyr?Lys?Lys?Ser?Val?Pro?Phe?Lys?Arg?Leu?Val?Lys
165?????????????????170?????????????????175Asn?Asp?Lys?Ile?Ala?Ile?Val?Tyr?Thr?Arg?Asp?Tyr?Arg?Val?Gly?Gln
180?????????????????185?????????????????190Ala?Phe?Gly?Gln?Pro?Thr?Ile?Lys?Met?Ala?Met?Val?Ser?Ser?Arg?Leu
195?????????????????200?????????????????205His?Gln?Tyr?Tyr?Leu?Phe?Ser?His?Ser?Asn?Gly?Arg?Tyr?Tyr?Asp?Ser
210?????????????????215?????????????????220Lys?Ala?Gln?Glu?Val?Ala?Gly?Phe?Leu?Leu?Glu?Thr?Pro?Val?Lys?Tyr225?????????????????230?????????????????235?????????????????240Thr?Arg?Ile?Ser?Ser?Pro?Phe?Ser?Tyr?Gly?Arg?Phe?His?Pro?Val?Leu
245?????????????????250?????????????????255Lys?Val?Lys?Arg?Pro?His?Tyr?Gly?Val?Asp?Tyr?Ala?Ala?Lys?His?Gly
260?????????????????265?????????????????270Ser?Leu?Ile?His?Ser?Ala?Ser?Asp?Gly?Arg?Val?Gly?Phe?Ile?Gly?Val
275?????????????????280?????????????????285Lys?Ala?Gly?Tyr?Gly?Lys?Val?Val?Glu?Ile?His?Leu?Asn?Glu?Leu?Arg
290?????????????????295?????????????????300Leu?Val?Tyr?Ala?His?Met?Ser?Ala?Phe?Ala?Asn?Gly?Leu?Lys?Lys?Gly305?????????????????310?????????????????315?????????????????320Ser?Phe?Val?Lys?Lys?Gly?Gln?Ile?Ile?Gly?Arg?Val?Gly?Ser?Thr?Gly
325?????????????????330?????????????????335Leu?Ser?Thr?Gly?Pro?His?Leu?His?Phe?Gly?Val?Tyr?Lys?Asn?Ser?Arg
340?????????????????345?????????????????350Pro?Ile?Asn?Pro?Leu?Gly?Tyr?Ile?Arg?Thr?Ala?Lys?Ser?Lys?Leu?His
355?????????????????360?????????????????365Gly?Lys?Gln?Arg?Glu?Val?Phe?Leu?Glu?Lys?Ala?Gln?Tyr?Ser?Lys?Gln
370?????????????????375?????????????????380Lys?Leu?Glu?Glu?Leu?Phe?Lys?Thr?His?Ser?Phe?Glu?Lys?Asn?Ser?Phe385?????????????????390?????????????????395?????????????????400Tyr?Leu?Leu?Glu?Gly?Phe
The data of 405 (2) SEQ ID NO:111:
(ⅰ) sequence signature:
(A) length: 296 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..296
(ⅹ ⅰ) sequence description: SEQ ID NO:111:Leu Phe Leu Val Lys Lys Ile Gly Val Val Ile Met Ile Leu Val Cys1 5 10 15Phe Leu Ala Cys Ser Gln Glu Ser Phe Ile Lys Met Gln Lys Lys Ala
20??????????????????25??????????????????30Gln?Glu?Gln?Glu?Asn?Asp?Gly?Ser?Lys?Arg?Pro?Ser?Tyr?Val?Asp?Ser
35??????????????????40??????????????????45Asp?Tyr?Glu?Val?Phe?Ser?Glu?Thr?Ile?Phe?Leu?Gln?Asn?Met?Val?Tyr
50??????????????????55??????????????????60Gln?Pro?Ile?Glu?Glu?Arg?Asn?Ala?Phe?Phe?Gln?Leu?Thr?Lys?Asp?Glu65??????????????????70??????????????????75??????????????????80Asp?Asn?Ser?Phe?Asn?Pro?Glu?Asn?Ser?Val?Ile?Leu?Leu?Asn?Glu?Pro
85??????????????????90??????????????????95Ser?Asp?Asn?Ser?Glu?Lys?Asn?Leu?Leu?Ser?Tyr?Pro?Asn?Asp?Pro?Asn
100?????????????????105?????????????????110Asn?Asn?Glu?Asp?Asn?Ala?Asn?Asn?Ser?Gln?Lys?Asn?Pro?Phe?Leu?Tyr
115?????????????????120?????????????????125Lys?Pro?Lys?Arg?Lys?Thr?Lys?Asn?Pro?Lys?Leu?Ile?Glu?Tyr?Ser?Gln
130?????????????????135?????????????????140Gln?Asp?Phe?Tyr?Pro?Leu?Lys?Asn?Gly?Asp?Ile?Ile?Met?Ser?Lys?Glu145?????????????????150?????????????????155?????????????????160Gly?Asp?Gln?Trp?Leu?Ile?Glu?Ile?Gln?Ser?Lys?Ala?Leu?Lys?Arg?Phe
165?????????????????170?????????????????175Leu?Lys?Asp?Gln?Asn?Asp?Lys?Asp?Arg?Gln?Ile?Gln?Thr?Phe?Thr?Phe
180?????????????????185?????????????????190Asn?Asp?Thr?Lys?Thr?Gln?Ile?Ala?Gln?Ile?Lys?Gly?Lys?Ile?Ser?Ser
195?????????????????200?????????????????205Tyr?Val?Tyr?Thr?Thr?Asn?Asn?Gly?Ser?Leu?Ser?Leu?Arg?Pro?Phe?Tyr
210?????????????????215?????????????????220Glu?Ser?Phe?Leu?Leu?Glu?Lys?Lys?Ser?Asp?Asn?Val?Tyr?Thr?Ile?Glu225?????????????????230?????????????????235?????????????????240Asn?Lys?Ala?Leu?Asp?Thr?Met?Glu?Ile?Ser?Lys?Cys?Gln?Met?Val?Leu
245?????????????????250?????????????????255Lys?Lys?His?Ser?Thr?Asp?Lys?Leu?Asp?Ser?Gln?His?Lys?Ala?Ile?Ser
260?????????????????265?????????????????270Ile?Asp?Leu?Asp?Phe?Lys?Lys?Glu?Arg?Phe?Lys?Ser?Asp?Thr?Glu?Leu
275?????????????????280?????????????????285Phe?Leu?Glu?Cys?Leu?Lys?Glu?Ser
The data of 290 295 (2) SEQ ID NO:112:
(ⅰ) sequence signature:
(A) length: 248 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..248
(ⅹ ⅰ) sequence description: SEQ ID NO:112:Val Ser Tyr Asp Asn Thr Asp Asp Tyr Tyr Phe Pro Arg Asn Gly Val1 5 10 15Ile Phe Ser Ser Tyr Ala Thr Met Ser Gly Leu Pro Ser Ser Gly Thr
20??????????????????25??????????????????30Leu?Asn?Ser?Trp?Asn?Gly?Leu?Gly?Gly?Asn?Val?Arg?Asn?Thr?Lys?Val
35??????????????????40??????????????????45Tyr?Gly?Lys?Phe?Ala?Ala?Tyr?His?His?Leu?Gln?Lys?Tyr?Leu?Leu?Ile
50??????????????????55??????????????????60Asp?Leu?Ile?Ala?Arg?Phe?Lys?Thr?Gln?Gly?Gly?Tyr?Ile?Phe?Arg?Tyr65??????????????????70??????????????????75??????????????????80Asn?Thr?Asp?Asp?Tyr?Leu?Pro?Leu?Asn?Ser?Thr?Phe?Tyr?Met?Gly?Gly
85??????????????????90??????????????????95Val?Thr?Thr?Val?Arg?Gly?Phe?Arg?Asn?Gly?Ser?Ile?Thr?Pro?Lys?Asp
100?????????????????105?????????????????110Glu?Phe?Gly?Leu?Trp?Leu?Gly?Gly?Asp?Gly?Ile?Phe?Thr?Ala?Ser?Thr
115?????????????????120?????????????????125Glu?Leu?Ser?Tyr?Gly?Val?Leu?Lys?Ala?Ala?Lys?Met?Arg?Leu?Ala?Trp
130?????????????????135?????????????????140Phe?Phe?Asp?Phe?Gly?Phe?Leu?Thr?Phe?Lys?Thr?Pro?Thr?Arg?Gly?Ser145?????????????????150?????????????????155?????????????????160Phe?Phe?Tyr?Asn?Ala?Pro?Thr?Thr?Thr?Ala?Asn?Phe?Lys?Asp?Tyr?Gly
165?????????????????170?????????????????175Val?Val?Gly?Ala?Gly?Phe?Glu?Arg?Ala?Thr?Trp?Arg?Ala?Ser?Thr?Gly
180?????????????????185?????????????????190Leu?Gln?Ile?Glu?Trp?Ile?Ser?Pro?Met?Gly?Pro?Leu?Val?Leu?Ile?Phe
195?????????????????200?????????????????205Pro?Ile?Ala?Phe?Phe?Asn?Gln?Trp?Gly?Asp?Gly?Asn?Gly?Lys?Lys?Cys
210?????????????????215?????????????????220Lys?Gly?Leu?Cys?Phe?Asn?Pro?Asn?Met?Asn?Asp?Tyr?Thr?Gln?His?Phe225?????????????????230?????????????????235?????????????????240Glu?Phe?Ser?Met?Gly?Thr?Arg?Phe
The data of 245 (2) SEQ ID NO:113:
(ⅰ) sequence signature:
(A) length: 335 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..335
(ⅹ ⅰ) sequence description: SEQ ID NO:113:Val Gln His Phe Asn Phe Leu Tyr Lys Asp Ser Leu Phe Ser Ile Ala1 5 10 15Leu Phe Thr Phe Ile Ile Ala Leu Val Ile Leu Leu Glu Gln Ala Arg
20??????????????????25??????????????????30Ala?Tyr?Phe?Thr?Arg?Lys?Arg?Asn?Lys?Lys?Phe?Leu?Gln?Lys?Phe?Ala
35??????????????????40??????????????????45Gln?Asn?Gln?Asn?Ala?Tyr?Ala?Ser?Ser?Glu?Asn?Leu?Asp?Glu?Leu?Leu
50??????????????????55??????????????????60Lys?His?Ala?Lys?Ile?Ser?Ser?Leu?Met?Phe?Leu?Ala?Arg?Ala?Tyr?Ser65??????????????????70??????????????????75??????????????????80Lys?Ala?Asp?Val?Glu?Met?Ser?Ile?Glu?Ile?Leu?Lys?Gly?Leu?Leu?Asn
85??????????????????90??????????????????95Arg?Pro?Leu?Lys?Asp?Glu?Glu?Lys?Ile?Ala?Val?Leu?Asp?Leu?Leu?Ala
100?????????????????105?????????????????110Lys?Asn?Tyr?Phe?Ser?Val?Gly?Tyr?Leu?Gln?Lys?Thr?Lys?Asp?Thr?Val
115?????????????????120?????????????????125Lys?Glu?Ile?Leu?Arg?Phe?Ser?Pro?Arg?Asn?Val?Glu?Ala?Leu?Leu?Lys
130?????????????????135?????????????????140Leu?Leu?His?Ala?Tyr?Glu?Leu?Glu?Lys?Asp?Tyr?Ser?Lys?Ala?Leu?Glu145?????????????????150?????????????????155?????????????????160Thr?Leu?Glu?Cys?Leu?Glu?Glu?Leu?Glu?Val?Pro?Lys?Ile?Glu?Thr?Ile
165?????????????????170?????????????????175Lys?Asn?Tyr?Leu?Tyr?Leu?Met?His?Leu?Ile?Glu?Asn?Lys?Glu?Asp?Ala
180?????????????????185?????????????????190Ala?Lys?Ile?Leu?His?Val?Ser?Lys?Ala?Ser?Leu?Asp?Leu?Lys?Lys?Ile
195?????????????????200?????????????????205Ala?Leu?Asn?His?Leu?Lys?Ser?His?Asp?Glu?Asn?Leu?Phe?Trp?Gln?Glu
210?????????????????215?????????????????220Ile?Asp?Thr?Thr?Glu?Arg?Leu?Glu?Asn?Val?Ile?Asp?Leu?Leu?Trp?Asp225?????????????????230?????????????????235?????????????????240Met?Asn?Ile?Pro?Ala?Phe?Ile?Leu?Glu?Lys?His?Ala?Leu?Leu?Gln?Asp
245?????????????????250?????????????????255Ile?Ala?Arg?Ser?Gln?Gly?Leu?Leu?Leu?Asp?His?Lys?Pro?Cys?Gln?Ile
260?????????????????265?????????????????270Phe?Glu?Leu?Glu?Val?Leu?Arg?Ala?Leu?Leu?His?Ser?Pro?Ile?Lys?Ala
275?????????????????280?????????????????285Ser?Leu?Thr?Phe?Glu?Tyr?Arg?Cys?Lys?His?Cys?Lys?Gln?Ile?Phe?Pro
290?????????????????295?????????????????300Phe?Glu?Ser?His?Arg?Cys?Pro?Val?Cys?Tyr?Gln?Leu?Ala?Phe?Met?Asp305?????????????????310?????????????????315?????????????????320Met?Val?Leu?Lys?Ile?Ser?Lys?Lys?Thr?His?Ala?Met?Gly?Val?Asp
The data of 325 330 335 (2) SEQ ID NO:114:
(ⅰ) sequence signature:
(A) length: 413 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..413
(ⅹ ⅰ) sequence description: SEQ ID NO:114:Met Arg Lys Ile Phe Ser Tyr Ile Ser Lys Val Leu Leu Phe Ile Gly1 5 10 15Val Val Tyr Ala Glu Pro Asp Ser Lys Val Glu Ala Leu Glu Gly Arg
20??????????????????25??????????????????30Lys?Gln?Glu?Ser?Ser?Leu?Asp?Lys?Lys?Ile?Arg?Gln?Glu?Leu?Lys?Ser
35??????????????????40??????????????????45Lys?Glu?Leu?Lys?Asn?Lys?Glu?Leu?Lys?Asn?Lys?Asp?Leu?Lys?Asn?Lys
50??????????????????55??????????????????60Glu?Glu?Lys?Lys?Glu?Thr?Lys?Ala?Lys?Arg?Lys?Pro?Arg?Ala?Glu?Val65??????????????????70??????????????????75??????????????????80His?His?Gly?Asp?Ala?Lys?Asn?Pro?Thr?Pro?Lys?Ile?Thr?Pro?Pro?Lys
85??????????????????90??????????????????95Ile?Lys?Gly?Ser?Ser?Lys?Gly?Val?Gln?Asn?Gln?Gly?Val?Gln?Asn?Asn
100?????????????????105?????????????????110Ala?Pro?Lys?Pro?Glu?Glu?Lys?Asp?Thr?Thr?Pro?Gln?Ala?Thr?Glu?Lys
115?????????????????120?????????????????125Asn?Lys?Glu?Thr?Ser?Pro?Ser?Ser?Gln?Phe?Asn?Ser?Ile?Phe?Gly?Asn
130?????????????????135?????????????????140Pro?Asn?Asn?Ala?Thr?Asn?Asn?Thr?Leu?Glu?Asp?Lys?Val?Val?Gly?Gly145?????????????????150?????????????????155?????????????????160Ile?Ser?Leu?Leu?Val?Asn?Gly?Ser?Pro?Ile?Thr?Leu?Tyr?Gln?Ile?Gln
165?????????????????170?????????????????175Glu?Glu?Gln?Glu?Lys?Ser?Lys?Val?Ser?Lys?Ala?Gln?Ala?Arg?Asp?Arg
180?????????????????185?????????????????190Leu?Ile?Ala?Glu?Arg?Ile?Lys?Asn?Gln?Glu?Ile?Glu?Arg?Leu?Lys?Ile
195?????????????????200?????????????????205His?Val?Asp?Asp?Asp?Lys?Leu?Asp?Gln?Glu?Met?Ala?Met?Met?Ala?Gln
210?????????????????215?????????????????220Gln?Gln?Gly?Met?Asp?Leu?Asp?His?Phe?Lys?Gln?Met?Leu?Met?Ala?Glu225?????????????????230?????????????????235?????????????????240Gly?His?Tyr?Lys?Leu?Tyr?Arg?Asp?Gln?Leu?Lys?Glu?His?Leu?Glu?Met
245?????????????????250?????????????????255Gln?Glu?Leu?Leu?Arg?Asn?Ile?Leu?Leu?Thr?Asn?Val?Asp?Thr?Ser?Ser
260?????????????????265?????????????????270Glu?Thr?Lys?Met?Arg?Glu?Tyr?Tyr?Asn?Lys?His?Lys?Glu?Gln?Phe?Ser
275?????????????????280?????????????????285Ile?Pro?Thr?Glu?Ile?Glu?Thr?Val?Arg?Tyr?Thr?Ser?Thr?Asn?Gln?Glu
290?????????????????295?????????????????300Asp?Leu?Glu?Arg?Ala?Met?Ala?Asp?Pro?Asn?Leu?Glu?Val?Pro?Gly?Val305?????????????????310?????????????????315?????????????????320Ser?Lys?Ala?Asn?Glu?Lys?Ile?Glu?Met?Lys?Thr?Leu?Asn?Pro?Gln?Ile
325?????????????????330?????????????????335Ala?Gln?Val?Phe?Ile?Ser?His?Glu?Gln?Gly?Ser?Phe?Thr?Pro?Val?Met
340?????????????????345?????????????????350Asn?Gly?Gly?Gly?Gly?Gln?Phe?Ile?Thr?Phe?Tyr?Ile?Lys?Glu?Lys?Arg
355?????????????????360?????????????????365Gly?Lys?Asn?Glu?Val?Ser?Phe?Ser?Gln?Ala?Lys?Gln?Phe?Ile?Ala?Gln
370?????????????????375?????????????????380Lys?Leu?Val?Glu?Glu?Ser?Lys?Asp?Lys?Ile?Leu?Glu?Glu?His?Phe?Glu385?????????????????390?????????????????395?????????????????400Lys?Leu?Arg?Val?Lys?Ser?Arg?Ile?Val?Met?Ile?Arg?Glu
The data of 405 410 (2) SEQ ID NO:115:
(ⅰ) sequence signature:
(A) length: 186 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..186
(ⅹ ⅰ) sequence description: SEQ ID NO:115:Met Ile Lys Arg Ile Ala Cys Ile Leu Ser Leu Ser Ala Ser Leu Ala1 5 10 15Leu Ala Gly Glu Val Asn Gly Phe Phe Met Gly Ala Gly Tyr Gln Gln
20??????????????????25??????????????????30Gly?Arg?Tyr?Gly?Pro?Tyr?Asn?Ser?Asn?Tyr?Ser?Asp?Trp?Arg?His?Gly
35??????????????????40??????????????????45Asn?Asp?Leu?Tyr?Gly?Leu?Asn?Phe?Lys?Leu?Gly?Phe?Val?Gly?Phe?Ala
50??????????????????55??????????????????60Asn?Lys?Trp?Phe?Gly?Ala?Arg?Val?Tyr?Gly?Phe?Leu?Asp?Trp?Phe?Asn65??????????????????70??????????????????75??????????????????80Thr?Ser?Gly?Thr?Glu?His?Thr?Lys?Thr?Asn?Leu?Leu?Thr?Tyr?Gly?Gly
85??????????????????90??????????????????95Gly?Gly?Asp?Leu?Ile?Val?Asn?Leu?Ile?Pro?Leu?Asp?Lys?Phe?Ala?Leu
100?????????????????105?????????????????110Gly?Leu?Ile?Gly?Gly?Val?Gln?Leu?Ala?Gly?Asn?Thr?Trp?Met?Phe?Pro
115?????????????????120?????????????????125Tyr?Asp?Val?Asn?Gln?Thr?Arg?Phe?Gln?Phe?Leu?Trp?Asn?Leu?Gly?Gly
130?????????????????135?????????????????140Arg?Met?Arg?Val?Gly?Asp?Arg?Ser?Ala?Phe?Glu?Ala?Gly?Val?Lys?Phe145?????????????????150?????????????????155?????????????????160Pro?Met?Val?Asn?Gln?Gly?Ser?Lys?Asp?Val?Gly?Leu?Ile?Arg?Tyr?Tyr
165?????????????????170?????????????????175Ser?Trp?Tyr?Val?Asp?Tyr?Val?Phe?Thr?Phe
The data of 180 185 (2) SEQ ID NO:116:
(ⅰ) sequence signature:
(A) length: 242 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..242
(ⅹ ⅰ) sequence description: SEQ ID NO:116:Met Lys Lys Phe Phe Ser Gln Ser Leu Leu Ala Leu Ile Ile Ser Met1 5 10 15Asn Ala Val Ser Gly Met Asp Gly Asn Gly Val Phe Leu Gly Ala Gly
20??????????????????25??????????????????30Tyr?Leu?Gln?Gly?Gln?Ala?Gln?Met?His?Ala?Asp?Ile?Asn?Ser?Gln?Lys
35??????????????????40??????????????????45Gln?Ala?Thr?Asn?Ala?Thr?Ile?Lys?Gly?Phe?Asp?Ala?Leu?Leu?Gly?Tyr
50??????????????????55??????????????????60Gln?Phe?Phe?Phe?Glu?Lys?His?Phe?Gly?Leu?Arg?Leu?Tyr?Gly?Phe?Phe65??????????????????70??????????????????75??????????????????80Asp?Tyr?Ala?His?Ala?Asn?Ser?Ile?Lys?Leu?Lys?Asn?Pro?Asn?Tyr?Asn
85??????????????????90??????????????????95Ser?Glu?Ala?Ala?Gln?Val?Ala?Ser?Gln?Ile?Leu?Gly?Lys?Gln?Glu?Ile
100?????????????????105?????????????????110Asn?Arg?Leu?Thr?Asn?Ile?Ala?Asp?Pro?Arg?Thr?Phe?Glu?Pro?Asn?Met
115?????????????????120?????????????????125Leu?Thr?Tyr?Gly?Gly?Ala?Met?Asp?Val?Met?Val?Asn?Val?Ile?Asn?Asn
130?????????????????135?????????????????140Gly?Ile?Met?Ser?Leu?Gly?Ala?Phe?Gly?Gly?Ile?Gln?Leu?Ala?Gly?Asn145?????????????????150?????????????????155?????????????????160Ser?Trp?Leu?Met?Ala?Thr?Pro?Ser?Phe?Glu?Gly?Ile?Leu?Val?Glu?Gln
165?????????????????170?????????????????175Ala?Leu?Val?Ser?Lys?Lys?Ala?Thr?Ser?Phe?Gln?Phe?Leu?Phe?Asn?Val
180?????????????????185?????????????????190Gly?Ala?Arg?Leu?Arg?Ile?Leu?Lys?His?Ser?Ser?Ile?Glu?Ala?Gly?Val
195?????????????????200?????????????????205Lys?Phe?Pro?Met?Leu?Lys?Lys?Asn?Pro?Tyr?Ile?Thr?Ala?Lys?Asn?Leu
The data of 210 215 220Asp Ile Gly Phe Arg Arg Val Tyr Ser Trp Tyr Val Asn Tyr Val Phe225,230 235 240Thr Phe (2) SEQ ID NO:117:
(ⅰ) sequence signature:
(A) length: 256 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..256
(ⅹ ⅰ) sequence description: SEQ ID NO:117:Met Gly Tyr Ala Ser Lys Leu Ala Leu Lys Ile Cys Leu Val Gly Leu1 5 10 15Cys Leu Phe Ser Thr Leu Gly Ala Glu His Leu Glu Gln Lys Gly Asn
20??????????????????25??????????????????30Tyr?Ile?Tyr?Lys?Gly?Glu?Glu?Ala?Tyr?Asn?Asn?Lys?Glu?Tyr?Glu?Arg
35??????????????????40??????????????????45Ala?Ala?Ser?Phe?Tyr?Lys?Ser?Ala?Ile?Lys?Asn?Gly?Glu?Ser?Leu?Ala
50??????????????????55??????????????????60Tyr?Ile?Leu?Leu?Gly?Ile?Met?Tyr?Glu?Asn?Gly?Arg?Gly?Val?Pro?Lys65??????????????????70??????????????????75??????????????????80Asp?Tyr?Lys?Lys?Ala?Val?Glu?Tyr?Phe?Gln?Lys?Ala?Val?Asp?Asn?Asp
85??????????????????90??????????????????95Ile?Pro?Arg?Gly?Tyr?Asn?Asn?Leu?Gly?Val?Met?Tyr?Lys?Glu?Gly?Lys
100?????????????????105?????????????????110Gly?Val?Pro?Lys?Asp?Glu?Lys?Lys?Ala?Val?Glu?Tyr?Phe?Arg?Ile?Ala
115?????????????????120?????????????????125Thr?Glu?Lys?Gly?Tyr?Thr?Asn?Ala?Tyr?Ile?Asn?Leu?Gly?Ile?Met?Tyr
130?????????????????135?????????????????140Met?Glu?Gly?Arg?Gly?Val?Pro?Ser?Asn?Tyr?Ala?Lys?Ala?Thr?Glu?Cys145?????????????????150?????????????????155?????????????????160Phe?Arg?Lys?Ala?Met?His?Lys?Gly?Asn?Val?Glu?Ala?Tyr?Ile?Leu?Leu
165?????????????????170?????????????????175Gly?Asp?Ile?Tyr?Tyr?Ser?Gly?Asn?Asp?Gln?Leu?Gly?Ile?Glu?Pro?Asp
180?????????????????185?????????????????190Lys?Asp?Lys?Ala?Val?Val?Tyr?Tyr?Lys?Met?Ala?Ala?Asp?Val?Ser?Ser
195?????????????????200?????????????????205Ser?Arg?Ala?Tyr?Glu?Gly?Leu?Ser?Glu?Ser?Tyr?Arg?Tyr?Gly?Leu?Gly
210?????????????????215?????????????????220Val?Glu?Lys?Asp?Lys?Lys?Lys?Ala?Glu?Glu?Tyr?Met?Gln?Lys?Ala?Cys225?????????????????230?????????????????235?????????????????240Asp?Phe?Asp?Zle?Asp?Lys?Asn?Cys?Lys?Lys?Lys?Asn?Thr?Ser?Ser?Arg
The data of 245 250 255 (2) SEQ ID NO:118:
(ⅰ) sequence signature:
(A) length: 657 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..657
(ⅹ ⅰ) sequence description: SEQ ID NO:118:Met Arg Lys Leu Phe Ile Pro Leu Leu Leu Phe Ser Ala Leu Glu Ala1 5 10 15Asn Glu Lys Asn Gly Phe Phe Ile Glu Ala Gly Phe Glu Thr Gly Leu
20??????????????????25??????????????????30Leu?Glu?Gly?Thr?Gln?Thr?Gln?Glu?Lys?Arg?His?Thr?Thr?Thr?Lys?Asn
35??????????????????40??????????????????45Thr?Tyr?Ala?Thr?Tyr?Ash?Tyr?Leu?Pro?Thr?Asp?Thr?Ile?Leu?Lys?Arg
50??????????????????55??????????????????60Ala?Ala?Asn?Leu?Phe?Thr?Asn?Ala?Glu?Ala?Ile?Ser?Lys?Leu?Lys?Phe65??????????????????70??????????????????75??????????????????80Ser?Ser?Leu?Ser?Pro?Val?Arg?Val?Leu?Tyr?Met?Tyr?Asn?Gly?Gln?Leu
85??????????????????90??????????????????95Thr?Ile?Glu?Asn?Phe?Leu?Pro?Tyr?Asn?Leu?Asn?Asn?Val?Lys?Leu?Ser
100?????????????????105?????????????????110Phe?Thr?Asp?Ala?Gln?Gly?Asn?Val?Ile?Asp?Leu?Gly?Val?Ile?Glu?Thr
115?????????????????120?????????????????125Ile?Pro?Lys?His?Ser?Lys?Ile?Val?Leu?Pro?Gly?Glu?Ala?Phe?Asp?Ser
130?????????????????135?????????????????140Leu?Lys?Ile?Asp?Pro?Tyr?Thr?Leu?Phe?Leu?Pro?Lys?Ile?Glu?Ala?Thr145?????????????????150?????????????????155?????????????????160Ser?Thr?Set?Ile?Ser?Asp?Ala?Asn?Thr?Gln?Arg?Val?Phe?Glu?Thr?Leu
165?????????????????170?????????????????175Asn?Lys?Ile?Lys?Thr?Asn?Leu?Val?Val?Asn?Tyr?Arg?Asn?Glu?Asn?Lys
180?????????????????185?????????????????190Phe?Lys?Asp?His?Glu?Asn?His?Trp?Glu?Ala?Phe?Thr?Pro?Gln?Thr?Ala
195?????????????????200?????????????????205Glu?Glu?Phe?Thr?Ash?Leu?Met?Leu?Asn?Met?Ile?Ala?Val?Leu?Asp?Ser
210?????????????????215?????????????????220Gln?Ser?Trp?Gly?Asp?Ala?Ile?Leu?Asn?Ala?Pro?Phe?Glu?Phe?Thr?Asn225?????????????????230?????????????????235?????????????????240Ser?Pro?Thr?Asp?Cys?Asp?Asn?Asp?Pro?Ser?Lys?Cys?Val?Asn?Pro?Gly
245?????????????????250?????????????????255Thr?Asn?Gly?Leu?Val?Asn?Ser?Lys?Val?Asp?Gln?Lys?Tyr?Val?Leu?Asn
260?????????????????265?????????????????270Lys?Gln?Asp?Ile?Val?Asn?Lys?Phe?Lys?Asn?Lys?Ala?Asp?Leu?Asp?Val
275?????????????????280?????????????????285Ile?Val?Leu?Lys?Asp?Ser?Gly?Val?Val?Gly?Leu?G1y?Ser?Asp?Ile?Thr
290?????????????????295?????????????????300Pro?Ser?Asn?Asn?Asp?Asp?Gly?Lys?His?Tyr?Gly?Gln?Leu?Gly?Val?Val305?????????????????310?????????????????315?????????????????320Ala?Ser?Ala?Leu?Asp?Pro?Lys?Lys?Leu?Phe?Gly?Asp?Asn?Leu?Lys?Thr
325?????????????????330?????????????????335Ile?Asn?Leu?Glu?Asp?Leu?Arg?Thr?Ile?Leu?His?Glu?Phe?Ser?His?Thr
340?????????????????345?????????????????350Lys?Gly?Tyr?Gly?His?Asn?Gly?Asn?Met?Thr?Tyr?Gln?Arg?Val?Pro?Val
355?????????????????360?????????????????365Thr?Lys?Asp?Gly?Gln?Val?Glu?Lys?Asp?Ser?Asn?Gly?Lys?Pro?Lys?Asp
370?????????????????375?????????????????380Ser?Asp?Gly?Leu?Pro?Tyr?Asn?Val?Cys?Ser?Leu?Tyr?Gly?Gly?Ser?Asn385?????????????????390?????????????????395?????????????????400Gln?Pro?Ala?Phe?Pro?Ser?Asn?Tyr?Pro?Asn?Ser?Ile?Tyr?His?Asn?Cys
405?????????????????410?????????????????415Ala?Asp?Val?Pro?Ala?Gly?Phe?Leu?Gly?Val?Thr?Ala?Ala?Val?Trp?Gln
420?????????????????425?????????????????430Gln?Leu?Ile?Asn?Gln?Asn?Ala?Leu?Pro?Ile?Asn?Tyr?Ala?Asn?Leu?Gly
435?????????????????440?????????????????445Ser?Gln?Thr?Asn?Tyr?Asn?Leu?Asn?Ala?Ser?Leu?Asn?Thr?Gln?Asp?Leu
450?????????????????455?????????????????460Ala?Asn?Ser?Met?Leu?Ser?Thr?Ile?Gln?Lys?Thr?Phe?Val?Thr?Ser?Ser465?????????????????470?????????????????475?????????????????480Val?Thr?Asn?His?His?Phe?Ser?Asn?Ala?Ser?Gln?Ser?Phe?Arg?Ser?Pro
485?????????????????490?????????????????495Ile?Leu?Gly?Val?Asn?Ala?Lys?Ile?Gly?Tyr?Gln?Asn?Tyr?Phe?Asn?Asp
500?????????????????505?????????????????510Phe?Ile?Gly?Leu?Ala?Tyr?Tyr?Gly?Ile?Ile?Lys?Tyr?Asn?Tyr?Ala?Lys
515?????????????????520?????????????????525Ala?Val?Asn?Gln?Lys?Val?Gln?Gln?Leu?Ser?Tyr?Gly?Gly?Gly?Ile?Asp
530?????????????????535?????????????????540Leu?Leu?Leu?Asp?Phe?Ile?Thr?Thr?Tyr?Ser?Asn?Lys?Asn?Ser?Pro?Thr545?????????????????550?????????????????555?????????????????560Gly?Ile?Gln?Thr?Lys?Arg?Asn?Phe?Ser?Ser?Ser?Phe?Gly?Ile?Phe?Gly
565?????????????????570?????????????????575Gly?Leu?Arg?Gly?Leu?Tyr?Asn?Ser?Tyr?Tyr?Val?Leu?Asn?Lys?Val?Lys
580?????????????????585?????????????????590Gly?Ser?Gly?Asn?Leu?Asp?Val?Ala?Thr?Gly?Leu?Asn?Tyr?Arg?Tyr?Lys
595?????????????????600?????????????????605His?Ser?Lys?Tyr?Ser?Val?Gly?Ile?Ser?Ile?Pro?Leu?Ile?Gln?Arg?Lys
610?????????????????615?????????????????620Ala?Ser?Val?Val?Ser?Ser?Gly?Gly?Asp?Tyr?Thr?Asn?Ser?Phe?Val?Phe625?????????????????630?????????????????635?????????????????640Asn?Glu?Gly?Ala?Ser?His?Phe?Lys?Val?Phe?Phe?Asn?Tyr?Gly?Trp?Val
The data of 645 650 655Phe (2) SEQ ID NO:119:
(ⅰ) sequence signature:
(A) length: 167 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..167
(ⅹ ⅰ) sequence description: SEQ ID NO:119:Met Lys Leu Val Ser Leu Ile Val Ala Leu Val Phe Cys Cys Phe Leu1 5 10 15Gly Ala Val Glu Leu Pro Gly Val Tyr Gln Thr Gln Glu Phe Leu Tyr
20??????????????????25??????????????????30Met?Lys?Ser?Ser?Phe?Val?Glu?Phe?Phe?Glu?His?Asn?Gly?Lys?Phe?Tyr
35??????????????????40??????????????????45Ala?Tyr?Gly?Ile?Ser?Asp?Val?Asp?Gly?Ser?Lys?Ala?Lys?Lys?Asp?Lys
50??????????????????55??????????????????60Leu?Asn?Pro?Asn?Pro?Lys?Leu?Arg?Asn?Arg?Ser?Asp?Lys?Gly?Val?Val65??????????????????70??????????????????75??????????????????80Phe?Leu?Ser?Asp?Leu?Ile?Lys?Val?Gly?Glu?Gln?Ser?Tyr?Lys?Gly?Gly
85??????????????????90??????????????????95Lys?Ala?Tyr?Asn?Phe?Tyr?Asp?Gly?Lys?Thr?Tyr?His?Val?Arg?Val?Thr
100?????????????????105?????????????????110Gln?Asn?Ser?Asn?Gly?Asp?Leu?Glu?Phe?Thr?Ser?Ser?Tyr?Asp?Lys?Trp
115?????????????????120?????????????????125Gly?Tyr?Val?Gly?Lys?Thr?Phe?Thr?Trp?Lys?Arg?Leu?Ser?Asp?Glu?Glu
130?????????????????135?????????????????140Ile?Lys?Asn?Leu?Lys?Leu?Lys?Arg?Phe?Asn?Leu?Asp?Glu?Val?Leu?Lys145?????????????????150?????????????????155?????????????????160Thr?Leu?Lys?Asp?Ser?Pro?Ile
The data of 165 (2) SEQ ID NO:120:
(ⅰ) sequence signature:
(A) length: 294 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..294
(ⅹ ⅰ) sequence description: SEQ ID NO:120:Met Ser Asn Gln Ala Ser His Leu Asp Asn Phe Met Asn Ala Lys Asn1 5 10 15Pro Lys Ser Phe Phe Asp Asn Lys Gly Asn Thr Lys Phe Ile Ala lle
20??????????????????25??????????????????30Thr?Ser?Gly?Lys?Gly?Gly?Val?Gly?Lys?Ser?Asn?Ile?Ser?Ala?Asn?Leu
35??????????????????40??????????????????45Ala?Tyr?Ser?Leu?Tyr?Lys?Lys?Gly?Tyr?Lys?Val?Gly?Val?Phe?Asp?Ala
50??????????????????55??????????????????60Asp?Ile?Gly?Leu?Ala?Asn?Leu?Asp?Val?Ile?Phe?Gly?Val?Lys?Thr?His65??????????????????70??????????????????75??????????????????80Lys?Asn?Ile?Leu?His?Ala?Leu?Lys?Gly?Glu?Ala?Lys?Leu?Gln?Glu?Ile
85??????????????????90??????????????????95Ile?Cys?Glu?Ile?Glu?Pro?Gly?Leu?Cys?Leu?Ile?Pro?Gly?Asp?Ser?Gly
100?????????????????105?????????????????110Glu?Glu?Ile?Leu?Lys?Tyr?Ile?Ser?Gly?Ala?Glu?Ala?Leu?Asp?Arg?Phe
115?????????????????120?????????????????125Val?Asp?Glu?Glu?Gly?Val?Leu?Ser?Ser?Leu?Asp?Tyr?Ile?Val?Ile?Asp
130?????????????????135?????????????????140Thr?Gly?Ala?Gly?Ile?Gly?Ala?Thr?Thr?Gln?Ala?Phe?Leu?Asn?Ala?Ser145?????????????????150?????????????????155?????????????????160Asp?Cys?Val?Val?Ile?Val?Thr?Thr?Pro?Asp?Pro?Ser?Ala?Ile?Thr?Asp
165?????????????????170?????????????????175Ala?Tyr?Ala?Cys?Ile?Lys?Ile?Asn?Ser?Lys?Asn?Lys?Asp?Glu?Leu?Phe
180?????????????????185?????????????????190Leu?Ile?Ala?Asn?Met?Val?Ala?Gln?Pro?Lys?Glu?Gly?Arg?Ala?Thr?Tyr
195?????????????????200?????????????????205Glu?Arg?Leu?Phe?Lys?Val?Ala?Lys?Asn?Asn?Ile?Ala?Ser?Leu?Glu?Leu
210?????????????????215?????????????????220His?Tyr?Leu?Gly?Ala?Ile?Glu?Asn?Ser?Ser?Leu?Leu?Lys?Arg?Tyr?Val225?????????????????230?????????????????235?????????????????240Arg?Glu?Arg?Lys?Ile?Leu?Arg?Lys?Ile?Ala?Pro?Asn?Asp?Leu?Phe?Ser
245?????????????????250?????????????????255Gln?Ser?Ile?Asp?Gln?Ile?Ala?Ser?Leu?Leu?Val?Ser?Lys?Leu?Glu?Thr
260?????????????????265?????????????????270Gly?Thr?Leu?Glu?Ile?Pro?Lys?Glu?Gly?Leu?Lys?Ser?Phe?Phe?Lys?Arg
275?????????????????280?????????????????285Leu?Leu?Lys?Tyr?Leu?Gly
The data of 290 (2) SEQ ID NO:121:
(ⅰ) sequence signature:
(A) length: 372 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..372
(ⅹ ⅰ) sequence description: SEQ ID NO:121:Leu Glu Pro Ser Arg Asn Arg Leu Lys His Ala Ala Phe Phe Val Gly1 5 10 15Leu Phe Ile Val Leu Phe Leu Ile Ile Met Lys His Gln Thr Ser Pro
20??????????????????25??????????????????30Tyr?Ala?Phe?Thr?His?Asn?Gln?Ala?Leu?Val?Thr?Gln?Thr?Pro?Pro?Tyr
35??????????????????40??????????????????45Phe?Thr?Gln?Leu?Thr?Ile?Pro?Lys?Pro?Asn?Asp?Ala?Leu?Ser?Ala?His
50??????????????????55??????????????????60Ala?Ser?Ser?Leu?Ile?Ser?Leu?Pro?Asn?Asp?Asn?Leu?Leu?Ser?Ala?Tyr65??????????????????70??????????????????75??????????????????80Phe?Ser?Gly?Thr?Lys?Glu?Gly?Ala?Arg?Asp?Val?Lys?Ile?Ser?Ala?Asn
85??????????????????90??????????????????95Leu?Phe?Asp?Ser?Lys?Thr?Asn?Arg?Trp?Ser?Glu?Ala?Phe?Ile?Leu?Leu
100?????????????????105?????????????????110Thr?Lys?Glu?Glu?Leu?Ser?His?His?Ser?His?Glu?Tyr?Ile?Lys?Lys?Leu
115?????????????????120?????????????????125Gly?Asn?Pro?Leu?Leu?Phe?Leu?His?Asp?Asn?Lys?Ile?Leu?Leu?Phe?Val
130?????????????????135?????????????????140Val?Gly?Val?Ser?Met?Gly?Gly?Trp?Ala?Thr?Ser?Lys?Ile?Tyr?Gln?Phe145?????????????????150?????????????????155?????????????????160Glu?Ser?Ala?Leu?Glu?Pro?Ile?His?Phe?Lys?Phe?Ala?Arg?Lys?Leu?Ser
165?????????????????170?????????????????175Leu?Ser?Pro?Phe?Leu?Asn?Leu?Ser?His?Leu?Val?Arg?Asn?Lys?Pro?Leu
180?????????????????185?????????????????190Asn?Thr?Thr?Asp?Gly?Gly?Phe?Met?Leu?Pro?Leu?Tyr?His?Glu?Leu?Ala
195?????????????????200?????????????????205Thr?Gln?Tyr?Pro?Leu?Leu?Leu?Lys?Phe?Asp?Gln?Gln?Asn?Asn?Pro?Arg
210?????????????????215?????????????????220Glu?Leu?Leu?Arg?Pro?Asn?Thr?Leu?Asn?His?Gln?Leu?Gln?Pro?Ser?Leu225?????????????????230?????????????????235?????????????????240Thr?Pro?Phe?Lys?Asp?Cys?Ala?Val?Met?Ala?Phe?Arg?Asn?His?Ser?Phe
245?????????????????250?????????????????255Lys?Asp?Ser?Leu?Met?Leu?Glu?Thr?Cys?Lys?Thr?Pro?Thr?Asp?Trp?Gln
260?????????????????265?????????????????270Lys?Pro?Ile?Ser?Thr?Asn?Leu?Lys?Asn?Leu?Asp?Asp?Ser?Leu?Asn?Leu
275?????????????????280?????????????????285Leu?Asn?Leu?Asn?Gly?Ile?Leu?Tyr?Leu?Ile?His?Asn?Pro?Ser?Asp?Leu
290?????????????????295?????????????????300Ser?Leu?Arg?Arg?Lys?Glu?Leu?Trp?Leu?Ser?Lys?Leu?Glu?Asn?Ser?Asn305?????????????????310?????????????????315?????????????????320Ser?Phe?Lys?Thr?Leu?Lys?Val?Leu?Asp?Lys?Ala?Asn?Glu?Val?Ser?Tyr
325?????????????????330?????????????????335Pro?Ser?Tyr?Ser?Leu?Asn?Pro?His?Phe?Ile?Asp?Ile?Val?Tyr?Thr?Tyr
340?????????????????345?????????????????350Asn?Arg?Ser?His?Ile?Lys?His?Ile?Arg?Phe?Asn?Met?Ala?Tyr?Leu?Asn
355?????????????????360?????????????????365Ser?Leu?Leu?Lys
The data of 370 (2) SEQ ID NO:122:
(ⅰ) sequence signature:
(A) length: 978 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori (ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..978 (ⅹ ⅰ) sequence description: SEQ ID NO:122:Met Lys Lys Arg Lys His Val Ser Lys Lys Val Phe Asn Val Ile Ile1 5 10 15Leu Phe Val Ala Val Phe Thr Leu Leu Val Val Ile His Lys Thr Leu
20??????????????????25??????????????????30Ser?Asn?Gly?Ile?His?Ile?Gln?Asn?Leu?Lys?Ile?Gly?Lys?Leu?Gly?Ile
35??????????????????40??????????????????45Ser?Glu?Leu?Tyr?Leu?Lys?Leu?Asn?Asn?Lys?Leu?Ser?Leu?Glu?Val?Glu
50??????????????????55??????????????????60Arg?Val?Asp?Leu?Ser?Ser?Phe?Phe?His?Gln?Lys?Pro?Thr?Lys?Lys?Arg65??????????????????70??????????????????75??????????????????80Leu?Glu?Val?Ser?Asp?Leu?Ile?Lys?Asn?Ile?Arg?Tyr?Gly?Ile?Trp?Ala
85??????????????????90??????????????????95Val?Ser?Tyr?Phe?Glu?Lys?Leu?Lys?Val?Lys?Glu?Ile?Ile?Leu?Asp?Asp
100?????????????????105?????????????????110Lys?Asn?Lys?Ala?Asn?Ile?Phe?Phe?Asp?Gly?Asn?Lys?Tyr?Glu?Leu?Glu
115?????????????????120?????????????????125Phe?Pro?Gly?Ile?Lys?Gly?Glu?Phe?Ser?Leu?Glu?Asp?Asp?Lys?Asn?Ile
130?????????????????135?????????????????140Lys?Leu?Lys?Ile?Ile?Asn?Leu?Leu?Phe?Lys?Asp?Val?Lys?Val?Gln?Val145?????????????????150?????????????????155?????????????????160Asp?Gly?Asn?Ala?His?Tyr?Ser?Pro?Lys?Ala?Arg?Lys?Met?Ala?Phe?Asn
165?????????????????170?????????????????175Leu?Ile?Val?Lys?Pro?Leu?Val?Glu?Pro?Ser?Ala?Ala?Ile?Tyr?Leu?Gln
180?????????????????185?????????????????190Gly?Leu?Thr?Asp?Leu?Lys?Thr?Ile?Glu?Leu?Lys?Ile?Asn?Thr?Ser?Pro
195?????????????????200?????????????????205Met?Lys?Ser?Leu?Ala?Phe?Leu?Lys?Pro?Leu?Phe?Gln?Arg?Gln?Ser?Gln
210?????????????????215?????????????????220Lys?Asn?Leu?Lys?Thr?Trp?Ile?Phe?Asp?Lys?Ile?Gln?Phe?Ala?Ser?Phe225?????????????????230?????????????????235?????????????????240Lys?Ile?Asp?Asn?Ala?Leu?Ile?Lys?Ala?Asn?Phe?Thr?Pro?Ser?Glu?Phe
245?????????????????250?????????????????255Ile?Pro?Ser?Leu?Leu?Glu?Asn?Ser?Val?Val?Lys?Ala?Thr?Leu?Ile?Lys
260?????????????????265?????????????????270Pro?Ser?Val?Val?Phe?Asn?Asp?Gly?Leu?Ser?Pro?Ile?Lys?Met?Asp?Lys
275?????????????????280?????????????????285Thr?Glu?Leu?Ile?Phe?Lys?Asn?Lys?Gln?Leu?Leu?Ile?Gln?Pro?Gln?Lys
290?????????????????295?????????????????300Ile?Thr?Tyr?Glu?Thr?Met?Glu?Leu?Thr?Gly?Ser?Tyr?Ala?Thr?Phe?Ser305?????????????????310?????????????????315?????????????????320Asn?Leu?Leu?Glu?Ala?Pro?Lys?Leu?Glu?Val?Phe?Leu?Lys?Thr?Thr?Pro
325?????????????????330?????????????????335Asn?Tyr?Tyr?Gly?Asp?Ser?Ile?Lys?Asp?Leu?Leu?Ser?Ala?Tyr?Lys?Val
340?????????????????345?????????????????350Val?Leu?Pro?Leu?Asp?Lys?Ile?Ser?Met?Pro?Ser?Ser?Ala?Asp?Leu?Lys
355?????????????????360?????????????????365Leu?Thr?Leu?Gln?Phe?Leu?Lys?Asn?Thr?Ala?Pro?Leu?Phe?Ser?Val?Gln
370?????????????????375?????????????????380Gly?Ser?Val?Asn?Leu?Gln?Glu?Gly?Thr?Phe?Ser?Leu?Tyr?Asn?Ile?Pro385?????????????????390?????????????????395?????????????????400Leu?Tyr?Thr?Gln?Ser?Ala?Gln?Ile?Asn?Leu?Asp?Ile?Ala?Gln?Glu?Tyr
405?????????????????410?????????????????415Gln?Tyr?Ile?Tyr?Ile?Asp?Thr?Ile?His?Thr?Arg?Tyr?Ala?Asn?Met?Leu
420?????????????????425?????????????????430Asp?Leu?Asp?Ala?Lys?Ile?Ala?Leu?Asp?Leu?Gly?Gln?Lys?Asn?Leu?Ser
435?????????????????440?????????????????445Leu?Asp?Ser?Leu?Val?His?Lys?Ile?Gln?Val?Asn?Thr?Asn?Asn?Asn?Ile
450?????????????????455?????????????????460Asn?Met?Arg?Ser?Tyr?Asp?Pro?Asn?Asn?Thr?Gln?Glu?Asp?Pro?Gln?Thr465?????????????????470?????????????????475?????????????????480Asn?Phe?Thr?Leu?Asp?Leu?Lys?Ser?Leu?His?Ser?Ile?Ile?Gln?Glu?Gly
485?????????????????490?????????????????495Glu?Asn?Ser?Glu?Val?Phe?Arg?Arg?Lys?Ile?Ile?Asp?Thr?Ile?Lys?Ala
500?????????????????505?????????????????510Gln?Ser?Glu?Asp?Lys?Phe?Thr?Lys?Asp?Val?Phe?Tyr?Ala?Thr?Gly?Asp
515?????????????????520?????????????????525Thr?Leu?Lys?Ser?Leu?Ser?Leu?Ser?Phe?Asp?Phe?Ser?Asn?Pro?Asp?His
530?????????????????535?????????????????540Ile?Gln?Trp?Ser?Val?Pro?Gln?Leu?Leu?Leu?Glu?Gly?Glu?Phe?Lys?Asp545?????????????????550?????????????????555?????????????????560Asn?Ala?Tyr?Thr?Phe?Lys?Ile?Lys?Asp?Leu?Lys?Lys?Ile?Lys?Pro?Tyr
565?????????????????570?????????????????575Ser?Pro?Ile?Met?Asp?Tyr?Ile?Ala?Leu?Lys?Asp?Gly?Ser?Leu?Glu?Val
580?????????????????585?????????????????590Ser?Thr?Ser?Asp?Phe?Val?Asn?Ile?Asp?Phe?Phe?Ala?Lys?Asp?Leu?Lys
595?????????????????600?????????????????605Ile?Asn?Leu?Pro?Ile?Tyr?Arg?Ser?Asp?Gly?Ser?His?Phe?Asp?Ser?Phe
610?????????????????615?????????????????620Ser?Leu?Phe?Gly?Ser?Ile?Asn?Lys?Asp?Glu?Ile?Ser?Val?Tyr?Thr?Pro625?????????????????630?????????????????635?????????????????640Ser?Lys?Ser?Ile?Ser?Ile?Lys?Val?Lys?Gly?Asp?Gln?Lys?Asp?Ile?Thr
645?????????????????650?????????????????655Leu?Asn?Asn?Ile?Asp?Leu?Ser?Ile?Asp?Asp?Phe?Leu?Asp?Ser?Lys?Met
660?????????????????665?????????????????670Pro?Ala?Ile?Ala?Gly?Leu?Phe?Ser?Lys?Glu?Arg?Lys?Glu?Lys?Pro?Ser
675?????????????????680?????????????????685Ser?Lys?Glu?Ile?Gln?Asp?Glu?Asp?Val?Phe?Ile?Ser?Ala?Lys?Gln?Arg
690?????????????????695?????????????????700Tyr?Glu?Lys?Ala?His?Lys?Ile?Ile?Pro?Ile?Ser?Thr?Arg?Ile?His?Ala705?????????????????710?????????????????715?????????????????720Lys?Asp?Val?Val?Leu?Ile?Tyr?Lys?Lys?Met?Pro?Phe?Pro?Leu?Glu?Asn
725?????????????????730?????????????????735Leu?Asp?Ile?Val?Ala?Gln?Asp?Asp?Arg?Val?Lys?Ile?Asp?Gly?Asn?Tyr
740?????????????????745?????????????????750Lys?Asn?Ala?Met?Ile?Met?Ala?Asp?Leu?Val?His?Gly?Ala?Leu?Tyr?Leu
755?????????????????760?????????????????765Lys?Ala?His?Asn?Phe?Ser?Gly?Asp?Tyr?Ile?Asn?Thr?Ile?Leu?Gln?Lys
770?????????????????775?????????????????780Asp?Phe?Val?Glu?Gly?Gly?Leu?Phe?Thr?Leu?Ile?Gly?Ala?Leu?Glu?Asp785?????????????????790?????????????????795?????????????????800Gln?Val?Phe?Asn?Gly?Glu?Leu?Lys?Phe?Gln?Asn?Thr?Ser?Leu?Lys?Asn
805?????????????????810?????????????????815Phe?Ala?Leu?Met?Gln?Asn?Met?Val?Asn?Leu?Ile?Asn?Thr?Ile?Pro?Ser
820?????????????????825?????????????????830Leu?Ile?Val?Phe?Arg?Asn?Pro?His?Leu?Gly?Ala?Asn?Gly?Tyr?Gln?Ile
835?????????????????840?????????????????845Lys?Thr?Gly?Ser?Val?Val?Phe?Gly?Ile?Thr?Lys?Glu?Tyr?Leu?Gly?Leu
850?????????????????855?????????????????860Glu?Lys?Ile?Asp?Leu?Val?Gly?Lys?Thr?Leu?Asp?Ile?Ala?Gly?Asn?Gly865?????????????????870?????????????????875?????????????????880Ile?Ile?Glu?Leu?Asp?Lys?Asn?Lys?Leu?Asp?Leu?Asn?Leu?Glu?Val?Ser
885?????????????????890?????????????????895Thr?Ile?Lys?Ala?Leu?Ser?Asn?Val?Leu?Asn?Lys?Ile?Pro?Ile?Val?Gly
900?????????????????905?????????????????910Tyr?Leu?Val?Leu?Gly?Lys?Gly?Gly?Lys?Ile?Thr?Thr?Asn?Val?Asn?Val
915?????????????????920?????????????????925Lys?Gly?Thr?Leu?Asp?Lys?Pro?Lys?Thr?Gln?Val?Thr?Leu?Ala?Ser?Asp
930?????????????????935?????????????????940Ile?Ile?Gln?Ala?Pro?Phe?Lys?Ile?Leu?Arg?Arg?Ile?Phe?Thr?Pro?Ile945?????????????????950?????????????????955?????????????????960Asp?Ile?Ile?Val?Asp?Glu?Val?Lys?Lys?Asn?Ile?Asp?Ser?Lys?Arg?Lys
The data of 965 970 975Leu Lys (2) SEQ ID NO:123:
(ⅰ) sequence signature:
(A) length: 477 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..477
(ⅹ ⅰ) sequence description: SEQ ID NO:123:Met Asn Thr Ile Ile Arg Tyr Ala Ser Leu Trp Gly Leu Cys Ile Thr1 5 10 15Leu Thr Leu Ala Gln Thr Pro Ser Lys Thr Pro Asp Glu Ile Lys Gln
20??????????????????25??????????????????30Ile?Leu?Asn?Asn?Tyr?Ser?His?Lys?Asn?Leu?Lys?Leu?Ile?Asp?Pro?Pro
35??????????????????40??????????????????45Thr?Ser?Ser?Leu?Glu?Ala?Thr?Pro?Gly?Phe?Leu?Pro?Ser?Pro?Lys?Glu
50??????????????????55??????????????????60Thr?Ala?Thr?Thr?Ile?Asn?Gln?Glu?Ile?Ala?Lys?Tyr?His?Glu?Lys?Ser65??????????????????70??????????????????75??????????????????80Asp?Lys?Ala?Ala?Leu?Gly?Leu?Tyr?Glu?Leu?Leu?Lye?Gly?Ala?Thr?Thr
85??????????????????90??????????????????95Asn?Leu?Ser?Leu?Gln?Ala?Gln?Glu?Leu?Ser?Val?Lys?Gln?Ala?Met?Lys
100?????????????????105?????????????????110Asn?His?Thr?Ile?Ala?Lys?Ala?Met?Phe?Leu?Pro?Thr?Leu?Asn?Ala?Ser
115?????????????????120?????????????????125Tyr?Asn?Phe?Lys?Asn?Glu?Ala?Arg?Asp?Thr?Pro?Glu?Tyr?Lys?His?Tyr
130?????????????????135?????????????????140Asn?Thr?Gln?Gln?Leu?Gln?Ala?Gln?Val?Thr?Leu?Asn?Val?Phe?Asn?Gly145?????????????????150?????????????????155?????????????????160Phe?Ser?Asn?Val?Asn?Asn?Val?Lys?Glu?Lys?Ser?Ala?Thr?Tyr?Arg?Ser
165?????????????????170?????????????????175Thr?Val?Ala?Asn?Leu?Glu?Tyr?Ser?Arg?Gln?Ser?Val?Tyr?Leu?Gln?Val
180?????????????????185?????????????????190Val?Gln?Gln?Tyr?Tyr?Glu?Tyr?Phe?Asn?Asn?Leu?Ala?Arg?Met?Ile?Ala
195?????????????????200?????????????????205Leu?Gln?Lys?Lys?Leu?Glu?Gln?Ile?Gln?Thr?Asp?Ile?Lys?Arg?Val?Thr
210?????????????????215?????????????????220Lys?Leu?Tyr?Asp?Lys?Gly?Leu?Thr?Thr?Ile?Asp?Asp?Leu?Gln?Ser?Leu225?????????????????230?????????????????235?????????????????240Lys?Ala?Gln?Gly?Asn?Leu?Ser?Glu?Tyr?Asp?Ile?Leu?Asp?Met?Gln?Phe
245?????????????????250?????????????????255Ala?Leu?Glu?Gln?Asn?Arg?Leu?Thr?Leu?Glu?Tyr?Leu?Thr?Asn?Leu?Ser
260?????????????????265?????????????????270Val?Lys?Asn?Leu?Lys?Lys?Thr?Thr?Ile?Asp?Ala?Pro?Asn?Leu?Gln?Leu
275?????????????????280?????????????????285Arg?Glu?Arg?Gln?Asp?Leu?Val?Ser?Leu?Arg?Glu?Gln?Ile?Ser?Ala?Leu
290?????????????????295?????????????????300Arg?Tyr?Gln?Asn?Lys?Gln?Leu?Asn?Tyr?Tyr?Pro?Lys?Ile?Asp?Val?Phe305?????????????????310?????????????????315?????????????????320Asp?Ser?Trp?Leu?Phe?Trp?Ile?Gln?Lys?Pro?Ala?Tyr?Ala?Thr?Gly?Arg
325?????????????????330?????????????????335Phe?Gly?Asn?Phe?Tyr?Pro?Gly?Gln?Gln?Asn?Thr?Ala?Gly?Val?Thr?Ala
340?????????????????345?????????????????350Thr?Leu?Asn?Ile?Phe?Asp?Asp?Ile?Gly?Leu?Ser?Leu?Gln?Lys?Gln?Ser
355?????????????????360?????????????????365Ile?Met?Leu?Gly?Gln?Leu?Ala?Asn?Glu?Lys?Asn?Leu?Ala?Tyr?Lys?Lys
370?????????????????375?????????????????380Leu?Glu?Gln?Glu?Lys?Asp?Glu?Gln?Leu?Tyr?Arg?Lys?Ser?Leu?Asp?Ile385?????????????????390?????????????????395?????????????????400Ala?Arg?Ala?Lys?Ile?Glu?Ser?Ser?Lys?Ala?Ser?Leu?Asp?Ala?Ala?Asn
405?????????????????410?????????????????415Leu?Ser?Phe?Ala?Asn?Ile?Lys?Arg?Lys?Tyr?Asp?Ala?Asn?Leu?Val?Asp
420?????????????????425?????????????????430Phe?Thr?Thr?Tyr?Leu?Arg?Gly?Leu?Thr?Thr?Arg?Phe?Asp?Ala?Glu?Val
435?????????????????440?????????????????445Ala?Tyr?Asn?Leu?Ala?Leu?Asn?Asn?Tyr?Glu?Val?Gln?Lys?Ala?Asn?Tyr
The data of 450 455 460Ile Phe Asn Ser Gly His Lys Ile Asp Asp Tyr Val His465,470 475 (2) SEQ ID NO:124:
(ⅰ) sequence signature:
(A) length: 412 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..412
(ⅹ ⅰ) sequence description: SEQ ID NO:124:Met Leu Ser Phe Ile Ser Ala Phe Asp Lys Arg Gly Val Ser Ile Arg1 5 10 15Leu Leu Thr Ala Leu Leu Leu Leu Phe Ser Leu Gly Leu Ala Lys Asp
20??????????????????25??????????????????30Leu?Glu?Ile?Gln?Thr?Phe?Val?Ala?Lys?Tyr?Leu?Ser?Lys?Asn?Gln?Lys
35??????????????????40??????????????????45Ile?Gln?Ala?Leu?Gln?Glu?Gln?Ile?Asp?Ala?Leu?Asp?Ser?Gln?Glu?Lys
50??????????????????55??????????????????60Val?Val?Ser?Lys?Trp?Asp?Asn?Pro?Ile?Leu?Tyr?Leu?Gly?Tyr?Asn?Asn65??????????????????70??????????????????75??????????????????80Ala?Asn?Val?Ser?Asp?Phe?Phe?Arg?Leu?Asp?Ser?Thr?Leu?Met?Gln?Asn
85??????????????????90??????????????????95Met?Ser?Leu?Gly?Leu?Ser?Gln?Lys?Val?Asp?Leu?Asn?Gly?Lys?Lys?Leu
100?????????????????105?????????????????110Thr?Gln?Ser?Lys?Met?Ile?Asn?Leu?Glu?Lys?Gln?Lys?Lys?Ile?Leu?Glu
115?????????????????120?????????????????125Leu?Lys?Lys?Thr?Lys?Gln?Gln?Leu?Val?Ile?Asn?Leu?Met?Ile?Asn?Gly
130?????????????????135?????????????????140Ile?Glu?Asn?Tyr?Lys?Asn?Gln?Gln?Glu?Ile?Glu?Leu?Leu?Asn?Thr?Ala145?????????????????150?????????????????155?????????????????160Ile?Lys?Asn?Leu?Glu?Asn?Thr?Leu?Tyr?Gln?Ala?Asn?His?Ser?Ser?Ser
165?????????????????170?????????????????175Pro?Asp?Leu?Ile?Ala?Ile?Ala?Lys?Leu?Glu?Ile?Leu?Lys?Ser?Leu?Leu
180?????????????????185?????????????????190Glu?Ile?Gln?Lys?Asn?Asp?Leu?Glu?Val?Ala?Leu?Ser?Ser?Ser?His?Tyr
195?????????????????200?????????????????205Ser?Met?Gly?Glu?Leu?Thr?Phe?Lys?Glu?Asn?Glu?Ile?Leu?Ser?Ile?Ala
210?????????????????215?????????????????220Pro?Lys?Asn?Phe?Glu?Phe?Asn?Asn?Glu?Gln?Glu?Leu?His?Asn?Ile?Ser225?????????????????230?????????????????235?????????????????240Ala?Thr?Asn?Tyr?Asp?Ile?Ala?Ile?Ala?Arg?Leu?Asp?Glu?Glu?Lys?Ala
245?????????????????250?????????????????255Gln?Lys?Asp?Ile?Thr?Leu?Ala?Lys?Lys?Ser?Phe?Leu?Glu?Asp?Ile?Asn
260?????????????????265?????????????????270Val?Thr?Gly?Val?Tyr?Tyr?Phe?Arg?Ser?Lys?Gln?Tyr?Tyr?Asn?Tyr?Asp
275?????????????????280?????????????????285Met?Phe?Ser?Val?Ala?Leu?Ser?Ile?Pro?Leu?Pro?Leu?Tyr?Gly?Lys?Gln
290?????????????????295?????????????????300Ala?Lys?Leu?Val?Glu?Gln?Lys?Lys?Lys?Glu?Ser?Leu?Ala?Phe?Lys?Ser305?????????????????310?????????????????315?????????????????320Glu?Val?Glu?Asn?Ala?Lys?Asn?Lys?Thr?Arg?His?Leu?Ala?Leu?Lys?Leu
325?????????????????330?????????????????335Leu?Lys?Lys?Leu?Glu?Thr?Leu?Gln?Lys?Asn?Leu?Glu?Ser?Ile?Asn?Lys
340?????????????????345?????????????????350Ile?Ile?Lys?Gln?Asn?Glu?Lys?Ile?Ala?Gln?Ile?Tyr?Ala?Leu?Asp?Leu
355?????????????????360?????????????????365Lys?Thr?Asn?Gly?Asp?Tyr?Asn?Ala?Trr?Tyr?Asn?Ala?Leu?Asn?Asp?Lys
370?????????????????375?????????????????380Ile?Thr?Ile?Gln?Ile?Thr?Gln?Leu?Glu?Thr?Leu?Ser?Ala?Leu?Asn?Ser385?????????????????390?????????????????395?????????????????400Ala?Tyr?Leu?Ser?Leu?Gln?Asn?Leu?Lys?Gly?Leu?Glu
The data of 405 410 (2) SEQ ID NO:125:
(ⅰ) sequence signature:
(A) length: 137 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..137
(ⅹ ⅰ) sequence description: SEQ ID NO:125:Met Arg Ile Val Arg Asn Leu Phe Leu Val Ser Phe Val Ala Tyr Ser1 5 10 15Ser Ala Phe Ala Ala Asp Leu Glu Thr Gly Thr Lys Asn Asp Lys Lys
20??????????????????25??????????????????30Ser?Gly?Lys?Lys?Phe?Tyr?Lys?Leu?His?Lys?Asn?His?Gly?Ser?Glu?Thr
35??????????????????40??????????????????45Glu?Thr?Lys?Asn?Asp?Lys?Lys?Leu?Tyr?Asp?Phe?Thr?Lys?Asn?Ser?Gly
50??????????????????55??????????????????60Leu?Glu?G1y?Val?Asp?Leu?Glu?Lys?Ser?Pro?Asn?Leu?Lys?Ser?His?Lys65??????????????????70??????????????????75??????????????????80Lys?Ser?Asp?Lys?Lys?Phe?Tyr?Lys?Gln?Leu?Ala?Lys?Asn?Asn?Ile?Ala
85??????????????????90??????????????????95Glu?Gly?Val?Ser?Met?Pro?Ile?Val?Asn?Phe?Asn?Lys?Ala?Leu?Ser?Phe
100?????????????????105?????????????????110G1y?pro?Tyr?Phe?Glu?Arg?Thr?Lys?Ser?Lys?Lys?Thr?Gln?Tyr?Met?Asp
115?????????????????120?????????????????125Gly?Gly?Leu?Met?Met?His?Ile?Arg?Phe
The data of 130 135 (2) SEQ ID NO:126:
(ⅰ) sequence signature:
(A) length: 309 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..309
(ⅹ ⅰ) sequence description: SEQ ID NO:126:Leu Met Pro Gln Asn Gln Leu Val Ile Thr Ile Ile Asp Glu Ser Gly1 5 10 15Ser Lys Gln Leu Lys Phe Ser Lys Asn Leu Lys Arg Asn Leu Ile Ile
20??????????????????25??????????????????30Ser?Val?Val?Ile?Leu?Leu?Leu?Ile?Val?Gly?Leu?Gly?Val?Gly?Phe?Leu
35?????????????????40??????????????????45Lys?Phe?Leu?Ile?Ala?Lys?Met?Asp?Thr?Met?Thr?Ser?Glu?Arg?Asn?Ala
50??????????????????55??????????????????60Val?Leu?Arg?Asp?Phe?Arg?Gly?Leu?Tyr?Gln?Lys?Asn?Tyr?Ala?Leu?Ala65??????????????????70??????????????????75??????????????????80Lys?Glu?Ile?Lys?Asn?Lys?Arg?Glu?Glu?Leu?Phe?Ile?Val?Gly?Gln?Lys
85??????????????????90??????????????????95Ile?Arg?Gly?Leu?Glu?Ser?Leu?Ile?Glu?Ile?Lys?Lys?Gly?Ala?Asn?Gly
100?????????????????105?????????????????110Gly?Gly?His?Leu?Tyr?Asp?Glu?Val?Asp?Leu?Glu?Asn?Leu?Ser?Leu?Asn
115?????????????????120?????????????????125Gln?Lys?His?Leu?Ala?Leu?Met?Leu?Ile?Pro?Asn?Gly?Met?Pro?Leu?Lys
130?????????????????135?????????????????140Thr?Tyr?Ser?Ala?Ile?Lys?Pro?Thr?Lys?Glu?Arg?Asn?His?Pro?Ile?Lys145?????????????????150?????????????????155?????????????????160Lys?Ile?Lys?Gly?Val?Glu?Ser?Gly?Ile?Asp?Phe?Ile?Ala?Pro?Leu?Asn
165?????????????????170?????????????????175Thr?Pro?Val?Tyr?Ala?Ser?Ala?Asp?Gly?Ile?Val?Asp?Phe?Val?Lys?Thr
180?????????????????185?????????????????190Arg?Ser?Asn?Ala?Gly?Tyr?Gly?Asn?Leu?Val?Arg?Ile?Glu?His?Ala?Phe
195?????????????????200?????????????????205Gly?Phe?Ser?Ser?Ile?Tyr?Thr?His?Leu?Asp?His?Val?Asn?Val?Gln?Pro
210?????????????????215?????????????????220Lys?Ser?Phe?Ile?Gln?Lys?Gly?Gln?Leu?Ile?Gly?Tyr?Ser?Gly?Lys?Ser225?????????????????230?????????????????235?????????????????240Gly?Asn?Ser?Gly?Gly?Glu?Lys?Leu?His?Tyr?Glu?Val?Arg?Phe?Leu?Gly
245?????????????????250?????????????????255Lys?Ile?Leu?Asp?Ala?Glu?Lys?Phe?Leu?Ala?Trp?Asp?Leu?Asp?His?Phe
260?????????????????265?????????????????270Gln?Ser?Ala?Leu?Glu?Glu?Asn?Lys?Phe?Ile?Glu?Trp?Lys?Asn?Leu?Phe
275?????????????????280?????????????????285Trp?Val?Leu?Glu?Asp?Ile?Val?Gln?Leu?Gln?Glu?His?Val?Asp?Lys?Asp
The data of 290 295 300Thr Leu Lys Gly Gln305 (2) SEQ ID NO:127:
(ⅰ) sequence signature:
(A) length: 332 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..332
(ⅹ ⅰ) sequence description: SEQ ID NO:127:Val Leu Tyr Phe Leu Thr Ser Leu Phe Ile Cys Ser Leu Ile Val Leu1 5 10 15Trp Ser Lys Lys Ser Met Leu Phe Val Asp Asn Ala Asn Lys Ile Gln
20??????????????????25??????????????????30Gly?Phe?His?His?Ala?Arg?Thr?Pro?Arg?Ala?Gly?Gly?Leu?Gly?Ile?Phe
35??????????????????40??????????????????45Leu?Ser?Phe?Ala?Leu?Ala?Cys?Tyr?Leu?Glu?Pro?Phe?Glu?Met?Pro?Phe
50??????????????????55??????????????????60Lys?Gly?Pro?Phe?Val?Phe?Leu?Gly?Leu?Ser?Leu?Val?Phe?Leu?Ser?Gly65??????????????????70??????????????????75??????????????????80Phe?Leu?Glu?Asp?Ile?Asn?Leu?Ser?Leu?Ser?Pro?Lys?Ile?Arg?Leu?Ile
85??????????????????90??????????????????95Leu?Gln?Ala?Val?Gly?Val?Val?Cys?Ile?Ile?Ser?Ser?Thr?Pro?Leu?Val
100?????????????????105?????????????????110Val?Ser?Asp?Phe?Ser?Pro?Leu?Phe?Ser?Leu?Pro?Tyr?Phe?Ile?Ala?Phe
115?????????????????120?????????????????125Leu?Phe?Ala?Ile?Phe?Met?Leu?Val?Gly?Ile?Ser?Asn?Ala?Ile?Asn?Ile
130?????????????????135?????????????????140Ile?Asp?Gly?Phe?Asn?Gly?Leu?Ala?Ser?Gly?Ile?Cys?Ala?Ile?Ala?Leu145?????????????????150?????????????????155?????????????????160Leu?Val?Ile?His?Tyr?Ile?Asp?Pro?Ser?Ser?Leu?Ser?Cys?Leu?Leu?Ala
165?????????????????170?????????????????175Tyr?Met?Val?Leu?Gly?Phe?Met?Val?Leu?Asn?Phe?Pro?Ser?Gly?Lys?Ile
180?????????????????185?????????????????190Phe?Leu?Gly?Asp?Gly?Gly?Ala?Tyr?Phe?Leu?Gly?Leu?Val?Cys?Gly?Ile
195?????????????????200?????????????????205Ser?Leu?Leu?His?Leu?Ser?Leu?Glu?Gln?Lys?Ile?Ser?Val?Phe?Phe?Gly
210?????????????????215?????????????????220Leu?Asn?Leu?Met?Leu?Tyr?Pro?Val?Ile?Glu?Val?Leu?Phe?Ser?Ile?Leu225?????????????????230?????????????????235?????????????????240Arg?Arg?Lys?Ile?Lys?Arg?Gln?Lys?Ala?Thr?Met?Pro?Asp?Asn?Leu?His
245?????????????????250?????????????????255Leu?His?Thr?Leu?Leu?Phe?Lys?Phe?Leu?Gln?Gln?Arg?Ser?Phe?Asn?Tyr
260?????????????????265?????????????????270Pro?Asn?Pro?Leu?Cys?Ala?Phe?Ile?Leu?Ile?Leu?Cys?Asn?Leu?Pro?Phe
275?????????????????280?????????????????285Ile?Leu?Ile?Ser?Val?Leu?Phe?Arg?Leu?Asp?Ala?Tyr?Ala?Leu?Ile?Val
290?????????????????295?????????????????300Ile?Ser?Leu?Val?Phe?Ile?Ala?Cys?Tyr?Leu?Ile?Gly?Tyr?Ala?Tyr?Leu305?????????????????310?????????????????315?????????????????320Asn?Arg?Gln?Val?Cys?Ala?Leu?Glu?Lys?Arg?Ala?Phe
The data of 325 330 (2) SEQ ID NO:128:
(ⅰ) sequence signature:
(A) length: 271 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..271
(ⅹ ⅰ) sequence description: SEQ ID NO:128:Met Asn Ile Phe Lys Arg Ile Ile Cys Val Thr Ala Ile Val Leu Gly1 5 10 15Phe Phe Asn Leu Leu Asp Ala Lys His His Lys Glu Lys Lys Glu Asp
20??????????????????25??????????????????30His?Lys?Ile?Thr?Arg?Glu?Leu?Lys?Val?Gly?Ala?Asn?Pro?Val?Pro?His
35??????????????????40??????????????????45Ala?Gln?Ile?Leu?Gln?Ser?Val?Val?Asp?Asp?Leu?Lys?Glu?Lys?Gly?Ile
50??????????????????55??????????????????60Lys?Leu?Val?Ile?Val?Ser?Phe?Thr?Asp?Tyr?Val?Leu?Pro?Asn?Leu?Ala65??????????????????70??????????????????75??????????????????80Leu?Asn?Asp?Gly?Ser?Leu?Asp?Ala?Asn?Tyr?Phe?Gln?His?Arg?Pro?Tyr
85??????????????????90??????????????????95Leu?Asp?Arg?Phe?Asn?Leu?Asp?Arg?Lys?Met?His?Leu?Val?Gly?Leu?Ala
100?????????????????105?????????????????110Asn?Ile?His?Val?Glu?Pro?Leu?Arg?Phe?Tyr?Ser?Gln?Lys?Ile?Thr?Asp
115?????????????????120?????????????????125Ile?Lys?Asn?Leu?Lys?Lys?Gly?Ser?Val?Ile?Ala?Val?Pro?Asn?Asp?Pro
130?????????????????135?????????????????140Ala?Asn?Gln?G1y?Arg?Ala?Leu?Ile?Leu?Leu?His?Lys?Gln?Gly?Leu?Ile145?????????????????150?????????????????155?????????????????160Ala?Leu?Lys?Asp?Pro?Ser?Asn?Leu?Tyr?Ala?Thr?Glu?Phe?Asp?Ile?Val
165?????????????????170?????????????????175Lys?Asn?Pro?Tyr?Asn?Ile?Lys?Ile?Lys?Pro?Leu?Glu?Ala?Ala?Leu?Leu
180?????????????????185?????????????????190Pro?Lys?Val?Leu?Gly?Asp?Val?Asp?Gly?Ala?Ile?Ile?Thr?Gly?Asn?Tyr
195?????????????????200?????????????????205Ala?Leu?Gln?Ala?Lys?Leu?Thr?Gly?Ala?Leu?Phe?Ser?Glu?Asp?Lys?Asp
210?????????????????215?????????????????220Ser?Pro?Tyr?Ala?Asn?Leu?Val?Ala?Ser?Arg?Glu?Asp?Asn?Ala?Gln?Asp225?????????????????230?????????????????235?????????????????240Glu?Ala?Ile?Lys?Ala?Leu?Ile?Glu?Ala?Leu?Gln?Ser?Glu?Lys?Thr?Arg
245?????????????????250?????????????????255Lys?Phe?Ile?Leu?Asp?Thr?Tyr?Lys?Gly?Ala?Ile?Ile?Pro?Ala?Phe
The data of 260 265 270 (2) SEQ ID NO:129:
(ⅰ) sequence signature:
(A) length: 316 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..316
(ⅹ ⅰ) sequence description: SEQ ID NO:129:Met Gln Glu Phe Ser Leu Trp Cys Asp Phe Ile Glu Arg Asp Phe Leu1 5 10 15Glu Asn Asp Phe Leu Lys Leu Ile Asn Lys Gly Ala Ile Cys Gly Ala
20??????????????????25??????????????????30Thr?Ser?Asn?Pro?Ser?Leu?Phe?Cys?Glu?Ala?Ile?Thr?Lys?Ser?Ala?Phe
35??????????????????40??????????????????45Tyr?Gln?Asp?Glu?Ile?Ala?Lys?Leu?Lys?Gly?Lys?Lys?Ala?Lys?Glu?Ile
50??????????????????55??????????????????60Tyr?Glu?Thr?Leu?Ala?Leu?Lys?Asp?Ile?Leu?Gln?Ala?Ser?Ser?Ala?Leu65??????????????????70??????????????????75??????????????????80Met?Pro?Leu?Tyr?Glu?Lys?Asp?Pro?Asn?Asn?Gly?Tyr?Ile?Ser?Leu?Glu
85??????????????????90??????????????????95Ile?Asp?Pro?Phe?Leu?Glu?Asp?Asp?Ala?Ile?Lys?Ser?Ile?Asp?Glu?Ala
100?????????????????105?????????????????110Lys?Arg?Leu?Phe?Lys?Thr?Leu?Asn?Arg?Pro?Asn?Val?Met?Ile?Lys?Val
115?????????????????120?????????????????125Pro?Ala?Ser?Glu?Ser?Ala?Phe?Glu?Val?Ile?Ser?Ala?Leu?Ala?Gln?Ala
130?????????????????135?????????????????140Ser?Ile?Pro?Ile?Asn?Val?Thr?Leu?Val?Phe?Ser?Pro?Lys?Ile?Ala?Gly145?????????????????150?????????????????155?????????????????160Glu?Ile?Ala?Gln?Ile?Leu?Ala?Lys?Glu?Ala?Arg?Lys?Arg?Ala?Val?Ile
165?????????????????170?????????????????175Ser?Val?Phe?Val?Ser?Arg?Phe?Asp?Lys?Glu?Ile?Asp?Pro?Leu?Val?Pro
180?????????????????185?????????????????190Gln?Asn?Leu?Gln?Ala?Gln?Ser?Gly?Ile?Met?Asn?Ala?Thr?Glu?Cys?Tyr
195?????????????????200?????????????????205Tyr?Gln?Ile?Asn?Gln?His?Ala?Asn?Lys?Leu?Ile?Ser?Thr?Leu?Phe?Ala
210?????????????????215?????????????????220Ser?Thr?Gly?Val?Lys?Ser?Asn?Ser?Leu?Ala?Lys?Asp?Tyr?Tyr?Ile?Lys225?????????????????230?????????????????235?????????????????240Ala?Leu?Cys?Phe?Lys?Asn?Ser?Ile?Asn?Thr?Ala?Pro?Leu?Asp?Ala?Leu
245?????????????????250?????????????????255Asn?Ala?Tyr?Leu?Leu?Asp?Pro?Asn?Thr?Glu?Cys?Gln?Thr?Pro?Leu?Lys
260?????????????????265?????????????????270Ile?Thr?Glu?Ile?Glu?Ala?Phe?Lys?Lys?Glu?Leu?Lys?Thr?His?Asn?Ile
275?????????????????280?????????????????285Asp?Leu?Glu?Asn?Thr?Ala?Gln?Lys?Leu?Leu?Lys?Glu?Gly?Leu?Ile?Ala
The data of 290 295 300Phe Lys Gln Ser Phe Glu Lys Leu Leu Ser Ser Phe305,310 315 (2) SEQ ID NO:130:
(ⅰ) sequence signature:
(A) length: 260 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..260
(ⅹ ⅰ) sequence description: SEQ ID NO:130:Met Lys Thr Asn Gly His Phe Lys Asp Phe Ala Trp Lys Lys Cys Phe1 5 10 15Leu Gly Ala Ser Val Val Ala Leu Leu Val Gly Cys Ser Pro His Ile
20??????????????????25??????????????????30Ile?Glu?Thr?Asn?Glu?Val?Ala?Leu?Lys?Leu?Asn?Tyr?His?Pro?Ala?Ser
35??????????????????40??????????????????45Glu?Lys?Val?Gln?Ala?Leu?Asp?Glu?Lys?Ile?Leu?Leu?Leu?Arg?Pro?Ala
50??????????????????55??????????????????60Phe?Gln?Tyr?Ser?Asp?Asn?Ile?Ala?Lys?Glu?Tyr?Glu?Asn?Lys?Phe?Lys65??????????????????70??????????????????75??????????????????80Asn?Gln?Thr?Thr?Leu?Lys?Val?Glu?Glu?Ile?Leu?Gln?Asn?Gln?Gly?Tyr
85??????????????????90??????????????????95Lys?Val?Ile?Asn?Val?Asp?Ser?Ser?Asp?Lys?Asp?Asp?Phe?Ser?Phe?Ala
100?????????????????105?????????????????110Gln?Lys?Lys?Glu?Gly?Tyr?Leu?Ala?Val?Ala?Met?Asn?Gly?Glu?Ile?Val
115?????????????????120?????????????????125Leu?Arg?Pro?Asp?Pro?Lys?Arg?Thr?Ile?Gln?Lys?Lys?Ser?Glu?Pro?Gly
130?????????????????135?????????????????140Leu?Leu?Phe?Ser?Thr?Gly?Leu?Asp?Lys?Met?Glu?Arg?Val?Leu?Ile?Pro145?????????????????150?????????????????155?????????????????160Ala?Gly?Phe?Val?Lys?Val?Thr?Ile?Leu?Glu?Pro?Met?Ser?Gly?Glu?Ser
165?????????????????170?????????????????175Leu?Asp?Ser?Phe?Thr?Met?Asp?Leu?Ser?Glu?Leu?Asp?Ile?Gln?Glu?Lys
180?????????????????185?????????????????190Phe?Leu?Lys?Thr?Thr?His?Ser?Ser?His?Ser?Gly?Gly?Leu?Val?Ser?Thr
195?????????????????200?????????????????205Met?Val?Lys?Gly?Thr?Asp?Asn?Ser?Asn?Asp?Ala?Ile?Lys?Ser?Ala?Leu
210?????????????????215?????????????????220Asn?Lys?Ile?Phe?Ala?Ser?Ile?Met?Gln?Glu?Met?Asp?Lys?Lys?Leu?Thr225?????????????????230?????????????????235?????????????????240Gln?Arg?Asn?Leu?Glu?Ser?Tyr?Gln?Lys?Asp?Ala?Lys?Glu?Leu?Lys?Asn
245?????????????????250?????????????????255Lys?Arg?Asn?Arg
The data of 260 (2) SEQ ID NO:131:
(ⅰ) sequence signature:
(A) length: 1382 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..1382
(ⅹ ⅰ) sequence description: SEQ ID NO:131:Leu Asn Phe Asn Asn Leu Thr Ala Asn Gly Ala Leu Asn Phe Asn Gly1 5 10 15Tyr Ala Pro Ser Leu Thr Lys Ala Leu Met Asn Val Ser Gly Gln Phe
20??????????????????25??????????????????30Val?Leu?Gly?Asn?Asn?Gly?Asp?Ile?Asn?Leu?Ser?Asp?Ile?Asn?Ile?Phe
35??????????????????40??????????????????45Asp?Asn?Ile?Thr?Lys?Ser?Val?Thr?Tyr?Asn?Ile?Leu?Asn?Ala?Gln?Lys
50??????????????????55??????????????????60Gly?Ile?Thr?Gly?Ile?Ser?Gly?Ala?Asn?Gly?Tyr?Glu?Lys?Ile?Leu?Phe65??????????????????70??????????????????75??????????????????80Tyr?Gly?Met?Lys?Ile?Gln?Asn?Ala?Thr?Tyr?Ser?Asp?Asn?Asn?Asn?Ile
85??????????????????90??????????????????95Gln?Thr?Trp?Ser?Phe?Ile?Asn?Pro?Leu?Asn?Ser?Ser?Gln?Ile?Ile?Gln
100?????????????????105?????????????????110Glu?Ser?Ile?Lys?Asn?Gly?Asp?Leu?Thr?Ile?Glu?Val?Leu?Asn?Asn?Pro
115?????????????????120?????????????????125Asn?Ser?Ala?Ser?Asn?Thr?Ile?Phe?Asn?Ile?Ala?Pro?Glu?Leu?Tyr?Asn
130?????????????????135?????????????????140Tyr?Gln?Asp?Ser?Lys?Gln?Asn?Pro?Thr?Gly?Tyr?Ser?Tyr?Asp?Tyr?Ser145?????????????????150?????????????????155?????????????????160Asp?Asn?Gln?Ala?Gly?Thr?Tyr?Tyr?Leu?Thr?Ser?Asn?Ile?Lys?Gly?Leu
165?????????????????170?????????????????175Phe?Thr?Pro?Lys?Gly?Ser?Gln?Thr?Pro?Gln?Thr?Pro?Gly?Thr?Tyr?Ser
180?????????????????185?????????????????190Pro?Phe?Asn?Gln?Pro?Leu?Asn?Ser?Leu?Asn?Ile?Tyr?Asn?Lys?Gly?Phe
195?????????????????200?????????????????205Ser?Ser?Glu?Asn?Leu?Lys?Thr?Leu?Leu?Gly?Ile?Leu?Ser?Gln?Asn?Ser
210?????????????????215?????????????????220Ala?Thr?Leu?Lys?Glu?Met?Ile?Glu?Ser?Asn?Gln?Leu?Asp?Asn?Ile?Thr225?????????????????230?????????????????235?????????????????240Asn?Ile?Asn?Glu?Val?Leu?Gln?Leu?Leu?Asp?Lys?Ile?Lys?Ile?Thr?Gln
245?????????????????250?????????????????255Ala?Gln?Lys?Gln?Ala?Leu?Leu?Glu?Thr?Ile?Asn?His?Leu?Thr?Asp?Asn
260?????????????????265?????????????????270Ile?Asn?Gln?Thr?Phe?Asn?Asn?Gly?Asn?Leu?Val?Ile?Gly?Ala?Thr?Gln
275?????????????????280?????????????????285Asp?Asn?Val?Thr?Asn?Ser?Thr?Ser?Ser?Ile?Trp?Phe?Gly?Gly?Asn?Gly
290?????????????????295?????????????????300Tyr?Ser?Ser?Pro?Cys?Ala?Leu?Asp?Ser?Ala?Thr?Cys?Ser?Ser?Phe?Arg305?????????????????310?????????????????315?????????????????320Asn?Thr?Tyr?Leu?Gly?Gln?Leu?Leu?Gly?Ser?Thr?Ser?Pro?Tyr?Leu?Gly
325?????????????????330?????????????????335Tyr?Ile?Asn?Ala?Asp?Phe?Lys?Ala?Lys?Ser?Ile?Tyr?Ile?Thr?Gly?Thr
340?????????????????345?????????????????350Ile?Gly?Ser?Ser?Asn?Ala?Phe?Glu?Ser?Gly?Gly?Ser?Ala?Asp?Val?Thr
355?????????????????360?????????????????365Phe?Gln?Ser?Ala?Asn?Asn?Leu?Val?Leu?Asn?Lys?Ala?Asn?Ile?Glu?Ala
370?????????????????375?????????????????380Gln?Ala?Thr?Asp?Asn?Ile?Phe?Asn?Leu?Leu?Gly?Gln?Glu?Gly?Ile?Asp385?????????????????390?????????????????395?????????????????400Lys?Ile?Phe?Asn?Gln?Gly?Asn?Leu?Ala?Asn?Val?Leu?Ser?Gln?Met?Ala
405?????????????????410?????????????????415Met?Glu?Lys?Ile?Lys?Gln?Ala?Gly?Gly?Leu?Gly?Asn?Phe?Ile?Glu?Asn
420?????????????????425?????????????????430Ala?Leu?Ser?Pro?Leu?Ser?Lys?Glu?Leu?Pro?Ala?Ser?Leu?Gln?Asp?Glu
435?????????????????440?????????????????445Thr?Leu?Gly?Gln?Leu?Ile?Gly?Gln?Asn?Asn?Leu?Asp?Asp?Leu?Leu?Asn
450?????????????????455?????????????????460Asn?Ser?Gly?Val?Met?Asn?Glu?Ile?Gln?Asn?Ile?Ile?Ser?Gln?Lys?Leu465?????????????????470?????????????????475?????????????????480Ser?Ile?Phe?Gly?Asn?Phe?Val?Thr?Pro?Ser?Ile?Ile?Glu?Asn?Tyr?Leu
485?????????????????490?????????????????495Ala?Lys?Gln?Ser?Leu?Lys?Ser?Met?Leu?Asp?Asp?Lys?Gly?Leu?Leu?Asn
500?????????????????505?????????????????510Phe?Ile?Gly?Gly?Tyr?Ile?Asp?Ala?Ser?Glu?Leu?Ser?Ser?Ile?Leu?Gly
515?????????????????520?????????????????525Val?Ile?Leu?Lys?Asp?Ile?Thr?Asn?Pro?Pro?Thr?Ser?Leu?Gln?Lys?Asp
530?????????????????535?????????????????540Ile?Gly?Val?Val?Ala?Asn?Asp?Leu?Leu?Asn?Glu?Phe?Leu?Gly?Gln?Asp545?????????????????550?????????????????555?????????????????560Val?Val?Lys?Lys?Leu?Glu?Ser?Gln?Gly?Leu?Val?Ser?Asn?Ile?Ile?Asn
565?????????????????570?????????????????575Asn?Val?Ile?Ser?Gln?Gly?Gly?Leu?Ser?Gly?Val?Tyr?Asn?Gln?Gly?Leu
580?????????????????585?????????????????590Gly?Ser?Val?Leu?Pro?Pro?Ser?Leu?Gln?Asn?Ala?Leu?Lys?Glu?Asn?Asp
595?????????????????600?????????????????605Leu?Gly?Thr?Leu?Leu?Ser?Pro?Arg?Gly?Leu?His?Asp?Phe?Trp?Gln?Lys
610?????????????????615?????????????????620Gly?Tyr?Phe?Asn?Phe?Leu?Ser?Asn?Gly?Tyr?Val?Phe?Val?Asn?Asn?Ser625?????????????????630?????????????????635?????????????????640Ser?Phe?Ser?Asn?Ala?Thr?Gly?Gly?Ser?Leu?Asn?Phe?Val?Ala?Asn?Lys
645?????????????????650?????????????????655Ser?Ile?Ile?Phe?Asn?Gly?Asp?Asn?Thr?Ile?Asp?Phe?Ser?Lys?Tyr?Gln
660?????????????????665?????????????????670Gly?Ala?Leu?Ile?Phe?Ala?Ser?Asn?Gly?Val?Ser?Asn?Ile?Asn?Ile?Thr
675?????????????????680?????????????????685Thr?Leu?Asn?Ala?Thr?Asn?Gly?Leu?Ser?Leu?Asn?Ala?Gly?Leu?Asn?Asn
690?????????????????695?????????????????700Val?Ser?Val?Gln?Lys?Gly?Glu?Ile?Cys?Ile?Asn?Leu?Ala?Asn?Cys?Pro705?????????????????710?????????????????715?????????????????720Thr?Thr?Lys?Asn?Ser?Ser?Pro?Ala?Asn?Ser?Ser?Val?Thr?Pro?Thr?Asn
725?????????????????730?????????????????735Glu?Ser?Leu?Ser?Val?His?Ala?Asn?Asn?Phe?Thr?Phe?Leu?Gly?Thr?Ile
740?????????????????745?????????????????750Ile?Ser?Asn?Gly?Ala?Ile?Asp?Leu?Ser?Gln?Val?Thr?Asn?Asn?Ser?Val
755?????????????????760?????????????????765Ile?Gly?Thr?Leu?Asn?Leu?Asn?Glu?Asn?Ala?Thr?Leu?Gln?Ala?Asn?Asn
770?????????????????775?????????????????780Leu?Thr?Ile?Thr?Asn?Ala?Phe?Asn?Asn?Ala?Sar?Asn?Ser?Thr?Ala?Asn785?????????????????790?????????????????795?????????????????800Ile?Asp?Gly?Asn?Phe?Thr?Leu?Asn?Gln?Gln?Ala?Thr?Leu?Ser?Thr?Asn
805?????????????????810?????????????????815Ala?Ser?Gly?Leu?Asn?Val?Met?Gly?Asn?Phe?Asn?Ser?Tyr?Gly?Asp?Leu
820?????????????????825?????????????????830Val?Phe?Asn?Leu?Ser?His?Ser?Val?Ser?His?Ala?Ile?Ile?Asn?Thr?Gln
835?????????????????840?????????????????845Gly?Thr?Ala?Thr?Ile?Met?Ala?Asn?Asn?Asn?Pro?Leu?Ile?Gln?Phe?Asn
850?????????????????855?????????????????860Ala?Ser?Ser?Lys?Glu?Val?Gly?Thr?Tyr?Thr?Leu?Ile?Asp?Ser?Ala?Lys865?????????????????870?????????????????875?????????????????880Ala?Ile?Tyr?Tyr?Gly?Tyr?Asn?Asn?Gln?Ile?Thr?Gly?Gly?Ser?Ser?Leu
885?????????????????890?????????????????895Asp?Asn?Tyr?Leu?Lys?Leu?Tyr?Ala?Leu?Ile?Asp?Ile?Asn?Gly?Lys?His
900?????????????????905?????????????????910Met?Val?Met?Thr?Asp?Asn?Gly?Leu?Thr?Tyr?Asn?Gly?Gln?Ala?Val?Ser
915?????????????????920?????????????????925Val?Lys?Asp?Gly?Gly?Leu?Val?Val?Gly?Phe?Lys?Asp?Ser?Gln?Asn?Gln
930?????????????????935?????????????????940Tyr?Ile?Tyr?Thr?Ser?Ile?Leu?Tyr?Asn?Lys?Val?Lys?Ile?Ala?Val?Ser945?????????????????950?????????????????955?????????????????960Asn?Asp?Pro?Ile?Asn?Asn?Pro?Gln?Ala?Pro?Thr?Leu?Lys?Gln?Tyr?Ile
965?????????????????970?????????????????975Ala?Gln?Ile?Gln?Gly?Val?Gln?Ser?Val?Asp?Ser?Ile?Asp?Gln?Ala?Gly
980?????????????????985?????????????????990Gly?Asn?Gln?Ala?Ile?Asn?Trp?Leu?Asn?Lys?Ile?Phe?Glu?Thr?Lys?Gly
995?????????????????1000????????????????1005Ser?Pro?Leu?Phe?Ala?Pro?Tyr?Tyr?Leu?Glu?Ser?His?Ser?Thr?Lys?Asp
1010????????????????1015????????????????1020Leu?Thr?Thr?Ile?Ala?Gly?Asp?Ile?Ala?Asn?Thr?Leu?Glu?Val?Ile?Ala1025????????????????1030????????????????1035????????????????1040Asn?Pro?Asn?Phe?Lys?Asn?Asp?Ala?Thr?Asn?Ile?Leu?Gln?Ile?Asn?Thr
1045????????????????1050????????????????1055Tyr?Thr?Gln?Gln?Met?Ser?Arg?Leu?Ala?Lys?Leu?Ser?Asp?Thr?Ser?Thr
1060????????????????1065????????????????1070Phe?Ala?Arg?Ser?Asp?Phe?Leu?Glu?Arg?Leu?Glu?Ala?Leu?Lys?Asn?Lys
1075????????????????1080????????????????1085Arg?Phe?Ala?Asp?Ala?Ile?Pro?Asn?Ala?Met?Asp?Val?Ile?Leu?Lys?Tyr
1090????????????????1095????????????????1100Ser?Gln?Arg?Asn?Arg?Val?Lys?Asn?Asn?Val?Trp?Ala?Thr?Gly?Val?Gly1105????????????????1110????????????????1115????????????????1120Gly?Ala?Ser?Phe?Ile?Ser?Gly?Gly?Thr?Gly?Thr?Leu?Tyr?Gly?Ile?Asn
1125????????????????1130????????????????1135Val?Gly?Tyr?Asp?Arg?Phe?Ile?Lys?Gly?Val?Ile?Val?Gly?Gly?Tyr?Ala
1140????????????????1145????????????????1150Ala?Tyr?Gly?Tyr?Ser?Gly?Phe?His?Ala?Asn?Ile?Thr?Gln?Ser?Gly?Ser
1155????????????????1160????????????????1165Ser?Asn?Val?Asn?Val?Gly?Val?Tyr?Ser?Arg?Ala?Phe?Ile?Lys?Arg?Ser
1170????????????????1175????????????????1180Glu?Leu?Thr?Met?Ser?Leu?Asn?Glu?Thr?Trp?Gly?Tyr?Asn?Lys?Thr?Phe1185????????????????1190????????????????1195????????????????1200Ile?Asn?Ser?Tyr?Asp?Pro?Leu?Leu?Ser?Ile?Ile?Asn?Gln?Ser?Tyr?Arg
1205????????????????1210????????????????1215Tyr?Asp?Thr?Trp?Thr?Thr?Asp?Ala?Lys?Ile?Asn?Tyr?Gly?Tyr?Asp?Phe
1220????????????????1225????????????????1230Met?Phe?Lys?Asp?Lys?Ser?Val?Ile?Phe?Lys?Pro?Gln?Val?Gly?Leu?Ser
1235????????????????1240????????????????1245Tyr?Tyr?Tyr?Ile?Gly?Leu?Ser?Gly?Leu?Arg?Gly?Ile?Met?Asp?Asp?Pro
1250????????????????1255????????????????1260Ile?Tyr?Asn?Gln?Phe?Arg?Ala?Asn?Ala?Asp?Pro?Asn?Lys?Lys?Ser?Val1265????????????????1270????????????????1275????????????????1280Leu?Thr?Ile?Asn?Phe?Ala?Leu?Glu?Ser?Arg?His?Tyr?Phe?Asn?Lys?Asn
1285????????????????1290????????????????1295Ser?Tyr?Tyr?Phe?Val?Ile?Ala?Asp?Val?Gly?Arg?Asp?Leu?Phe?Ile?Asn
1300????????????????1305????????????????1310Ser?Met?Gly?Asp?Lys?Met?Val?Arg?Phe?Ile?Gly?Asn?Asn?Thr?Leu?Ser
1315????????????????1320????????????????1325Tyr?Arg?Asp?Gly?Gly?Arg?Tyr?Asn?Thr?Phe?Ala?Ser?Ile?Ila?Thr?Gly
1330????????????????1335????????????????1340Gly?Glu?Ile?Arg?Leu?Phe?Lys?Thr?Phe?Tyr?Val?Asn?Ala?Gly?Ile?Gly1345????????????????1350????????????????1355????????????????1360Ala?Arg?Phe?Gly?Leu?Asp?Tyr?Lys?Asp?Ile?Asn?Ile?Thr?Gly?Asn?Ile
1365????????????????1370????????????????1375Gly?Met?Arg?Tyr?Ala?Phe
The data of 1380 (2) SEQ ID NO:132:
(ⅰ) sequence signature:
(A) length: 262 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..262
(ⅹ ⅰ) sequence description: SEQ ID NO:132:Met Lys Lys Ile Gly Leu Ser Leu Cys Leu Val Leu Ser Leu Gly Phe1 5 10 15Leu Lys Ala His Glu Val Ser Ala Glu Glu Ile Ala Asp Ile Phe Tyr
20??????????????????25??????????????????30Lys?Leu?Asn?Ala?Lys?Glu?Pro?Lys?Met?Lys?Ile?Asn?His?Thr?Lys?Gly
35??????????????????40??????????????????45Phe?Cys?Ala?Lys?Gly?Val?Phe?Leu?Pro?Asn?Pro?Gln?Ala?Arg?Glu?Asp
50??????????????????55??????????????????60Leu?Glu?Val?Pro?Leu?Leu?Asn?Glu?Lys?Glu?Ile?Pro?Ala?Ser?Val?Arg65??????????????????70??????????????????75??????????????????80Tyr?Ser?Leu?Gly?Gly?Val?Ala?Met?Asp?Asp?Lys?Ser?Lys?Val?Arg?Gly
85??????????????????90??????????????????95Met?Ala?Leu?Lys?Leu?Glu?Asn?Gln?Asn?Ala?Ser?Trp?Thr?Met?Val?Met
100?????????????????105?????????????????110Leu?Asn?Thr?Glu?Ile?Asn?Phe?Ala?Lys?Asn?Pro?Glu?Glu?Phe?Ala?Gln
115?????????????????120?????????????????125Phe?Phe?Glu?Met?Arg?Leu?Pro?Lys?Asn?Gly?Lys?Val?Asp?Glu?Ala?Arg
130?????????????????135?????????????????140Ile?Lys?Lys?Leu?Tyr?Glu?Glu?Val?Pro?Ser?Tyr?Arg?Asn?Phe?Ala?Ala145?????????????????150?????????????????155?????????????????160Tyr?Met?Lys?Thr?Ile?Gly?Ile?Ser?Ser?Ser?Val?Ala?Asn?Thr?Pro?Tyr
165?????????????????170?????????????????175Tyr?Ser?Val?His?Ala?Phe?Lys?Phe?Lys?Asp?Lys?Lys?Glu?Lys?Leu?Leu
180?????????????????185?????????????????190Pro?Ala?Arg?Trp?Lys?Phe?Val?Pro?Lys?Glu?Gly?Val?Lys?Tyr?Leu?Asn
195?????????????????200?????????????????205Pro?Gln?Glu?Leu?Lys?Gln?Lys?Asp?Ser?Asn?Tyr?Leu?Leu?Ser?Ser?Phe
210?????????????????215?????????????????220Gln?Gln?His?Leu?Lys?Asn?Lys?Pro?Ile?Glu?Tyr?Gln?Met?Tyr?Leu?Val225?????????????????230?????????????????235?????????????????240Phe?Ala?Asn?Gln?Asn?Asp?Ala?Thr?Asn?Asp?Thr?Thr?Ala?Leu?Trp?Lys
245?????????????????250?????????????????255Gly?Ser?Ile?Arg?Asn?Tyr
The data of 260 (2) SEQ ID NO:133:
(ⅰ) sequence signature:
(A) length: 246 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..246
(ⅹ ⅰ) sequence description: SEQ ID N0:133:Met Lys Gln Phe Lys Lys Lys Pro Lys Lys Ile Lys Arg Ser His Gln1 5 10 15Asn Gln Lys Thr Ile Leu Lys Arg Pro Leu Trp Leu Met Pro Leu Leu
20??????????????????25??????????????????30Ile?Gly?Gly?Phe?Ala?Ser?Gly?Val?Tyr?Ala?Asp?Gly?Thr?Asp?Ile?Leu
35??????????????????40??????????????????45Gly?Leu?Ser?Trp?Gly?Glu?Lys?Ser?Gln?Lys?Val?Cys?Val?His?Arg?Pro
50??????????????????55??????????????????60Trp?Tyr?Ala?Ile?Trp?Ser?Cys?Asp?Lys?Trp?Glu?Glu?Lys?Thr?Gln?Gln65??????????????????70??????????????????75??????????????????80Phe?Thr?Gly?Asn?Gln?Leu?Ile?Thr?Lys?Thr?Trp?Ala?Gly?Gly?Asn?Ala
85??????????????????90??????????????????95Ala?Asn?Tyr?Tyr?His?Ser?Gln?Asn?Asn?Gln?Asp?Ile?Thr?Ala?Asn?Leu
100?????????????????105?????????????????110Lys?Asn?Asp?Asn?Gly?Thr?Tyr?Phe?Leu?Ser?Gly?Leu?Tyr?Asn?Tyr?Thr
115?????????????????120?????????????????125Gly?Gly?Glu?Tyr?Asn?Gly?Gly?Asn?Leu?Asp?Ile?Glu?Leu?Gly?Ser?Asn
130?????????????????135?????????????????140Ala?Thr?Phe?Asn?Leu?Gly?Ala?Ser?Ser?Gly?Asn?Ser?Phe?Thr?Ser?Trp145?????????????????150?????????????????155?????????????????160Tyr?Pro?Asn?Gly?His?Thr?Asp?Val?Thr?Phe?Ser?Ala?Gly?Thr?Ile?Asn
165?????????????????170?????????????????175Val?Asn?Asn?Ser?Val?Glu?Val?Gly?Asn?Arg?Val?Gly?Ser?Gly?Ala?Gly
l80?????????????????185?????????????????190Thr?His?Thr?Gly?Thr?Ala?Thr?Leu?Asn?Leu?Asn?Ala?Asn?Lys?Val?Thr
195?????????????????200?????????????????205Ile?Asn?Ser?Asn?Ile?Ser?Ala?Tyr?Lys?Thr?Ser?Gln?Val?Asn?Val?Gly
210?????????????????215?????????????????220Asn?Ala?Asn?Ser?Val?Ile?Thr?Ile?Asn?Ser?Val?Ser?Leu?Asn?Gly?Glu225?????????????????230?????????????????235?????????????????240Tyr?Leu?Gln?Phe?Phe?Ser
The data of 245 (2) SEQ ID NO:134:
(ⅰ) sequence signature:
(A) length: 245 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅲ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..245
(ⅹ ⅰ) sequence description: SEQ ID NO:134:Met Ile Lys Lys Thr Leu Ala Ser Val Leu Leu Gly Leu Ser Leu Met1 5 10 15Ser Val Leu Asn Ala Lys Glu Cys Val Ser Pro Ile Thr Arg Ser Val
20??????????????????25??????????????????30Lys?Tyr?His?Gln?Gln?Ser?Ala?Glu?Ile?Arg?Ala?Leu?Gln?Leu?Gln?Ser
35??????????????????40??????????????????45Tyr?Lys?Met?Ala?Lys?Met?Ala?Leu?Asp?Asn?Asn?Leu?Lys?Leu?Val?Lys
50??????????????????55??????????????????60Asp?Lys?Lys?Pro?Ala?Val?Ile?Leu?Asp?Leu?Asp?Glu?Thr?Val?Leu?Asn65??????????????????70??????????????????75??????????????????80Thr?Phe?Asp?Tyr?Ala?Gly?Tyr?Leu?Val?Lys?Asn?Cys?Ile?Lys?Tyr?Thr
85??????????????????90??????????????????95Pro?Glu?Thr?Trp?Asp?Lys?Phe?Glu?Lys?Glu?Gly?Ser?Leu?Thr?Leu?Ile
100?????????????????105?????????????????110Pro?Gly?Ala?Leu?Asp?Phe?Leu?Glu?Tyr?Ala?Asn?Ser?Lys?Gly?Val?Lys
115?????????????????120?????????????????125Ile?Phe?Tyr?Ile?Ser?Asn?Arg?Thr?Gln?Lys?Asn?Lys?Ala?Phe?Thr?Leu
130?????????????????135?????????????????140Lys?Thr?Leu?Lys?Ser?Phe?Lys?Leu?Pro?Gln?Val?Ser?Glu?Glu?Ser?Val145?????????????????150?????????????????155?????????????????160Leu?Leu?Lys?Glu?Lys?Gly?Lys?Pro?Lys?Ala?Val?Arg?Arg?Glu?Leu?Val
165?????????????????170?????????????????175Ala?Lys?Asp?Tyr?Ala?Ile?Val?Leu?Gln?Val?Gly?Asp?Thr?Leu?His?Asp
180?????????????????185?????????????????190Phe?Asp?Ala?Ile?Phe?Ala?Lys?Asp?Ala?Lys?Asn?Ser?Gln?Glu?Gln?Gln
195?????????????????200?????????????????205Ala?Lys?Val?Leu?Gln?Asn?Ala?Gln?Lys?Phe?Gly?Thr?Glu?Trp?Ile?Ile
210?????????????????215?????????????????220Leu?Pro?Asn?Ser?Leu?Tyr?Gly?Thr?Trp?Glu?Asp?Gly?Pro?Ile?Lys?Ala225?????????????????230?????????????????235?????????????????240Trp?Gln?Asn?Lys?Lys
The data of 245 (2) SEQ ID NO:135:
(ⅰ) sequence signature:
(A) length: 288 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..288
(ⅹ ⅰ) sequence description: SEQ ID NO:135:Leu Trp Cys Leu Lys Thr Pro Ile Ile Gly His Gly Met Lys Lys Lys1 5 10 15Ala Lys Val Phe Trp Cys Cys Phe Lys Met Ile Arg Trp Leu Tyr Leu
20??????????????????25??????????????????30Ala?Val?Phe?Phe?Leu?Leu?Ser?Val?Ser?Asp?Ala?Lys?Glu?Ile?Ala?Met
35??????????????????40??????????????????45Gln?Arg?Phe?Asp?Lys?Gln?Asn?His?Lys?Ile?Phe?Glu?Ile?Leu?Ala?Asp
50??????????????????55??????????????????60Lys?Val?Ser?Ala?Lys?Asp?Asn?Val?Ile?Thr?Ala?Ser?Gly?Asn?Ala?Ile65??????????????????70??????????????????75??????????????????80Leu?Leu?Asn?Tyr?Asp?Val?Tyr?Ile?Leu?Ala?Asp?Lys?Val?Arg?Tyr?Asp
85??????????????????90??????????????????95Thr?Lys?Thr?Lys?Glu?Ala?Leu?Leu?Glu?Gly?Asn?Ile?Lys?Val?Tyr?Arg
100?????????????????105?????????????????110Gly?Glu?Gly?Leu?Leu?Val?Lys?Thr?Asp?Tyr?Val?Lys?Leu?Ser?Leu?Asn
115?????????????????120?????????????????125Glu?Lys?Tyr?Glu?Ile?Ile?Phe?Pro?Phe?Tyr?Val?Gln?Asp?Ser?Val?Ser
130?????????????????135?????????????????140Gly?Ile?Trp?Val?Ser?Ala?Asp?Ile?Ala?Ser?Gly?Lys?Asp?Gln?Lys?Tyr145?????????????????150?????????????????155?????????????????160Lys?Ile?Lys?Asn?Met?Ser?Ala?Ser?Gly?Cys?Ser?Ile?Asp?Asn?Pro?Ile
165?????????????????170?????????????????175Trp?His?Val?Asn?Ala?Thr?Ser?Gly?Ser?Phe?Asn?Met?Gln?Lys?Ser?His
180?????????????????185?????????????????190Leu?Ser?Met?Trp?Asn?Pro?Lys?Ile?Tyr?Val?Gly?Asp?Ile?Pro?Val?Leu
195?????????????????200?????????????????205Tyr?Leu?Pro?Tyr?Ile?Phe?Met?Ser?Thr?Ser?Asn?Lys?Arg?Thr?Thr?Gly
210?????????????????215?????????????????220Phe?Leu?Tyr?Pro?Glu?Phe?Gly?Thr?Ser?Asn?Leu?Asp?Gly?Phe?Ile?Tyr225?????????????????230?????????????????235?????????????????240Leu?Gln?Pro?Phe?Tyr?Leu?Ala?Pro?Lys?Asn?Ser?Trp?Asp?Met?Thr?Phe
245?????????????????250?????????????????255Thr?Pro?Gln?Ile?Arg?Tyr?Lys?Arg?Gly?Phe?Gly?Leu?Asn?Phe?Glu?Ala
260?????????????????265?????????????????270Arg?Tyr?Ile?Asn?Ser?Lys?Thr?Gln?Val?Phe?Ile?Gln?Cys?Ala?Leu?Phe
The data of 275 280 285 (2) SEQ ID NO:136:
(ⅰ) sequence signature:
(A) length: 128 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..128
(ⅹ ⅰ) sequence description: SEQ ID NO:136:Leu Met Phe Lys Lys Met Cys Leu Ser Leu Leu Met Ile Ser Gly Val1 5 10 15Cys Val Gly Ala Lys Asp Leu Asp Phe Lys Leu Asp Tyr Arg Ala Thr
20??????????????????25??????????????????30Gly?Gly?Lys?Phe?Met?Gly?Lys?Met?Thr?Asp?Ser?Ser?Leu?Leu?Ser?Ile
35??????????????????40??????????????????45Thr?Sar?Met?Asn?Asp?Glu?Pro?Val?Val?Ile?Lys?Asn?Leu?Ile?Val?Asn
50??????????????????55??????????????????60Arg?Gly?Asn?Ser?Cys?Glu?Ala?Thr?Lys?Lys?Val?Glu?Pro?Lys?Phe?Gly65??????????????????70??????????????????75??????????????????80Asp?Lys?Phe?Lys?Lys?Glu?Lys?Leu?Phe?Asp?His?Glu?Leu?Lys?Tyr?Ser
85??????????????????90??????????????????95Gln?Gln?Ile?Phe?Tyr?Arg?Leu?Asp?Cys?Lys?Pro?Asn?Gln?Leu?Leu?Glu
100?????????????????105?????????????????110Val?Lys?Ile?Ile?Thr?Asp?Lys?Gly?Glu?Tyr?Tyr?His?Lys?Phe?Ser?Lys
The data of 115 120 125 (2) SEQ ID NO:137:
(ⅰ) sequence signature:
(A) length: 169 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..169
(ⅹ ⅰ) sequence description: SEQ ID NO:137:Met Gln Ala Leu Lys Ser Leu Leu Glu Val Ile Thr Lys Leu Gln Asn1 5 10 15Leu Gly Gly Tyr Leu Met His Ile Ala Ila Phe Ile Ile Phe Ile Trp
20??????????????????25??????????????????30Ile?Gly?Gly?Leu?Lys?Phe?Val?Pro?Tyr?Glu?Ala?Glu?Gly?Ile?Ala?Pro
35??????????????????40??????????????????45Phe?Val?Ala?Asn?Ser?Pro?Phe?Phe?Ser?Phe?Met?Tyr?Lys?Phe?Glu?Lys
50??????????????????55??????????????????60Pro?Ala?Tyr?Lys?Gln?His?Lys?Met?Ser?Glu?Ser?Gln?Ser?Met?Gln?Glu65??????????????????70??????????????????75??????????????????80Glu?Met?Gln?Asp?Asn?Pro?Lys?Ile?Val?Glu?Asn?Lys?Glu?Trp?His?Lys
85??????????????????90??????????????????95Glu?Asn?Arg?Thr?Tyr?Leu?Val?Ala?Glu?Gly?Leu?Gly?Ile?Thr?Ile?Met
100?????????????????105?????????????????110Ile?Leu?Gly?Ile?Leu?Val?Leu?Leu?Gly?Leu?Trp?Met?Pro?Leu?Met?Gly
115?????????????????120?????????????????125Val?Val?Gly?Gly?Leu?Leu?Val?Ala?Gly?Met?Thr?Ile?Thr?Thr?Leu?Phe
130?????????????????135?????????????????140Phe?Phe?Ile?His?Asn?Ala?Arg?Ser?Val?Cys?Gln?Ser?Ala?Phe?Pro?Met145?????????????????150?????????????????155?????????????????160Ala?Phe?Trp?Gly?Trp?Lys?Ala?Ser?Gly
The data of 165 (2) SEQ ID NO:138:
(ⅰ) sequence signature:
(A) length: 487 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..487
(ⅹ ⅰ) sequence description: SEQ ID NO:138:Met Ile Glu Trp Met Gln Asn His Arg Lys Tyr Leu Val Val Thr Ile1 5 10 15Trp Ile Ser Thr Ile Ala Phe Ile Ala Ala Gly Met Ile Gly Trp Gly
20??????????????????25??????????????????30Gln?Tyr?Ser?Phe?Ser?Leu?Asp?Ser?Asp?Ser?Ala?Ala?Lys?Val?Gly?Gln
35??????????????????40??????????????????45Ile?Lys?Ile?Ser?Gln?Glu?Glu?Leu?Ala?Gln?Glu?Tyr?Arg?Arg?Leu?Lys
50??????????????????55??????????????????60Asp?Ala?Tyr?Ala?Glu?Ser?Ile?Pro?Asp?Phe?Lys?Glu?Leu?Thr?Glu?Asp65??????????????????70??????????????????75??????????????????80Gln?Ile?Lys?Ala?Met?His?Leu?Glu?Lys?Ser?Ala?Leu?Asp?Ser?Leu?Ile
85??????????????????90??????????????????95Asn?Gln?Ala?Leu?Leu?Arg?Asn?Phe?Ala?Leu?Asp?Leu?Gly?Leu?Gly?Ala
100?????????????????105?????????????????110Thr?Lys?Gln?Glu?Val?Ala?Lys?Glu?Ile?Arg?Lys?Thr?Asn?Val?Phe?Gln
115?????????????????120?????????????????125Lys?Asp?Gly?Val?Phe?Asp?Glu?Glu?Leu?Tyr?Lys?Asn?Ile?Leu?Lys?Gln
130?????????????????135?????????????????140Ser?His?Tyr?Arg?Pro?Lys?His?Phe?Glu?Glu?Ser?Val?Glu?Arg?Leu?Leu145?????????????????150?????????????????155?????????????????160Ile?Leu?Gln?Lys?Ile?Ser?Ala?Leu?Phe?Pro?Lys?Thr?Thr?Thr?Pro?Leu
165?????????????????170?????????????????175Glu?Gln?Ser?Ser?Leu?Ser?Leu?Trp?Ala?Lys?Leu?Gln?Asp?Lys?Leu?Asp
180?????????????????185?????????????????190Ile?Leu?Ile?Leu?Asn?Pro?Asn?Asp?Val?Lys?Ile?Ser?Leu?Asn?Glu?Glu
195?????????????????200?????????????????205Glu?Met?Lys?Lys?Tyr?Tyr?Glu?Asn?His?Arg?Lys?Asp?Phe?Lys?Lys?Pro
210?????????????????215?????????????????220Thr?Ser?Phe?Lys?Thr?Arg?Ser?Leu?Tyr?Phe?Asp?Ala?Ser?Leu?Glu?Lys225?????????????????230?????????????????235?????????????????240Thr?Asp?Leu?Lys?Glu?Leu?Glu?Glu?Tyr?Tyr?His?Lys?Asn?Lys?Val?Ser
245?????????????????250?????????????????255Tyr?Leu?Asp?Lys?Glu?Gly?Lys?Leu?Gln?Asp?Phe?Lys?Ser?Val?Gln?Glu
260?????????????????265?????????????????270Gln?Val?Lys?His?Asp?Leu?Asn?Met?Gln?Lys?Ala?Asn?Glu?Lys?Ala?Leu
275?????????????????280?????????????????285Arg?Ser?Tyr?Ile?Ala?Leu?Lys?Lys?Gly?Asn?Ala?Gln?Asn?Tyr?Thr?Thr
290?????????????????295?????????????????300Gln?Asp?Phe?Glu?Lys?Asn?Asn?Ser?Pro?Tyr?Thr?Ala?Glu?Ile?Thr?Gln305?????????????????310?????????????????315?????????????????320Lys?Leu?Thr?Ala?Leu?Lys?Pro?Leu?Glu?Val?Leu?Lys?Pro?Glu?Pro?Phe
325?????????????????330?????????????????335Lys?Asp?Gly?Phe?lle?Val?Val?Gln?Leu?Val?Ser?Gln?Ile?Lys?Asp?Glu
340?????????????????345?????????????????350Leu?Gln?Asn?Phe?Asp?Glu?Ala?Lys?Ser?Ala?Leu?Lys?Thr?Arg?Leu?Thr
355?????????????????360?????????????????365Gln?Glu?Lys?Thr?Leu?Met?Ala?Leu?Gln?Thr?Leu?Ala?Lys?Glu?Lys?Leu
370?????????????????375?????????????????380Lys?Asp?Phe?Lys?Gly?Lys?Ser?Val?Gly?Tyr?Val?Ser?Pro?Asn?Phe?Gly385?????????????????390?????????????????395?????????????????400Gly?Thr?Ile?Ser?Glu?Leu?Asn?Gln?Glu?Glu?Ser?Ala?Lys?Phe?Ile?Asn
405?????????????????410?????????????????415Thr?Leu?Phe?Asn?Arg?Gln?Glu?Lys?Lys?Gly?Phe?Val?Thr?Ile?Gly?Asn
420?????????????????425?????????????????430Lys?Val?Val?Leu?Tyr?Gln?Ile?Thr?Glu?Gln?Asn?Phe?Asn?His?Pro?Phe
435?????????????????440?????????????????445Ser?Ala?Glu?Glu?Asn?Gln?Tyr?Met?Gln?Arg?Leu?Val?Asn?Asn?Thr?Lys
450?????????????????455?????????????????460Thr?Asp?Phe?Phe?Asp?Lys?Ala?Leu?Ile?Glu?Glu?Leu?Lys?Lys?Arg?Tyr465?????????????????470?????????????????475?????????????????480Lys?Ile?Val?Lys?Tyr?Ile?Gln
The data of 485 (2) SEQ ID NO:139:
(ⅰ) sequence signature:
(A) length: 142 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..142
(ⅹ ⅰ) sequence description: SEQ ID NO:139:Met Lys Thr Asn Phe Tyr Lys Ile Lys Leu Leu Phe Ala Trp Cys Leu1 5 10 15Ile Ile Gly Met Phe Asn Ala Pro Leu Asn Ala Asp Gln Asn Thr Asp
20??????????????????25??????????????????30Ile?Lys?Asp?Ile?Ser?Pro?Glu?Asp?Met?Ala?Leu?Asn?Ser?Val?Gly?Leu
35??????????????????40??????????????????45Val?Ser?Arg?Asp?Gln?Leu?Lys?Ile?Glu?Ile?Pro?Lys?Glu?Thr?Leu?Glu
50??????????????????55??????????????????60Gln?Lys?Val?Ala?Ile?Leu?Asn?Asp?Tyr?Asn?Asp?Lys?Asn?Val?Asn?Ile65??????????????????70??????????????????75??????????????????80Lys?Phe?Asp?Asp?Ile?Ser?Leu?Gly?Ser?Phe?Gln?Pro?Asn?Asp?Asn?Leu
85??????????????????90??????????????????95Gly?Ile?Asn?Ala?Met?Trp?Gly?Ile?Gln?Asn?Leu?Leu?Met?Ser?Gln?Met
100?????????????????105?????????????????110Met?Ser?Asn?Tyr?Gly?Pro?Asn?Asn?Ser?Phe?Met?Tyr?Gly?Tyr?Ala?Pro
115?????????????????120?????????????????125Thr?Tyr?Ser?Asp?Ser?Ser?Phe?Leu?Pro?Pro?Ile?Leu?Gly?Tyr
The data of 130 l35,140 (2) SEQ ID NO:140:
(ⅰ) sequence signature:
(A) length: 208 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..208
(ⅹ ⅰ) sequence description: SEQ ID NO:140:Leu Ile Asn Asn Asn Asn Asn Asn Lys Lys Leu Arg Gly Phe Phe Leu1 5 10 15Lys Val Leu Leu Ser Leu Val Val Phe Ser Ser Tyr Gly Ser Ala Asn
20??????????????????25??????????????????30Asp?Asp?Lys?Glu?Ala?Lys?Lys?Glu?Ala?Leu?Glu?Lys?Glu?Lys?Asn?Thr
35??????????????????40??????????????????45Pro?Asn?Gly?Leu?Val?Tyr?Thr?Asn?Leu?Asp?Phe?Asp?Ser?Phe?Lys?Ala
50??????????????????55??????????????????60Thr?Ile?Lys?Asn?Leu?Lys?Asp?Lys?Lys?Val?Thr?Phe?Lys?Glu?Val?Asn65??????????????????70??????????????????75??????????????????80Pro?Asp?Ile?Ile?Lys?Asp?Glu?Val?Phe?Asp?Phe?Val?Ile?Val?Asn?Arg
85??????????????????90??????????????????95Val?Leu?Lys?Lys?Ile?Lys?Asp?Leu?Lys?His?Tyr?Asp?Pro?Val?Ile?Glu
100?????????????????105?????????????????110Lys?Ile?Phe?Asp?Glu?Lys?Gly?Lys?Glu?Met?Gly?Leu?Asn?Val?Glu?Leu
115?????????????????120?????????????????125Gln?Ile?Asn?Pro?Glu?Val?Lys?Asp?Phe?Phe?Thr?Phe?Lys?Ser?Ile?Ser
130?????????????????135?????????????????140Thr?Thr?Asn?Lys?Gln?Arg?Cys?Phe?Leu?Ser?Leu?His?Gly?Glu?Thr?Arg145?????????????????150?????????????????155?????????????????160Glu?Ile?Leu?Cys?Asp?Asp?Lys?Leu?Tyr?Asn?Val?Leu?Leu?Ala?Val?Phe
165?????????????????170?????????????????175Asn?Ser?Tyr?Asp?Pro?Asn?Asp?Leu?Leu?Lys?His?Ile?Ser?Thr?Ile?Glu
180?????????????????185?????????????????190Ser?Leu?Lys?Lys?Ile?Phe?Tyr?Thr?Ile?Thr?Cys?Glu?Ala?Val?Tyr?Leu
The data of 195 200 205 (2) SEQ ID NO:141:
(ⅰ) sequence signature:
(A) length: 245 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..245
(ⅹ ⅰ) sequence description: SEQ ID NO:141:Met Ala Gly Thr Gln Ala Ile Tyr Glu Ser Ser Ser Ala Gly Phe Leu1 5 10 15Ser Gln Val Ser Ser Ile Ile Ser Ser Thr Ser Gly Val Ala Gly Pro
20??????????????????25??????????????????30Phe?Ala?Gly?Ile?Val?Ala?Gly?Ala?Met?Thr?Ala?Ala?Ile?Ile?Pro?Ile
35??????????????????40??????????????????45Val?Val?Gly?Phe?Thr?Asn?Pro?Gln?Met?Thr?Ala?Ile?Met?Thr?Gln?Tyr
50??????????????????55??????????????????60Asn?Gln?Ser?Ile?Ala?Glu?Ala?Val?Ser?Val?Pro?Met?Lys?Ala?Ala?Asn65??????????????????70??????????????????75??????????????????80Gln?Gln?Tyr?Asn?Gln?Leu?Tyr?Gln?Gly?Phe?Asn?Asp?Gln?Ser?Met?Ala
85??????????????????90??????????????????95Val?Gly?Asn?Asn?Ile?Leu?Asn?Ile?Ser?Lys?Leu?Thr?Gly?Glu?Phe?Asn
100?????????????????105?????????????????110Ala?Gln?Gly?Asn?Tnr?Gln?Ser?Ala?Gln?Ile?Ser?Ala?Val?Asn?Ser?Gln
115?????????????????120?????????????????125Ile?Ala?Ser?Ile?Leu?Ala?Ser?Asn?Thr?Thr?Pro?Lys?Asn?Pro?Ser?Ala
130?????????????????135?????????????????140Ile?Glu?Ala?Tyr?Ala?Thr?Asn?Gln?Ile?Ala?Val?Pro?Ser?Val?Pro?Thr145?????????????????150?????????????????155?????????????????160Thr?Val?Glu?Met?Met?Ser?Gly?Ile?Leu?Gly?Asn?Ile?Thr?Ser?Ala?Ala
165?????????????????170?????????????????175Pro?Lys?Tyr?Ala?Leu?Ala?Leu?Gln?Glu?Gln?Leu?Arg?Ser?Gln?Ala?Ser
180?????????????????185?????????????????190Asn?Ser?Ser?Met?Asn?Asp?Thr?Ala?Asp?Ser?Leu?Asp?Ser?Cys?Thr?Ala
195?????????????????200?????????????????205Leu?Gly?Ala?Leu?Val?Gly?Ser?Ser?Lys?Val?Phe?Phe?Ser?Cys?Met?Gln
210?????????????????215?????????????????220Ile?Ser?Met?Thr?Pro?Met?Ser?Val?Ser?Met?Pro?Thr?Val?Met?Pro?Asn225?????????????????230?????????????????235?????????????????240Thr?Ser?Gly?Cys?His
The data of 245 (2) SEQ ID NO:142:
(ⅰ) sequence signature:
(A) length: 367 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..367
(ⅹ ⅰ) sequence description: SEQ ID NO:142:Met Ile Lys Ser Val Glu Ile Glu Asn Tyr Lys Asn Phe Glu His Leu1 5 10 15Lys Met Glu Asn Phe Lys Leu Ile Asn Phe Phe Thr Gly Gln Asn Asp
20??????????????????25??????????????????30Ala?Gly?Lys?Thr?Asn?Leu?Leu?Glu?Ala?Leu?Tyr?Thr?Asn?Thr?Gly?Leu
35??????????????????40??????????????????45Cys?Asp?Pro?Thr?Ala?Asn?Gln?Val?Ser?Leu?Pro?Pro?Glu?His?Ala?Val
50??????????????????55??????????????????60Asn?Ile?Ser?Glu?Phe?Arg?Lys?Ile?Lys?Leu?Asp?Ala?Asp?Asn?Leu?Lys65??????????????????70??????????????????75??????????????????80Thr?Phe?Phe?Tyr?Gln?Gly?Asn?Thr?Ala?Asn?Pro?Ile?Ser?Ile?Arg?Thr
85??????????????????90??????????????????95Glu?Phe?Glu?His?Ala?Thr?Ile?Pro?Leu?Thr?Ile?Gln?Tyr?Pro?Thr?Gln
100?????????????????105?????????????????110Thr?Ser?Tyr?Ser?Lys?Asp?Ile?Asn?Leu?Asn?Ser?Asp?Asp?Ala?His?Met
115?????????????????120?????????????????125Thr?Asn?Leu?Ile?Asn?Thr?Thr?Ile?Thr?Lys?Pro?Gln?Leu?Gln?Phe?Ser
130?????????????????135?????????????????140Tyr?Asn?Pro?Ser?Leu?Ser?Pro?Met?Thr?Met?Thr?Tyr?Glu?Phe?Glu?Arg145?????????????????150?????????????????155?????????????????160Gln?Asn?Leu?Gly?Leu?Ile?His?Ser?Asn?Leu?Asp?Lys?Ile?Ala?Gln?Thr
165?????????????????170?????????????????175Tyr?Lys?Glu?Asn?Ala?Met?Phe?Ile?Pro?Ile?Glu?Leu?Ser?Ile?Val?Asn
180?????????????????185?????????????????190Ser?Leu?Lys?Ala?Leu?Glu?Asn?Leu?Gln?Leu?Ala?Ser?Lys?Glu?Lys?Glu
195?????????????????200?????????????????205Leu?Ile?Glu?Ile?Leu?Gln?Cys?Phe?Asn?Pro?Asn?Ile?Leu?Asn?Ala?Asn
210?????????????????215?????????????????220Thr?Ile?Arg?Lys?Ser?Val?Tyr?Ile?Gln?Ile?Lys?Asp?Glu?Asn?Thr?Pro225?????????????????230?????????????????235?????????????????240Leu?Glu?Glu?Ser?Pro?Lys?Arg?Leu?Leu?Asn?Leu?Phe?Gly?Trp?Gly?Phe
245?????????????????250?????????????????255Ile?Lys?Phe?Phe?Ile?Met?Val?Ser?Ile?Leu?Ile?Asp?Asn?Arg?Val?Lys
260?????????????????265?????????????????270Tyr?Leu?Phe?Ile?Asp?Glu?Ile?Glu?Ser?Gly?Leu?His?His?Thr?Lys?Met
275?????????????????280?????????????????285Gln?Glu?Phe?Leu?Lys?Ala?Leu?Phe?Lys?Leu?Ala?Gln?Lys?Leu?Gln?Ile
290?????????????????295?????????????????300Gln?Ile?Phe?Ala?Thr?Thr?His?Asn?Lys?Glu?Phe?Leu?Leu?Asn?Ala?Ile305?????????????????310?????????????????315?????????????????320Asn?Thr?Ile?Ser?Asp?Asn?Glu?Thr?Gly?Val?Phe?Lys?Asp?Ile?Ala?Leu
325?????????????????330?????????????????335Phe?Glu?Leu?Glu?Lys?Glu?Ser?Ala?Ser?Gly?Phe?Ile?Arg?His?Ser?Tyr
340?????????????????345?????????????????350Ser?Met?Leu?Glu?Lys?Ala?Leu?Tyr?Arg?Gly?Met?Glu?Val?Arg?Gly
The data of 355 360 365 (2) SEQ ID NO:143:
(ⅰ) sequence signature:
(A) length: 409 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..409
(ⅹ ⅰ) sequence description: SEQ ID NO:143:Met Ser Leu Ile Arg Val Asn Gly Glu Ala Phe Lys Leu Ser Leu Glu1 5 10 15Ser Leu Glu Glu Asp Pro Phe Glu Thr Lys Glu Thr Leu Glu Thr Leu
20??????????????????25??????????????????30Glu?Thr?Leu?Ile?Lys?Gln?Thr?Ser?Val?Val?Leu?Leu?Ala?Ala?Gly?Glu
35??????????????????40??????????????????45Ser?Lys?Arg?Phe?Ser?Arg?Ala?Ile?Lys?Lys?Gln?Trp?Leu?Arg?Ser?His
50??????????????????55??????????????????60His?Thr?Pro?Leu?Trp?Leu?Ser?Val?Tyr?Glu?Ser?Phe?Lys?Glu?Ala?Leu65??????????????????70??????????????????75??????????????????80Asp?Phe?Lys?Glu?Val?Ile?Leu?Val?Val?Ser?Glu?Leu?Asp?Tyr?Val?Tyr
85??????????????????90??????????????????95Ile?Gln?Arg?His?Tyr?Pro?Lys?Ile?Lys?Leu?Val?Lys?Gly?Gly?Ala?Ser
100?????????????????105?????????????????110Arg?Gln?Glu?Ser?Val?Arg?Asn?Ala?Leu?Lys?Val?Ile?Asp?Ser?Thr?Tyr
115?????????????????120?????????????????125Thr?Ile?Thr?Ser?Asp?Val?Ala?Arg?Gly?Leu?Ala?Asn?Met?Glu?Ala?Leu
130?????????????????135?????????????????140Lys?Ser?Leu?Phe?Leu?Thr?Leu?Gln?Gln?Thr?Ser?His?Tyr?Cys?Ile?Ala145?????????????????150?????????????????155?????????????????160Pro?Tyr?Leu?Pro?Cys?Tyr?Asp?Thr?Ala?Ile?Tyr?Tyr?Asn?Glu?Ala?Leu
165?????????????????170?????????????????175Asp?Arg?Glu?Ala?Ile?Lys?Leu?Ile?Gln?Thr?Pro?Gln?Leu?Ser?His?Thr
180?????????????????185?????????????????190Lys?Thr?Leu?Gln?Ser?Ala?Leu?Asn?Gln?Gly?Gly?Phe?Lys?Asp?Glu?Ser
195?????????????????200?????????????????205Ser?Ala?Ile?Leu?Gln?Ala?Pha?Pro?Asn?Ser?Val?Ser?Tyr?Ile?Glu?Gly
210?????????????????215?????????????????220Ser?Lys?Asp?Leu?His?Lys?Leu?Thr?Thr?Ser?Gly?Asp?Leu?Lys?Phe?Phe225?????????????????230?????????????????235?????????????????240Thr?Pro?Phe?Phe?Asn?Pro?Ala?Lys?Asp?Thr?Phe?Ile?Gly?Met?Gly?Phe
245?????????????????250?????????????????255Asp?Thr?His?Ala?Phe?Ile?Lys?Asp?Lys?Pro?Met?Val?Leu?Gly?Gly?Val
260?????????????????265?????????????????270Val?Leu?Asp?Cys?Glu?Phe?Gly?Leu?Lys?Ala?His?Ser?Asp?Gly?Asp?Ala
275?????????????????280?????????????????285Leu?Leu?His?Ala?Val?Ile?Asp?Ala?Ile?Leu?Gly?Ala?Ile?Lys?Gly?Gly
290?????????????????295?????????????????300Asp?Ile?Gly?Glu?Trp?Phe?Pro?Asp?Asn?Asp?Pro?Lys?Tyr?Lys?Asn?Ala305?????????????????310?????????????????315?????????????????320Ser?Ser?Lys?Glu?Leu?Leu?Lys?Ile?Val?Leu?Asp?Phe?Ser?Gln?Ser?Ile
325?????????????????330?????????????????335Gly?Phe?Glu?Leu?Leu?Glu?Met?Gly?Ala?Thr?Ile?Phe?Ser?Glu?Ile?Pro
340?????????????????345?????????????????350Lys?Ile?Thr?Pro?Tyr?Lys?Pro?Ala?Ile?Leu?Glu?Asn?Leu?Ser?Gln?Leu
355?????????????????360?????????????????365Leu?Gly?Leu?Glu?Lys?Ser?Gln?Ile?Ser?Leu?Lys?Ala?Thr?Thr?Met?Glu
370?????????????????375?????????????????380Lys?Met?Gly?Phe?Ile?Gly?Lys?Gln?Glu?Gly?Leu?Leu?Val?Gln?Ala?His385?????????????????390?????????????????395?????????????????400Val?Ser?Met?Arg?Tyr?Lys?Gln?Lys?Leu
The data of 405 (2) SEQ ID NO:144:
(ⅰ) sequence signature:
(A) length: 270 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..270
(ⅹ ⅰ) sequence description: SEQ ID NO:144:Met Lys Lys Phe Val Ala Leu Gly Leu Leu Ser Ala Val Leu Ser Ser1 5 10 15Ser Leu Leu Ala Glu Gly Asp Gly Val Tyr Ile Gly Thr Asn Tyr Gln
20??????????????????25??????????????????30Leu?Gly?Gln?Ala?Arg?Leu?Asn?Ser?Asn?Ile?Tyr?Asn?Thr?Gly?Asp?Cys
35??????????????????40??????????????????45Thr?Gly?Ser?Val?Val?Gly?Cys?Pro?Pro?Gly?Leu?Thr?Ala?Asn?Lys?His
50??????????????????55??????????????????60Asn?Pro?Gly?Gly?Thr?Asn?Ile?Asn?Trp?His?Ser?Lys?Tyr?Ala?Asn?Gly65??????????????????70??????????????????75??????????????????80Ala?Leu?Asn?Gly?Phe?Gly?Leu?Asn?Val?Gly?Tyr?Lys?Lys?Phe?Phe?Gln
85??????????????????90??????????????????95Phe?Lys?Ser?Leu?Asp?Met?Thr?Ser?Lys?Trp?Phe?Gly?Phe?Arg?Val?Tyr
100?????????????????105?????????????????110Gly?Leu?Phe?Asp?Tyr?Gly?His?Ala?Asp?Leu?Gly?Lys?Gln?Val?Tyr?Ala
115?????????????????120?????????????????125Pro?Asn?Lys?Ile?Gln?Leu?Asp?Met?Val?Ser?Trp?Gly?Val?Gly?Ser?Asp???130??????????????????135?????????????????140Leu?Leu?Ala?Asp?Ile?Ile?Asp?Lys?Asp?Asn?Ala?Ser?Phe?Gly?Ile?Phe145?????????????????150?????????????????155?????????????????160Gly?Gly?Val?Ala?Ile?Gly?Gly?Asn?Thr?Trp?Lys?Ser?Ser?Ala?Ala?Asn
165?????????????????170?????????????????175Tyr?Trp?Lys?Glu?Gln?Ile?Ile?Glu?Ala?Lys?Gly?Pro?Asp?Val?Cys?Thr
180?????????????????185?????????????????190Pro?Thr?Tyr?Cys?Asn?Pro?Asn?Ala?Pro?Tyr?Ser?Thr?Asn?Thr?Ser?Thr
195?????????????????200?????????????????205Val?Ala?Phe?Gln?Val?Trp?Leu?Asn?Phe?Gly?Val?Arg?Ala?Asn?Ile?Tyr
210?????????????????215?????????????????220Lys?His?Asn?Gly?Val?Glu?Phe?Gly?Val?Arg?Val?Pro?Leu?Leu?Ile?Asn225?????????????????230?????????????????235?????????????????240Lys?Phe?Leu?Ser?Ala?Gly?Pro?Asn?Ala?Thr?Asn?Leu?Tyr?Tyr?His?Leu
245?????????????????250?????????????????255Lys?Arg?Asp?Tyr?Ser?Leu?Tyr?Leu?Gly?Tyr?Asn?Tyr?Thr?Phe
The data of 260 265 270 (2) SEQ ID NO:145:
(ⅰ) sequence signature:
(A) length: 438 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..438
(ⅹ ⅰ) sequence description: SEQ ID NO:145:Met Ala Tyr Lys Pro Asn Lys Lys Lys Leu Lys Glu Leu Arg Glu Gln1 5 10 15Pro Asn Leu Phe Ser Ile Leu Asp Lys Gly Asp Val Ala Thr Asn Asn
20??????????????????25??????????????????30Pro?Val?Glu?Glu?Ser?Asp?Lys?Ala?Asn?Lys?Ile?Gln?Glu?Pro?Leu?Pro
35??????????????????40??????????????????45Tyr?Val?Val?Lys?Thr?Gln?Ile?Asn?Lys?Ala?Ser?Met?Ile?Ser?Arg?Asp
50??????????????????55??????????????????60Pro?Ile?Glu?Trp?Ala?Lys?Tyr?Leu?Ser?Phe?Glu?Lys?Arg?Val?Tyr?Lys65??????????????????70??????????????????75??????????????????80Asp?Asn?Ser?Lys?Glu?Asp?Val?Asn?Phe?Phe?Ala?Asn?Gly?Glu?Ile?Lys
85??????????????????90??????????????????95Glu?Ser?Ser?Arg?Val?Tyr?Glu?Ala?Asn?Lys?Glu?Gly?Phe?Glu?Arg?Arg
100?????????????????105?????????????????110Ile?Thr?Lys?Arg?Tyr?Asp?Leu?Ile?Asp?Arg?Asn?Ile?Asp?Arg?Asn?Arg
115?????????????????120?????????????????125Glu?Phe?Phe?Ile?Lys?Glu?Ile?Glu?Ile?Leu?Thr?His?Thr?Asn?Ser?Leu
130?????????????????135?????????????????140Lys?Glu?Leu?Lys?Glu?Gln?Gly?Leu?Glu?Ile?Gln?Leu?Thr?His?His?Asn145?????????????????150?????????????????155?????????????????160Glu?Thr?His?Lys?Lys?Ala?Leu?Glu?Asn?Gly?Asn?Glu?Ile?Val?Lys?Glu
165?????????????????170?????????????????175Tyr?Asp?His?Leu?Lys?Asp?Ile?Tyr?Gln?Glu?Val?Glu?Arg?Thr?Lys?Asp
180?????????????????185?????????????????190Gly?Gly?Leu?Val?Arg?Glu?Ile?Ile?Pro?Ser?Ile?Ser?Ser?Ala?Glu?Tyr
195?????????????????200?????????????????205Phe?Lys?Leu?Tyr?Asn?Lys?Leu?Pro?Phe?Glu?Ser?Ile?Asn?Asn?Glu?Asn
210?????????????????215?????????????????220Thr?Lys?Leu?Asn?Thr?Asn?Asp?Asn?Glu?Glu?Val?Lys?Lys?Leu?Glu?Phe225?????????????????230?????????????????235?????????????????240Glu?Leu?Ala?Lys?Glu?Val?His?Ile?Leu?Ile?Leu?Glu?Gln?Gln?Leu?Leu
245?????????????????250?????????????????255Ser?Ala?Thr?Asn?Tyr?Tyr?Ser?Trp?Ile?Asp?Lys?Asp?Asp?Asn?Ala?Asn
260?????????????????265?????????????????270Phe?Ala?Trp?Lys?Met?Mis?Arg?Leu?Ile?Asn?Glu?Asn?Lys?Leu?Lys?Glu
275?????????????????280?????????????????285Asn?His?Leu?Ser?Ala?Asn?Asn?Ala?Asn?Lys?Ile?Lys?Gln?Phe?Phe?Phe
290?????????????????295?????????????????300Asn?Asn?Gly?Ser?Ile?Leu?Gly?Trp?Thr?Lys?Glu?Glu?Gln?Ser?Ala?Ile305?????????????????310?????????????????315?????????????????320Gln?Glu?Asn?Arg?Asp?Tyr?Ser?Leu?Arg?Ser?Ala?Leu?Leu?Ser?Leu?Glu
325?????????????????330?????????????????335Glu?Ile?Ala?Gln?Ala?Lys?Ile?Glu?Leu?Gln?Lys?Tyr?Tyr?Glu?Ser?Val
340?????????????????345?????????????????350Tyr?Val?Asn?Gly?Asp?Gly?Asn?Lys?Arg?Glu?Ile?Lys?Pro?Phe?Lys?Glu
355?????????????????360?????????????????365Ile?Leu?Arg?Asp?Thr?Asn?Asn?Phe?Glu?Lys?Ala?Tyr?Lys?Glu?Arg?Tyr
370?????????????????375?????????????????380Asp?Lys?Leu?Val?Ser?Leu?Ser?Ala?Ala?Ile?Ile?Gln?Ala?Lys?Glu?Gly385?????????????????390?????????????????395?????????????????400Gly?Asn?Glu?Arg?Pro?Asn?Ser?Ser?Ala?Asn?Asn?Asn?Asn?Pro?Ile?Lys
405?????????????????410?????????????????415Asn?Thr?Ile?Glu?Thr?Asn?Thr?Ser?Asn?Asn?Ile?Ile?Gln?Asn?Asn?Asp
420?????????????????425?????????????????430Asn?Ile?Ile?Ile?Gln?Ile
The data of 435 (2) SEQ ID NO:146:
(ⅰ) sequence signature:
(A) length: 215 amino acid
(B) type: amino acid
(D) topological structure: linearity
(ⅱ) molecule type: protein
(ⅲ) hypothesis: be
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..215
(ⅹ ⅰ) sequence description: SEQ ID NO:146:Met Gln Ala Leu Lys Ser Leu Leu Glu Val Ile Thr Lys Leu Gln Asn1 5 10 15Leu Gly Gly Tyr Leu Met His Ile Ala Ile Phe Ile Ile Phe Ile Trp
20??????????????????25??????????????????30Ile?Gly?Gly?Leu?Lys?Phe?Val?Pro?Tyr?Glu?Ala?Glu?Gly?Ile?Ala?Pro
35??????????????????40??????????????????45Phe?Val?Ala?Asn?Ser?Pro?Phe?Phe?Ser?Phe?Met?Tyr?Lys?Phe?Glu?Lys
50??????????????????55??????????????????60Pro?Ala?Tyr?Lys?Gln?His?Lys?Met?Ser?Glu?Ser?Gln?Ser?Met?Gln?Glu65??????????????????70??????????????????75??????????????????80Glu?Met?Gln?Asp?Asn?Pro?Lys?Ile?Val?Glu?Asn?Lys?Glu?Trp?His?Lys
85??????????????????90??????????????????95Glu?Asn?Arg?Thr?Tyr?Leu?Val?Ala?Glu?Gly?Leu?Gly?Ile?Thr?Ile?Met
100?????????????????105?????????????????110Ile?Leu?Gly?Ile?Leu?Val?Leu?Leu?Gly?Leu?Trp?Met?Pro?Leu?Met?Gly
115?????????????????120?????????????????125Val?Val?Gly?Gly?Leu?Leu?Val?Ala?Gly?Met?Thr?Ile?Thr?Thr?Leu?Ser
130?????????????????135?????????????????140Phe?Leu?Phe?Thr?Thr?Pro?Glu?Val?Phe?Val?Asn?Gln?His?Phe?Pro?Trp145?????????????????150?????????????????155?????????????????160Leu?Ser?Gly?Ala?Gly?Arg?Leu?Val?Val?Lys?Asp?Leu?Ala?Leu?Phe?Ala
165?????????????????170?????????????????175Gly?Gly?Leu?Phe?Val?Ala?Gly?Phe?Asp?Ala?Lys?Arg?Tyr?Leu?Glu?Gly
180?????????????????185?????????????????190Lys?Gly?Phe?Cys?Leu?Met?Asp?Arg?Ser?Ser?Val?Gly?Ile?Lys?Thr?Lys
195?????????????????200?????????????????205Cys?Ser?Ser?Gly?Cys?Cys?Ser
The data of 210 215 (2) SEQ ID NO:147:
(ⅰ) sequence signature:
(A) length: 20 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..20
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:147:TATACCATGG TGGGCGCTAA 20 (2) SEQ ID NO:148:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:148:ATGAATTCGA GTAAGGATTT TTG 23 (2) SEQ ID NO:149:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:149:TTAACCATGG TGAAAAGCGA TA 22 (2) SEQ ID NO:150:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:150:TAGAATTCGC ATAACGATCA ATC 23 (2) SEQ ID NO:151:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:151:ATATCCATGG TGAGTTTGAT GA 22 (2) SEQ ID NO:152:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:152:ATGAATTCAA TTTTTTATTT TGCCA 25 (2) SEQ ID NO:153:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:153:AATTCCATGG TGGGGGCTAT G 21 (2) SEQ ID NO:154:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:154:ATGAATTCTC GATAGCCAAA ATC 23 (2) SEQ ID NO:155:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:155:AATTCCATGG TGCATAACTT CCATT 25 (2) SEQ ID NO:156:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:156:AAGAATTCTC TAGCATCCAA ATGGA 25 (2) SEQ ID NO:157:
(ⅰ) sequence signature:
(A) length: 24 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..24
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:157:ATTTCCATGG TCATGTCTCA TATT 24 (2) SEQ ID NO:158:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:158:ATGAATTCCA TCTTTTATTC CAC 23 (2) SEQ ID NO:159:
(ⅰ) sequence signature:
(A) length: 27 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..27
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:159:AACCATGGTG ATTTTAAGCA TTGAAAG 27 (2) SEQ ID NO:160:
(ⅰ) sequence signature:
(A) length: 28 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..28
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:160:AAGAATTCCA CTCAAAATTT TTTAACAG 28 (2) SEQ ID NO:161:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:161:GATCATCCAT ATGTTATCTT CTAAT 25 (2) SEQ ID NO:162:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:162:TGAATTCAAC CATTTTAACC CTG 23 (2) SEQ ID NO:163:
(ⅰ) sequence signature:
(A) length: 27 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..27
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:163:TATACCATGG TGAAATTTTT TCTTTTA 27 (2) SEQ ID NO:164:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:164:AGAATTCAAT TGCGTCTTGT AAGAAG 25 (2) SEQ ID NO:165:
(ⅰ) sequence signature:
(A) length: 24 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..24
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:165:TATACCATGG TGATGGACAA ACTC 24 (2) SEQ ID NO:166:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:166:ATGAATTCCC ACTTGGGGCG ATA 23 (2) SEQ ID NO:167:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:167:TTATGGATCC AAACCAATTA AAACT 25 (2) SEQ ID NO:168:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:168:TATCTCGAGT TATAGAGAAG GGC 23 (2) SEQ ID NO:169:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:169:TTAACCATGG TGAAAAGCGA TA 22 (2) SEQ ID NO:170:
(ⅰ) sequence signature:
(A) length: 24 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..24
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:170:TAGAATTCGC CTCTAAAACT TTAG 24 (2) SEQ ID NO:171:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:171:TTAACCATGG TGAAAAGCGA TA 22 (2) SEQ ID NO:172:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:172:TAGAATTCGC ATAACGATCA ATC 23 (2) SEQ ID NO:173:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:173:ATATCCATGG TGAGTTTGAT GA 22 (2) SEQ ID NO:174:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:174:ATGAATTCAA TTTTTTATTT TGCCA 25 (2) SEQ ID NO:175:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:175:AATTCCATGG CTATCCAAAT CCG 23 (2) SEQ ID NO:176:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:176:ATGAATTCGC CAAAATCGTA GTATT 25 (2) SEQ ID NO:177:
(ⅰ) sequence signature:
(A) length: 24 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..24
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:177:GATACCATGG AATTTATGAA AAAG 24 (2) SEQ ID NO:178:
(ⅰ) sequence signature:
(A) length: 25 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..25
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:178:TGAATTCGAA AAAGTGTAGT TATAC 25 (2) SEQ ID NO:179:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:179:CCCTTCATTT TAGAAATCG 19 (2) SEQ ID NO:180:
(ⅰ) sequence signature:
(A) length: 20 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..20
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:180:ATTTCAACCA ATTCAATGCG 20 (2) SEQ ID NO:181:
(ⅰ) sequence signature:
(A) length: 20 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..20
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:181:GCCCCTTTTG ATTTGAAGCT 20 (2) SEQ ID NO:182:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:182:TCGCTCCAAG ATACCAAGAA GT 22 (2) SEQ ID NO:183:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:183:CTTGAATTAG GGGCAAAGAT CG 22 (2) SEQ ID NO:184:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:184:ATGCGTTTTT ACCCAAAGAA GT 22 (2) SEQ ID NO:185:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:185:ATAACGCCAC TTCCTTATTG GT 22 (2) SEQ ID NO:186:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:186:CTTTGGGTAA AAACGCATC 19 (2) SEQ ID NO:187:
(ⅰ) sequence signature:
(A) length: 20 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..20
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:187:CGATCTTTGA TCCTAATTCA 20 (2) SEQ ID NO:188:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:188:ATCAAGTTGC CTATGCTGA 19 (2) SEQ ID NO:189:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:189:TTGAACACTT TTGATTATGC GG 22 (2) SEQ ID NO:190:
(ⅰ) sequence signature:
(A) length: 23 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..23
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:190:GGATTATGCG ATTGTTTTAC AAG 23 (2) SEQ ID NO:191:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:191:GTCTTTAGCA AAAATGGCGT C 21 (2) SEQ ID NO:192:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:192:AATGAGCGTA AGAGAGCCTT C 21 (2) SEQ ID NO:193:
(ⅰ) sequence signature:
(A) length: 18 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..18
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:193:CTTATGGGGG TATTGTCA 18 (2) SEQ ID NO:194:
(ⅰ) sequence signature:
(A) length: 18 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..18
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:194:AGCATGTGGG TATCCAGC 18 (2) SEQ ID NO:195:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:195:AGGTTGTTGC CTAAAGACT 19 (2) SEQ ID NO:196:
(ⅰ) sequence signature:
(A) length: 18 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..18
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:196:CTGCCTCCAC CTTTGATC 18 (2) SEQ ID NO:197:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:197:ACCAATATCA ATTGGCACT 19 (2) SEQ ID NO:198:
(ⅰ) sequence signature:
(A) length: 18 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..18
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:198:ACTTGGAAAA GCTCTGCA 18 (2) SEQ ID NO:199:
(ⅰ) sequence signature:
(A) length: 19 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..19
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:199:CTTGCTTGTC ATATCTAGC 19 (2) SEQ ID NO:200:
(ⅰ) sequence signature:
(A) length: 18 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..18
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:200:GTTGAAGTGT TGGTGCTA 18 (2) SEQ ID NO:201:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:201:CAAGCAAGTG GTTTGGTTTT AG 22 (2) SEQ ID NO:202:
(ⅰ) sequence signature:
(A) length: 22 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..22
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:202:TGGAAAGAGC AAATCATTGA AG 22 (2) SEQ ID NO:203:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:203:GCCCATAATC AAAAAGCCCA T 21 (2) SEQ ID NO:204:
(ⅰ) sequence signature:
(A) length: 24 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..24
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:204:CTAAAACCAA ACCACTTGCT TGTC 24 (2) SEQ ID NO:205:
(ⅰ) sequence signature:
(A) length: 16 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..16
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:205:GTAAAACGAC GGCCAG 16 (2) SEQ ID NO:206:
(ⅰ) sequence signature:
(A) length: 17 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..17
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:206:CAGGAAACAG CTATGAC 17 (2) SEQ ID NO:207:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: the data of SEQ ID NO:207:ATCTTACCTA TCACCTCAAA T 21 (2) SEQ ID NO:208:
(ⅰ) sequence signature:
(A) length: 21 base-pairs
(B) type: nucleic acid
(C) chain: two strands
(D) topological structure: annular
(ⅱ) molecule type: DNA (genome)
(ⅲ) hypothesis: not
(ⅳ) antisense: not
(ⅵ) source:
(A) biology: helicobacter pylori
(ⅸ) feature:
(A) title/keyword: misc_ feature
(B) position: 1..21
(ⅹ ⅰ) sequence description: SEQ ID NO:208:AGACAGCAAC ATCTTTGTGA A 21

Claims (65)

1. the nucleic acid of a separation, described nucleic acid contain the nucleotide sequence of coding helicobacter pylori polypeptide, described polypeptide be selected from the amino acid sequence of SEQ ID NO:74-SEQ ID NO:146 at least about 60% homology.
2. the nucleic acid of a separation, described nucleic acid contain the nucleotide sequence that coding is selected from the helicobacter pylori polypeptide of SEQ ID NO:74-SEQID NO:146.
3. the nucleic acid of the separation of the helicobacter pylori polypeptide of encoding, described nucleic acid contain and the nucleotide sequence that is selected from SEQ ID NO:1-SEQ ID NO:73 or its complement nucleotide sequence at least about 60% homology.
4. the nucleic acid of the separation of claim 1, described nucleic acid contains nucleotide sequence or its complement that is selected from SEQ ID NO:1-SEQID NO:73.
5. isolated nucleic acid molecule of helicobacter pylori polypeptide of encoding, described nucleic acid contain under tight hybridization conditions can with the nucleotide sequence of the making nucleic acid molecular hybridization that contains the nucleotide sequence that is selected from SEQ ID NO:1-SEQ ID NO:73 or its complement.
6. contain the nucleic acid of separation that length is at least the nucleotide sequence of 8 nucleotide, wherein said sequence under tight hybridization conditions can with contain the nucleotide sequence that is selected from SEQ ID NO:1-SEQ ID NO:73 or the nucleic acid hybridization of its complement.
7. the nucleic acid of a separation, described nucleic acid contains nucleotide sequence or its complement of coding helicobacter pylori cell membrane polypeptide or its fragment, and described nucleic acid is selected from: SEQ ID NO:3, SEQ IDNO:25, SEQ ID NO:48, SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQID NO:43, SEQ ID NO:11, SEQ ID NO:71, SEQ ID NO:17, SEQ IDNO:57, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:21.
8. the nucleic acid of the separation of claim 7, wherein said helicobacter pylori cell membrane polypeptide or its fragment are by membrane polypeptides or its fragment in the helicobacter pylori that is selected from following nucleic acid or its complement coding: SEQ ID NO:3, SEQ ID NO:25 and SEQ ID NO:48.
9. the nucleic acid of the separation of claim 7, wherein said helicobacter pylori membrane polypeptides or its fragment are by the helicobacter pylori ospa polypeptide or its fragment that are selected from following nucleic acid or its complement coding: SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQID NO:43, SEQID NO:11 and SEQ ID NO:71.
10. the nucleic acid of the separation of claim 9, wherein said helicobacter pylori ospa polypeptide or its fragment are by being selected from helicobacter pylori polypeptide or its fragment following nucleic acid or its complement coding, that have terminal phenylalanine residue and the terminal tyrosine of C bunch: SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ ID NO:43, SEQ ID NO:11 and SEQ ID NO:71.
11. the nucleic acid of the separation of claim 9, wherein said helicobacter pylori ospa polypeptide or its fragment are by being selected from following nucleic acid or its complement helicobacter pylori polypeptide or its fragment coding, that have terminal phenylalanine residue: SEQ ID NO:16, SEQ ID NO:45, SEQID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56 and SEQID NO:58.
12. the nucleic acid of a separation, described nucleic acid contains the nucleotide sequence of coding helicobacter pylori cell membrane polypeptide or its fragment, and wherein polypeptide is selected from SEQ ID NO:76, SEQ ID NO:98, SEQ ID NO:121, SEQ ID NO:89, SEQ ID NO:83, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84, SEQ ID NO:144, SEQ ID NO:90, SEQ ID NO:130, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:94.
13. the nucleic acid of the separation of claim 12, wherein said helicobacter pylori cell membrane polypeptide or its fragment are the interior membrane polypeptides of helicobacter pylori or its segments that is selected from SEQ ID NO:76, SEQ ID NO:98 and SEQ ID NO:121.
14. the nucleic acid of the separation of claim 12, wherein said helicobacter pylori cell membrane polypeptide or its fragment are to be selected from following helicobacter pylori ospa polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:83, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84, SEQ ID NO:144, SEQ ID NO:90 and SEQ ID NO:130.
15. the nucleic acid of the separation of claim 14, wherein said helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have the terminal tyrosine of terminal phenylalanine residue and C bunch helicobacter pylori polypeptide or its fragment: SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQID NO:84 and SEQ ID NO:144.
16. the nucleic acid of the separation of claim 14, wherein said helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have terminal phenylalanine residue helicobacter pylori polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:118, SEQ ID NO:1 08, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:1 29 and SEQ ID NO:131.
17. the nucleic acid of a separation, described nucleic acid contains nucleotide sequence or its complement of coding helicobacter pylori secrete polypeptide or its fragment, and described nucleic acid is selected from SEQ ID NO:72, SEQ IDNO:32, SEQ ID NO:51, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68.
18. the nucleic acid of a separation, described nucleic acid contains the nucleotide sequence of coding helicobacter pylori secrete polypeptide or its fragment, and wherein polypeptide is selected from SEQ ID NO:145, SEQ ID NO:105, SEQ ID NO:124, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:95, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:122, SEQ ID NO:126, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140 and SEQ ID NO:141.
19. the nucleic acid of a separation, described nucleic acid contains nucleotide sequence or its complement of coding helicobacter pylori cell polypeptide or its fragment, and this nucleic acid is selected from SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:47, SEQ ID NO:50, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:73.
20. the nucleic acid of a separation, described nucleic acid contains the nucleotide sequence of coding helicobacter pylori cell polypeptide or its fragment, and wherein polypeptide is selected from SEQ ID NO:85, SEQ ID NO:88, SEQ ID NO:93, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:133, SEQ ID NO:137, SEQ ID NO:142, SEQ ID NO:143 and SEQ ID NO:146.
21. a probe, described probe contain the nucleotide sequence of being made up of the nucleotide sequence that is selected from SEQ ID NO:1-SEQ ID NO:73 or at least 8 nucleotide in its complement.
22. contain the claim 1 that effectively links to each other with transcription regulatory element, the recombinant expression carrier of each nucleic acid in 2,3,4,5,6,7,12,17,18,19 or 20.
23. contain the cell of the recombinant expression carrier of claim 22.
24. produce the method for helicobacter pylori polypeptide, described method is included in the cell of cultivating claim 23 under the condition that allows expression of polypeptides.
25. the method for claim 24 also comprises purified polypeptide from cell.
26. detect the method that helicobacter nucleic acid exists in sample, comprise,
(a) sample is contacted with each nucleic acid in claim 6 or 21 so that can form the hybridization product between the helicobacter nucleic acid in probe and the sample; And
(b) detect the hybridization product that forms in the step (a), wherein detect the hybridization product and represent to exist in the sample helicobacter nucleic acid.
27. the helicobacter pylori polypeptide of a separation, described polypeptide contain and are selected from the amino acid sequence of the helicobacter pylori polypeptide of SEQ ID NO:74-SEQ ID NO:146 at least about 60% homology.
28. the helicobacter pylori polypeptide of a separation, wherein the nucleic acid of coding said polypeptide contains and is selected from the nucleotide sequence of the nucleotide sequence of SEQ ID NO:1-SEQ ID NO:73 at least about 60% homology.
29. the helicobacter pylori polypeptide of the separation of claim 28, wherein said polypeptide is by being selected from the nucleotide sequence coded of SEQ ID NO:1-SEQ ID NO:73.
30. the helicobacter pylori polypeptide of a separation, wherein the nucleic acid of coding said polypeptide is hybridized with the nucleic acid that is selected from SEQ ID NO:1-SEQ ID NO:73 or its complement under tight hybridization conditions.
31. the helicobacter pylori polypeptide of a separation, described polypeptide contain the amino acid sequence that is selected from SEQ ID NO:74-SEQ ID NO:146.
32. helicobacter pylori cell membrane polypeptide or its segment of separating, wherein said polypeptide is selected from SEQID NO:76, SEQ ID NO:98, SEQ ID NO:121, SEQ ID NO:89, SEQ IDNO:83, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ IDNO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ IDNO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ IDNO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:74, SEQ IDNO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84, SEQ IDNO:144, SEQ ID NO:90, SEQ ID NO:130, SEQ ID NO:78, SEQ IDNO:79, SEQ ID NO:81 and SEQ ID NO:94.
33. the polypeptide of the separation of claim 32, wherein said helicobacter pylori cell membrane polypeptide or its fragment are the interior membrane polypeptides of helicobacter pylori or its segments that is selected from SEQ ID NO:76, SEQ ID NO:98 and SEQ ID NO:121.
34. the polypeptide of the separation of claim 32, wherein said helicobacter pylori cell membrane polypeptide or its fragment are to be selected from following helicobacter pylori ospa polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:83, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84, SEQ ID NO:144, SEQ ID NO:90 and SEQ ID NO:130.
35. the polypeptide of the separation of claim 34, wherein said helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have the terminal tyrosine of terminal phenylalanine residue and C bunch helicobacter pylori polypeptide or its fragment: SEQ ID NO:74, SEQ ID NO:115, SEQ ID NO:87, SEQ ID NO:116, SEQ ID NO:84 and SEQ ID NO:144.
36. the polypeptide of the separation of claim 34, wherein said helicobacter pylori ospa polypeptide or its fragment are to be selected from following, as to have terminal phenylalanine residue helicobacter pylori polypeptide or its fragment: SEQ ID NO:89, SEQ ID NO:118, SEQ ID NO:108, SEQ ID NO:110, SEQ ID NO:80, SEQ ID NO:112, SEQ ID NO:128, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:101, SEQ ID NO:103, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129 and SEQ ID NO:131.
37. helicobacter pylori cell membrane polypeptide or its segment of separating, wherein said polypeptide is by being selected from following nucleic acid coding: SEQ ID NO:3, SEQ ID NO:25, SEQ ID NO:48, SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ IDNO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ ID NO:43, SEQ ID NO:11, SEQ ID NO:71, SEQ ID NO:17, SEQ ID NO:57, SEQ ID NO:5, SEQID NO:6, SEQ ID NO:8, SEQ ID NO:21.
38. the polypeptide of the separation of claim 37, wherein said helicobacter pylori cell membrane polypeptide or its fragment are by membrane polypeptides in the helicobacter pylori that is selected from following nucleic acid coding or its fragment: SEQ ID NO:3, SEQ ID NO:25 and SEQ ID NO:48.
39. the polypeptide of the separation of claim 37, wherein said helicobacter pylori cell membrane polypeptide or its fragment are by the helicobacter pylori ospa polypeptide that is selected from following nucleic acid coding or its fragment: SEQ ID NO:16, SEQ ID NO:10, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQID NO:1 8, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ IDNO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ ID NO:43, SEQ ID NO:11 and SEQ ID NO:71.
40. the polypeptide of the separation of claim 39, wherein said helicobacter pylori ospa polypeptide or its fragment are by being selected from helicobacter pylori polypeptide or its fragment following nucleic acid coding, that have the terminal tyrosine of terminal phenylalanine residue and C bunch: SEQ ID NO:1, SEQ ID NO:42, SEQ ID NO:14, SEQ ID NO:43, SEQ ID NO:11 and SEQ ID NO:71.
41. the polypeptide of the separation of claim 39, wherein said helicobacter pylori ospa polypeptide or its fragment are by being selected from helicobacter pylori polypeptide following nucleic acid coding, that have terminal phenylalanine residue or its fragment: SEQ ID NO:16, SEQ ID NO:45, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:7, SEQ ID NO:39, SEQ ID NO:55, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56 and SEQ ID NO:58.
42. helicobacter pylori cell polypeptide or its segment of separating, wherein said polypeptide is selected from: SEQID NO:85, SEQ ID NO:88, SEQ ID NO:93, SEQ ID NO:96, SEQ IDNO:97, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:120, SEQ IDNO:123, SEQ ID NO:133, SEQ ID NO:137, SEQ ID NO:142, SEQ IDNO:143 and SEQ ID NO:146.
43. helicobacter pylori cell polypeptide or its segment of separating, wherein said polypeptide is by being selected from following nucleic acid coding: SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:20, SEQID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ IDNO:47, SEQ ID NO:50, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:73.
44. helicobacter pylori secrete polypeptide or its segment of separating, wherein said polypeptide is selected from: SEQID NO:145, SEQ ID NO:105, SEQ ID NO:124, SEQ ID NO:75, SEQID NO:77, SEQ ID NO:82, SEQ ID NO:86, SEQ ID NO:95, SEQ IDNO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:107, SEQ IDNO:109, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:114, SEQ IDNO:117, SEQ ID NO:119, SEQ ID NO:122, SEQ ID NO:126, SEQ IDNO:132, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ IDNO:138, SEQ ID NO:139, SEQ ID NO:140 and SEQ ID NO:141.
45. helicobacter pylori secrete polypeptide or its segment of separating, wherein said polypeptide is by being selected from following nucleic acid coding: SEQ ID NO:72, SEQ ID NO:32, SEQ ID NO:51, SEQID NO:2, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:22, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68.
46. a fusion, described albumen contain the helicobacter pylori polypeptide that effectively links to each other with non-helicobacter pylori polypeptide, described helicobacter pylori polypeptide contains the amino acid sequence that is selected from SEQ ID NO:74-SEQ ID NO:146.
47. be used to prevent or treat the bacterin preparation of helicobacter pylori infections, described preparation contains at least a claim 1 that is selected from of effective dose, the nucleic acid of each separation in 2,3,4,5,6,7,12,17,18,19 or 20.
48. be used to prevent or treat the bacterin preparation of helicobacter pylori infections, described preparation contains at least a claim 26 that is selected from of effective dose, each helicobacter pylori polypeptide or its segment in 27,28,29,30,31,32,37,42,43,44 or 45.
49. the bacterin preparation of claim 47 also contains pharmaceutically useful carrier.
50. the bacterin preparation of claim 48 also contains pharmaceutically useful carrier.
51. the bacterin preparation of claim 49, wherein pharmaceutically useful carrier comprises adjuvant.
52. the bacterin preparation of claim 50, wherein pharmaceutically useful carrier comprises adjuvant.
53. the bacterin preparation of claim 49, wherein pharmaceutically useful carrier comprises the system of transporting.
54. the bacterin preparation of claim 50, wherein pharmaceutically useful carrier comprises the system of transporting.
55. the bacterin preparation of claim 53, the system that wherein transports comprises live vector.
56. the bacterin preparation of claim 54, the system that wherein transports comprises live vector.
57. the bacterin preparation of claim 55, wherein live vector is bacterium or virus.
58. the bacterin preparation of claim 56, wherein live vector is bacterium or virus.
59. the bacterin preparation of claim 53, wherein pharmaceutically useful carrier also comprises adjuvant.
60. the bacterin preparation of claim 54, wherein pharmaceutically useful carrier also comprises adjuvant.
61. treatment experimenter's helicobacter pylori infections or reduction experimenter infect the method for helicobacter pylori risk, comprise the bacterin preparation that gives claim 47 to the experimenter, thus the risk that treatment experimenter's helicobacter pylori infections or reduction experimenter infect helicobacter pylori.
62. treatment experimenter's helicobacter pylori infections or reduction experimenter infect the method for helicobacter pylori risk, comprise the bacterin preparation that gives claim 48 to the experimenter, thus the risk that treatment experimenter's helicobacter pylori infections or reduction experimenter infect helicobacter pylori.
63. produce the method for bacterin preparation, described method comprises: thus helicobacter pylori polypeptide or its segment of separation that will at least a SEQ of being selected from IDNO:74-SEQ ID NO:146 are mixed the formation bacterin preparation with pharmaceutically suitable carrier.
64. produce the method for bacterin preparation, described method comprises:
(a) provide helicobacter pylori polypeptide or its segment of the separation of at least a SEQ of being selected from ID NO:74-SEQ ID NO:146; With
(b) thus the helicobacter pylori polypeptide of at least a described separation or its segment mixed with pharmaceutically suitable carrier form bacterin preparation.
65. produce the method for bacterin preparation, described method comprises:
(a) cultured cell under condition that allow to express the helicobacter pylori polypeptide that is selected from SEQ ID NO:74-SEQ ID NO:146 or its segment;
(b) from described cell, isolate described helicobacter pylori polypeptide; With
(c) thus the helicobacter pylori polypeptide of at least a described separation or its segment mixed with pharmaceutically suitable carrier form bacterin preparation.
CN97199233A 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof Pending CN1235513A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73915096A 1996-10-28 1996-10-28
US08/739,150 1996-10-28
US75973996A 1996-12-06 1996-12-06
US08/759,739 1996-12-06
US89192897A 1997-07-14 1997-07-14
US08/891,928 1997-07-14

Publications (1)

Publication Number Publication Date
CN1235513A true CN1235513A (en) 1999-11-17

Family

ID=27419246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97199233A Pending CN1235513A (en) 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof

Country Status (19)

Country Link
EP (1) EP0973394A4 (en)
JP (1) JP2001504329A (en)
KR (1) KR20000052831A (en)
CN (1) CN1235513A (en)
AR (1) AR009600A1 (en)
AU (1) AU734052B2 (en)
BR (1) BR9712587A (en)
CA (1) CA2265523A1 (en)
EE (1) EE9900176A (en)
ID (1) ID22065A (en)
IL (1) IL129397A0 (en)
IS (1) IS5005A (en)
NO (1) NO991995L (en)
NZ (1) NZ334568A (en)
PL (1) PL333169A1 (en)
SA (1) SA98180918A (en)
SK (1) SK34699A3 (en)
TR (1) TR199900940T2 (en)
WO (1) WO1998018323A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115581201A (en) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 Diploid rose F induced by stem segment as explant 1 -61 plant regeneration method

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003824A1 (en) * 1993-07-27 1995-02-09 Csl Limited Treatment of h. pylori associated gastroduodenal disease
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
DE19730425A1 (en) 1997-07-16 1999-01-21 Henkel Teroson Gmbh Heat-curing laundry-resistant shell sealant
WO2000006743A2 (en) * 1998-07-27 2000-02-10 Connaught Laboratories Limited Chlamydia antigens and corresponding dna fragments and uses thereof
SE9901548D0 (en) * 1999-04-29 1999-04-29 Astra Ab Helicobacter pylori antigens
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
CN101532001A (en) 2000-03-08 2009-09-16 诺维信公司 Variants with altered properties
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
GB0010370D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
US9359627B2 (en) 2011-03-17 2016-06-07 National University Corporation Mie University Antibody production method
US10828358B2 (en) * 2015-12-14 2020-11-10 Technische Universität München Helicobacter pylori vaccines
CN115724922B (en) * 2022-07-19 2023-08-22 四川大学华西医院 Helicobacter pylori vaccine recombinant protein antigen TonB, preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9300139L (en) * 1993-01-19 1994-07-20 Medicarb Ab Preparation of a new drug

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115581201A (en) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 Diploid rose F induced by stem segment as explant 1 -61 plant regeneration method

Also Published As

Publication number Publication date
TR199900940T2 (en) 1999-09-21
EP0973394A1 (en) 2000-01-26
AU734052B2 (en) 2001-05-31
JP2001504329A (en) 2001-04-03
KR20000052831A (en) 2000-08-25
IL129397A0 (en) 2000-02-17
EP0973394A4 (en) 2005-03-30
NZ334568A (en) 2000-04-28
BR9712587A (en) 1999-10-26
CA2265523A1 (en) 1998-05-07
NO991995D0 (en) 1999-04-27
EE9900176A (en) 1999-12-15
SA98180918A (en) 2005-12-03
AU5093398A (en) 1998-05-22
PL333169A1 (en) 1999-11-22
NO991995L (en) 1999-06-28
AR009600A1 (en) 2000-04-26
WO1998018323A1 (en) 1998-05-07
SK34699A3 (en) 2000-04-10
ID22065A (en) 1999-08-26
IS5005A (en) 1999-03-18

Similar Documents

Publication Publication Date Title
CN1224708C (en) i (Neisseria meningitidis) antigens
JP5349448B2 (en) P. gingivalis antigen composition
CN1117149C (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
CN1280619A (en) i(Chlamydia trachomatic) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
CN1636062A (en) Novel streptococcus pneumonia open reading frames encoding polypeptide antigens and uses thereof
CN1235513A (en) Nucleic acid and amino acid sequences ralating to helicobacter pylori and vaccine compositions thereof
CN1176658A (en) Vaccine and antitoxin for treatment and prevention of C. difficile disease
CN1284965A (en) Novel surface protein of i (neisseria meningitidis)
CN1437653A (en) Antigenic polypeptides
CN1489628A (en) Compounds and methods for treatment and diagnosis of chlamydial infection
CN1235555A (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
CN1192241A (en) Streptococcal heat shock proteins members of the HSP70 family
CN1263436A (en) Identification of polynucleotides encoding novel helicobacter polypeptides in helicobacter genome
EP1009859A1 (en) Lyme disease vaccines
CA2249746C (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
CN1351653A (en) Anti-bacterial vaccine compositions
CN1294632A (en) Compsns. derived from i(mycobacterium vaccae) and methods for their use
CN1220703A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions theirof
CN1246799A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
CA2516971A1 (en) Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
CN1204253C (en) Neisseria lactoferrin binding protein
CN1342088A (en) Polypeptide comprising amino acid of AN N-terminal choline binding protein truncate, vaccine derived therefrom and uses thereof
CN1331699A (en) Methods of identifying antigen gene sequences
CN1210401C (en) Compound from moraxella catarrhalis
CN1326509A (en) MOraxella catarrhalis ABSB034 polypeptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication